View conference programme - The British Society for Rheumatology

Acknowledgements 

We would like to acknowledge and thank our sponsors, 

whose contribution to Rheumatology 2012 ensure we deliver 

a quality scientific meeting, and give access to a range of 

quality educational symposia and an innovative exhibition 

Platinum sponsors 

Abbott | stand 38 

Treat to target symposium: the patient at the heart of treat to target 

New practical tools to optimise the consultation process 

Wednesday 2 May, 18.00 – 19.30 

Page 50 

Would like to thank for their generous support 

Platinum 

New developments in spondyloarthritis 

Diagnosis, management and clinical advances in axial SpA 

Thursday 3 May, 07.30 – 09.00 

Page 56 

Roche products Ltd | stand 98 

Assessing the evidence: the benefits of IL-6R Inhibition in RA 

Wednesday 2 May, 18.00 – 19.30 

Page 53 

Gold Sponsors 

Bristol-Myers Squibb Pharmaceuticals | stand 114 

Getting it right: optimising RA treatment strategies in the evolving NHS 

Wednesday 2 May, 07.30 – 09.00 

Page 34 

Silver Sponsors 

Cellestis GmbH | stand 64 

Screening of TB infection in pre TNF-alpha patients. How IGRA improves outcomes 

Wednesday 2 May, 07.30 – 09.00 

Page 37 

Gold 

Silver 

Pfizer Inc. | stand 34 

Emerging treatment directions: signalling changes in rheumatoid arthritis 

Tuesday 1 May, 17.45 – 19.15 

Page 30 

UCB | stand 26

Contents 

Presidents’ welcome 2 

General information 4-5 

Floor plan 6-7 

BSR Prizes and awards 8-9 

BHPR Prizes and awards 10 

Keynote speakers 12-13 

Poster categories and tours 14 

Rheumatology 2013 15 

Meeting at a glance 

Meeting at a glance 17-19 

Additional meetings 20 

Programme: 

Tuesday 1 May 2012 21-32 

Programme: 

Wednesday 2 May 2012 33-52 

1-3 May| SECC, Glasgow, UK | Rheumatology 2012 1 

Oral presentation of abstracts 67-78 

Poster viewing: 

Tuesday 1 May 2012 79-92 


Wednesday 2 May 2012 93-108 


Thursday 3 May 2012 109-124 

Exhibition 

Exhibitor list 126 

Exhibition floor plan 127 

Rheumatology 2012 exhibitors 128-133 

Abstract reviewers 134 

Prize and bursary assesors 135 

Notes 136-144 

Programme: 

Thursday 3 May 2012 53-66 

BSR, Bride House, 

18-20 Bride Lane, London EC4Y 8EE 

Telephone: +44 (0) 20 7842 0900 

Fax: +44 (0) 20 7842 0901 

Email: events@rheumatology.org.uk 

Website: www.rheumatology.org.uk/conference 

A Company limited by guarantee with charitable status 

VAT No. 404 5637 66 

Company Reg. No. 3470316 

Charity Reg. No. 1067124 

Design and produced by: AD Design www.ad-design.uk.com 

® 

MIX 

From responsible 

sources 

FSC ® TT-COC-002846 

www.fsc.org

2 Rheumatology 2012 | 1-3 May| SECC, Glasgow, UK 

Presidents’ welcome 

Dear friends and colleagues, 

Welcome to Rheumatology 2012! We are delighted that you 

are able to join us at the UK’s leading rheumatology event. 

The conference offers an invaluable chance for the whole 

rheumatology team to come together to learn, network and 

hear about the latest developments in the field. 

We are all working in an increasingly challenging environment 

and so it is more important than ever that we come together as 

a community to support each other and raise the profile of the 

specialty. 

As always, we would love to hear your thoughts about the 

conference. You will receive an email inviting you to complete 

the conference survey and we would encourage you to give us 

your comments and suggestions to make sure that your 

conference gets better and better each year. 

Prof David L Scott and Mrs Lindsey Hawley 

‘Networking with colleagues in 

rheumatology is invaluable and the 

conference is the perfect opportunity 

to do just that’ Delegate 2011 

Connect with us via Twitter, Facebook or Linkedin: 

@RheumatologyUK 

⧣Rheum2012 

facebook.com/rheumatologyUK 

Search ‘Groups’: 

Rheumatology 2012


Meet the BSR Events team 

The BSR Events team have worked hard to make sure that 

Rheumatology 2012 is as successful a conference as possible. 

If you have any problems at all while at the conference, please do 

come and speak to one of the team via the registration desk. 

Louis Bellintani James Glavin Saheeda Rahman Briony Wilson 

Education and Events Director of Events Senior Events Senior Events 

Officer and Marketing Officer Officer 

You can contact the Events team at 

events@rheumatology.org.uk


General information 

Registration opening hours 

Monday 30 April 16.00-20.00 

Tuesday 1 May 08.00-19.30 

Wednesday 2 May 07.00-18.30 

Thursday 3 May 07.00-16.00 

Exhibition opening hours 

Tuesday 1 May 09.00-18.30 

Wednesday 2 May 09.00-17.00 

Thursday 3 May 08.45-14.30 

Abstract supplement 

All accepted abstracts have been published 

as a supplement in BSR’s journal 

Rheumatology. Abstracts are freely available 

online on the journal’s website at 

www.rheumatology.oxfordjournals.org 

All conference delegates will receive a hard 

copy abstract book in their delegate bag 

and a lanyard featuring an integrated USB 

stick with an electronic version of the 

abstract book. 

Badges 

Your name badge gives you access to any 

session taking place on the days for which 

you have registered. Please wear your badge 

visibly when at Rheumatology 2012 – 

stewards will not allow people without badges 

to access sessions or the exhibition areas. 

CPD 

The conference is accredited by the Royal 

College of Physicians (up to 18 credits - six 

per day) and by the Royal College of Nursing 

(up to 19 study hours). A certificate of 

attendance is included in your delegate bag. 

Please ensure that your badge is scanned 

once each day that you are at the 

conference in order to receive your CPD 

points. Scanners will be available at the 

registration desks and at the entrance of 

the exhibition area in Hall 5. 

Please ensure that your 

badge is scanned once 

each day that you are at 

the conference in order to 

receive your CPD points 

First time at the conference? 

We want you to get the most out of 

your time at Rheumatology 2012 

so if there’s anything the BSR team can 

do to help come and find us at the 

registration desk or on the BSR Stand 32 

CPD for Essentials in Rheumatology 

In order to receive CPD recognition for 

attending the Essentials programme, please 

ensure that you are scanned in to the room 

before each session. 

Catering 

Your registration fee for the conference 

includes lunch and tea and coffee for each 

day that you have registered. There are 

multiple catering points located throughout 

the exhibition areas. 

Accommodation 

If you have booked through our appointed 

accommodation agents, Reservations 

Highway, you can contact them with any 

accommodation queries on 

(0)1423 525 577.




⧣Rheum2012 



Rheumatology 2012 

Speaker preview 

All speakers are asked to check in their 

presentation at the speaker preview room no 

later than two hours prior to your session 

start time. The speaker preview room is 

situated in Carron Room 2 (see venue map 

page 6/7). If your session is first thing in the 

morning, you may want to check in your 

presentation the night before. Speaker 

badges can be picked up from the 

registration desk in Hall 5. 

Cyber café 

The Cyber café, is situated in the exhibition 

area in Hall 5 and is free for all delegates 

to use. Check your emails and comment on 

BSR’s social media channels. 

Social Media 

We encourage your use of social media in 

and around Rheumatology 2012. Search on 

Twitter for the hashtag #Rheum2012 to 

follow the feed of tweets related to the 

conference and be sure to include 

#Rheum2012 in any tweets that you send 

out. Use social media to contact other 

attendees: suggest sessions to attend and 

posters to visit, plan to meet up in the 

Exhibition Hall or at the social events. 

Provide helpful feedback to The Events team, 

discuss topics of interest and/or speakers 

and make suggestions for next year’s 

meeting. Happy tweeting! 

Room capacities 

We have tried to allocate rooms to ensure 

that the room size is appropriate for the 

session, based on the information given to us 

by delegates when they book. We apologise 

in advance if you are not able to attend a 

session due to the room being full. 

Press area 

The Rheumatology 2012 press area is 

situated next to the poster area in Hall 5 

(see exhibition floor plan page 127). 

Members of the press can use the area to 

issue press releases and as a meeting point. 

On request, the Events team can organise 

one-to-one interviews with key speakers and 

spokespeople at the conference, subject to 

availability. 

Property and cloakroom 

Delegates are responsible for their property 

at all times. Neither the BSR nor the venue 

can accept liability for loss or damage of 

personal items. Please keep bags and 

packages with you at all times or use the 

cloakroom provided. Unattended items can 

cause unnecessary security alerts. 

Business centre 

Delegates can use the Cyber café in the 

exhibition area (Hall 5) for accessing the 

internet and printing. The SECC also has a 

business centre where you can access a 

range of business services such as 

photocopying and faxing. 

Prayer space 

If you require a quiet space during the course 

of the conference, please contact a member 

of the Events team via the registration desk in 

Hall 5. 

First aid 

Trained first aiders will be on duty throughout 

the event. Please contact one of the Events 

team or one of the venue’s stewards in the 

event of an incident. There is a first aid suite 

situated on the main SECC concourse staffed 

by qualified first aid staff. 

Smoking policy 

Smoking is not permitted anywhere within 

the conference venue. 

Disclaimer 

Please note that the BSR and BHPR accept 

no responsibility for views expressed by the 

speakers at the event.


DOOR 4.4 

F M 

Poster area 

F F M 

F 

Ground level 

ALL 4 

HALL 5 

OOR 

4C 

DOOR 

4B 

M 

M 

Exhibition 

Exit 

Registration 

Exhibition 

Entrance 

M 

F 

Concourse 

< MAIN ENTRANCE 

DOOR 

2A 

F M 

F 

M 

HALL 1 

M 

F 

Lomond 

Auditorium 

Alsh 1 Alsh 2 

Etive 

LOCH SUITE 

Fyne 

Café 

M 

F 

Boisdale Boisdale 

2 1 

Linked corridor to 

Clyde Auditorium 

CONFERENCE CENTRE 


Gala 1 & 2 

(Upper Level) 

Forth 

(Ground Level)


Upper level 

Katrine 

Leven 

Morar 

Ness 

M 

F 

Concourse 

M 

F 

Carron 

1 

Carron 

2 

Speaker preview 

LOCH SUITE 

Lomond 

Auditorium 

Upper Level 

Dochart 

2 

Dochart 

1 

Linked corridor to 

Clyde Auditorium


BSR Prizes and awards 

BSR is proud to recognise and celebrate achievements and innovations that change 

the face of rheumatology 

Michael Mason 

The esteemed Michael Mason Prize is awarded by the Heberden 

Committee for excellence in clinical or scientific research in the field 

of rheumatology, the winner receives: £1,000, the Michael Mason 

award, complimentary conference registration and the opportunity 

to present their work during the plenary session of that year. 

Dr Kimme Hyrich, University of Manchester, Manchester 

The silver standard: measuring treatment effects using 

observational data 

Tuesday 1 May, 14.00 – 16.00, Jewels in the Crown, page 30 

Garrod Prize 

The prestigious Garrod Prize is open to scientists with a non-clinical 

background currently working in rheumatology or a related discipline. 

The winner receives: £1,000, The Garrod award, complimentary 

conference registration and the opportunity to present their work 

during the plenary session of that year. 

Mrs Elizabeth Camacho, University of Manchester, Manchester 

The relationship between pregnancy and long-term functional 

disability in women with inflammatory polyarthritis: results from 

the Norfolk Arthritis Register (NOAR) 

Tuesday 1 May, 14.00 – 16.00, Jewels in the Crown, page 30 

Young Investigator Award 

Awarded to young investigative rheumatologists who have included 

an imaginative hypothesis with results that could advance knowledge 

within the field. Winners receive: complimentary registration to 

Rheumatology 2012, publication of the winning abstract in the 

BSR journal Rheumatology plus the opportunity to present the 

research at Rheumatology 2012. 

Miss Youridies Vattakuzhi, Kennedy Institute of Rheumatology, 

London 

Dual specificity phosphatase 1 is a crucial negative regulator 

of inflammatory osteolysis and a mediator of therapeutic effects 

of dexamethasone in collagen-induced arthritis 

Thursday 3 May, 14.00 – 15.30, Molecular mechanisms of disease: 

inflammatory arthritis II, page 63 

Dr Jennifer Humphreys, University of Manchester, Manchester 

Incidence of rheumatoid arthritis in the UK using the 2010 

ACR/EULAR classification criteria; and comparison with estimates 

using the 1987 ACR criteria 

Thursday 3 May, 09.00 – 10.30, Oral abstracts: epidemiology and 

outcomes, page 56 

Dr Joanna Cobb, University of Manchester, Manchester 

Analysis of the immunochip in a large cohort of oligo- and 

polyarthritis juvenile idiopathic arthritis cases confirms previous 

and identifies novel associations 

Thursday 3 May, 14.00 – 15.30, Oral abstracts: genetics, page 64 

Dr Amy Naylor, University of Birmingham, Birmingham 

The mesenchymal stromal cell marker cd248 regulates 

inflammatory arthritis and bone formation 

Thursday 3 May, 14.00 – 15.30, Molecular mechanisms of disease: 

inflammatory arthritis II, page 63 

Dr Clare Warrell, Royal Free Hampstead Hospital NHS Trusts, London 

Is there an association between warfarin and survival in ssc-pah 

patients treated with first line bosentan monotherapy? 

Wednesday 2 May, 11.45 – 13.15, Oral abstracts: connective 

tissue diseases, page 42


Every year the BSR runs a programme of prizes and awards 

to raise the profile of achievements within rheumatology and 

to encourage those working to improve patient care. To find 

out more about our popular range of bursaries, prizes and 

awards please visit www.rheumatology.org.uk/prizes 

Medical Student Bursaries 

Awarded to UK medical students whose abstract submission scored 

highly and was judged by the Heberden Committee to be of 

particularly good quality. Winners receive: complimentary 

conference registration, economy travel expenses, two nights’ 

accommodation and the opportunity to present their work 

at Rheumatology 2012 

Mr Matthew Casey, University of Glasgow, Glasgow 

Can peer assisted learning delivered by medical 

students be useful in training senior colleagues in 

use of REMS technique for mss examination? 

A pilot study 

Poster 278, Thursday 3 May, 10.30 – 11.30, Poster viewing 

Ms Helen Monk, Keele University, Keele 

Are rheumatoid arthritis patients screened for cardiovascular 

disease in primary care? 

Wednesday 2 May, 14.45 – 16.15, Oral abstracts: primary care 

page 46 

Ms Elizabeth Jackson, Brighton and Sussex Medical School, Brighton 

A case control study of risk factors for elective hip replacement 

or resurfacing surgery in HIV-infected adults 

Poster 116, Wednesday 2 May, 10.45 – 11.45, Poster viewing 

Mr Amin Oomatia, University of Cambridge, Cambridge 

Peripheral neuropathy in systemic lupus erythematosus 

Poster 337, Thursday 3 May, 10.30 – 11.30, Poster viewing 

Innovations Award 2012 Supported by Abbott 

The awards will recognise innovation in rheumatology: 

a project, initiative or pioneering new strategy that has 

been utilised in practice to improve patient care. 

Dr Giuseppina Abignano, Leeds Institute of Molecular Medicine, Leeds 

Optical coherence tomography validation: a new quantitative 

imaging biomarker for affected skin in scleroderma 

Wednesday 2 May, 11.45 – 13.15, Oral abstracts: connective 

tissue diseases, page 42 

‘The award has given me the opportunity to 

be here that I might have missed otherwise. 

Listening to others starting out in research 

has inspired and enthused me’ Prize winner 2011


IN RA, WHEN COMBINATION WITH MTX IS NOT AN OPTION, 

Think 

THINK BIOLOGIC 

MONOTHERAPY 

® 

PRESCRIBING INFORMATION ROACTEMRA ® (tocilizumab): 

Please refer to RoActemra SPC for full prescribing 

information. 

Indication: RoActemra, in combination with methotrexate (MTX), 

is indicated for the treatment of adult patients with moderate to 

severe active rheumatoid arthritis who have had an inadequate 

response or intolerance to previous DMARDs or TNF antagonists. 

RoActemra can be given as monotherapy if continued treatment 

with MTX is inappropriate. RoActemra has been shown to reduce 

the rate of progression of joint damage as measured by X-ray and 

to improve physical function when given in combination with MTX. 

Dosage and Administration: Recommended posology is 8mg/ 

kg iv infusion given over one hour diluted to a volume of 100ml 

and given once every 4 weeks. For patients with body weight over 

100kg, doses exceeding 800mg per infusion are not recommended. 

Doses above 1.2g have not been evaluated. Treatment should be 

initiated by an appropriately experienced healthcare professional 

and patients should be given the Patient Alert Card. Dose 

adjustments: No dose adjustment is required in elderly patients, 

or in patients with mild renal impairment. Dose adjustments to 

4mg/kg, or interruptions, are recommended in the event of raised 

liver enzymes, low absolute neutrophil count or low platelet count 

(see SPC for details). RoActemra should not be initiated in patients 

with absolute neutrophil count below 2x10 9 /l. Contraindications: 

Hypersensitivity to any component of the product; active, severe 

infections. Precautions: Infections: Serious and sometimes fatal 

infections have been reported with RoActemra. In cases of serious 

infection interrupt therapy until controlled. Caution in patients 

with recurring/chronic infections, or other conditions which may 

predispose to infection. Severe neutropenia may be associated 

with an increased risk of serious infections. Tuberculosis: Screen 

for and treat latent TB prior to starting therapy. Viral reactivation: 

Viral reactivation (e.g. hepatitis B virus) has been reported with 

biologic therapies for RA. Diverticulitis: Caution in patients with 

a history of intestinal ulceration or diverticulitis. Patients with 

symptoms of complicated diverticulitis should be evaluated 

promptly. Hypersensitivity reactions: Fatal anaphylaxis may occur 

in patients who have experienced hypersensitivity reactions during 

previous infusions even if they have received premedication 

with steroids and antihistamines. Appropriate treatment should 

be available for immediate use in the event of an anaphylactic 

reaction. If serious hypersensitivity/serious infusion related 

reactions occur stop RoActemra treatment and permanently 

discontinue. Active hepatic disease/impairment: Use with caution 

in patients with active hepatic disease/impairment. Hepatic 

transaminase elevations: Not recommended in patients with 

baseline ALT or AST >5xULN; caution in patients with ALT or AST 

>1.5xULN. Monitor ALT/AST levels according to SPC. Consider 

other liver function tests including bilirubin if clinically indicated. 

Haematological abnormalities: Caution in patients with platelet 

count


Keynote speakers 

Tuesday 1 May, 14.00 – 16.00 

Keynote: Jewels in the Crown 

Sir Philip Craven, President, International 

Paralympic Committee 

Sir Philip Craven is a five time 

Paralympian in Wheelchair Basketball 

(1972-1988) and Swimming (1972). 

His international achievements in 

Wheelchair Basketball include World 

championship/Gold Cup (1973), Gold 

medal – European Championship (1991 

and 1994) and Bronze medal – World 

Championship/Gold Cup (1975). Sir Philip has also received a 

number of prestigious awards including Knight Bachelor by HM 

Queen Elizabeth II for services to Paralympic Sport (2005) and 

Member of the Order of the British Empire (MBE) by HM Queen 

Elizabeth II for services to Wheelchair Basketball (1991). 

Sir Philip is the current President of the International 

Paralympic Committee. His major contributions to Paralympic 

sport include Member of the International Olympic Committee 

(IOC) (since 2003), Member of the Executive Board, British 

Olympic Association (since 2003), Board Member of the London 

2012 Organizing Committee for the Olympic and Paralympic 

Games (since 2005) and Member of the IOC Commission for 

Culture and Olympic Education (since 2005). Sir Philip Craven’s 

professional career has included Performance Director, GBWBA 

Men’s Wheelchair Basketball Team (1998-2002), Chief 

Executive Officer, International Wheelchair Basketball Federation 

(1994-1998) and Company Secretary, British Coal Corporation 

(Western Area) (1986-1991). 

Tuesday 1 May, 11.30 – 13.00 

Droitwich Lecture 

Dr Jackie Hill, Senior Lecturer in Rheumatology, 

University of Leeds, Leeds 

Jackie has worked in rheumatology for 

over 30 years as a practitioner, a 

senior lecturer and a researcher. She 

was one of the first rheumatology nurses 

in the UK to hold nurse led clinics and 

undertook the seminal research into 

outcomes from these clinics. She 

obtained her Masters Degree in 1991, 

her PhD in 2000 and in 1990 was honoured with Fellowship of 

the Royal College of Nursing for an outstanding contribution to 

the science and art of rheumatology nursing. Jackie is a former 

Chair of the RCN Rheumatology Nursing Forum, President of 

BHPR and has sat on several EULAR committees. More recently 

she was co-convenor of the EULAR Nursing Task Force which 

published Recommendations for the Basic and Advanced Role of 

the Nurse in the Management of Chronic Inflammatory Arthritis. 

Before her retirement in July 2011 she was co-director of the 

Academic and Clinical Unit for Musculoskeletal Nursing, a reviewer 

for ten journals and a grant application reviewer for six national 

bodies including NIHR. Jackie was the Associate Editor of 

Musculoskeletal Care and editor/author of three books and ten 

book chapters. She has published over 130 papers and has given 

numerous presentations and keynote lectures at national and 

international conferences.


Tuesday 1 May, 16.30 – 17.30 

Heberden Round 

Prof Philip Conaghan, Professor of Musculoskeletal 

Medicine, University of Leeds, Leeds 

Professor Conaghan’s major research 

interests are in understanding pathogenesis 

and therapeutic response in osteoarthritis 

and rheumatoid arthritis, with a special 

focus on the role of imaging. His research 

incorporates a spectrum from translational 

and proof-of-concept work through to large 

clinical trials. He is Professor of 

Musculoskeletal Medicine at the University of Leeds, and Chairs the 

NICE OA Guidelines Development Group and Arthritis Research UK’s 

OA Clinical Studies Group. He previously chaired the Assessment of 

Structural Change Working Group of the OARSI-FDA OA Initiative. 

He recently completed his term as inaugural Chair of the EULAR 

Standing Committee on Imaging, is leader for the OMERACT 

Imaging & Biomarkers workstream and is President of the 

International Society for Musculoskeletal Imaging in Rheumatology. 

He has authored over 250 papers, book chapters and books. 

Wednesday 2 May 16.45 – 17.45 

Heberden Oration 

Prof Paul Wordsworth, Professor of Rheumatology and 

Consultant Rheumatologist, Nuffield Department of 

Orthopaedics, Rheumatology and Musculoskeletal 

Sciences, Oxford 

Professor Wordsworth works in the NIHR 

Oxford Musculoskeletal Biomedical 

Research Unit. His clinical and research 

interests are particularly oriented towards 

understanding the genetic basis of 

musculoskeletal diseases. These include 

monogenic disorders, such as Marfan 

syndrome and skeletal dysplasias, but also 

complex polygenic inflammatory arthropathies. He is a co-founder 

of the international consortium investigating the genetics of 

ankylosing spondylitis that identified the association with IL23R 

and ERAP1. His group also helped to solve the crystal structure of 

ERAP1 in 2011. He is co-author of Clinical and Biochemical 

Disorders of the Skeleton and has published over 300 original 

scientific papers, mainly on the genetics of rheumatic diseases. 

He is a Fellow of Green Templeton College.


Poster categories and tours 

Tuesday 1 May 2012 | 10.30 – 11.30 

BHPR research: qualitative 1 – 10 

BHPR research: quantitative 11 – 17 

BHPR: clinical evaluation and audit delivery 18 - 42 

Imaging 43 - 51 

Metabolic and crystal arthropathies 52 - 53 

Miscellaneous rheumatic diseases 54 - 59 

Rheumatoid arthritis: clinical features 60 - 68 

Rheumatoid arthritis: comorbidities 69 – 81 

Scleroderma and related disorders 82 - 95 

Spondylarthropathies (including psoriatic arthritis) 96 – 110 

Wednesday 2 May 2012 | 10.45 – 11.45 

Muscle disorders 111 - 115 

Orthopaedics and rehabilitation 116 - 117 

Osteoarthritis 118 - 135 

Osteoporosis and metabolic bone disease 136 - 151 

Paediatric and adolescent rheumatology 152 - 160 

Primary care 161 - 167 

Psychology, measurement and management of pain 168 - 173 

Rheumatoid arthritis: treatment 174 - 230 

Soft tissue and regional musculoskeletal disease, 231 

fibromyalgia 

Thursday 3 May 2012 | 10.30 – 11.30 

Basic science 232 - 245 

Biology of bone, cartilage and connective tissue disease 246 

Cell receptor-ligand Interaction, signalling, activation 247 - 248 

and apoptosis 

Cytokines and inflammatory mediators 249 - 253 

Rheumatoid arthritis: aetiopathogenesis and 254 – 257 

animal models 

Case reports 258 – 277 

Education research 278 - 288 

Epidemiology 289 - 299 

Genetics 300 - 303 

Health services research, economics and 304 - 328 

outcomes research 

Sjögren’s syndrome and other connective tissue 329 - 330 

disorders 

SLE and antiphospholipid syndrome 331 - 343 

Vasculitis 344 - 350 

A poster drop off/pick up and hanging service is available. 

Drop off your poster the day prior to your session and one 

of our poster staff will hang it for you. 

Poster tours 2012 

Our poster tours are guided by leaders in the field and will be 

highlighting a selection of BSR and BHPR posters helping delegates 

make the most of poster viewing sessions. Each tour will take 

approximately 45 minutes and will consist of approximately 10 

carefully selected high scoring abstracts. 

Places on the tours are limited, so please register in advance at 

the poster registration desk, in the poster area. 

Tuesday 1 May 10.40 – 11.25 

Tour 

BHPR 

Rheumatoid arthritis 

Spondyloarthropathies 

Wednesday 2 May 10.50 – 11.35 

Tour 

Osteoarthritis 

Rheumatoid arthritis: treatment 

Thursday 3 May 10.40 – 11.25 

Tour 

Basic science 

Connective tissue diseases 

Leader 

Prof Krysia Dziedzic 

Prof Kevin Davies 

Dr Karl Gaffney 

Leader 

Dr Nick Shenker 

Dr Chris Edwards 

Leader 

To be confirmed 

Dr Frances Hall

Rheumatology 2013 

is the UK’s leading rheumatology event and 

offers delegates an unparalleled opportunity to 

expand their knowledge and network with the whole 

rheumatology community. 

23-25 April | Birmingham, UK 

So join us next year in Birmingham 

96% of your colleagues would recommend that you do! 

Be a part of Rheumatology 2013 

You can contribute to the conference and ensure that we maintain the high quality 

of our programme by submitting an abstract or submitting a proposal for a 

conference session. Tell us what you need us to deliver at next year’s event. 

Full details can be found at www.rheumatology.org.uk/conference 

Conference session proposal deadline: Friday 18 May 2012 

Abstract deadline: Wednesday 21 November 2012 

Early bird registration: Friday 1 February 2013 

www.rheumatology.org.uk/conference

20.00 - Late | Wednesday 2 May 2012 

Conference dinner and ceilidh | Òran Mór 

Join us for an unforgettable evening of 

traditional Scottish food and dancing at 

Òran Mór, a breathtaking converted church 

in the heart of Glasgow’s West End. 

This event will provide you with the perfect 

opportunity to network with collegues while 

experiencing real Scottish hospitality. 

Limited tickets are available from the 

registration desk £40 (inc VAT)


1-3 May 2012 | SECC, Glasgow, UK 


1-3 May 2012

1-3 May 2012 | Meeting at a glance 17 

Tuesday 1 May 2012 

09.00 - 10.30 

Reproductive issues in rheumatology | Clyde Auditorium 21 

Clinical trials to advance the development of 21 

new therapies | Hall 1 

Hypermobility - overmedicalised? A debate 22 

Lomond Auditorium 

BHPR: Physical activity and exercise in inflammatory 22 

arthritis | Forth Room 

Oral abstracts: Spondyloarthropathies | Alsh Room 23 

SIG: BHPR Connective tissue disease | Dochart Room 23 

SIG: Lung disease in rheumatoid arthritis | Boisdale Room 24 

10.30 - 11.30 | Tea and coffee 

Poster viewing and exhibition 

Poster tours: BHPR | RA | Spondyloarthropathies | Poster area 

Registration necessary 

11.30 - 13.00 

INBANK, BSR Registers and the new information age 25 

Hall 1 

Sport and exercise medicine | Lomond Auditorium 25 

Sex discrimination in the autoimmune rheumatic 26 

diseases | Clyde Auditorium 

BHPR: Droitwich Lecture, lifetime achievement award 26 

and prizes | Forth Room 

Oral abstracts: Imaging | Alsh Room 27 

SIG: Polymyalgia rheumatica and giant cell arteritis 28 

Boisdale Room 

SIG: RA outcomes | Dochart Room 28 

13.00 - 14.00 | Lunch 

Exhibition 

13.00 - 14.00 

BHPR AGM | Forth Room 29 

BHPR Post graduate research student network 29 

Leven Room 

BSRBR open meeting | Hall 1 29 

14.00 - 16.00 

Jewels in the Crown | Clyde Auditorium 30 

16.00 - 16.30 | Tea and coffee 

Exhibition 

16.30 - 17.30 

Heberden Round | Clyde Auditorium 30 

17.30 - 17.45 

Industry supported symposia catering | Forth Room 30 

17.45 - 19.15 

Industry supported symposium: Pfizer Inc | Forth Room 30 

19.30 - 21.00 

Presidents’ reception | Crowne Plaza Hotel 31

18 Meeting at a glance | 1-3 May 2012 

Wednesday 2 May 2012 

07.30 - 09.00 

Industry supported symposia: 

Bristol-Myers Squibb | Alsh Room 33 

Cellestis GmbH | Boisdale Room 35 

09.15 - 10.45 

Essentials: Disease management | Clyde Auditorium 35 

Mimickers of myositis and treatment update 36 


Osteoporosis: topical issues | Hall 1 36 

BHPR: Primary care rheumatology: leading the way 37 

Forth Room 

Oral abstracts: RA treatments and outcomes 37 

Dochart Room 

SIG: MSK health in multi ethnic minorities | Morar Room 38 

SIG: Genetics of inflammatory arthritis | Gala Room 38 

SIG: Scleroderma | Leven Room 39 

10.45 - 11.45 | Tea and coffee 


Poster tours: Osteoarthritis | RA: treatment | Poster area 


11.45 - 13.15 

Essentials: Symptom diagnosis and management 41 


ARMA: Devolution of health: what can we learn? 40 


Rheumatological challenges in primary care | Boisdale Room 40 

BHPR plenary orals | Hall 1 41 

Oral abstracts: connective tissue diseases | Alsh Room 42 

SIG: Vasculitis | Forth Room 42 

SIG: Paediatric and adolescent rheumatology 43 

Gala Room 

13.15 - 14.45 

BSR AGM | Dochart Room 43 

BHPR: How to get your abstract published | Leven Room 43 

14.45 - 16.15 

Essentials: Keeping up to date, clinical 44 

decision making | Clyde Auditorium 

BHPR: Current thinking on conservative management 44 

of back pain | Hall 1 

Juvenile-onset SLE and childhood scleroderma 45 

Forth Room 

Recent advances in osteoarthritis therapy 45 


Oral abstracts: Primary care | Alsh Room 46 

SIG: Heritable disorders of connective tissue 46 

Boisdale Room 

SIG: BHPR Rheumatoid arthritis | Gala Room 47 

16.15 - 16.45 | Tea and coffee 

Exhibition 

16.45 - 17.45 

Heberden Oration | Clyde Auditorium 47 

17.45 - 18.00 

Industry supported symposia catering 48 

18.00 - 19.30 

Industry supported symposia: 

Abbott | Forth Room 48 

Roche | Hall 1 51 

20.00 - Late 

Conference dinner and ceilidh | Òran Mór 51 

13.15 - 14.45 | Lunch 

Exhibition

1-3 May 2012 | Meeting at a glance 19 

Thursday 3 May 2012 

07.30 - 09.00 

Industry supported symposium: Abbott | Forth Room 53 

SIG: Myositis | Leven Room 53 

09.00 - 10.30 

Science: Molecular mechanisms of disease: 

osteoarthritis | Dochart Room 54 

Optimising therapy for rheumatoid arthritis 

Clyde Auditorium 54 

BHPR: Pain and motor function: mechanisms and 55 

treatment approaches | Lomond Auditorium 

Trainee: Interactive quiz and clinical teaching | Hall 1 55 

Oral abstracts: Epidemiology | Alsh Room 56 

SIG: Sjögren’s syndrome | Boisdale Room 1 56 

SIG: MSK ultrasound | Boisdale Room 2 57 

10.30 - 11.30 | Tea and coffee 


Poster tours: Basic science/CTD | Poster area 


13.00 - 14.00 | Lunch 

Exhibition 

13.00 - 14.00 

Trainee: RATs AGM | Hall 1 61 

BHPR: NICE and NHS Evidence and the information 

revolution | Forth Room 61 

14.00 - 15.30 

Science: Molecular mechanisms of disease: 63 

inflammatory arthritis II | Dochart Room 

Trainee: Rheumatology and the NHS | Hall 1 62 

BHPR: Improving work participation: new developments 62 

in reducing work absence for people with 

musculoskeletal conditions | Forth Room 

What’s new in ankylosing spondylitis pathogenesis, 63 

assessment and treatment | Clyde Auditorium 

Oral abstracts: Genetics | Alsh Room 64 

SIG: Education | Boisdale Room 1 64 

SIG: Osteoarthritis | Boisdale Room 2 65 

11.30 - 13.00 

Advances in psoriatic arthritis | Clyde Auditorium 58 

Science: Molecular mechanisms of disease: 59 

inflammatory arthritis I | Dochart Room 

Trainee: Ask the experts: myositis | Hall 1 58 

BHPR: The management of upper limb dysfunction 59 

in people with rheumatoid arthritis | Forth Room 

Oral abstracts: Education | Alsh Room 60 

SIG: Osteoporosis | Boisdale Room 1 60 

SIG: Foot and ankle | Boisdale Room 2 61 

15.30 - 17.00 

SIG: Spondyloarthritis | Carron Room 1 65 

17.00 End of meeting

20 Meeting at a glance | 1-3 May 2012 

Additional meetings 


Closed meetings (invitees only) 

10.30-11.30 Author clinic Carron Room 1 


Open meetings 

07.30-08.30 CMF breakfast Gala Room 


09.00-12.45 Glasgow Clinical Research Facility Carron Room 1 

09.15-10.45 CAC regional chairs Ness Room 

15.45-16.45 OTTER trial Morar Room 

Thursday 3 may 2012 

Open meetings 

13.00-14.00 BSR standards guidelines and audit Leven Room 

working group 


10.30-11.30 Musculoskeletal ultrasound SIG meeting Ness Room 

10.30-11.30 TRACTISS Morar Room 



⧣Rheum2012 




Programme 

Tue 1 May 2012 

Programme: 

Tuesday 1 May 2012

Ankylosing Spondylitis Register 

Launched 

The BSR Biologics Registers team are pleased to announce that 

the Ankylosing Spondylitis (AS) register officially started in April 

2012. The register will build on the success of the Rheumatoid 

Arthritis register and will gather important data on AS patients 

being treated with Adalimumab and Etanercept anti-TNF therapies. 

The AS team is based at the University of Aberdeen and are led 

by Professor Gary Macfarlane, who will be presenting on the 

register in Hall 1 on Tuesday from 11.30 to 11.50. 

Straight after this session there will be a BSR Biologics 

Registers lunchtime open meeting from 13.00 to 14.00, 

where Dr Gareth Jones will provide further information 

and be available to answer any questions on BSRBR-AS. 

We are keen to receive expressions of interest from any centre 

interested in contributing patients to this important new study 

please talk to us on the BSR Biologics Registers stand or 

email us via ELawton@rheumatology.org.uk 

The British Society for 

Rheumatology 

Biologics Registers 

Ankylosing Spondylitis

Tuesday 1 May 2012 | Programme 21 


Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event 

Award winner | IRS (interactive audience response system) 

09.00 - 10.30 Reproductive issues in rheumatology: do you know how to advise your patients? | Clyde Auditorium 

Chairs: Dr Ian Giles, UCL, London | Prof Caroline Gordon, University of Birmingham, Birmingham 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide delegates with up to date knowledge of the issues surrounding rheumatological 

conditions and drugs in conception, pregnancy, and lactation 

Delegates will be aware of the current state of knowledge amongst rheumatologists and 

obstetricians surrounding the safe use of rheumatological drugs in conception, pregnancy 

and lactation 

Delegates will be aware of the need for a national consensus on the use of rheumatological 

drugs in conception, pregnancy and lactation, and how such a consensus can be achieved 

Delegates will have a better understanding of the complications in pregnancy associated 

with rheumatological conditions 

09.00 Is pregnancy a stress test for subsequent development of autoimmunity? 

Dr David Williams, UCLH, London 

09.20 Drugs in conception, pregnancy, and lactation: towards a national consensus 

Dr Munther Khamashta, St Thomas’ Hospital, London 

09.40 Safety of biologics in pregnancy? 

Prof Monika Østensen, Sörlandet Hospital, Kristiansand, Norway 

10.00 Rheumatological conditions in pregnancy and the puerperium 

Prof Catherine Nelson-Piercy, Guy’s and St Thomas’ Foundation Trust, London 

10.20 Discussion 

09.00 - 10.30 IRS | Clinical trials to advance the development of new therapies | Hall 1 

Chair: Dr Duncan Porter, Gartnavel General Hospital, Glasgow 

Aim: 

Outcome 1: 

Outcome 2: 

This session is to inform rheumatologists about performing clinical trials in rheumatoid arthritis 

Delegates will understand how stratified medicine and biomarkers can be applied to improve 

therapeutic responses in patients 

Delegates will understand the influence of genetics on responses observed in clinical trials 

09.00 Conducting clinical trials in rheumatoid arthritis: practicalities and potential pitfalls 

Prof Paul Emery, University of Leeds, Leeds 

09.25 Stratified medicine and biomarkers 

Prof Mahesh Parmar, UCL, London 

09.50 Design, analysis and reporting of pharmacogenetic studies 

Prof Anne Barton, University of Manchester, Manchester 

10.20 Discussion

22 Programme | Tuesday 1 May 2012 



09.00 - 10.30 IRS | Hypermobility: overmedicalised? A debate | Lomond Auditorium 

Chairs: Prof Howard Bird, University of Leeds, Leeds | Prof Anthony Redmond, University of Leeds, Leeds 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To transparently debate key controversial aspects of our diagnosis and management of child and adult joint 

laxity/hypermobility (as currently defined); this should inform clinical and academic future direction 

Delegates will gain an understanding of evidence underpinning management and learn new 

epidemiological data 

Delegates will participate in healthy discussion on pros and cons of current diagnosis and management 

Delegates will decide which of the opposing viewpoints is most convincing 

09.00 First proposition 

Dr Jacqui Clinch, University of Bath, Bath 

09.20 Second proposition 

Prof Alan Silman, University of Manchester, Manchester 

09.40 First opposition 

Prof Rodney Grahame, UCL, London 

10.00 Second opposition 

Dr Alan Hakim, Whipps Cross University Hospital, London 

09.00 - 10.30 Physical activity and exercise in inflammatory arthritis | Forth Room 

Chairs: Dr Fiona Cramp, University of the West of England, Bristol | Dr Claire Goodchild, 

King’s College London, London 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide an overview of the role of physical activity and exercise in the management of 

inflammatory arthritis 

Attendees will understand the effects of physical activity and exercise in those with inflammatory 

arthritis 

Attendees will understand the current UK physical activity guidelines, the uptake and physical 

activity preferences in people with rheumatic diseases 

Attendees will consider the implementation of a home based physical activity programme for 

people with inflammatory arthritis 

09.00 The efficacy and safety of exercise for RA patients. The case for exercise as a treatment for RA: 

is anyone listening? 

Prof Andrew Lemmey, Bangor University, Bangor 

09.35 Understanding physical inactivity in rheumatic diseases: the patients perspective 

Ms Victoria Manning, King’s College London, London 

10.00 Implementation of a physical activity programme for people with rheumatoid arthritis using 

motivational interviewing 

Dr Emalie Hurkmans, Leiden University Medical Centre, Leiden, The Netherlands




09.00 - 10.30 Oral abstracts: Spondyloarthropathies | Alsh Room 

Chair: Dr Paul Bowness, University of Oxford, Oxford 

9.00 Detecting axial spondyloarthritis (ASpA) amongst primary care back pain referrals 

Mrs Claire Harris, Northwick Park Hospital, Harrow 

9.15 Validation of a screening questionnaire for axial SpA in a UK population 

Dr Karl Gaffney, Norfolk and Norwich University Hospital, Norwich 

9.30 The prevalence and burden of ankylosing spondylitis in Europe: a systematic review 

Ms Linda Morton, University of Aberdeen, Aberdeen 

9.45 Work disability in established psoriatic arthritis: a cross sectional study using the work productivity 

activity index (WPAI) 

Dr Willi Tillett, Royal National Hospital for Rheumatic Diseases, Bath 

10.00 Influence of leflunomide on the levels of matrix metalloproteinase-3 (MMP-3) and pyridinoline (PYR) in 

patients with psoriatic arthritis (PsA) 

Dr Dmytro Fedkov, Kiev National Medical, Kyiv, Ukraine 

10.15 Evaluation of efficacy and safety of secukinumab in the treatment of patients with moderate-to-severe 

ankylosing spondylitis 

Prof Paul Emery, University of Leeds, Leeds 

09.00 - 10.30 BHPR SIG: Connective tissue disease | Dochart Room 

Chair: Mrs Sue Brown, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide an overview of the complexities of disease presentations and management approaches 

in scleroderma, including digital ulcer disease and pulmonary hypertension 

To gain an understanding of the diagnostic process for those with scleroderma, including 

management and treatment options 

To become aware of the significance of digital ulcer disease in scleroderma, its impact on the 

patient and the supportive role of the nurse specialist 

To gain an understanding of the importance of a multi-disciplinary approach in effective and early 

diagnosis, treatment and management of scleroderma associated lung and cardiac disease 

09.00 Diagnosing scleroderma and treatment options, the role of the rheumatologist 

Dr John Pauling, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath 

09.20 Managing digital ulcers and supporting patients with scleroderma, the role of the clinical 

nurse specialist 

Mrs Sue Brown, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath 

09.40 Lung and pulmonary vascular disease in scleroderma, the role of the specialist pulmonary physician 

Dr Jay Suntharalingham, Royal United Hospital, Bath 

10.00 Cardiac and pulmonary vascular disease in scleroderma, the role of the specialist cardiologist 

Dr Gerry Coghlan, Royal Free Hospital NHS Foundation Trust, London 

10.20 Questions




09.00 - 10.30 SIG: Lung disease in rheumatoid arthritis | Boisdale Room 

Chair: Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To update on progress with the National Database of interstitial lung disease in RA, educate members on 

the use of novel treatments for interstitial lung disease in RA and inform members of the latest data on 

serology in lung disease complicating RA 

To ensure that members are aware of the plans for a national database for ILD in RA and the challenges 

in developing this 

To educate members about the growing body of evidence for the use of novel therapies for the treatment 

of interstitial lung disease in RA 

To update members with the latest data on the serological associations with lung disease in patients 

with RA 

9.00 Welcome and Introduction 

Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead 

9.05 The extent of ILD assessed by high resolution CT and correlation with survival 

Dr Nav Sathi, St Helens Hospital, Merseyside 

9.25 Safety and efficacy of rituximab in patients with RA-ILD 

Dr Shouvik Dass, Leeds Teaching Hospitals NHS Trust, Leeds 

9.45 Immunosuppressives in the treatment of RA-ILD in Wales 

Dr Yasmeen Ahmad, Bangor University, Bangor 

10.05 Autoantibodies and HLA studies in RA-ILD: what should we focus on? 

Dr Hector Chinoy, University of Manchester, Manchester 

10.25 Summary of agreed actions 

10.30 - 11.30 Poster viewing and exhibition | Tea and coffee 

Categories: 

Poster tours: 

BHPR 

BHPR 

Imaging 

Rheumatoid arthritis 

Metabolic and crystal arthropathies Spondyloarthropathies 

Miscellaneous rheumatic diseases 

Rheumatoid arthritis: clinical features 

Rheumatoid arthritis: comorbidities 

Scleroderma and related disorders 

Spondylarthropathies (including psoriatic arthritis)




11.30 - 13.00 INBANK, BSR Registers and the new information age | Hall 1 

Chairs: Prof Deborah Bax, Royal Hallamshire Hospital, Sheffield | Prof David L Scott, King’s 

College London, London 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To inform the membership about new and emerging data resources in rheumatology, and to raise 

awareness of the opportunities afforded by the establishment of INBANK as a national resource for 

clinical data linkage to biological samples and NHS outcomes 

Understand the value of national data resources in rheumatology and raise awareness of datasets 

including the newly established ankylosing spondylitis biologics register and the national joint register 

Understand how INBANK will function and allow clinicians both to audit their own clinical performance 

and participate in research 

Allow participants to ask questions about key issues including consent, access, security and resources 

11.30 Advances in drug information in rheumatic disease: the ankylosing spondylitis register 

Prof Gary Macfarlane, University of Aberdeen, Aberdeen 

11.50 The power of data linkage: lessons from the National Joint Register 

Prof Alex MacGregor, University of East Anglia, Norwich 

12.10 INBANK: a national musculoskeletal information platform 

Prof Alan Silman, Arthritis Research UK 

12.30 INBANK in practice 

Dr William Dixon, University of Manchester, Manchester 


11.30 - 13.00 Sport and exercise medicine | Lomond Auditorium 

Chairs: Prof Nicola Maffulli, Queen Mary University of London, Barts and the London School of Medicine and 

Dentistry, London | Dr Roger Wolman, Royal National Orthopaedic Hospital, London 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide delegates an overview of the challenges faced by modern sport and exercise medicine practice 

Delegates will be able to identify the key issues concerning modern sport and exercise medicine 

practice, and discuss these in an open, interactive session 

Delegates will be aware of how these issues may affect rheumatology in the future 

Delegates will have a better understanding of how sports and exercise medicine and 

rheumatology will be able to interact to provide optimal medical care 

11.30 British sport and exercise medicine: a five minute history of a specialty 

Prof Nicola Maffulli, Queen Mary University of London, Barts and the London School of Medicine and 

Dentistry, London 

11.35 Exercise: a unique therapeutic intervention for primary, secondary and tertiary disease prevention. 

Let’s all prescribe it! 

Dr Christopher Hughes, Queen Mary University of London, Barts and the London School of Medicine and 

Dentistry, London 

11.55 Anterior cruciate ligament reconstruction: good for your knee? 

Prof Anthony Bull, Imperial College London, London 

12.15 Platelet-rich plasma in musculoskeletal medicine: some truths 

Dr Umile Giuseppe Longo, University Campus Biomedico, Rome, Italy 

12.40 Taking care of tender tendons 

Prof Nicola Maffulli, Queen Mary University of London, Barts and the London School of Medicine and 

Dentistry, London




11.30 - 13.00 Why can’t a man be more like a woman? Sex discrimination in autoimmune rheumatic 

diseases | Clyde Auditorium 

Chairs: Prof David Isenberg, University College London Hospital, London | Dr Patrick Gordon, King’s College 

Hospital, London 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide a thought provoking session on the evident disparity in the prevalence, causes and 

consequences of autoimmune rheumatic disease (ARDs) involvement between men and women 

To achieve a better understanding of the disparity and differential effects of ARDs on men and women 

To achieve a better understanding of the links between the immune and endocrine systems 

To achieve a better understanding of whether hormonal manipulation might play a part in the 

therapy of ARDs 

11.30 Sex hormones modulate autoimmunity 

Dr Betty Diamond, Feinstein Institute Medical Research, New York, USA 

11.55 Male lupus: the Loch Ness monster syndrome revisited 

Prof David Isenberg, University College London Hospital, London 

12.10 Rheumatoid arthritis in men 

Prof John Isaacs, University of Newcastle, Newcastle Upon Tyne 

12.25 Scleroderma in men 

Prof Christopher Denton, Royal Free Hospital, London 

12.40 Blocking female hormones: smart or stupid? 

Prof Anisur Rahman, University College London Hospital, London 

11.30 - 13.00 Droitwich Lecture, Lifetime achievement award and prizes | Forth Room 

Chair: Mrs Lindsey Hawley, President BHPR 

11.30 Droitwich Lecture: Rheumatology nursing: a journey of discovery 

Dr Jackie Hill, Senior Lecturer in Rheumatology Nursing, University of Leeds, Leeds 

12.15 Lifetime achievement award 

Dr Jackie Hill, Senior Lecturer in Rheumatology Nursing, University of Leeds, Leeds 

12.20 Chris Moran poster prize 

This prize will be awarded to a poster author at the conference 

12.25 BHPR/Arthritis Research UK research UK silver medal research prize 

Physical inactivity among UK adults with rheumatic diseases: an evaluation of physical activity participation, 

recommendation and preferences 

Miss Victoria Manning, King's College London, London 

12.30 Arthritis Research UK physiotherapy silver medal prize 

Comparison of stratified primary care management for low back pain with current best practice (STarT Back): 

a randomised controlled trial 

Dr Jonathan Hill, Keele University, Keele




Droitwich Lecture, Lifetime achievement award and prizes | Forth Room 

12.35 Arthritis Research UK/PRCA podiatry silver medal prize 

Factors predicting the outcome of foot and ankle surgery in patients with rheumatoid arthritis 

Mr Michael Backhouse, University of Leeds, Leeds 

12.40 Arthritis Research UK occupational therapy prize 

Mrs Kate Hackett, Newcastle University, Newcastle 

Functional impairment and primary Sjögren’s syndrome: A case for occupational therapy? 

12.45 Arthritis Research UK nurses prize 

Don’t forget to clean your teeth - does informing patients about the link between dental hygiene and 

Rheumatoid Arthritis encourage better dental care? 

Mrs Patricia Cornell, Poole Hospital NHS Foundation Trust, Poole 

11.30 - 13.00 Oral abstracts: Imaging | Alsh Room 

Chair: Dr Helena Marzo-Ortega, Chapel Allerton Hospital, Leeds 

11.30 Hand osteoarthritis pain has peripheral and central components demonstrated by algometer scores 

and functional MRI 

Dr Nidhi Sofat, St George’s, University of London, London 

11.45 Ultrasound features of osteophytes and cartilage thickness at the knee are associated with pain 

and functional impairment: the Newcastle thousand families study 

Dr Ajay Abraham, Newcastle University, Newcastle upon Tyne 

12.00 The diagnostic utility of salivary gland ultrasound for the investigation of Sjögren’s syndrome 

Dr Andrew Carr, Newcastle Dental Hospital, Newcastle upon Tyne 

12.15 Long-term radiographic outcome in psoriatic arthritis patients treated with Golimumab: 104 week 

results from the go-reveal study 

Dr Chandrabhusan Chattopadhyay, Wrightington Hospital, Wigan 

12.30 Early effect of Secukinumab in reducing spinal inflammation as detected by magnetic resonance 

imaging in patients with ankylosing spondylitis 

Prof Jaap Van Laar, Newcastle University, Newcastle upon Tyne 

12.45 Tocilizumab as monotherapy or in combination with methotrexate associated with early reductions in 

tissue inflammation: 12 week results from a magnetic resonance imaging substudy of a randomized 

controlled trial 

Prof Philip Conaghan, University of Leeds, Leeds




11.30 - 13.00 SIG: Polymyalgia rheumatica and giant cell artertis | Boisdale Room 

Chair: Prof Bhaskar Dasgupta, Southend University Hospital, Southend 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To increase awareness of the attendees of advances in the diagnosis, guidelines on management, 

clinical trials, biomarkers and patient support in PMR and GCA 

Attendees will learn about the EULAR ACR Classification Criteria for PMR and the approach to 

differentiate PMR from other conditions that present with a polymyalgic syndrome 

Attendees will learn about the management of PMR and GCA in PMR and development of 

pathways to improve diagnosis and reduce ischemic complications 

Attendees will learn about the status of ongoing clinical trials in PMR, GCA and large vessel vasculitis 

11.30 PMR Classification Criteria 

Prof Bhaskar Dasgupta, Southend University Hospital, Southend 

11.45 Pathways and management of PMR and GCA in primary care 

Prof Christian Mallen, Keele University, Keele 

12.00 Clinical trials in PMR, GCA and large vessel vasculitis 

Prof Carlo Salvarani, Azienda Ospedaliera Arcispedale Santa Maria Nuova Reggio Emilia, Italy 

12.15 Annexin and its receptor in PMR and GCA 

Prof Mauro Perretti, St Barts Hospital, London 

12.30 Development of a patient support organisation for PMR and GCA 

Dr Kate Gilbert, Chair, PMRGCAUK 


11.30 - 13.00 SIG: RA outcomes | Dochart Room 

Chair: Dr Adam Young, St Albans City Hospital, St Albans 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To discuss topical and recent issues in management and outcomes of early RA by leaders in this field 

Understand the many facets of pain in RA 

Appreciate the importance of joint failure in RA as measured by orthopaedic surgery 

Debate the different perspectives proposed for DAS28 cut offs for biological therapy 

11.30 Pain in early RA: inflammatory or central sensitisation? 

Prof David Walsh, The University of Nottingham, Nottingham 

11.50 Orthopaedic interventions for RA: clinical and health economic aspects 

Dr Elena Nikiphorou, St Albans City Hospital and UCL, London | Prof Steve Morris, UCL, London 

12.10 DAS28 criteria for initiation of biologics in early RA: a clinician’s view 

Dr Patrick Kiely, St George’s Hospital, London 

12.30 DAS28 criteria for initiation of biologics in early RA: NICE perspectives 

Dr Chris Deighton, Derby Hospitals NHS Trust, Derby 

12.50 Discussion




13.00 - 14.00 Exhibition | Lunch 

13.00 - 14.00 BHPR AGM | Forth Room 

Join your colleagues over lunch and meet BHPR Council members to hear what they have been doing on your 

behalf and how they plan to meet the challenges of the year ahead. Your attendance, which is highly valued, 

automatically enters you into a prize draw for a chance to win free registration to the 2013 conference 

in Birmingham. You will have the chance to network with members of the newly formed rheumatology 

physiotherapy SIG. 

13.00 - 14.00 BSRBR open meeting | Hall 1 

Aim: 

Outcome 1: 

Outcome 2: 

To inform all those wanting to understand the implications of Register research for their practice 

Update the membership on the latest news about the recruitment to the BSR-Biologics Registers and 

the research being conducted with it 

Provide a forum for discussion on all aspects of the registers 

Open to all with an interest in the Biologics Registers, whether as a contributor of patient data or as a researcher 

interested in accessing the data. There will be an update of the latest news on recruitment and research. 

13.00 - 14.00 BHPR Post graduate research student network: a practical guide to post-doctoral career 

progression | Leven Room 

Chairs: Dr Michael Backhouse, University of Leeds, Leeds | Ms Lindsay Hooper, University of Southampton, 

Southampton 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide a coordinated network for early career researchers that facilitates peer group discussion 

and support from a range of leading academics 

Attendees will be able to identify the key steps in developing post-doctoral careers 

Attendees will gain practical tips on developing collaborative networks, managing funding portfolios 

and structuring programs of research 

Attendees will have the opportunity to discuss the lecture content with peers and senior 

academics, facilitating the opportunity to develop their own collaborative links 

13.00 Introduction from the chair 

Dr Michael Backhouse, University of Leeds, Leeds 

13.05 Post-PhD career planning 

Prof Nadine Foster, Keele University, Keele 

13.25 Facilitated group discussion 

Prof Sarah Hewlett and Dr Tessa Sanderson, University of West of England, Bristol




14.00 - 16.00 Jewels in the Crown | Clyde Auditorium 

Chairs: Prof David L Scott, President BSR | Mrs Lindsey Hawley, President BHPR 

14.00 Self determination: the driving force of all paralympians 

Sir Phillip Craven MBE, President of the International Paralympic Committee (IPC) 

14.20 Michael Mason prize winner: Silver standard: measuring treatment effects using observational data 

Dr Kimme Hyrich, University of Manchester, Manchester 

14.40 Garrod Prize winner: The relationship between pregnancy and long-term functional disability in 

women with inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR) 

Mrs Elizabeth Camacho, University of Manchester, Manchester 

15.00 Epidemiology of sporting injuries on elite soccer players: a longitudinal study 

Mr Philip Cooper, MRC Lifecourse Epidemiology Unit, Southampton 

15.20 Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe 

systemic lupus erythematosus (SLE): results from Emblem, a phase IIB study 

Prof Caroline Gordon, University of Birmingham, Birmingham 

15:40 Will I waste your time? Delays in help-seeking for RA flares 

Ms Caroline Flurey, University of the West of England, Bristol 

16.00 - 16.30 Exhibition | Tea and coffee 

16.30 - 17.30 Heberden Round: The new rheumatoid arthritis | Clyde Auditorium 

Chair: Prof David L Scott, President BSR 

Prof Philip Conaghan, Chair of Musculoskeletal Medicine, University of Leeds, Leeds 

17.30 - 17.45 Industry supported symposium catering 

17.45 - 19.15 Industry supported symposium | Forth Room 

Pfizer Inc. 


Dr Patrick Kiely, St George's Healthcare NHS Trust, London 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To deliver an informative and interactive programme on the latest advances in rheumatoid arthritis, focusing 

on how signalling cascades offer opportunities for new treatment targets 

Understand the role of signalling pathways in the pathogenesis of rheumatoid arthritis and their potential as 

therapeutic targets 

Distinguish between differing modes of action of emerging agents targeting signalling pathways currently in 

development for rheumatoid arthritis 

Review the clinical profiles of emerging treatments based on available clinical evidence

Emerging Treatment Directions: 

Signalling Changes in Rheumatoid Arthritis 

Forth Room 

Tuesday 1st May 2012 | 17.45 – 19.15 

Agenda 

Chair’s introduction 

Intracellular signalling pathways – Exploring potential targets 

Targeting intracellular pathways – Examining the clinical perspective 

Interactive panel discussion: A scientific exchange 

Date of preparation: February 2012 

INF001 

This symposium is sponsored 

and funded by Pfizer




Pfizer Inc. 



Dr Patrick Kiely, St George’s Healthcare NHS Trust, London 

17.50 Intracellular signalling pathways: exploring potential targets 

Professor John D Isaacs, Institute of Cellular Medicine, Newcastle University, Newcastle 

18.20 Targeting intracellular pathways: examining the clinical perspective 

Professor Ernest Choy, Institute of Infection and Immunity, Cardiff University, Cardiff 

18.55 Interactive panel discussion: a scientific exchange 

Panel including Prof Peter Taylor, Kennedy Institute of Rheumatology, University of Oxford, Oxford 

19.30 - 21.00 Presidents’ reception 

19.30 - 21.00 | Tuesday 1 May 2012 

Presidents’ Reception | Crowne Plaza Hotel 

The Presidents of BSR and BHPR invite 

all conference attendees to join them for 

a champagne reception at the nearby 

Crowne Plaza Hotel. The perfect opportunity 

to meet and continue your discussions with 

rheumatology colleagues and industry peers 

in a relaxed and informal setting. 

Drinks, canapés and entertainment will be provided 

This event is free to attend for registered delegates. 

This networking event cannot be missed!

Programme 

Wed 2 May 2012 

Programme: 

Wednesday 2 May 2012

A Bristol-Myers Squibb satellite symposium 

Getting it right: optimising 

RA treatment strategies in 

the evolving NHS 

Wednesday 2 May 2012, 07:30–09:00 

Alsh Room, Level 0, SECC, Glasgow, UK 

RHEUMATOLOGY 2012 

Organised and funded by 

Date of preparation: February 2012 427UK12PM007 

Chair: Professor Philip Conaghan, 

University of Leeds, UK 

The new NHS and rheumatology: 

what does the future hold? 

Dr Mark Davies, RES Consortium, Andover, UK 

Is MOA of biologics important when 

choosing an RA treatment? 

Professor Paul Garside, University of Glasgow, UK 

Patient profiling in RA: what do we know? 

Where are we heading? 

Dr Andrew Östör, Addenbrooke’s Hospital, Cambridge, UK 

Tailoring biologic treatment to patient 

profiles in RA 

Dr Rieke Alten, Schlosspark-Klinik, University Medicine Berlin, 

Germany 

Chairman’s closing remarks 

Q&A session 

Breakfast will be provided

Wednesday 2 May 2012 | Programme 33 


Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session | Networking event 

Industry supported symposium | 


07.30 - 09.00 Industry supported symposium: | Alsh Room 

Bristol-Myers Squibb 

Getting it right: optimising RA treatment strategies in the evolving NHS 

Chair: Prof Philip Conaghan, University of Leeds, Leeds 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To educate delegates on how they can tailor biologic treatment choices in rheumatoid arthritis (RA) to deliver 

value both for patients and the NHS, in context of the evolving NHS (QIPP, QoF). To deliver an update on the 

differing mode of actions of biologic therapy, examining whether the different MOAs available offer different 

outcomes for patients. The session will also explore the current theories/research into the RA patient 

profiling, and show how tailoring biologic therapy can offer better outcomes for the patient whilst delivering 

value to the NHS 

Delegates will have a better understanding of how the NHS changes (White Paper, QIPP agenda) could affect 

the role of the rheumatologist and specialist RA services. Highlighting the need for services to be able to 

demonstrate the best outcomes for patients, whilst driving efficiencies 

Delegates will have an update into the current research that is taking place into patient profiles/subtypes in 

RA and how these can be used to deliver better outcomes 

Delegates will understand how using a tailored approach to biologic therapy can improve patient 

outcomes/demonstrate value to the NHS, within the framework of currently available NICE guidance 

07.30 The new NHS and rheumatology: what does the future hold? 

Dr Mark Davies, RES Consortium, Andover 

07.50 Is the mode of action of biologics important when choosing an RA treatment? 

Prof Paul Garside, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow 

08.05 Patient profiling in RA: what do we know? Where are we heading? 

Dr Andrew Östör, Rheumatology Research Unit, Addenbrooke’s Hospital, Cambridge 

08.25 Tailoring biologic treatment to patient profiles in RA 

Dr Rieke Alten, Director of Rheumatology Research Center, Schlosspark-Klinik, 

University Medicine Berlin, Germany 

08.45 Conclusion: To conclude the meeting there will be closing remarks from the Chairperson, followed by a panel 

Q&A to draw conclusions on the session as a whole, whilst giving delegates the opportunity to ask questions of 

each separate session

Symposium – Cellestis GmbH 

Wednesday, May 2 nd , 2012 

Conference Room Boisdale 

7.30 – 9.00 am 

Screening of TB infection in pre TNF-alpha patients. 

How IGRA improves outcomes. 

Chair: Sue Oliver NRAS and RCN, Barnstaple 

Lecture 1: Background to TB incidence and prevalence in UK 

Prof. Peter Davies, Liverpool 

Lecture 2: Latent Tuberculosis Infection (LTBI) Screening in Autoimmune, 

Immunosuppressed Patients 

Prof. Stephan D. Gadola, Southampton 

Lecture 3: Pre-Biologic Screening for Latent Tuberculosis Infection (LTBI) 

in North East England – Data and Case Studies 

Karl Nicholl, Newcastle-Upon-Tyne





07.30 - 09.00 Industry supported symposium: | Boisdale Room 

Cellestis GmbH 

Screening of TB infection in pre TNF-alpha patient. How IGRA improves outcomes 

Chair: Sue Oliver NRAS and RCN, Barnstaple 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide delegates with an overview of the incidence and prevalence of TB and the issues surrounding 

misdiagnosis of latent TB infection in the pre-biologic setting. 

Delegates will be made aware of the incidence and prevalence of TB and LTBI in the UK 

Presented data will highlight the implications of misdiagnosis of LTBI, whilst suggesting some better 

screening practices 

Delegates will be made aware, by supporting data, that screening for LTBI using risk factors as a sole 

method has significant drawbacks 

07.30 Background to TB incidence and prevalence in UK 

Prof Peter Davies, Liverpool and Broadgreen Hospitals, Liverpool 

08.00 Latent tuberculosis infection (LTBI) screening in autoimmune, immune-suppressed patients 

Prof Stephan D Gadola, Southampton University Hospitals, Southampton 

08.30 Pre-biologic screening for latent tuberculosis infection (LTBI) in North East England: data and case studies 

Karl Nicholl, Biologics Nurse Specialist, Freeman Hospital, Newcastle-Upon-Tyne 

09.15 - 10.45 Essentials in rheumatology: disease management | Clyde Auditorium 

A comprehensive update covering everything you need to know about changes in rheumatology 

Chairs: Prof John Axford, St George’s Hospital, London | Dr Charles Mackworth-Young, Charing Cross 


Aim: 

Outcome: 

To prepare rheumatologists for revalidation and provide a valuable educational opportunity for trainees 

Delegates will have been brought up to date on disease management 

09.15 Metabolic bone diseases 

Prof Juliet Compston, University of Cambridge, Cambridge 

09.45 Psoriatic arthritis 

Prof Oliver Fitzgerald, St Vincent’s University Hospital, Dublin 

10.15 Antiphosphlipid syndrome 

Prof Anisur Rahman, UCL, London

36 Programme | Wednesday 2 May 2012 




09.15 - 10.45 Mimickers of myositis and treatment update: room for improvement and lessons from 

neurology | Lomond Auditorium 

Chair: Dr Robert Cooper, Hope Hospital, Manchester 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide delegates with an overview of the issues surrounding misdiagnosis in myositis and an update in 

best practice 

Delegates will be able to identify the key factors in securing a diagnosis of metabolic/mitochondrial myopathy 

or dystrophy and excluding inflammatory myopathy 

Delegates will have a better understanding of the key clinical features in inclusion body myositis, how the 

diagnosis may be missed and current management strategies 

Delegates will receive an update on current best practice in the management of myositis 

09.15 Adult onset metabolic/mitochondrial myopathies and dystrophies: how these cases can be missed 

Dr Mark Roberts, Salford Royal NHS Foundation Trust, Salford 

09.45 Inclusion body myositis and misdiagnosis of polymyositis 

Dr Matt Parton, National Hospital of Neurology and Neurosurgery, London 

10.15 Treatment update and best practice in inflammatory myopathy 

Prof Chester Oddis, Arthritis Institute, Pittsburgh, USA 

09.15 - 10.45 Osteoporosis: topical issues | Hall 1 

Chair: Dr Emma Clark, University of Bristol, Bristol 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide general rheumatologists and trainees with an update on topical issues in osteoporosis 

To understand the association between calcium/vitamin D supplementation and cardiovascular outcomes 

To discuss ways of maximising adherence with bisphosphonates 

To highlight how recent advances in genetics of High Bone Mass could impact on clinical practice 

09.15 Should we stop regular prescribing of calcium/vitamin D supplementation because of the risk of 

adverse cardiovascular outcomes? 

Prof Bo Abrahamsen, University of Southern Denmark, Odense, Denmark 

09.40 Bisphosphonates: what can we do to maximise adherence? 

Prof Rob Horne, University of London, London 

10.05 Causes of high bone mass and the clinical relevance 

Dr Celia Gregson, University of Bristol, Bristol 

10.30 Discussion





09.15 - 10.45 Primary care rheumatology: leading the way | Forth Room 

Chairs: Dr Louise Warburton, NHS Telford and Wrekin, Telford | Ms Melanie Holden, Keele University, Keele 

Outcome 1: 

Outcome 2: 

Outcome 3: 

Delegates will gain an understanding of models of established primary care based musculoskeletal services 

Delegates will have an awareness of the role and contribution of allied health professionals working 

in primary care 

Delegates will explore the implications of commissioning changes for allied health professionals 

09.15 Primary care led rheumatology services 

Dr Jill Firth, Pennine Musculoskeletal Partnership, Oldham 

09:40 Musculoskeletal interface clinics: how physiotherapy has contributed to this model of care 

Mrs Kay Stevenson, Haywood Hospital, Stoke on Trent 

10.05 Business planning for a patient centred rheumatology service 

Mrs Ann Todd, Pennine Musculoskeletal Partnership, Oldham 


09.15 - 10.45 Oral abstracts: RA treatment and outcomes | Dochart Room 

Chair: Dr Andrew Östör, Addenbrooke’s Hospital, Cambridge 

9.15 Validation of JADAS in all subtypes of juvenile idiopathic arthritis (JIA) in the clinical setting 

Dr Flora McErlane, University of Manchester, Manchester 

9.30 Has orthopaedic intervention for RA changed in line with combination and anti-TNF therapies? 

An evaluation of joint surgery rates and prognostic factors in two UK inception cohorts (1986-2011) 

ERAS/ERAN 

Dr Elena Nikiphorou, St Albans City Hospital, St Albans 

9.45 Predicting responses to anti-TNFα therapy in patients with rheumatoid arthritis using metabolomic 

analysis of urine 

Dr Sabrina Kapoor, University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust, 

Birmingham 

10.00 Doubleblind study of Tocilizumab + Methotrexate vs Tocilizumab + placebo in patients with active 

rheumatoid arthritis despite prior Methotrexate: progression of structural damage, quality of life, 

and physical function at 24 weeks 

Prof Philip Conaghen, University of Leeds, Leeds 

10.15 Secukinumab treatment provides sustained response over one year in patients with rheumatoid arthritis 

Dr Patrick Durez, Université Catholique de Louvain, Louvain, Belgium 

10.30 Withdrawal of Adalimumab in early rheumatoid arthritis patients who attained stable low disease activity 

with Adalimumab plus Methotrexate: results of a phase 4, double-blind, placebo-controlled trial 

Prof Paul Emery, Leeds Teaching Hospital, Leeds





09.15 - 10.45 SIG: MSK health in multi ethnic minorities | Morar Room 

Chair: Prof Kuntal Chakravarty, Queens Hospital, Romford 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To develop awareness of health issues in multi ethnic minorities with special emphasis on MSK health 

To understand the global issues on multi ethnic minority health issues 

To develop programmes of research and audit 

To develop strategy of improving the health care with special emphasis on MSK health 

09.15 Global health issues in multi ethnic minority: UK perspective 

Dr Sonya Fernandez, Kent University, Canterbury 

09.45 What research should be done in minority communities and how to publish 

Dr Kamran Abbasi, The Royal Society of Medicine, London 

10.15 Taking patient education into newer immigrant communities 

Ms Chandrika Gordhan, University of Birmingham, Birmingham 

09.15 - 10.45 SIG: Genetics of inflammatory arthritis | Gala Room 

Chair: Prof Anne Barton, University of Manchester, Manchester 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To illustrate how advances in the understanding of the genetic basis of rheumatic diseases may 

impact clinically 

The attendees will understand the role of genetic markers in risk prediction and how this is being 

applied in the clinical setting 

Delegates will appreciate that treatment response is multi-factorial and will understand that genetics, 

environmental, host factors and epigenetics all play a role 

Novel approaches to analysis of outcome will be described with reference to juvenile idiopathic arthritis 

09.15 Using genetics to inform risk prediction in RA 

Dr Sophia Steer, King’s College Hospital, London 

09.35 Predicting treatment response 

Prof Anne Barton, University of Manchester, Manchester 

09.55 The role of epigenetics in prediction of treatment response 

Prof Gerry Wilson, University of Sheffield, Sheffield 

10.15 Translation of genetic studies into prediction of outcome in JIA 

Prof Wendy Thomson, University of Manchester, Manchester 

10.35 Panel discussion





09.15 - 10.45 SIG: Scleroderma | Leven Room 

Chair: Prof Chris Denton, UCL Medical School/Royal Free Hospital 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To discuss some of the challenging areas of management of systemic sclerosis and present consensus 

best practice pathways that have been developed over the past 18 months by scleroderma centres in the 

UK. This is a major initiative of the UK scleroderma study group (UKSSG) that has developed draft 

consensus pathways for digital vasculopathy and for gastrointestinal complications of scleroderma 

(systemic sclerosis) 

Appreciation of multi-disciplinary definition of the domains of major clinical involvement of the 

gastrointestinal tract in scleroderma 

Understanding the interplay between upper and lower limb vasculopathy leading to complications of 

secondary Raynaud’s phenomenon in scleroderma 

Challenges in early detection of systemic sclerosis and appropriate stratification of cases for high intensity 

treatment such as immunosuppression with stem cell rescue 

09.15 Development of expert consensus best practice management for systemic sclerosis: a UK scleroderma 

study group (UKSSG) initiative 

Prof Chris Denton, UCL Medical School/Royal Free Hospital, London 

09.25 Gastrointestinal tract manifestations of systemic sclerosis 

Dr Charles Murray, Royal Free Hospital, London 

09.45 Complications of scleroderma vasculopathy: Raynaud’s phenomenon, digital ulcers and critical digital 

ischaemia 

Prof Ariane Herrick, Salford Royal Hospital and University of Manchester 

10.05 Early diagnosis of scleroderma: prevention rather than treatment. Secondary Raynaud’s and risk 

stratification by autoantibody profile 

Dr John Pauling, Royal National Hospital for Rheumatic Diseases, Bath 


Categories: 

Poster tours: 

Muscle disorders 


Orthopaedics and rehabilitation 



Osteoporosis and metabolic bone disease 

Paediatric and adolescent rheumatology 

Primary care 

Psychology, measurement and management of pain 


Soft tissue and regional musculoskeletal disease, fibromyalgia





11.45 - 13.15 ARMA session | Lomond Auditorium 

Devolution of health: what can we learn? 

Chair: Dr Anthony Redmond, University of Leeds, Leeds 

11.45 Focus on England: Taking forward the MSK networks and an update on commissioning activity 

Mrs Laura Guest, CEO British Society for Rheumatology 

12.15 Focus on Scotland 

Dr Sarah Mitchell, National Programme Manager for the Delivery Framework for Adult Rehabilitation, 

Scottish Government Health Department 

This project has three key work areas: 

1) Multi professional MSK care pathways 

2) A pilot using NHS 24 telephony to provide a national advice triage service to signpost to information 

and local MSK services 

3) Embedding working health services Scotland in all MSK pathways 

12.45 Focus on Wales 

Wales project speaker to be confirmed 

11.45 - 13.15 Rheumatological challenges in primary care | Boisdale Room 

Chair: Dr Elspeth Wise, Encompass Healthcare, Washington 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

Outcome 4: 

To provide delegates with an understanding of difficulties in diagnosing rheumatological conditions and 

associated problems in primary care 

Awareness of how frequently rheumatological problems present in primary care 

Understanding of how to diagnose early inflammatory arthritis in primary care 

Increased knowledge of co-morbidity associated with polymyalgia rheumatica 

Understanding of how to differentiate inflammatory back pain from other causes of low back pain in 

primary care 

11.45 What musculoskeletal problems does the average GP see? 

Dr Mark Porcheret, Arthritis Research UK Primary Care Centre, Keele 

12.00 How to better diagnose early inflammatory arthritis in primary care 

Dr Karim Raza, University of Birmingham, Birmingham 

12.25 Polymyalgia rheumatica: more than just shoulder pain 

Prof Christian Mallen, Arthritis Research UK Primary Care Centre, Keele 

12.50 Seeing the wood for the trees: diagnosing inflammatory back pain in primary care 

Prof Ingemar Petersson, Skane University Hospital, Lund, Sweden





11.45 - 13.15 Essentials in rheumatology: symptom diagnosis and management | Clyde Auditorium 




Aim: 

Outcome: 


Delegates will have had the opportunity to discuss symptom diagnosis 

11.45 Ocular manifestations of rheumatological disorders 

Mr Carlos Pavesio, Moorfields Eye Hospital, London 

12:15 Is there infection? Arthritis, bones and prosthetics 

Prof Tony Berendt, Nuffield Orthopaedic Centre, Oxford 

12.45 Improving patient management: what do patients want? 

Prof Sir Gordon Duff, University of Sheffield, Sheffield 

11.45 - 13.15 BHPR plenary orals | Hall 1 

Chair: Dr Richard Rees, St Mary’s Hospital, London I Mr Robert Field, Dorset HealthCare University 

Foundation Trust, Dorset 

11.45 The impact of pain on successful ageing 

Dr Ross Wilkie, Keele University, Keele 

12.00 Forefoot bursae are a prognostic indicator of disabling foot complications in patients with RA: results of 

a prospective three-year study 

Ms Lindsey Hooper, University of Southhampton, Southampton 

12.15 The continuing professional development for health professionals working within musculoskeletal 

services: a national UK survey 

Dr Jo Adams, University of Southampton, Southampton 

12.30 Debridement of painful forefoot plantar callosities in rheumatoid arthritis: the CARROT randomised 

controlled trial 

Mrs Heidi Siddle, University of Leeds, Leeds 

12.45 Psychological well-being in early rheumatoid arthritis: findings from the early rheumatoid arthritis 

network (ERAN) 

Dr S Norton, University of Cambridge, Cambridge 

13.00 Health professionals’ perceptions of the effects of exercise on joint health in rheumatoid arthritis (RA) 

patients II: a follow-up focus group study 

Ms Serena Halls, Bangor University, Cardiff





11.45 - 13.15 Oral abstracts: connective tissue diseases | Alsh Room 

Chair: Dr Betty Diamond, Feinstein Institute Medical Research, New York, USA 

11.45 Variability in the phenotype of metabolic syndrome over time in a multicentre international inception cohort 

of patients with SLE 

Dr Ben Parker, University of Manchester, Manchester 

12.00 Nitrated nucleosome levels in patients with systemic lupus erythematosus: associations with ethnicity, 

autoantibody status and disease activity 

Dr Sara Croca, University College London, London 

12.15 Is there an association between Warfarin and survival in SSC-PAH patients treated with first line 

bosentan monotherapy? 

Dr Clare Warrell, Royal Free Hampstead NHS Trust, London 

12.30 ANTI-EIF2 is associated with interstitial lung disease in patients with systemic sclerosis 

Dr Zoe Betteridge, Royal National Hospital for Rheumatic Diseases, Bath 

12.45 Optical coherence tomography validation: a new quantitative imaging biomarker for affected skin in 

scleroderma 

Dr Giuseppina Abignano, Leeds Institute of Molecular Medicine, Leeds 

13.00 The clinical relevance of ANTI-RO52 and ANTI-RO60 in patients in the United Kingdom primary Sjögren’s 

syndrome registry (UKPSSR) 

Dr Josephine Vila, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Sunderland 

11.45 - 13.15 SIG: Vasculitis | Forth Room 

Chairs: Prof Raashid Luqmani, University of Oxford, Oxford | Dr Chetan Mukhtyar, Norfolk and Norwich University 

Hospitals, Norwich 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide an update on current areas of research in systemic vasculitis, emphasising the potential 

for attendees to take an active role 

To gain an understanding of the diverse research projects curently conducted in systemic vasculitis 

To understand the evidence base for current management in systemic vasculitis (including emerging 

diagnostic tests and therapeutics) 

To enable attendees to take an active role in vasculitis studies now and in the future 

11.45 Quality of life in ANCA associated vasculitis (VASQoL study findings) 

Dr Neil Basu, University of Aberdeen, Aberdeen 

12.00 Update on developing diagnostic and classification criteria in systemic vasculitis (DCVAS)/ 

Update on the temporal artery biopsy vs ultrasound study (TABUL) 

Dr Joanna Robson and Prof Raashid Luqmani, University of Oxford, Oxford 

12.15 Use of the General Practice Research database in vasculitis: focus on aortic aneurysm risk in GCA 

Prof Nigel Arden, University of Oxford, Oxford 

12.30 European Vasculitis Study Group (EUVAS) therapeutic trials in vasculitis where have we got to and where 

are we going? 

Dr David Jayne, Addenbrooke’s Hospital, Cambridge, 

12.45 Genome wide association studies in ANCA associated vasculitis 

Dr Richard Watts, University of East Anglia, Ipswich 






11.45 - 13.15 SIG: Paediatric and adolescent rheumatology | Gala Room 

Chairs: Dr Clare Pain, Alder Hey Hospital, Liverpool I Dr Alison Jordan, University Hopsitals 

Birmingham, Birmingham 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To focus on the changing role of paediatric and adult rheumatologists in the care of young people, 

including discussion of the drivers and barriers for change and consumer involvement 

Delegates will have discussed how we ensure adult services provide rheumatologists with appropriate 

skills and experience to take on the care of young people 

Delegates will have addressed how we engage young people / consumers in their care and 

involving them in research 

Delegates will have fedback on what they would like the paediatric and adolescent SIG to achieve in the future 

11.45 Standards of care for children and young people with JIA 

Dr Eileen Baildam, Alder Hey Hospital, Liverpool 

12.10 Adolescent training Issues and RCP involvement 

Dr Rachel Tatterall, Sheffield Teaching Hospitals NHS Trust, Sheffield 

12.35 Involving young people in rheumatology research 

Dr Janet McDonagh, Birmingham Children’s Hospital, Birmingham 



13.15 - 14.45 BSR AGM | Dochart Room 

Join your colleagues over lunch and meet the Trustees and committee members of your society. Hear what they 

have been doing on your behalf and how they plan to meet the challenges of the year ahead. Your attendance 

is highly valued and lunch will be provided 

13.15 - 14.45 How to get your abstract published | Leven Room 

Chair: Ms Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide delegates with the tools to submit a quality abstract submission 

Delegates will understand the key issues surrounding a quality abstract submission 

Delegates will be able to critically analyse an abstract submission with a view to improving the quality 

Delegates will be able to re-formulate an abstract to make a quality submission 

13.15 Abstract review: what the reviewers are looking for in a quality abstract submission 

Ms Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole 

13.30 Group work: critically analyzing 2-3 abstracts 

Ms Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole | Ms Diana Finney, Sussex Community 

NHS Trust, Brighton | Dr Sarah Ryan, Haywood Hospital, Stoke on Trent





14.45 - 16.15 Current thinking on conservative management of back pain | Hall 1 

Chairs: Mrs Sue Gurden, Aneurin Bevan Health Board, Abergavenny | Prof Nadine Foster, Keele 

University, Keele 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To update delegates on current thinking on low back pain management 

Delegates will have an increased knowledge of tools available to aid treatment selection in low back pain 

in the clinic 

Delegates will have an increased knowledge of health economics and it’s clinical application in treatment 

selection and service delivery in low back pain 

Delegates will have an increased knowledge of the influence of patient’s and practitioner’s health beliefs 

on rehabilitation in low back pain 

14.45 Can we choose the best treatment for back pain patients? 

Dr Jonathan Hill, Keele University, Keele 

15.05 Are back pain treatments cost-effective? What clinicians need to know about health economics 

Dr Duncan Critchley, King’s College London, London 

15.25 Low back pain in primary care 

Prof Martin Underwood, University of Warwick, Coventry 

15:45 The direct and indirect impact of health beliefs in low back pain on outcomes 

Dr Tamar Pincus, University of London, Egham 

14.45 - 16.15 IRS | Essentials in rheumatology: Keeping up to date, clinical decision making - what is the 

evidence? | Clyde Auditorium 




Put your clinical decision making to the test using interactive voting keypads 

Aim: 

Outcome: 


Delegates will have had their clinical decision making skills tested 

14.45 Ankylosing spondylitis 

Prof Roger Sturrock, Glasgow Royal Infirmary, Glasgow 

15.30 Vasculitis 

Dr David Jayne, Addenbrookes Hospital, Cambridge





14.45 - 16.15 Juvenile-onset SLE and childhood scleroderma: new insights into pathology, treatment and 

outcomes | Forth Room 

Chairs: Dr Jacqui Clinch, University of Bath, Bath | Prof David Isenberg, UCL, London 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

Gain insight into recent developments in the diagnosis, treatment and research domains in childhood SLE 

and scleroderma 

Improved knowledge concerning SLE in the developing child/adolescent 

Understand importance of optimal control of childhood lupus, particularly in relation to long term outcome 

as adults 

Improved understanding of childhood scleroderma, and impact of this disease in adult rheumatology 

practice 

14.45 What is the natural history of scleroderma with its onset in childhood? 

Dr Eileen Baildam, Alder Hey Children’s NHS Foundation Trust, Liverpool 

15.10 Why is it important to know about lupus in children? 

Prof Michael Beresford, University of Liverpool, Liverpool 

15.35 Improving and optimising long term outcomes of patients with juvenile-onset SLE 

Dr Clarissa Pilkington, Great Ormond Street Hospital, London 

16.00 Panel discussion 

14.45 - 16.15 Recent advances in osteoarthritis therapy | Lomond Auditorium 

Chairs: Prof Philip Conaghan, University of Leeds, Leeds | Dr George Peat, Keele University, Keele 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide delegates with a state of the art update on the clinical management and structural 

modification of OA 

Understand the varying effectiveness of mechanical interventions in the clinical management and 

structural modification of lower limb OA 

Understand the therapeutic role and effectiveness of structural modifying drugs in OA 

Gain understanding of joint distraction as a method of tissue modification in OA 

14.45 Mechanical effectiveness of foot orthoses in foot osteoarthritis 

Mrs Jill Halstead, University of Leeds, Leeds 

15.05 Varying effectiveness of mechanical interventions in knee OA 

Dr Richard Jones, University of Salford, Salford 

15.25 Tissue structure modification in late stage osteoarthritis is feasible 

Prof Floris Lafeber, University Medical Center Utrecht, Utrecht, The Netherlands 

15.45 The role of strontium ranelate in the treatment of osteoarthritis 

Prof Cyrus Cooper, Southampton General Hospital, Southampton





14.45 - 16.15 Oral abstracts: Primary Care | Alsh Room 

Chair: Dr Louise Warburton, NHS Telford and Wrekin, Telford 

14.45 Audit to assess GP awareness and documentation of biologic and DMARD drugs in primary care patient 

records 

Dr Charlotte Goodhead, Queen Elizabeth Hospital Gateshead, Gateshead 

15.00 The MRC physiodirect trial: a pragmatic randomised controlled trial of ‘physiodirect’ telephone 

assessment and advice services versus usual care for musculoskeletal problems 

Dr Annette Bishop, Keele University, Keele 

15.15 Frequency of musculoskeletal symptoms and presenting complaints in video observed primary care 

consultations with patients aged 45 and over 

Dr Zoe Paskins, Arthritis Research UK Primary Care Centre, Keele 

15.30 Deciding to consult the general practitioner for symptomatic osteoarthritis: a choice-based conjoint 

analysis study 

Ms Domenica Coxon, Keele University, Keele 

15.45 Are rheumatoid arthritis patients screened for cardiovascular disease in primary care? 

Ms Helen Monk, Keele University, Keele 

16.00 Gout, allopurinol and erectile dysfunction: an epidemiological study in a primary care 

consultation database 

Dr Edward Roddy, Arthritis Research UK Primary Care Centre, Stoke on Trent 

14.45 - 16.15 SIG: Heritable disorders of connective tissue | Boisdale Room 

Chair: Prof Howard Bird, University of Leeds, Leeds 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To equip rheumatology clinicians with knowledge and understanding of the impact of chronic pain in 

EDS/JHS and the evidence base for its alleviation by physical and cognitive interventions 

Delegates will acquire a greater appreciation of the multi-systemic nature of EDS/JHS, including chronic 

pain, dysautonomia and gastrointestinal dysmotility 

Delegates will be able to offer a multidisciplinary strategy for the rehabilitation of patients with severe 

deconditioning, reduced mobility and independence 

Delegates will acquire a greater familiarity with new developments in relevant therapeutic modalities in 

the published literature 

14.45 Hypermobility, fibromyalgia and chronic pain 

Dr Alan Hakim, Whipps Cross Hospital, London 

15.05 Medical rehabilitation and pain control 

Dr Helen Cohen, Royal National Orthopaedic Hospital, Stanmore 

15.25 Physical rehabilitation: role of physiotherapy/OT 

Rosemary Keer, Hospital of St John and St Elizabeth’s, London 

15.45 Cognitive interventions in EDS/JHS and chronic pain 

Dr Clare Daniel, UCLH, London 






14.45 - 16.15 BHPR SIG: Rheumatoid arthritis | Gala Room 

Chair: Ms Janet Cushnaghan, Southampton General Hospital, Southampton 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To hold a session on rheumatoid arthritis of interest to BHPR and BSR members. Topics to be covered are 

tocilizumab therapy and early arthritis 

Delegates will learn new information on tocilizumab therapy 

Delegates will learn about the delays to presentation and treatment in RA 

Delegates will have an opportunity to ask questions and participate in discussion on the topics presented 

14.45 Tocilizumab: all you need to know 

Sandra Robinson, Senior Research Nurse, Newcastle Upon Tyne 

15.15 Early management: are we meeting NICE guidelines? 

Dr Peter Prouse, Basingstoke and North Hampshire Hospital 

15.45 Delay in presenting as a patient: the reasons why 

Dr Rebecca Stack, Sandwell and West Birmingham Hospitals NHS Trust 

16.15 - 16.45 Exhibition | Tea and coffee 

16.45 - 17.45 Heberden Oration | Clyde Auditorium 

Lessons in rheumatology from extreme phenotypes and subtle genotypes 

Chair: Prof David L Scott, President BSR 

Prof Paul Wordsworth, Professor of Rheumatology and Consultant Rheumatologist, Nuffield Department 

of Orthopaedics, Rheumatology and Musculoskeletal Sciences 

‘A highly professional event, made me proud to 

be part of this speciality’ Delegate 2011





17.45 - 18.00 Industry supported symposium catering 

18.00 - 19.30 Industry supported symposium: | Forth Room 

Abbott 

The patient at the heart of Treat to Target 

New practical tools to optimise the consultation process 

Chair: Prof Paul Emery, Chapel Allerton Hospital, Leeds 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide delegates with the latest advances in T2T and practical guidance on how best to engage patents 

in T2T to optimise outcomes 

Delegates will be given access to latest advances in T2T, including initiatives that incorporate ultrasound 

and patient audit 

Delegates will better understand the ‘ideal’ target and ‘ideal’ outcomes that are practical to achieve for 

different patients 

Delegates will be provided with a new tool that assists with patient involvement in T2T in the consultation 

process 

18.00 Welcome and introduction 

Prof Paul Emery, Chapel Allerton Hospital, Leeds 

18.05 New initiatives to drive Treat to Target 

Prof Paul Emery, Chapel Allerton Hospital, Leeds 

18.20 Translating clinical targets into realistic personalised goals 

Prof Peter Taylor, University of Oxford, Oxford 

18.50 TRACK to optimise the consultation process 

Dr Andrew Östör, Addenbrooke’s Hospital, Cambridge and Kate Gadsby, Rheumatology Nurse Specialist, 

Derbyshire Royal Infirmary, Derby 

19.15 Question and answer session 

All speakers (facilitated by Prof Paul Emery) 

19.25 Thank you and close 

Prof Paul Emery, Chapel Allerton Hospital, Leeds

CPD accredited 

Treat To Target 

Symposium 

THE PATIENT AT 

THE HEART OF 

TREAT TO TARGET 

New practical tools to optimise 

the consultation process 


18.00-19.30 

(Light refreshments served from 17.45) 

Forth Room 

Chair: Prof. Paul Emery 

Speakers: Prof. Peter Taylor, Dr Andrew Östör and Kate Gadsby 

This Treat to Target initiative is led by the UK Treat to Target Steering 

Committee and funded by Abbott Laboratories 

Date of Preparation: February 2012 AXHUR120178a

ASSESSING THE EVIDENCE: 

the benefits of IL-6R 

inhibition in RA 

Wednesday 2nd May 2012 

Canapés 17.45 

Symposium 18.00–19.30 

Venue Hall 1 

CHAIR: 

Professor Ernest Choy Cardiff University School of Medicine 

SPEAKERS: 

Professor John Isaacs Newcastle University 

Professor Naveed Sattar University of Glasgow 

Professor George Kitas Russell’s Hall Hospital, Dudley 

Professor David Linch University College London 

This symposium is sponsored by Roche Products Ltd 

and Chugai Pharma UK Ltd. 

RCUKACTE00445 February 2012





18.00 - 19.30 Industry supported symposium: | Hall 1 

Roche 

Assessing the evidence: the benefits of IL-6R inhibition in RA 

Chair: Prof Ernest Choy, Cardiff University School of Medicine, Cardiff 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide delegates with an overview of the use of IL-6R inhibition in patients with rheumatoid arthritis 

Delegates will be updated on the latest data on the use of IL-6R inhibition in rheumatoid arthritis 

Delegates will learn about infections and CV risks and their impact on daily practice, and how these risks 

can be managed 

Delegates will have a good understanding of the haematological manifestations relating to rheumatoid 

arthritis and IL-6R inhibition 

18.00 The use of IL-6R inhibition in rheumatoid arthritis 

Prof Ernest Choy, Cardiff University School of Medicine, Cardiff 

18.15 The significance of infection risk and relevant patient management 

Prof John Isaacs, Newcastle University, Newcastle 

18.30 Cardiovascular risk and the role of IL-6 

Prof Naveed Sattar, University of Glasgow, Glasgow 

18.45 Practical management of CV risk in patients with RA 

Professor George Kitas, Russell’s Hall Hospital, Dudley 

19.00 The effects of IL-6 on neutrophils, platelets and anaemia 

Professor David Linch, University College London, London 

19.15 Question and answer session, followed by summary and close 

20.00 - Late Conference dinner and ceilidh 

Join us for our networking dinner. Enjoy an unforgettable evening of traditional Scottish food, drink and 

entertainment at Òran Mór, which appropriately means the ‘great melody of life’ 

The evening will begin at 20.00 and tickets are only £40 (inc VAT).

We encourage your use of social media 

in and around Rheumatology 2012 


⧣Rheum2012 

Search on Twitter for the hashtag #Rheum2012 to 

follow the feed of tweets related to the conference 

and include #Rheum2012 in any tweets 

that you send out. 

• Converse with other attendees 

• Suggest sessions to attend and posters to visit 

• Plan to meet up in the Exhibition or at the 

social events 

• Provide helpful feedback to BSR staff and make 

suggestions for next year’s meeting 




Programme: 


Programme 

Thu 3 May 2012

New developments 

in spondyloarthritis 

Diagnosis, management and 

clinical advances in axial SpA 

Thursday 3rd May 2012, 

7:30 – 9:00am 

Forth Room 

Rheumatology 2012, 

SECC, Glasgow 

Chair 

Prof Paul Wordsworth 

Speakers 

Dr Helena Marzo-Ortega 

Dr Alex Bennett 

Prof Désirée van der Heijde 

This symposium is organised and funded by Abbott Laboratories. 

Date of preparation: February 2012. AXHUR120167p

Thursday 3 May 2012 | Programme 53 


Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group 


07.30 - 09.00 Industry supported symposium: | Forth Room 

Abbott 

Abbott Axial SpA symposium 

New developments in spondyloarthritis: diagnosis, management and clinical advances in axial SpA 

Prof Paul Wordsworth, Botnar Research Centre, Oxford 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide diagnosis, management, and treatment guidance for axial spondyloarthritis (SpA) 

Delegates should be able to recognise distinguishing factors and classification criteria attributed to axial SpA 

Delegates should be able to recognise the assessment capabilities of using whole spine MRI and the 

advantages of adding this to classification process 

Delegates should be aware of new research advances relating to the management of axial SpA 

07.30 Welcome and introduction 


07.40 The concept of axial SpA 

Dr Helena Marzo Ortega, Leeds Musculoskeletal Biomedical Research Unit, Leeds 

08.00 MRI for diagnosis and prognosis of SpA 

Dr Alex Bennett, Defence Medical Rehabilitation Centre, Epsom 

08.20 New evidence for anti-TNF treatment in patients with axial SpA 

Prof Désirée van der Heidje, Leiden University Medical Centre, The Netherlands 

08.40 Question and answer 

Panel 

08.55 Summary and close 


07.30 - 09.00 SIG: Myositis | Leven Room 

Chair: Dr Hector Chinoy, Dr Hector Chinoy, University of Manchester, Manchester 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide an update on pertinent issues in myositis and upcoming research/clinical activities 

To discuss the latest investigations used in the diagnosis and differential diagnosis of myositis 

To discuss current controversies in the management of inflammatory myositis 

To gain an understanding of the research topics undertaken through UKMYONET 

07.30 Update on Arthritis Research UK Clinical Studies Group involvement in CTDs 

Professor David Isenberg, UCL, London 

07.45 Update on antibody testing in inflammatory myopathy 

Prof Neil McHugh, Royal National Hospital for Rheumatic Disease, Bath | Dr Harsha Gunawardena, 

North Bristol NHS Trust, Bristol 

08.00 Standardisation of histopathological testing in myositis 

Dr Patrick Gordon, King’s College Hospital, London

54 Programme | Thursday 3 May 2012 



SIG: Myositis (cont) | Leven Room 

08.15 Treatment issues in myositis: case presentations and discussion 

Dr Chris Edwards, Southampton University Hospitals NHS Trust, Southampton 

08.30 Genome wide association studies in inflammatory myopathy and UK MYONET genetic study 

Prof Robert Cooper, Salford Royal NHS Foundation Trust, Salford 


09.00 - 10.30 Molecular mechanisms of disease: osteoarthritis | Dochart Room 

Chair: Dr Tonia Vincent, Imperial College London, London 

Aim: 

Outcome 1: 

Outcome 2: 

To give attendees an overview and understanding of key issues in the molecular mechanisms of osteoarthritis 

Delegates will be aware of current dogma of molecular pathogenesis in osteoarthritis 

Delegates will be aware of novel laboratory research in osteoarthritis 

09.00 Keynote talk on osteoarthritis 

Dr Tonia Vincent, Imperial College London, London 

09.10 Identification of novel osteoarthritis genes using Zebrafish 

Dr Chrissy Hammond, University of Bristol, Bristol 

09.30 Is adrenomedullin a potential therapeutic for osteoarthritis while its truncated peptide 22-52 acts as a 

pro degenerative factor? 

Dr Frédéric Velard, Lariboisière Hospital, Paris, France 

09.50 Investigation of the role of UFM1 specific peptidase 2 in Beukes hip dysplasia 

Mr Michal Dudek, University of Manchester, Manchester 

10.10 Cannabidiol blocks the inhibitory effects of the GPR55 agonist L-alpha-lysophosphatidylinositol on 

mechanosensitive knee joint afferents 

Mr Kenneth Paton, University of Nottingham, Nottingham 

09.00 - 10.30 Optimising therapy for rheumatoid arthritis | Clyde Auditorium 

Chairs: Dr Maya Buch, University of Leeds, Leeds | Prof Michael Ehrenstein, UCL, London 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

Provide an update on new therapies in RA and how to more effectively use existing therapies to 

achieve remission 

Understand the principles of treat to target in RA 

Appreciate how new therapies will fit into the current treatment pathway for RA 

Update on the challenges and treatment of extrarticular manifestations of RA 

09.00 Achieving tight control in RA 

Prof Ronald Van Vollenhoven, Karolinska University Hospital, Stockholm, Sweden 

09.25 New therapies for RA: is there room? 

Dr Maya Buch, University of Leeds, Leeds 

09.50 Extra-articular complications in RA: impact of biologic therapies and unmet patient need 

Prof Ian Bruce, University of Manchester, Manchester 





09.00 - 10.30 Pain and motor function: mechanisms and treatment approaches | Lomond Auditorium 

Chairs: Prof Mike Hurley, St George’s University of London, London | Prof Jackie Campbell, University of 

Northampton, Northampton 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To explain how pain interacts at the cortical and peripheral level with the sensorimotor system and 

how therapies can be targeted to improve musculoskeletal pain using osteoarthritis as a model 

Delegates will have a greater understanding of how chronic musculoskeletal pain interacts and 

changes peripheral and central motor control systems 

They will understand how these changes in function can be identified and explored in the clinical 

research setting 

Delegates will have a greater understanding of how therapies can be designed to reduce pain and 

improve function in the community setting 

09.00 Keeping control of function in the presence of pain: how does the brain cope? 

Prof Candy McCabe, Royal National Hospital for Rheumatic Diseases, Bath and University of the West 

of England, Bath 

09.25 Changes in sensorimotor behavior with pain and how to monitor these in a movement analysis laboratory 

Prof Charlotte Häger, Umeå University, Umeå, Sweden 

09.50 Developing effective and affordable community based interventions to improve osteoarthritic pain 

Dr Nicola Walsh, University of the West of England, Bristol 


09.00 - 10.30 IRS |Interactive quiz and clinical teaching | Hall 1 

Chairs: Dr Ben Parker, University of Manchester, Manchester | Dr Sonia Panchal, University Hospital of 

Leicester NHS Trust, Leicester 

Aim: 

Outcome 1: 

Outcome 2: 

To review and update clinical teaching of spondyloarthropathies using interactive voting pads to 

encourage participation 

To review the spondyloarthropathies 

To update clinical teaching 

09.00 Psoriatic arthritis 

Dr Philip Helliwell, University of Leeds, Leeds 

09:45 Ankylosing spondylitis 

Dr Andrew Keat, Northwick Park Hospital, Harrow




09.00 - 10.30 Oral abstracts: Epidemiology and outcomes | Alsh Room 

Prof Gary Macfarlane, University of Aberdeen, Aberdeen I Dr Hoda Mijafari, University of Manchester, 

Manchester 

9.00 The risk of solid cancer in patients receiving anti-tumour necrosis factor therapy for rheumatoid arthritis: 

results from the British Society for Rheumatology Biologics Register 

Dr Louise Mercer, University of Manchester, Manchester 

9.15 Systemic rheumatoid vasculitis in the biologic era 

Dr Eleana Ntatsaki, Norfolk and Norwich University Hospital, Norwich 

9.30 Incidence of rheumatoid arthritis in the UK using the 2010 ACR/EULAR classification criteria; and 

comparison with estimates using the 1987 ACR criteria 

Dr Jennifer Humphreys, University of Manchester, Manchester 

9.45 Smoking and rheumatoid factor status in predicting responses to biologics 

Dr Abdul Khan, King’s College Hospital, London 

10.00 Breast is best. Lifecourse influences on the development of knee osteophytes: the Newcastle thousand 

families study 

Dr Ajay Abraham, Newcastle University, Newcastle upon Tyne 

10.15 Association of systemic sclerosis with different autoantibody subgroups and malignancies: a retrospective 

registry-based UK cohort study 

Dr Pia Moinzadeh, Royal Free Hospital, London 

09.00 - 10.30 SIG: Sjögren’s syndrome | Boisdale Room 1 

Chair: Dr Simon Bowman, University Hospitals Birmingham, Birmingham | Dr Elisabeth Price, Great Western 

Hospital, Marlborough Road, Swindon 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To review recent advances in oral diagnosis and ocular diagnosis, treatment and research in Sjögren’s 

syndrome. To review current ongoing clinical research in Sjögren’s syndrome and discuss new initiatives 

Participants will have updated their knowledge on the oral and ocular manifestations of Sjögren’s 

syndrome 

Participants will have been brought up to date on current research and current and future treatments 

Participants will have received an update on the current multicentre studies 

09.00 Sjögren’s: oral perspectives 

Dr Gill Smith, Department of Oral Medicine at the Dental Hospital, Glasgow 

09.20 Sjögren’s: the ophthalmology perspective 

Mr Sanjay Mantry and Dr Ramesh Arora, General Hospital, Glasgow 

09.40 Update on TRACTISS 

Dr Simon Bowman, Queen Elizabeth Medical Centre, Birmingham 

10.00 Update on UKPSSRS and future directions for Sjögren’s research 

Dr Fai Ng, Newcastle University, Newcastle upon Tyne 





09.00 - 10.30 SIG: MSK ultrasound | Boisdale Room 2 

Chair: Dr Cristina Estrach, Aintree Hospital, Liverpool 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide a platform to discuss and share research and training topics to further advance and promote 

musculoskeletal ultrasound in rheumatology 

Attendees will learn about new training developments 

Attendees will be updated in the latest research and direction of ultrasound in rheumatology 

Attendees will have the opportunity to discuss and share local and national initiatives and projects 

09.00 SIG update 

Dr Cristina Estrach, Aintree University Hospitals NHS Foundation Trust, Liverpool 

Training developments: 

09.15 Update Anatomy course 

Dr David Wright, City Hospital Sunderland, Sunderland 

09.25 West Midlands training project 

Dr Rainer Klocke, Dudley Hospitals, Dudley 

09.35 The Scottish training programme 

Dr Anna Ciechomska, Inverclyde Royal Hospital, Greenock 

09.45 The Yorkshire training programme 

Dr Zunaid Karim, Pinderfields General Hospital, Wakefield 

10.00 Where are we going with ultrasound? 

Prof Peter Taylor, Kennedy Institute, Oxford 

10.20 Questions and discussion 


Categories: 

Poster tours: 

Basic science 

Basic science 

Biology of bone, cartilage and connective tissue disease Connective tissue diseases 

Case reports 

Cell receptor-ligand interaction, signalling, activation and apoptosis 

Cytokines and inflammatory mediators 

Education research 

Epidemiology 

Genetics 

Health services research, economics and outcomes research 

Rheumatoid arthritis: aetiopathogenesis and animal models 

Sjögren’s syndrome and other connective tissue disorders 

SLE and antiphospholipid syndrome 

Vasculitis




11.30 - 13.00 Advances in psoriatic arthritis | Clyde Auditorium 

Chairs: Prof Costantino Pitzalis, Barts and The London School of Medicine, London | Prof Roger Sturrock, 

University of Glasgow, Glasgow 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To learn about psoriatic arthritis, from pathogenesis to novel therapies 

Gain insights on how pathogenesis may contribute to diverse subset evolution both from the joint 

and skin prospective 

Understand the issues relating to establishing and running a specialist PsA clinic 

Be informed on the latest therapeutic strategies to treat PsA 

11.30 Advances in pathogenesis: the rheumatology view - what biological processes drive different 

disease expressions in PsA? 

Prof Costantino Pitzalis, Barts and The London School of Medicine, London 

11.50 Advances in pathogenesis: the dermatology view 

Prof Frank Nestle, St John’s Institute of Dermatology, London 

12.10 Establishing a specialist PsA clinic: pitfalls and opportunities to improve patient care 

Prof Neil McHugh, University of Bath, Bath 

12.30 Advances in the treatment of PsA 

Dr Philip Helliwell, University of Leeds, Leeds 

11.30 - 13.00 Ask the experts: myositis | Hall 1 



Aim: 

Outcome 1: 

Outcome 2: 

To discuss the evidence-based approach to myopathies 

To evaluate complex cases of myopathy with specific reference to the current evidence 

To discuss complex cases of myopathy 

11.30 Trainees will present three cases to the experts and experts will present two to three slides 

demonstrating the evidence to support the advice on best practice 

Dr Hector Chinoy, University of Manchester, Manchester | Prof David Isenberg, UCL, London




11.30 - 13.00 Molecular mechanisms of disease: inflammatory arthritis I | Dochart Room 

Chair: Prof Michael Ehrenstein, UCL, London 

Aim: 

Outcome 1: 

Outcome 2: 

To give attendees an overview and understanding of key issues in the molecular mechanisms 

of inflammatory arthritis 

Delegates will be aware of current dogma of molecular pathogenesis in inflammatory arthritis 

Delegates will be aware of novel laboratory research in inflammatory arthritis 

11.30 Keynote talk on inflammatory arthritis 

Prof Michael Ehrenstein, UCL, London 

11.40 ANTI-VCA and EBNA1 antibodies are produced in the rheumatoid synovium in the presence of ectopic 

lymphoid structures and correlates with ACPA production 

Ms Cristina Croia, Queen Mary University of London, London 

12.00 TLR9 induces tolerance to apoptotic cells and is responsible for inducing regulatory B cells 

Dr Mohini Gray, University of Edinburgh, Edinburgh 

12.20 Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with 

heightened T and B cell responses 

Dr Gareth Jones, Cardiff University, Cardiff 

12.40 Anti-TNF antibody therapy, but not TNF receptor blockade, induces IL-17 suppressing regulatory T cells 

Ms Jenny McGovern, University College London, London 

11.30 - 13.00 The management of upper limb dysfunction in people with rheumatoid arthritis | Forth Room 

Chairs: Ms Jenny Ratcliffe, Macclesfield District General Hospital, Macclesfield | Prof Krysia Dziedzic, Keele 

University, Keele 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide an update on the evidence based rehabilitation of upper limb dysfunction in people with 

rheumatoid arthritis (RA) 

Attendees will gain an understanding of recent advances in the rehabilitation of upper limb dysfunction 

in RA 

Attendees will gain an insight into the current surgical management of upper limb dysfunction in RA 

Attendees will gain an understanding of functional outcome measurement of upper limb dysfunction in RA 

11.30 Current surgical management of the rheumatoid hand and wrist: indications and outcomes 

Prof Jagdeep Nanchahal, Imperial College London, London 

11.50 Hand and upper limb function assessment in rheumatoid arthritis 

Mrs Catherine Ball, Imperial College London, London 

12.10 Exercise therapy in the management of upper limb dysfunction in rheumatoid arthritis 

Dr Lindsay Bearne, King’s College London, London 

12:30 The role of upper limb splinting in the management of people with rheumatoid arthritis 

Dr Jo Adams, University of Southampton, Southampton




11.30 - 13.00 Oral abstracts: Education | Alsh Room 

Chair: Dr Lesley Kay, Freeman Hospital, Newcastle upon Tyne 

11.30 NRAS workwise workshops online resources: tools for people with RA to help them remain in the 

workplace/get back to work 

Mrs Clare Jacklin, National Rheumatoid Arthritis Society, Maidenhead 

11.45 Designing virtual patients for musculoskeletal education: a grounded theory qualitative study 

Dr Jes Bateman, University Hospitals Coventry and Warwickshire NHS Trust, Coventry 

12.00 Have you been to Capri? www.capri.scot.nhs.uk early results of a clinic for arthritis patients in remission 

on the internet 

Dr Helen Harris, NHS Fife, Kirkcaldy 

12.15 The evaluation of an arthritis education outreach programme to black and minority ethnic communities 

Mrs Chandrika Gordhan, University of Birmingham, Birmingham 

12.30 Patient experiences, attitudes and expectations towards receiving information about anti-TNF: a 

qualitative study 

Dr Paul Arkell, Keele University, Keele 

12.45 National Rheumatoid Arthritis Society survey: impact of RA on the family 

Mrs Clare Jacklin, National Rheumatoid Arthritis Society, Maidenhead 

11.30 - 13.00 SIG: Osteoporosis | Boisdale Room 1 

Chair: Dr Emma Clarke, University of Bristol, Bristol 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To discuss the management of acute and chronic vertebral fractures for allied health professionals 

To increase knowledge for allied health care professionals, especially nurses, physiotherapist and 

occupational therapists of acute vertebral fracture management. Focusing on pain relief and 

conservative methods of pain relief 

To increase knowledge and awareness of management of chronic vertebral fracture and further 

fracture prevention. Suitable for all allied health professionals including dietician, pharmacists and 

podiatrists 

To discuss the role of allied health care professionals within various fracture liason service models, 

vertebral pain mangement and prevention of further fracture 

11.30 The management of pain and chronic vertebral fracture and role within fracture liaison service 

Cathy Churchman, Weston General Hospital, Weston-super-Mare | Rachel Lewis MCSP, North Bristol NHS 

Trust, Bristol




11.30 - 13.00 SIG: Foot and ankle | Boisdale Room 2 

Chair: Dr Anthony Redmond, University of Leeds, Leeds 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide an update on current developments in the foot and ankle with an emphasis on 

degenerative disorders 

To set out the current areas of research activity in foot and ankle research relating to OA 

To provide a state of the art review of current knowledge 

To provide a forum to identify future research directions and explore collaborations 

11.30 Researching foot osteoarthritis in primary care 

Dr Edward Roddy, Keele University, Keele 

11.45 Foot outcomes from the Chingford cohort study of 1,000 women over 22 years 

Dr Catherine Bowen, University of Southampton, Southampton 

12.00 Foot modeling in degenerative disease and its effect on biomechanical response to interventions 

Dr Richard Jones, University of Salford, Salford 

12.15 Modeling function in barefoot and shod conditions 

Dr Jill Halstead, University of Leeds, Leeds 

12.30 Clinical and biomechanical foot assessments and knee OA in the COASt (Clinical Outcomes in 

knee arthroplasty) study 

Ms Lucy Gates, University of Southampton, Southampton 



13.00 - 14.00 RATS AGM | Hall 1 

Lunch will be provided 

13.00 - 14.00 NICE and NHS Evidence and the information revolution | Forth Room 

Chairs: Dr Michael Backhouse, University of Leeds, Leeds | Prof Martijn Steuitjens, Glasgow Caledonian 

University, Glasgow 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

Outcome 4: 

To demonstrate the key features of NHS Evidence and lead a discussion around further development 

opportunities for the service 

Delegates will be able to see how features of the site work and identify what will be useful to them 

Delegates will be able to discuss any future ideas/developments that could be made around their needs 

Delegates will learn about the practical QIPP examples that are available and learn how to submit 

their own case studies 

Delegates will have more confidence in using the resource in their work around decision-making 

processes 

13.00 Presentation and discussion facilitation 

Dr Gillian Leng, Deputy Chief Executive, NICE




14.00 - 15.30 Rheumatology and the NHS | Hall 1 



Aim: 

Outcome 1: 

To update trainees on political changes in the NHS 

To review the NHS changes as they affect rheumatology and trainees, from both primary and secondary 

care perspectives 

14.00 A year in politics: an update on political influences on rheumatology and its trainees 

Dr Chris Deighton, Derbyshire Royal Infirmary, Derby 

14.45 Changes in the NHS: a rheumatology provider’s perspective 

Dr Alan Nye, Pennine MSK Partnership, Manchester 

14.00 - 15.30 Improving work participation: new developments in reducing work absence for people with 

musculoskeletal conditions | Forth Room 

Chairs: Dr Ross Wilkie, Keele University, Keele | Mrs Victoria Chamberlain, Trafford Hospital Centre 

Manchester Foundation NHS Trust, Manchester 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide delegates with an overview of recent advances in approaches and future plans to reduce 

work absence for people with musculoskeletal conditions 

Attendees have a clear understanding of the importance of supporting people with arthritis / MSDs 

in remaining and returning to work, and of the role of health professionals in this 

Attendees learn about practical tools (e.g. the fit-note) and examples of best practice in supporting 

people with arthritis / MSDs in remaining and returning to work 

Attendees are aware of further developments in policy and practice to reduce work absence 

14.00 What is next for musculoskeletal conditions and work? 

Prof Dame Carol Black, Department for Work and Pensions, London 

14.20 What has the “fit-note” done for us? Reflections on the impact on work absence and disability 

Dr Bill Gunneyon, Department for Work and Pensions, London 

14.40 Rheumatology and work: evolving practice 

Dr David Walker, Freeman Hospital, Newcastle upon Tyne 

15.00 The barriers for returning to work 

Ms Adele Higginbottom, Arthritis Research UK Primary Care Centre, Keele




14.00 - 15.30 Molecular mechanisms of disease: inflammatory arthritis II | Dochart Room 

Chair: to be confirmed 

Aim: 

Outcome 1: 

Outcome 2: 

To give attendees an overview and understanding of key issues in the molecular mechanisms 

of inflammatory arthritis 

Delegates will be aware of current dogma of molecular pathogenesis in inflammatory arthritis 

Delegates will be aware of novel laboratory research in inflammatory arthritis 

14.00 Inhibition of NAMPT (PBEF/Visfatin) decreases the ability of human neutrophils to generate reactive 

oxidants, but does not impair bacterial killing 

Ms Kate Roberts, University of Liverpool, Liverpool 

14.15 Neutrophil microparticles as potential novel effectors of joint disease 

Ms Sarah Headland, Barts and the London School of Medicine and Dentistry, London 

14.30 Resolvin D1 limits PMN recruitment to inflammatory loci: receptor dependent bioactions 

Dr Lucy Norling, Barts and The London Medical School, London 

14.45 The mesenchymal stromal cell marker CD248 regulates inflammatory arthritis and bone formation 

Dr Amy Naylor, University of Birmingham, Birmingham 

15.00 The regulation of arthritic bone erosions by IL-10 

Dr Claire Greenhill, Cardiff University, Cardiff 

15.15 Dual specificity phosphatase 1 is a crucial negative regulator of inflammatory osteolysis and a 

mediator of therapeutic effects of dexamethasone in collagen-induced arthritis 

Ms Youridies Vattakuzhi, Kennedy Institute of Rheumatology, London 

14.00 - 15.30 What’s new in ankylosing spondylitis pathogenesis, assessment and treatment | Clyde Auditorium 

Chairs: Prof Paul Bowness, Nuffield Orthopaedic Centre NHS Trust, Oxford | Dr Jonathan Packham, University 

Hospital of North Staffordshire, Stoke on Trent 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To give attendees an overview of new developments in the genetics, pathogenesis and treatment 

of ankylosing spondylitis 

Delegates will be aware the genetic contribution and pathogenic theories of ankylosing spondylitis 

pathogenesis 

Delegates will be able to describe the new ASA criteria for Axial SpA and the ASDAS 

Delegates will be able to describe the critically evaluate the efficacies of new treatments for 

ankylosing spondylitis 

14.00 Overview of ankylosing spondylitis genetics and pathogenesis 

Prof Paul Bowness, Nuffield Orthopaedic Centre NHS Trust, Oxford 

14.30 What’s new in the clinical assessment of AS? 

Prof Désirée van der Heijde, Leiden University Medical Center, Leiden, The Netherlands 

15.00 New therapies for ankylosing spondylitis, targeting the Th17 pathway? 

Prof Dominique Baeten, University of Amsterdam, Amsterdam, The Netherlands




14.00 - 15.30 Oral abstracts: Genetics | Alsh Room 

Chair: Prof Anne Barton, University of Manchester, Manchester 

14.00 Global gene expression analysis of dedifferentiated chondrocytes 

Mr Alan Mueller, University of Liverpool, Liverpool 

14.15 Largest UK rheumatoid arthritis genome wide association study to date of 8,300 samples strengthens 

confirmed loci and highlights more potential RA genetic risk factors 

Dr Gisela Orozco, University of Manchester, Manchester 

14.30 Fine mapping in over 14,000 rheumatoid arthritis cases and 18,500 controls refine associations to 

known loci, indicate multiple independent affects and reveal novel associations 

Dr Stephen Eyre, The University of Manchester, Manchester 

14.45 Investigation of idiopathic inflammatory myopathy for shared genetic risk factors with other autoimmune 

disorders 

Dr Meghna Jani, Salford Royal NHS Foundation Trust, Manchester 

15.00 Analysis of the immunochip in a large cohort of oligo- and polyarthritis juvenile idiopathic arthritis 

cases confirms previous and identifies novel associations 


15.15 Genome-wide association study of methotrexate response identifies novel genes in a large cohort of 

European juvenile idiopathic arthritis cases 


14.00 - 15.30 SIG: Education | Boisdale Room 1 

Chair: Dr Lesley Kay, Newcastle University, Newcastle Upon Tyne I Prof Andrew Hassell, Keele University School 

of Medicine and Haywood Hospital, Keele 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To provide an update on Arthritis Research UK educational developments over the last 12 months 

Participants will understand (and participate in) the Arthritis Research UK tool for evalution of online 

learning resources 

Participants will be informed of the results of a study of CPD activities among rheumatology nurses 

and allied health professionals 

The opportunity for participants to discuss work in progress: educational developments or research 

14.00 Development of a tool to evaluate online learning resources in rheumatology 

Dr David Walker, Newcastle upon Tyne Hospitals Trust, Newcastle upon Tyne | Dr Tom Margham, 

Arthritis Research UK 

14.40 Informing the educational needs of rheumatology nurses and AHPs: the experiences of people with 

osteoarthritis and rheumatoid arthritis 

Dr Sarah Ryan, Haywood Hospital, Stoke-on-Trent 

15.00 Open forum of educational developments 

Prof Andrew Hassell, Keele University School of Medicine and Haywood Hospital, Keele


14.00 - 15.30 SIG: Osteoarthritis | Boisdale Room 2 

Chair: Dr Fraser Birrell, Newcastle University, Newcastle I Ms Anne Smith, North Tyneside General Hospital, 

North Shields 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

To reflect on achievements of the OA CSG over the first four years and learn from other CSGs in shaping 

future strategy 

Know the strategy, submission and review processes of the Arthritis Research UK OA Clinical Studies Group 

Learn how to become involved in ongoing studies 

Have had the opportunity to network with other researchers and discuss research ideas 

14.00 Introduction and welcome 

Dr Fraser Birrell, Newcastle University, Newcastle upon Tyne 

14.05 Progress of the Inflammatory Arthritis CSG 

Prof John Isaacs, Newcastle University, Newcastle upon Tyne 

14.20 Clinical Studies Group for OA and Related Disorders strategy 

Prof Philip Conaghan, University of Leeds, Leeds 

14.40 Translating ideas into action and results: group work 

Hand OA 

Facilitator: Dr Krysia Dziedzic, Keele University, Keele 

Knee OA 

Facilitator: Dr George Peat, Keele University, Keele 

Hip OA 

Facilitator: Dr Ish Atchia, Northumbria Healthcare, Newcastle upon Tyne 

15.20 Question and answer session 

15.30 - 17.00 SIG: Spondyloarthritis | Carron Room 1 

Chairs: Prof Dennis McGonagle, University of Leeds, Leeds I Dr Raj Sengupta, The Royal National Hospital 

for Rheumatic Diseases, Bath 

Aim: 

Outcome 1: 

Outcome 2: 

Outcome 3: 

Outcome 4: 

To update delegates on the recent advances in the diagnosis and management of spondyloarthritis 

Delegates will participate in a discussion to formulate the key Quality indicators for spondyloarthritis 

Attendees will be able to appreciate the benefits and limitations of using MRI imaging in the diagnosis 

of SpA 

To better understand emergent imaging markers of PsA disease evolution 

To understand the post TNF therapy landscape in PsA 


Prof Dennis McGonagle, University of Leeds, Leeds | Dr Raj Sengupta, The Royal National Hospital for 

Rheumatic Diseases, Bath 

15.40 Quality indicators for SpA in the UK 

Dr Jon Packham, Keele University, Keele 

16.00 Pitfalls with diagnosis in spinal MRI scans 

Dr Alex Bennett, Guys and St Thomas’ Teaching Hospitals, London 

16.20 Emerging cytokines and cytokine signalling molecules as therapeutic targets in psoriasis 

Dr Miriam Witttmann, University of Leeds, Leeds 

16.40 The transition between psoriasis and arthritis: an imaging perspective 

Dr Zoe Ash, University of Leeds, Leeds 

17.00 End of meeting

66 Programme | Thursday 3 May 2012

Oral presentation 

of abstacts 

Oral presentation 

of abstracts

BSR and BHPR oral presentation of abstracts 


1-3 May 2012 | Oral presentation of abtracts 67 

09.00 – 10.30 

Spondyloarthropathies 

1. 

Rheumatology, Royal National Hospital for Rheumatic 

Diseases, Bath, United Kingdom; 2. Pharmacy and 

Pharmacology, University of Bath, Bath, United Kingdom 

O1 

O2 

O3 

O4 

DETECTING AXIAL SPONDYLOARTHRITIS AMONGST 

PRIMARY CARE BACK PAIN REFERRALS 

Claire Harris 1 , Denis Remedios 2 , Tanya Aptowitzer 3 , Andrew 

Keat 1 ; 

1. 

Rheumatology Department, Northwick Park Hospital, Harrow, 

United Kingdom; 2. Radiology Department, Northwick Park 

Hospital, Harrow, United Kingdom; 3. Physiotherapy 

department, Northwick Park Hospital, Harrow, United Kingdom 

VALIDATION OF A SCREENING QUESTIONNAIRE FOR AXIAL 

SPONDYLOARTHRITIS IN A UK POPULATION 

Louise Hamilton 1 , Geoffrey Guile 3 , Abdelghani Belkhiri 2 , 

David Newman 2 , Andoni Toms 2 , Alex Macgregor 1,3 , 

Karl Gaffney 1 ; 

1. 

Rheumatology Department, Norfolk and Norwich University 

Hospital, Norwich, United Kingdom; 2. Radiology Department, 

Norfolk and Norwich University Hospital, Norwich, United 

Kingdom; 3. Norwich Medical School, University of East Anglia, 

Norwich, United Kingdom 

THE PREVALENCE AND BURDEN OF ANKYLOSING 

SPONDYLITIS IN EUROPE: A SYSTEMATIC REVIEW 

Linda Morton 1 , Gareth T. Jones 1 , Alan G. MacDonald 2 , 

Christina Downham 1 , Gary J. Macfarlane 1 ; 

1. 

Aberdeen Musculoskeletal Research Group (Epidemiology), 

University of Aberdeen, Aberdeen, United Kingdom; 

2. 

Department of Rheumatology, Aberdeen Royal Infirmary, 

Aberdeen, United Kingdom 

WORK DISABILITY IN ESTABLISHED PSORIATIC ARTHRITIS: 

A CROSS-SECTIONAL STUDY USING THE WORK 

PRODUCTIVITY ACTIVITY INDEX 

William Tillett 1 , Deepak Jadon 1 , Dinny Wallis 1 , Luisa Costa 1 , 

Nicola Waldron 1 , Nina Griffith 1 , Charlotte Cavill 2 , 

Eleanor Korendowych 1 , Corinne de Vries 2 , Neil McHugh 1,2 ; 

O5 

O6 

INFLUENCE OF LEFLUNOMIDE ON THE LEVELS OF MATRIX 

METALLOPROTEINASE-3 AND PYRIDINOLINE IN PATIENTS 

WITH PSORIATIC ARTHRITIS 

Oleg Iaremenko, Dmytro Fedkov; 

Department of Internal Medicine, National Medical University 

O.O.Bogomolets, Kyiv, Ukraine 

EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB 

IN THE TREATMENT OF PATIENTS WITH MODERATE-TO- 

SEVERE ANKYLOSING SPONDYLITIS 

Paul Emery 1 , Dominique Baeten 2 , Joachim Sieper 3 , Jurgen 

Braun 4 , D. van der Heijde 5 , Iain McInnes 6 , Jaap Van Laar 7 , 

R. Landewe 8 , Bryan P. Wordsworth 9 , Jurgen Wollenhaupt 10 , 

Herbert Kellner 11 , I. Paramarta 2 , Arthur Bertolino 12 

Andrew M. Wright 13 , Wolfgang Hueber 12 ; 

1. 

Department of Medicine, University of Leeds, Leeds, United 

Kingdom; 2. Academic Medical Center, University of 

Amsterdam, Amsterdam, Netherlands; 3. Department of 

Gastroenterology, Charite Campus Benjamin Franklin, Berlin, 

Germany; 4. Department of Medicine, Rheumazentrum 

Ruhrgebiet, Herne, Germany; 5. Department of Rheumatology, 

Leiden University Medical Center, Leiden, Netherlands; 

6. 

Glasgow Biomedical Research Centre, University of Glasgow, 

Glasgow, United Kingdom; 7. Department of Medicine, 

Newcastle University, Newcastle upon Tyne, United Kingdom; 

8. 

Department of Medicine, Maastricht University Medical 

Center, Maastricht, Netherlands; 9. Department of Medicine, 

Nuffield Orthopaedic Centre, Oxford, United Kingdom; 

10. 

Klinik für Rheumatologie, Eilbeck Hospital, Hamburg, 

Germany; 11. Department of Medicine, Center for Inflammatory 

Joint Diseases, Munich, Germany; 12. TM Dermatology, Novartis 

Institutes for BioMedical Research, Basel, Switzerland; 

13. 

M&S Statistics, Novartis Pharma AG, Basel, Switzerland

68 Oral presentation of abtracts | 1-3 May 2012 

O7 

O8 

O9 

11.30 – 13.00 

Imaging 

HAND OSTEOARTHRITIS PAIN HAS PERIPHERAL AND 

CENTRAL COMPONENTS DEMONSTRATED BY ALGOMETER 

SCORES AND FUNCTIONAL MRI 

Nidhi Sofat 1,2 , Cori Smee 2 , Monika Hermansson 2 , 

Julekha Wajed 1 , Kaushik Sanyal 1 , Patrick Kiely 1 , 

Matthew Howard 3 , Franklyn A. Howe 4 , Thomas R. Barrick 4 ; 

1. 

Rheumatology, St George’s, University of London, London, 

United Kingdom; 2. Biomedical Sciences, St George’s, 

University of London, London, United Kingdom; 3. Institute of 

Psychiatry, King’s College London, London, United Kingdom; 

4. 

Clinical Sciences, St George’s, University of London, London, 

United Kingdom 

ULTRASOUND FEATURES OF OSTEOPHYTES AND CARTILAGE 

THICKNESS AT THE KNEE ARE ASSOCIATED WITH PAIN AND 

FUNCTIONAL IMPAIRMENT: THE NEWCASTLE THOUSAND 

FAMILIES STUDY 

Ajay M. Abraham 1 , Mark S. Pearce 1 , Kay D. Mann 1 , 

Roger M. Francis 3 , Fraser Birrell 2 ; 

1. 

Institute of Health and Society, Newcastle University, 

Newcastle upon Tyne, United Kingdom; 2. Musculoskeletal 

Research Group, Institute of Cellular Medicine, Newcastle 

University, Newcastle upon Tyne, United Kingdom; 3. Institute 

for Ageing and Health, Newcastle University, Newcastle upon 

Tyne, United Kingdom 

THE DIAGNOSTIC UTILITY OF SALIVARY GLAND ULTRASOUND 

FOR THE INVESTIGATION OF SJÖGREN’S SYNDROME 

Andrew Carr 1 , Iain Macleod 1 , Wan-Fai Ng 2 ; 

1. 

Dental and Maxillofacial Radiology, Newcastle Dental 

Hospital, Newcastle upon Tyne, United Kingdom; 

2. 

Musculoskeletal Research Group, Institute of Cellular 

Medicine, Faculty of Medical Sciences, Newcastle University, 

Newcastle upon Tyne, United Kingdom 

O10 

O11 

LONG-TERM RADIOGRAPHIC OUTCOME IN PSORIATIC 

ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB: 104 

WEEK RESULTS FROM THE GO-REVEAL STUDY 

Arthur Kavanaugh 1 , Desiree Van de Heide 2 , 

Chandrabhusan Chattopadhyay 3 , Dafna Gladman 4 , 

Philip Mease 5 , Iain McInnes 6 , Gerald Krueger 7 , Weichun Xu 8 , 

Neil Goldstein 8 , Anna Beutler 8 ; 

1. 

Immunology, University of California, San Diego, San Diego, 

California, United States of America; 2. Rheumatology, Leiden 

University Medical Center, Leiden, Netherlands; 

3. 

Rheumatology, Wrightington Hospital, Wigan, United 

Kingdom; 4. Rheumatology, Toronto Western Hospital, Toronto, 

Ontario, Canada; 5. Rheumatology, Swedish Medical Center/ 

University of Washington, Seattle, Washington, United States 

of America; 6. Rheumatology, University of Glasgow, Glasgow, 

United Kingdom; 7. Dermatology, University of Utah Health 

Sciences Center, Salt Lake City, Utah, United States of 

America; 8. Immunology, Janssen Research and Development, 

Inc, Malvern, Pennsylvania, United States of America 

EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL 

INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE 

IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS 

Jaap Van Laar 1 , Xenofon Baraliakos 2 , Jurgen Braun 2 , 

Didier D. Laurent 3 , Dominique Baeten 4 , D. van der Heijde 5 , 

Joachim Sieper 6 , Paul Emery 7 , Iain McInnes 8 , R. Landewe 9 , 

Bryan P. Wordsworth 10 , Jürgen Wollenhaupt 11 , 

Herbert Kellner 12 , Andrew M. Wright 13 , Sandro Gsteiger 13 , 

Wolfgang Hueber 3 ; 

1. 

Department of Medicine, Newcastle University, Newcastle 

upon Tyne, United Kingdom; 2. Department of Medicine, 

Rheumazentrum Ruhrgebiet, Herne, Germany; 3. Translational 

Medicine Dermatology, Novartis Institutes for BioMedical 

Research, Basel, Switzerland; 4. Academic Medical Center, 

University of Amsterdam, Amsterdam, Netherlands; 

5. 

Department of Rheumatology, Leiden University Medical 

Center, Leiden, Netherlands; 6. Department of 

Gastroenterology, Charitè Campus Benjamin Franklin, Berlin, 

Germany; 7. Department of Medicine, University of Leeds, 

Leeds, United Kingdom; 8. Glasgow Biomedical Research 

Centre, University of Glasgow, Glasgow, United Kingdom; 

9. 

Department of Medicine, Maastricht University Medical 

Center, Maastricht, Netherlands; 10. Department of Medicine, 

Nuffield Orthopaedic Centre, Oxford, United Kingdom; 11. Klinik 

für Rheumatologie, Eilbeck Hospital, Hamburg, Germany; 

12. 

Department of Medicine, Center for Inflammatory Joint 

Diseases, Munich, Germany; 13. M&S Statistics, Novartis 

Pharma AG, Basel, Switzerland


O12 

TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION 

WITH METHOTREXATE ASSOCIATED WITH EARLY 

REDUCTIONS IN TISSUE INFLAMMATION: 12 WEEK 

RESULTS FROM A MAGNETIC RESONANCE IMAGING 

SUBSTUDY OF A RANDOMIZED CONTROLLED TRIAL 

Philip G. Conaghan 1 , Charles G. Peterfy 2 , Julie DiCarlo 2 , 

Ewa Olech 3 , Alan R. Alberts 4 , Jeffrey A. Alper 5 , 

Jenny Devenport 6 , Andrew M. Anisfeld 6 ,Orrin M. Troum 7 

1. 

NIHR-Leeds Biomedical Research Unit and Leeds Institute of 

Molecular Medicine, University of Leeds, Leeds, United 

Kingdom 2. Spire Sciences LLC, San Francisco, CA, USA, 

3. 

Oklahoma Medical Research Foundation, Oklahoma City, OK, 

USA, 4. West Broward Rheumatology Associates, Inc., Tamarac, 

FL, USA, 5. Jeffrey Alper MD Research, Naples, FL, USA, 

6. 

Genentech, South San Francisco, CA, 7. USC Keck School of 

Medicine, Santa Monica, CA, USA 

PA2 

EPRATUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL 

IMPROVEMENTS IN PATIENTS WITH MODERATE-TO-SEVERE 

SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM 

EMBLEM, A PHASE IIB STUDY 

Caroline Gordon 1 , K. Kalunian 2 , M. Petri 3 , V. Strand 4 , 

B. Kilgallen 5 , A. Barry 5 , D. Wallace 6 ; 

1. 

Rheumatology, University of Birmingham, Birmingham, 

United Kingdom; 2. University of California, San Diego, School 

of Medicine, La Jolla, California, United States of America; 

3. 

Medicine, The John Hopkins University, Baltimore, Maryland, 

United States of America; 4. Division of Immunology and 

Rheumatology, Stanford University, Palo Alto, California, United 

States of America; 5. UCB Inc, Smyrna, Georgia, United States 

of America; 6. Medicine, Cedars-Sinai Medical Center and 

UCLA School of Medicine, Los Angeles, California, United 

States of America 

PA1 

14.00 – 16.00 

BSR and BHPR plenary abstracts 

EPIDEMIOLOGY OF SPORTING INJURIES AMONG ELITE 

SOCCER PLAYERS: A LONGITUDINAL STUDY 

Philip Cooper 1 , Mo Gimpel 3 , Greg Deakin 1 , Karen Jameson 1 , 

Malcolm Godtschailk 3 , Stephan Gadola 2 , Maria Stokes 2 , 

Cyrus Cooper 1,2 ; 

PA3 

WILL I WASTE YOUR TIME? DELAYS IN SEEKING HELP FOR 

RA FLARES 

Caroline A. Flurey 1 , Marianne Morris 1 , Jon Pollock 1 , 

Rod Hughes 3 , Pam Richards 2 , Sarah Hewlett 1 ; 

1. 

Faculty of Health and Life Sciences, University of the West of 

England, Bristol, United Kingdom; 2. Rheumatology, University 

Hospitals Bristol, Bristol, United Kingdom; 3. Rheumatology, 

St Peter’s Hospital, Chertsey, United Kingdom 

1. 

University of Southampton, MRC Lifecourse Epidemiology 

Unit, Southampton, United Kingdom; 2. NIHR Musculoskeletal 

BRU, University of Southampton, Southampton, United 

Kingdom; 3. Department of Sports Medicine, Southampton 

Football Club, Southampton, United Kingdom



O13 

09.15 – 10.45 

RA treatment and outcomes 

VALIDATION OF JADAS IN ALL SUBTYPES OF JUVENILE 

IDIOPATHIC ARTHRITIS IN A CLINICAL SETTING 

Flora McErlane 1,2 , Michael W. Beresford 1,3 , 

Eileen M. Baildam 3 , Wendy Thomson 2 , Kimme Hyrich 2 , 

Alice Chieng 7 , Joyce Davidson 5 , Helen E. Foster 4 , 

Janet Gardner-Medwin 5 , Mark Lunt 2 , Lucy Wedderburn 6 ; 

1. 

Institute of Child Health, University of Liverpool, Liverpool, 

United Kingdom; 2. School of Translational Medicine, University 

of Manchester, Manchester, United Kingdom; 3. Paediatric 

Rheumatology, Alder Hey Children’s Hospital, Liverpool, United 

Kingdom; 4. Rheumatology, Newcastle Medical School, 

Newcastle upon Tyne, United Kingdom; 5. Rheumatology, Royal 

Hospital for Sick Children, Glasgow, United Kingdom; 

6. 

Rheumatology Unit, Institute of Child Health, London, United 

Kingdom; 7. Rheumatology, Royal Manchester Children’s 

Hospital, Manchester, United Kingdom 

O16 

1. 

Rheumatology Research Group, University of Birmingham, 

Birmingham, United Kingdom; 2. Rheumatology, University of 

Birmingham & Sandwell & West Birmingham Hospitals NHS 

Trust, Birmingham, United Kingdom; 3. Rheumatology, 

University Hospitals Birmingham NHS Foundation Trust, 

Birmingham, United Kingdom; 4. Kennedy Institute of 

Rheumatology, University of Oxford, Oxford, United Kingdom; 

5. 

Rheumatology, Imperial College, London, United Kingdom; 

6. 

Institute of Infection, Immunity and Inflammation, University 

of Glasgow, Glasgow, United Kingdom 

DOUBLEBLIND STUDY OF TOCILIZUMAB + METHOTREXATE 

VERSUS TOCILIZUMAB + PLACEBO IN PATIENTS WITH 

ACTIVE RHEUMATOID ARTHRITIS DESPITE PRIOR 

METHOTREXATE: PROGRESSION OF STRUCTURAL DAMAGE, 

QUALITY OF LIFE AND PHYSICAL FUNCTION AT 24 WEEKS 

Maxime Dougados 1 , Karsten Kissel 2 , Howard Amital 3 , 

Philip Conaghan 4 , Emilio Martin-Mola 5 , Evgeny Nasonov 6 , 

Georg Schett 7 , Orrin Troum 8 , Tiina Veldi 9 , Corrado Bernasconi 2 , 

Tom Huizinga 10 ; 

O14 

O15 

HAS ORTHOPAEDIC INTERVENTION FOR RHEUMATOID 

ARTHRITIS CHANGED IN LINE WITH COMBINATION AND 

ANTI-TNF THERAPIES? AN EVALUATION OF JOINT SURGERY 

RATES AND PROGNOSTIC FACTORS IN TWO UK INCEPTION 

COHORTS (1986-2011) 

Elena Nikiphorou 1 , Lewis Carpenter 2 , Patrick Kiely 3 , 

David Walsh 4 , Josh Dixey 5 , Adam Young 1 ; 

1. 

Rheumatology, ERAS/ERAN, St Albans, United Kingdom; 

2. 

Centre for Lifespan & Chronic Illness Research, University of 

Hertfordshire, Hatfield, United Kingdom; 3. Rheumatology, 

St George’s Healthcare NHS Trust, London, United Kingdom; 

4. 

Academic Rheumatology, Arthritis Research UK Pain Centre, 

University of Nottingham, Nottingham, United Kingdom; 

5. 

Rheumatology, New Cross Hospital, Wolverhampton, 


PREDICTING RESPONSES TO ANTI-TNFα THERAPY IN 

PATIENTS WITH RHEUMATOID ARTHRITIS USING 

METABOLOMIC ANALYSIS OF URINE 

Sabrina R. Kapoor 1,2 , Andrew Filer 1,3 , Martin Fitzpatrick 1 , 

Benjamin A. Fisher 5 , Peter C. Taylor 4 , Christopher Buckley 1,2 , 

Iain McInnes 6 , Karim Raza 1,2 , Stephen P. Young 1 ; 

O17 

1. 

Rheumatology, Paris-Descartes University, Cochin Hospital, 

Paris, France; 2. Roche, F. Hoffmann-La Roche Ltd, Basel, 

Switzerland; 3. Rheumatology, Sheba Medical Center, 

Tel-hashomer, Israel; 4. NIHR-Leeds Biomedical Research Unit, 

University of Leeds, Leeds, United Kingdom; 5. Rheumatology, 

Hospital Universitario La Paz, Madrid, Spain; 6. Rheumatology, 

Institute of Rheumatology, Moscow, Russian Federation; 

7. 

Department of Internal Medicine, Institute for Clinical 

Immunology, University of Erlangen-Nuremberg, Erlangen, 

Germany; 8. Rheumatology, Keck School of Medicine, University 

of Southern California, Santa Monica, California, United States 

of America; 9. Rheumatology, East-Tallinn Central Hospital, 

Tallinn, Estonia; 10. Rheumatology, Leiden University Medical 

Center, Leiden, Netherlands 

SECUKINUMAB TREATMENT PROVIDES SUSTAINED RE- 

SPONSE OVER ONE YEAR IN PATIENTS WITH RHEUMATOID 

ARTHRITIS 

Patrick Durez 1 , Mark C. Genovese 2 , Hanno B. Richards 3 , 

Jerzy Supronik 4 , Eva Dokoupilova 5 , Jacob A. Aelion 6 , 

Sang-Heon Lee 7 , Christine E. Codding 8 , Herbert Kellner 9 , 

Takashi Ikawa 10 , Sophie Hugot 3 , Gregory Ligozio 11 , 

Shephard Mpofu 3 ;


1. 

Rheumatology, Université Catholique de Louvain, Louvain, 

Belgium; 2. Immunology and Rheumatology, Stanford University, 

Palo Alto, California, United States of America; 3. Integrated 

Hospital Care, Novartis Pharma AG, Basel, Switzerland; 

4. 

Department of Medicine, NZOZ Centrum Medyczne Artur 

Racewicz, Bialystok, Poland; 5. Department of Medicine, 

Medical Plus, Uherske Hradiste, Czech Republic; 6. Department 

of Medicine, Arthritis Clinic, Jackson, Tennessee, United States 

of America; 7. Internal Medicine, Konkuk University Medical 

Center, Seoul, Republic of Korea; 8. Rheumatology & Internal 

Medicine, Health Research of Oklahoma, Oklahoma, United 

States of America; 9. Rheumatology, Centre for Inflammatory 

Joint Diseases, Munich, Germany; 10. Department of Medicine, 

Kobe-Konan Yamate Clinic, Kobe, Japan; 11. Integrated Hospital 

Care, Novartis Pharmaceuticals Corporation, East Hanover, 

New Jersey, United States of America 

O19 

O20 

11.45 – 13.15 

BHPR 

THE IMPACT OF PAIN ON SUCCESSFUL AGEING 

Ross Wilkie 1 , Abdelouahid Tajar 2 , John Mcbeth 1 ; 

1. 

Keele University, Keele, United Kingdom; 2. Centre for 

Statistics in Medicine, Oxford University, Oxford, United 

Kingdom 

FOREFOOT BURSAE ARE A PROGNOSTIC INDICATOR OF 

DISABLING FOOT COMPLICATIONS IN PATIENTS WITH 

RHEUMATOID ARTHRITIS: RESULTS OF A PROSPECTIVE 

THREE-YEAR STUDY 

Lindsey S. Hooper 1,2 , Catherine J. Bowen 1,2 , Lucy Gates 1,2 , 

David Culliford 1 , Christopher J. Edwards 1,2 , Nigel K. Arden 2,3 ; 

O18 

WITHDRAWAL OF ADALIMUMAB IN EARLY RHEUMATOID 

ARTHRITIS PATIENTS WHO ATTAINED STABLE LOW DISEASE 

ACTIVITY WITH ADALIMUMAB PLUS METHOTREXATE: 

RESULTS OF A PHASE 4, DOUBLE-BLIND, 

PLACEBO-CONTROLLED TRIAL 

Arthur Kavanaugh 1 , Paul Emery 2 , Roy Fleischmann 3 , 

Ronald Van Vollenhoven 4 , Karel Pavelka 5 , Patrick Durez 6 , 

Benoît Guérette 7 , Sourav Santra 8 , Laura Redden 8 , 

Hartmut Kupper 9 , Josef S. Smolen 10 ; 

1. 

Division of Rheumatology, Allergy and Immunology, University 

of California, San Diego, La Jolla, California, United States of 

America; 2. Department of Rheumatology, Leeds Teaching 

Hospital, Leeds, United Kingdom; 3. Department of 

Rheumatology, University of Texas Southwestern, Dallas, Texas, 

United States of America; 4. Department of Rheumatology, The 

Karolinska Institute, Stockholm, Sweden; 5. Department of 

Rheumatology, Charles University, Prague, Czech Republic; 

6. 

Department of Rheumatology, Université Catholique de 

Louvain, Brussels, Belgium; 7. GPRD, Abbott, Rungis, France; 

8. 

GPRD, Abbott, Abbott Park, IL; 9. GPRD, Abbott, 

Ludwigshafen, Germany; 10. Department of Rheumatology, 

Medical University of Vienna and Hietzing Hospital, Vienna, 

Austria 

O21 

O22 

1. 

Faculty of Health Sciences, University of Southampton, 

Southampton, United Kingdom; 2. Rheumatology, Southampton 

University Hospitals NHS Trust, Southampton, United Kingdom; 

3. 

Nuffield Department of Orthopaedics, Rheumatology and 

Musculoskeletal Sciences, University of Oxford, Oxford, 


THE CONTINUING PROFESSIONAL DEVELOPMENT FOR 

HEALTH PROFESSIONALS WORKING WITHIN 

MUSCULOSKELETAL SERVICES: A NATIONAL UK SURVEY 

Jo Adams 1 , Sarah Ryan 2 , Hannah Haywood 1 , Helen Pain 1 ; 

1. 


Southampton, United Kingdom; 2. Staffordshire Rheumatology 

Centre, Haywood Hospital, Stoke-on-Trent, United Kingdom 

DEBRIDEMENT OF PAINFUL FOREFOOT PLANTAR 

CALLOSITIES IN RHEUMATOID ARTHRITIS: THE CARROT 

RANDOMISED CONTROLLED TRIAL 

Heidi J. Siddle 1,2 , Anthony C. Redmond 1 , Robin Waxman 1 , 

Abigail R. Dagg 3 , Begonya Alcacer-Pitarch 1 , 

Richard A. Wilkins 1 , Philip S. Helliwell 1 ; 

1. 

Division of Musculoskeletal Disease, University of Leeds, 

Leeds, United Kingdom; 2. Foot Health Department, Leeds 

Teaching Hospitals NHS Trust, Leeds, United Kingdom; 

3. 

Podiatry Department, The Mid Yorkshire Hospitals NHS Trust, 

Wakefield, United Kingdom


O23 

O24 

O25 

O26 

PSYCHOLOGICAL WELL-BEING IN EARLY RHEUMATOID 

ARTHRITIS: FINDINGS FROM THE EARLY RHEUMATOID 

ARTHRITIS NETWORK 

Sam Norton 1 , Patrick Kiely 3 , David Walsh 4 , Richard Williams 5 , 

Adam Young 2 ; 

1. 

Institute of Public Health, University of Cambridge, 

Cambridge, United Kingdom; 2. Rheumatology Department, City 

Hospital, St Albans, United Kingdom; 3. Department of 

Rheumatology, St George’s Healthcare NHS Trust, London, 

United Kingdom; 4. Department of Rheumatology, Sherwood 

Forest Hospitals NHS Foundation Trust, Nottingham, United 

Kingdom; 5. Department of Rheumatology, Hereford Hospitals 

NHS Trust, Hereford, United Kingdom 

HEALTH PROFESSIONALS’ PERCEPTIONS OF THE EFFECTS 

OF EXERCISE ON JOINT HEALTH IN RHEUMATOID ARTHRITIS 

PATIENTS II: A FOLLOW-UP FOCUS GROUP STUDY 

Serena Halls 1 , Rebecca-Jane Law 1 , Jeremy Jones 1,2 , 

David Markland 1 , Peter Maddison 1 , Jeanette Thom 1 ; 

1. 

School of Sport, Health and Exercise Sciences, Bangor 

University, Bangor, United Kingdom; 2. Rheumatology, Betsi 

Cadwaladr University Health Board, Bangor, United Kingdom 

Connective tissue diseases 

VARIABILITY IN THE PHENOTYPE OF METABOLIC SYNDROME 

OVER TIME IN A MULTICENTRE INTERNATIONAL INCEPTION 

COHORT OF PATIENTS WITH SLE 

Ben Parker 1 , Murray B. Urowitz 3 , Dafna D. Gladman 3 , 

Ian Bruce 1,2 , On Behalf of the SLICC Registry 3 ; 

1. 

Arthritis Research UK Epidemiology Unit, University of 

Manchester, Manchester, United Kingdom; 2. Kellgren Centre 

for Rheumatology, Manchester Royal Infirmary, Manchester, 

United Kingdom; 3. Centre for Prognosis Studies, Toronto 

Western Hospital, Toronto, Ontario, Canada 

NITRATED NUCLEOSOME LEVELS IN PATIENTS WITH 

SYSTEMIC LUPUS ERYTHEMATOSUS – ASSOCIATIONS WITH 

ETHNICITY, AUTOANTIBODY STATUS AND ETHNICITY 

Sara C. Croca, Charis Pericleous, Harry Yong, David Isenberg, 

Ian Giles, Anisur Rahman, Yiannis Ioannou; 

O27 

O28 

O29 

BSR Young investigator award winner 

IS THERE AN ASSOCIATION BETWEEN WARFARIN AND 

SURVIVAL IN SSC-PAH PATIENTS TREATED WITH FIRST-LINE 

BOSENTAN MONOTHERAPY? 

Clare E. Warrell 1 , David Dobarro 1 , Clive Handler 1 , 

Christopher P. Denton 2 , Benjamin E. Schreiber 1 , 

John G. Coghlan 1 ; 

1. 

Pulmonary Hypertension, Royal Free Hampstead NHS Trust, 

London, United Kingdom; 2. Rheumatology, Royal Free 

Hampstead NHS Trust and UCL Medical School, London, 


ANTI-EIF2 IS ASSOCIATED WITH INTERSTITIAL LUNG 

DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS 

Zoe E. Betteridge 1,2 , Felix Woodhead 8,3 , Christopher Bunn 4 , 

Christopher P. Denton 5 , David Abraham 4 , Sujal Desai 6 , 

Roland du Bois 7 , Athol Wells 3 , Neil McHugh 1,2 ; 

1. 

Bath Institute for Rheumatic Diseases, University of Bath, 

Bath, United Kingdom; 2. Rheumatology, Royal National 

Hospital for Rheumatic Diseases, Bath, United Kingdom; 

3. 

National Heart and Lung Institute, Imperial College, London, 

United Kingdom; 4. Department of Immunology, Royal Free 

Hospital, London, United Kingdom; 5. Centre for Rheumatology, 

Royal Free Hospital, London, United Kingdom; 6. Department of 

Radiology, Kings College Hospital, London, United Kingdom; 

7. 

Medicine, National Jewish Health, Denver, Colorado, United 

States of America; 8. Respiratory Medicine, University Hospitals 

Coventry and Warwickshire, Coventry, United Kingdom 

BSR medical student bursary winner 

OPTICAL COHERENCE TOMOGRAPHY VALIDATION: A NEW 

QUANTITATIVE IMAGING BIOMARKER FOR AFFECTED SKIN 

IN SCLERODERMA 

Giuseppina Abignano 1,2 , Sibel Aydin 1 , 

Conception Castillo-Gallego 1 , Daniel Woods 3 , Adam Meekings 3 , 

Dennis McGoonagle 1 , Paul Emery 1 , Francesco Del Galdo 1 ; 

1. 

Section of Musculoskeletal Diseases, Leeds Institute of 

Molecular Medicine, Leeds, United Kingdom; 2. Rheumatology 

Unit, Second University of Naples, Naples, Italy; 3. Michelson, 

Diagnostics Ltd, Kent, United Kingdom 

Rheumatology, University College London, London, 

United Kingdom


O30 

THE CLINICAL RELEVANCE OF ANTI-RO52 AND ANTI-RO60 

IN PATIENTS IN THE UNITED KINGDOM PRIMARY SJÖGREN’S 

SYNDROME REGISTRY (UKPSSR) 

Josephine Vila 2 , Sheryl Mitchell 2 , Simon Bowman 2 , 

Elizabeth Price 3 , Colin T. Pease 4 , Paul Emery 4 , 

Jacqueline Andrews 4 , Michele Bombardieri 5 , Nurhan Sutcliffe 5 , 

Constantino Pitzalis 5 , Peter Lanyon 6 , John Hunter 7 , 

Monica Gupta 7 , John McLaren 8 , Marian Regan 9 , 

Annie Cooper 10 , Ian Giles 11 , David Isenberg 11 , 

Saravanan Vadivelu 12 , David Coady 13 , Bridget Griffiths 2 , 

Dennis Lendrem 2 , Heather Foggo 2 , Jessica Tarn 2 , Wan-Fai Ng 1 ; 

1. 

Musculoskeletal Research Group, Institute of Cellular 

Medicine, Newcastle University, Newcastle upon Tyne, United 

Kingdom; 2. Rheumatology, Newcastle upon Tyne Hospitals 

NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; 

3. 

Rheumatology, Great Western Hospitals NHS Foundation 

Trust, Swindon, United Kingdom; 4. Section of Musculoskeletal 

Disease, Leeds Institute of Molecular Medicine, University of 

Leeds, Leeds, United Kingdom; 5. Rheumatology, Barts and the 

London NHS Trust UK, London, United Kingdom; 

6. 

Rheumatology, Nottingham University Hospital, Nottingham, 

United Kingdom; 7. Rheumatology, Gartnavel Genral Hospital, 

Glasgow, United Kingdom; 8. Rheumatology, NHS Fife, 

Whiteman’s Brae Hospital, Kirkaldy, United Kingdom; 

9. 

Rheumatology, Royal Derby Hospital, Derby, United Kingdom; 

10. 

Rheumatology, Royal Hampshire County Hospital, 

Winchester, United Kingdom; 11. Rheumatology, University 

College London Hospitals NHS Foundation Trust, London, 

United Kingdom; 12. Rheumatology, Queen Elizabeth Hospital, 

Gateshead, United Kingdom; 13. Rheumatology, Sunderland 

Royal Hospital, Sunderland, United Kingdom 

O32 

O33 

O34 

THE MRC PHYSIODIRECT TRIAL: A PRAGMATIC 

RANDOMISED CONTROLLED TRIAL OF PHYSIODIRECT 

TELEPHONE ASSESSMENT AND ADVICE SERVICES VERSUS 

USUAL CARE FOR MUSCULOSKELETAL PROBLEMS 

Chris Salisbury 1 , Nadine E. Foster 2 , Annette Bishop 2 , 

Jo Coast 3 , Angelo Franchini 1 , Jeanette Hall 4 , 

Sandra Hollinghurst 1 , Cherida Hopper 1 , Sean Grove 4 , 

Surinder Kaur 1 , Alan Montgomery 1 ; 

1. 

Academic Unit of Primary Health Care, University of Bristol, 

Bristol, United Kingdom; 2. Arthritis Research UK Primary Care 

Centre, Keele University, Keele, United Kingdom; 3. Department 

of Helath Economics, University of Birmingham, Birmingham, 

United Kingdom; 4. MSK Outpatients, Bristol Community 

Health, Bristol, United Kingdom 

FREQUENCY OF MUSCULOSKELETAL SYMPTOMS AND 

PRESENTING COMPLAINTS IN VIDEO-OBSERVED PRIMARY 

CARE CONSULTATIONS WITH PATIENTS AGED 45 AND OVER 

Zoe Paskins 1 , Tom Sanders 1 , Peter R. Croft 1 , Andy B. Hassell 1 ; 

1. 

Arthritis Research UK Primary Care Centre, Keele, 


DECIDING TO CONSULT THE GENERAL PRACTITIONER FOR 

SYMPTOMATIC OSTEOARTHRITIS: A CHOICE-BASED 

CONJOINT ANALYSIS STUDY 

Domenica E. Coxon 1 , Martin Frisher 2 , Kelvin P. Jordan 1 , 

Clare Jinks 1 , George Peat 1 ; 

1. 

Arthritis Research UK Primary Care Centre, Keele University, 

Keele, United Kingdom; 2. Department of Medicines 

Management, Keele University, Keele, United Kingdom 

O31 

14.45 – 16.15 

Primary care 

AUDIT TO ASSESS GP AWARENESS AND DOCUMENTATION 

OF BIOLOGIC AND DMARDS IN PRIMARY CARE PATIENT 

RECORDS 

Charlotte Goodhead 1 , Priya Shekar 1 , Clive Kelly 1 , Gail Francis 1 , 

Ann-Marie Bailey 2 , Lynsey Thompson 1 , Jennifer Hamilton 1 ; 

1. 

Rheumatology, Queen Elizabeth Hospital Gateshead, 

Gateshead, United Kingdom; 2. South of Tyne and Wear 

Medicines Management, Sunderland teaching primary 

care trust, Sunderland, United Kingdom 

O35 

O36 

BSR Medical student bursary winner 

ARE RHEUMATOID ARTHRITIS PATIENTS SCREENED FOR 

CARDIOVASCULAR DISEASE IN PRIMARY CARE? 

Helen L. Monk 1 , Sara Muller 1 , Christian Mallen 1 , 

Samantha L. Hider 1 ; 

1. 


Keele, United Kingdom 

GOUT, ALLOPURINOL AND ERECTILE DYSFUNCTION: 

AN EPIDEMIOLOGICAL STUDY IN A PRIMARY CARE 

CONSULTATION DATABASE 

Edward Roddy 1 , Sara Muller 1 , Richard Hayward 1 , 

Christian Mallen 1 ; 

1. 

Arthritis Research UK Primary Care Centre, Stoke-on-Trent, 

United Kingdom



09.00 – 10.30 

Epidemiology and outcomes 

S1 

S2 

Molecular mechanisms of disease: osteoarthritis 

IDENTIFICATION OF NOVEL OSTEOARTHRITIS GENES USING 

ZEBRAFISH 

Chrissy Hammond 1 ; 

1. 

Biochemistry, University of Bristol, Bristol, United Kingdom 

IS ADRENOMEDULLIN A POTENTIAL THERAPEUTIC FOR 

OSTEOARTHRITIS, WHILE ITS TRUNCATED PEPTIDE 22-52 

ACTS AS A PRO-DEGENERATIVE FACTOR? 

Frédéric Velard 1,2 , Marie-Dominique Ah Kioon 1,2 , 

Dominique Côme 1,2 , Narjes Hafsia 1,2 , Hilène Lin 1,2 , 

Hang-Korng Ea 1,2 , Frédéric Lioté 1,2 ; 

1. 

INSERM, U606, Paris, France; 2. Hôpital, Lariboisière, 

Paris, France 

O37 

O38 

THE RISK OF SOLID CANCER IN PATIENTS RECEIVING 

ANTI-TUMOUR NECROSIS FACTOR THERAPY FOR 

RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH 

SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER 

Louise Mercer 1 , James Galloway 1 , Audrey Low 1 , Kath Watson 1 , 

Mark Lunt 1 , William Dixon 1 , BSRBR Control Centre 

Consortium 1 , Deborah Symmons 1 , Kimme Hyrich 1 , 

on behalf of the BSRBR 2 ; 

1. 

Arthritis Research UK Epidemiology Unit, The University of 

Manchester, Manchester, United Kingdom; 2. British Society 

for Rheumatology, London, United Kingdom 

SYSTEMIC RHEUMATOID VASCULITIS IN THE BIOLOGIC ERA 

Eleana Ntatsaki 1 , Richard A. Watts 2,3 , Janice Mooney 2 , 

David G.I. Scott 1,3 ; 

S3 

INVESTIGATION OF THE ROLE OF UFM1 SPECIFIC 

PEPTIDASE 2 IN BEUKES HIP DYSPLASIA 

Michal Dudek 1 , Gillian A. Wallis 1 ; 

1. 

University of Manchester, Manchester, United Kingdom 

1. 

Rheumatology, Norfolk and Norwich University Hospital, 

Norwich, United Kingdom; 2. Norwich Medical School, 

University of East Anglia, Norwich, United Kingdom; 

3. 

Rheumatology, Ipswich Hospital NHS Trust, Ispwich, 


S4 

CANNABIDIOL BLOCKS THE INHIBITORY EFFECTS OF THE 

GPR55 AGONIST L-ALPHA-LYSOPHOSPHATIDYLINOSITOL ON 

MECHANOSENSITIVE KNEE JOINT AFFERENTS 

Kenneth Paton 1 , John Harris 1 , David A. Kendall 2 , 

Sara Kelly 3,1 ; 

1. 

School of Biosciences, University of Nottingham, 

Nr Loughborough, United Kingdom; 2. School of Biomedical 

Sciences, University of Nottingham, Nottingham, United 

Kingdom; 3. Arthritis Research UK Pain Centre, University of 

Nottingham, Nottingham, United Kingdom 

O39 


INCIDENCE OF RHEUMATOID ARTHRITIS IN THE UK 

USING THE 2010 ACR/EULAR CLASSIFICATION CRITERIA 

AND COMPARISON WITH ESTIMATES USING THE 1987 

ACR CRITERIA 

Jennifer Humphreys 1 , Suzanne M. Verstappen 1 , 

Tarnya Marshall 2 , Mark Lunt 1 , Kimme Hyrich 1 , 

Deborah P. Symmons 1 ; 

1. 

Arthritis Research UK Epidemiology Unit, School of 

Translational Medicine, University of Manchester, Manchester, 

United Kingdom; 2. Department of Rheumatology, Norfolk and 

Norwich University Hospital, Norwich, United Kingdom 

O40 

SMOKING AND RHEUMATOID FACTOR STATUS IN 

PREDICTING RESPONSES TO BIOLOGICS 

Abdul Khan 1 , David L. Scott 1 ; 

1. 

Rheumatology, Kings College Hospital, London, 

United Kingdom


O41 

O42 

BREAST IS BEST. LIFECOURSE INFLUENCES ON THE 

DEVELOPMENT OF KNEE OSTEOPHYTES: THE NEWCASTLE 

THOUSAND FAMILIES STUDY 

Ajay Abraham 1 , Mark S. Pearce 1 , Kay D. Mann 1 , 

Roger M. Francis 2 , Fraser Birrell 3 ; 

1. 


Newcastle upon Tyne, United Kingdom; 2. Institute for Ageing 

and Health, Newcastle University, Newcastle upon Tyne, 

United Kingdom; 3. Musculoskeletal Research Group, Institute 

of Cellular Medicine, Newcastle University, Newcastle upon 

Tyne, United Kingdom 

ASSOCIATION OF SYSTEMIC SCLEROSIS WITH DIFFERENT 

AUTOANTIBODY SUBGROUPS AND MALIGNANCIES: A 

RETROSPECTIVE REGISTRY-BASED UK COHORT STUDY 

Pia Moinzadeh 1,2 , Carmen Fonseca 1 , Martin Hellmich 3 , 

Ami Shah 4 , Cecilia Chighizola 5 , Christopher P. Denton 1 , 

Voon Ong 1 ; 

1. 

Centre for Rheumatology and Connective Tissue Diseases, 

UCL Medical School, Royal Free Hospital, London, United 

Kingdom; 2. Dermatology, University of Cologne, Cologne, 

Germany; 3. Institute of Medical Statistics, Informatics and 

Epidemiology, University of Cologne, Cologne, Germany; 

4. 

Division of Rheumatology, Johns Hopkins University School 

of Medicine, Baltimore, Maryland, United States of America; 

5. 

Rheumatology Division, Department of Internal Medicine, 

School of Medicine, Milan, Italy 

S6 

S7 

S8 

TLR9 INDUCES TOLERANCE TO APOPTOTIC CELLS AND IS 

RESPONSIBLE FOR INDUCING REGULATORY B CELLS 

Katherine Miles 1 , Jonathan Heaney 1 , Zaneta Sibinska 1 , 

Donald Salter 1 , John Savill 1 , David Gray 2 , Mohini Gray 1 ; 

1. 

Queen’s Medical Research Institute, University of Edinburgh, 

Edinburgh, United Kingdom; 2. Institute of Immunology & 

Infection Research, University of Edinburgh, Edinburgh, 


INTERLEUKIN-27 RECEPTOR-DEFICIENT MICE DEVELOP 

EXACERBATED INFLAMMATORY ARTHRITIS ASSOCIATED 

WITH HEIGHTENED T- AND B-CELL RESPONSES 

Gareth W. Jones 1,2 , Claire J. Greenhill 1 , Anwen S. Williams 1 , 

Mari A. Nowell 1 , Brendan J. Jenkins 2 , Simon A. Jones 1 ; 

1. 

Institute of Infection and Immunity, Cardiff University, Cardiff, 

United Kingdom; 2. Centre for Innate Immunity and Infectious 

Diseases, Monash Institute of Medical Research, Clayton, 

Victoria, Australia 

ANTI-TNF ANTIBODY THERAPY, BUT NOT TNF RECEPTOR 

BLOCKADE, INDUCES IL-17 SUPPRESSING REGULATORY 

T CELLS 

Jenny McGovern 1 , Dao X. Nguyen 1 , Clare A. Notley 1 , 

Claudia Mauri 1 , David Isenberg 1 , Michael Ehrenstein 1 ; 

1. 

Centre for Rheumatology, University College London, London, 


11.30 – 13.00 

Education 

S5 

Molecular mechanisms of disease: inflammatory arthritis I 

ANTI-VCA AND EBNA1 ANTIBODIES ARE PRODUCED IN THE 

RHEUMATOID SYNOVIUM IN THE PRESENCE OF ECTOPIC 

LYMPHOID STRUCTURES AND CORRELATES WITH ACPA 

PRODUCTION 

Cristina Croia 1 , Michele Bombardieri 1 , Aloisi Francesca 2 , 

Barbara Serafini 2 , Frances Humby 1 , Stephen Kelly 1 , 

Paola Migliorini 3 , Costantino Pitzalis 1 ; 

1. 

Experimental Medicine and Rheumatology, Queen Mary 

University of London, London, United Kingdom; 2. Cell Biology 

and Neuroscience, Istituto Superiore di Sanita’, Rome, Italy; 

3. 

Internal Medicine, University of Pisa, Pisa, Italy 

O43 

O44 

NATIONAL RHEUMATOID ARTHRITIS SOCIETY WORKWISE 

WORKSHOPS’ ONLINE RESOURCES: TOOLS TO HELP 

PEOPLE WITH RHEUMATOID ARTHRITIS REMAIN IN THE 

WORKPLACE OR GET BACK TO WORK 

Clare Jacklin 1 , Ailsa M. Bosworth 1 ; 

1. 

External Affairs, National Rheumatoid Arthritis Society, 

Maidenhead, United Kingdom 

DESIGNING VIRTUAL PATIENTS FOR MUSCULOSKELETAL 

EDUCATION: A GROUNDED THEORY QUALITATIVE STUDY 

James Bateman 1,2 , Maggie Allen 2 , Dipti Samani 2 , 

David Davies 1 ; 

1. 

Institute of Clinical Education, University of Warwick, 

Coventry, United Kingdom; 2. Department of Rheumatology, 

University Hospitals Coventry and Warwickshire NHS Trust, 

Coventry, United Kingdom


O45 

HAVE YOU BEEN TO CAPRI? WWW.CAPRI.SCOT.NHS.UK 

EARLY RESULTS OF A CLINIC FOR ARTHRITIS PATIENTS IN 

REMISSION ON THE INTERNET 

Helen E. Harris 1 , Suzanne Brannan 3 , Gavin Venters 2 , 

Alan McQuillian 2 , Fiona Lovegrove 1 , Jane Gibson 1 , 

David Chinn 4 , John S. Mclaren 1 ; 

1. 

Fife Rheumatic Diseases Unit, NHS Fife, Kirkcaldy, United 

Kingdom; 2. Information Technology Department, NHS 

Scotland, Edinburgh, United Kingdom; 3. Opthalmology 

Department, Queen Margaret Hospital, Dunfermline, United 

Kingdom; 4. Research and Development, NHS Fife, 

Dunfermline, United Kingdom 

S9 

14.00 – 15.30 

Molecular mechanisms of disease: inflammatory 

arthritis II 

INHIBITION OF NAMPT (PBEF/VISFATIN) DECREASES THE 

ABILITY OF HUMAN NEUTROPHILS TO GENERATE REACTIVE 

OXIDANTS, BUT DOES NOT IMPAIR BACTERIAL KILLING 

Kate J. Roberts 1 , Robert J. Moots 2 , Steven W. Edwards 1 ; 

1. 

Institute of Integrative Biology, University of Liverpool, 

Liverpool, United Kingdom; 2. Institute of Ageing and Chronic 

Disease, University Hospital Aintree, University of Liverpool, 

Liverpool, United Kingdom 

O46 

O47 

THE EVALUATION OF AN ARTHRITIS EDUCATION 

OUTREACH PROGRAMME FOR BLACK AND ETHNIC 

MINORITY COMMUNITIES 

Chandrika Gordhan 3,1 , Rebecca J. Stack 1,2 , Kanta Kumar 1,2 , 

Ishraga Awad 4 , Karim Raza 1,2 , Paul Bacon 3,1 ; 

1. 

Rheumatology Research Group, School of Immunity and 

Infection, University of Birmingham, Birmingham, United 

Kingdom; 2. Rheumatology Department, Sandwell and West 

Birmingham Hospitals NHS Trust, Birmingham, United 

Kingdom; 3. Birmingham Arthritis Resource Centre, Birmingham 

Central Library, Birmingham, United Kingdom; 4. Public Health 

Medicine, Sandwell Primary Care Trust, West Bromwich, 


PATIENT EXPERIENCES, ATTITUDES AND EXPECTATIONS 

TOWARDS RECEIVING INFORMATION ABOUT ANTI-TNF: 

A QUALITATIVE STUDY 

Paul Arkell 1,2 , Sarah Ryan 2 , Ann Brownfield 2 , 

Jonathan Packham 1,2 ; 

S10 

S11 

NEUTROPHIL MICROPARTICLES AS POTENTIAL NOVEL 

EFFECTORS OF JOINT DISEASE 

Sarah E. Headland 1 , Mauro Perretti 1 ; 

1. 

William Harvey Research Institute, Barts & the London 

School of Medicine & Dentistry, London, United Kingdom 

RESOLVIN D1 LIMITS PMN RECRUITMENT TO 

INFLAMMATORY LOCI: RECEPTOR DEPENDENT BIOACTIONS 

Lucy Norling 1 , Jesmond Dalli 2,1 , Roderick Flower 1 , 

Charles Serhan 2 , Mauro Perretti 1 ; 

1. 

William Harvey Research Institute, Barts and The London 

Medical School, London, United Kingdom; 2. Anesthesiology, 

Perioperative and Pain Medicine, Brigham and Women’s 

Hospital and Harvard Medical School, Boston, Massachusetts, 

United States of America 

1. 

Primary Care and Health Sciences Department, Keele 

University, Keele, United Kingdom; 2. The Haywood Hospital 

Rheumatology Department, University Hospital of North 

Staffordshire, Stoke-on-Trent, United Kingdom 

O48 

NATIONAL RHEUMATOID ARTHRITIS SOCIETY SURVEY: 

IMPACT OF RHEUMATOID ARTHRITIS ON THE FAMILY 

Clare Jacklin 1 , Ailsa M. Bosworth 1 , Kate Wilkinson 1 ; 

1. 

External Affairs, National Rheumatoid Arthritis Society, 

Maidenhead, United Kingdom


S12 


THE MESENCHYMAL STROMAL CELL MARKER CD248 

REGULATES INFLAMMATORY ARTHRITIS AND BONE 

FORMATION 

Amy Naylor 1 , Eman Azzam 2 , Stuart Smith 1 , Adam Croft 1 , 

Jeremy Duffield 5 , David Huso 6 , Steffen Gay 3 , Caroline Ospelt 3 , 

Mark Cooper 1 , Clare Isacke 4 , Simon Goodyear 2 , 

Michael Rogers 2 , Chris Buckley 1 ; 

1. 


Birmingham, United Kingdom; 2. Musculoskeletal Programme, 

University of Aberdeen, Aberdeen, United Kingdom; 

3. 

Department of Rheumatology, University Hospital Zurich, 

Zurich, Switzerland; 4. Institute of Cancer Research, Royal 

Cancer Hospital, London, United Kingdom; 5. Institute for Stem 

Cell and Regenerative Medicine, University of Washington, 

Washington, United States of America; 6. Molecular and 

Comparative Pathobiology, Johns Hopkins University, 

Baltimore, Maryland, United States of America 

O49 

O50 

Genetics 

GLOBAL GENE EXPRESSION ANALYSIS OF 

DEDIFFERENTIATED CHONDROCYTES 

Alan J. Mueller 1 , Elizabeth G. Laird 1 , Simon R. Tew 1 , 

Peter D. Clegg 1 ; 

1. 

Musculoskeletal Biology, Institute of Ageing and Chronic 

Disease, University of Liverpool, Neston, United Kingdom 

LARGEST UK RHEUMATOID ARTHRITIS GENOME WIDE 

ASSOCIATION STUDY TO DATE OF 8,300 SAMPLES 

STRENGTHENS CONFIRMED LOCI AND HIGHLIGHTS 

MORE POTENTIAL RA GENETIC RISK FACTORS 

Gisela Orozco 1 , Steve Eyre 1 , John Bowes 1 , Edward Flynn 1 , 

Anne Barton 1 , Jane Worthington 1 ; 

1. 


Manchester, Manchester, United Kingdom 

S13 

THE REGULATION OF ARTHRITIC BONE EROSIONS BY IL-10 

Claire J. Greenhill 1 , Anwen S. Williams 1 , Gareth W. Jones 1 , 

Mari A. Nowell 1 , Abdul N. Moideen 1 , Marcela Rosas 1 , 

Phil R. Taylor 1 , Ian R. Humphreys 1 , Simon A. Jones 1 ; 

1. 

Institute of Infection and Immunity, Cardiff University, Cardiff, 



O51 

FINE MAPPING IN OVER 14,000 RHEUMATOID ARTHRITIS 

CASES AND 18,500 CONTROLS REFINE ASSOCIATIONS TO 

KNOWN LOCI, INDICATE MULTIPLE INDEPENDENT AFFECTS 

AND REVEAL NOVEL ASSOCIATIONS 

Steve Eyre 1 , John Bowes 1 , Anne Barton 1 , Chris Amos 2 , 

Dorothée Diogo 3 , Annette Lee 4 , Leonid Padyukov 5 , 

Eli A. Stahl 3 , Javier Martin 5 , Solbritt Rantapaa-Dahlqvist 6 , 

Soumya Raychaudhuri 3 , Robert Plenge 3 , Lars Klareskog 7 , 

Peter Gregersen 4 , Jane Worthington 1 ; 

S14 

DUAL SPECIFICITY PHOSPHATASE 1 IS A CRUCIAL NEGATIVE 

REGULATOR OF INFLAMMATORY OSTEOLYSIS AND A 

MEDIATOR OF THERAPEUTIC EFFECTS OF DEXAMETHASONE 

IN COLLAGEN-INDUCED ARTHRITIS 

Youridies Vattakuzhi 1 , Nicole J. Horwood 1 , Andy R. Clark 1 ; 

1. 

Kenndy Institute of Rheumatology, London, United Kingdom 

1. 

Musculoskeletal Research Group, The University of 

Manchester, Manchester, United Kingdom; 2. Epidemiology, 

University of Texas, Houston, Texas, United States of America; 

3. 

Division of Genetics, Harvard Medical School, Boston, 

Massachusetts, United States of America; 4. Centre for 

Genomics and Human Genetics, Feinstein Institute for Medical 

Research, New York, New York, United States of America; 

5. 

Instituto de Parasitology, CSIC Granada, Granada, Spain; 

6. 

Rheumatology, Umea University, Umea, Sweden; 

7. 

Rheumatology, Karolinska University Hospital Solna, 

Stockholm, Sweden


O52 

INVESTIGATION OF IDIOPATHIC INFLAMMATORY MYOPATHY 

FOR SHARED GENETIC RISK FACTORS WITH OTHER 

AUTOIMMUNE DISORDERS 

Meghna Jani 1 , Hector Chinoy 1,2 , Janine Lamb 2 , Platt Hazel 2 , 

Lucy Wedderburn 3 , Jiri Vencovsky 4 , Katalin Danko 5 , 

Ingrid Lundberg 6 , Albert Selva O’Callaghan 7 , 

Timothy Radstake 8 , William E.R. Ollier 2 , Robert G. Cooper 1 ; 

1. 

Rheumatic Diseases Centre, Salford Royal NHS Foundation 

Trust, Salford, United Kingdom; 2. Centre for Integrated 

Genomic Medical Research, University of Manchester, 

Manchester, United Kingdom; 3. Rheumatology Unit, Institute 

of Child Health, University College London, London, United 

Kingdom; 4. Rheumatology, Institute of Rheumatology, Prague, 

Czech Republic; 5. Division of Clinical Immunology, Medical and 

Health Science Center, University of Debrecen, Debrecen, 

Sweden; 6. Rheumatology Unit, Karolinska Institutet, 

Stockholm, Sweden; 7. Internal Medicine Department, Vall 

d’Hebron General Hospital, Barcelona, Spain; 8. Department of 

Rheumatology, Radboud University, Nijmegen Medical Center, 

Nijmegen, Netherlands 

O54 

GENOME-WIDE ASSOCIATION STUDY OF METHOTREXATE 

RESPONSE IDENTIFIES NOVEL GENES IN A LARGE COHORT 

OF EUROPEAN JUVENILE IDIOPATHIC ARTHRITIS CASES 

Joanna Cobb 1 , Anne Hinks 1 , Edward Flynn 1 , Shashi Hirani 2 , 

Fiona Patrick 3 , Laura Kassoumeri 3 , Simona Ursu 3 , 

Halima Moncrieffe 3 , Maja Bulatovic 4 , Marek Bohm 5 , 

Bertrand van Zelst 6 , Pavla Dolezalova 5 , Robert de Jonge 6 , 

Nico Wulffraat 4 , Stan Newman 2 , Wendy Thomson 1 , 

Lucy Wedderburn 3 ; 

1. 


Manchester, Manchester, United Kingdom; 2. School of 

Community & Health Sciences, City University London, 

London, United Kingdom; 3. Institute of Child Health, University 

College London, London, United Kingdom; 4. Department of 

Paediatric Immunology, Wilhelmina Children’s Hospital, 

University Medical Centre Utrecht, Utrecht, Netherlands; 

5. 

First Faculty of Medicine, General Faculty Hospital, Prague, 

Czech Republic; 6. Department of Rheumatology, Erasmus 

University Medical Centre, Rotterdam, Netherlands 


O53 

ANALYSIS OF THE IMMUNOCHIP IN A LARGE COHORT OF 

OLIGO- AND POLYARTHRITIS JUVENILE IDIOPATHIC 

ARTHRITIS CASES CONFIRMS PREVIOUS AND IDENTIFIES 

NOVEL ASSOCIATIONS 

Joanna Cobb 1 , Anne Hinks 1 , John Bowes 1 , Kathryn Steel 1 , 

Marc Sudman 2 , Miranda C. Marion 3 , Mehdi Keddache 4 , 

Lucy R. Wedderburn 5 , Johannes P. Haas 6 , David N. Glass 2 , 

Carl D. Langefeld 3 , Wendy Thomson 1 , Susan D. Thompson 2 ; 

1. 


Manchester, Manchester, United Kingdom; 2. Cincinnati 

Children’s Hospital Medical Center, Cincinnati Children’s 

Hospital, Cincinnati, Ohio, United States of America; 

3. 

Department of Biostatistical Sciences, Wake Forest University 

School of Medicine, Winston-Salem, North Carolina, United 

States of America; 4. Division of Human Genetics, Cincinnati 

Children’s Hospital Medical Center, Cincinnati, Ohio, United 

States of America; 5. Institute of Child Health, University 

College London, London, United Kingdom; 6. German Centre 

for Rheumatology in Children and Young People, 

Garmische-Partenkirchen, Germany



Poster viewing 

Tue 1 May 2012

Poster viewing: Tuesday 1 May 2012 

Tuesday 1 May 2012 | Poster viewing 79 

BHPR research: qualitative 

1 COMPLEX REASONING DETERMINES PATIENTS’ PERCEPTION 

OF OUTCOME FOLLOWING FOOT SURGERY IN RHEUMATOID 

ARTHRITIS 

Michael R. Backhouse 1,2 , Karen A. Vinall 1 , 

Anthony Redmond 1,2 , Philip Helliwell 1,2 , Anne-Maree Keenan 1 

1. 

Section of Musculoskeletal Disease, University of Leeds, 

Leeds, United Kingdom. 2. Leeds Musculoskeletal Biomedical 

Research Unit, University of Leeds, Leeds, United Kingdom. 

2 AN EVALUATION OF PATIENTS’ PERSPECTIVES OF 

PARTICIPATING IN A TWO WEEK INPATIENT ANKYLOSING 

SPONDYLITIS (AS) REHABILITATION PROGRAMME 

Rebecca M. Dale 1,2 , Amanda Thomas 1 , Diane Aronson 1 , 

Julie Turner-Cobb 2 , Raj Sengupta 1 , Brisa France 1 , Ingrid Hill 1 

1. 

Rheumatology Department, Royal National Hospital for 

Rheumatic Diseases, Bath, United Kingdom. 2. Health 

Psychology Department, University of Bath, Bath, 

United Kingdom. 

3 “YOU MAKE YOUR OWN LUCK”: THREE DIFFERENT 

PERCEPTIONS OF LIVING WITH RA: A Q-METHODOLOGICAL 

STUDY 

Caroline A. Flurey 1 , Marianne Morris 1 , Jon Pollock 1 , 

Rod Hughes 3 , Pam Richards 2 , Sarah Hewlett 1 

1. 


England, Bristol, United Kingdom. 2. Rheumatology, University 

Hospitals Bristol, Bristol, United Kingdom. 3. Rheumatology, 

St Peter’s Hospital, Chertsey, United Kingdom. 

4 WHAT I WANT THE HEALTH PROFESSIONAL TO KNOW: 

THE EXPERIENCES OF PEOPLE WITH OSTEOARTHRITIS 

AND RHEUMATOID ARTHRITIS 

Sarah Ryan 1 , Kate Lille 1 , Jo Adams 2 , Inam Haq 3 

1. 

School of Nursing & Midwifery, Keele University, Stoke on 

Trent, United Kingdom. 2. School of Health Sciences, University 

of Southampton, Southampton, United Kingdom. 3. Medical 

Education, Arthritis Research UK, London, United Kingdom. 

5 EXPLORING OCCUPATIONAL GAIN IN PEOPLE WITH 

INFLAMMATORY ARTHRITIS RECEIVING ANTI-TNFα 

Margaret McArthur 1 , Lynne Goodacre 1 , Linda Birt 1 

1. 

School of Allied Health Professions, University of East Anglia, 

Norwich, United Kingdom. 

6 “JUST DO SOMETHING ABOUT MY FEET”: FOOT PROBLEMS 

AND ACCESS TO FOOT CARE IN PEOPLE WITH RHEUMATOID 

ARTHRITIS 

Oonagh Wilson 1 , John Kirwan 2 , Emma Dures 1 , Enid Quest 2 , 

Sarah Hewlett 1 

1. 


England, Bristol, United Kingdom. 2. Academic Rheumatology 

Unit, University of Bristol, Bristol, United Kingdom. 

7 OBSERVATIONAL STUDY OF EXERCISE AND RA: PATIENTS 

PERCEPTIONS AND EFFECT ON DISEASE ACTIVITY 

MEASURES 

Rizwan Rajak 1 , Tasmin Thomas 1 , Tom Lawson 1 

1. 

Rheumatology Dept, Princess of Wales Hospital, ABM Health 

Board, Bridgend, United Kingdom. 

8 EXPLORING THE EXPERIENCES AND NEEDS OF YOUNG 

ADULTS (16-25 YRS), WITH A CHRONIC INFLAMMATORY 

MUSCULOSKELETAL DISEASE WITHIN AN ADULT 

RHEUMATOLOGY SERVICE: A QUALITATIVE STUDY 

Sharon Petford 1,3 , Elizabeth Hale 1 , George D. Kitas 1 , 

Sarah Ryan 2,3 

1. 

Rheumatology, The Dudley Group of Hospitals NHS 

Foundation Trust, Dudley, United Kingdom. 2. Rheumatology, 

The Haywood Hospital, Stoke-on-Trent, United Kingdom. 

3. 

Nursing, Keele University, Newcastle-under-Lyme, 


Don’t forget 

to sign up for 

poster tours!

80 Poster viewing | Tuesday 1 May 2012 

9 INVOLVING SERVICE USERS IN TRIAL DESIGN: OUTCOMES, 

SPLINT SELECTION AND PLACEBO DESIGN IN A TRIAL OF 

TREATMENT FOR THUMB BASE OSTEOARTHRITIS 

Rachael Gooberman-Hill 1 , Clare Jinks 2 , Krysia Dziedzic 2 , 

Sofia Barbosa Bouças 3 , Kelly Hislop 3 , Carol Rhodes 2 , 

Jo Adams 3 

1. 

Musculoskeletal Research Unit, School of Clinical Sciences, 

University of Bristol, Bristol, United Kingdom. 2. Primary Care 

Sciences, Keele University, Keele, United Kingdom. 3. Faculty 

of Health Sciences, University of Southampton, Southampton, 


10 ‘…WELL, I PUT IT DOWN TO HAVING A CLEAR CONSCIENCE; 

BEING POLITE TO ALL PEOPLE AND BEING A MEMBER OF 

THE LABOUR PARTY.’ PREVENTION OF KNEE PAIN: A 

QUALITATIVE STUDY IN SYMPTOMLESS OLDER ADULTS 

Fizzah Ali 1 , Clare Jinks 1 , Bie Nio Ong 1 

1. 

Arthritis Research UK Primary Care Centre, Primary Care 

Sciences, Keele University, Keele, United Kingdom. 

BHPR Research - quantitative 

11 CONCURRENT VALIDATION OF THREE NOVEL ACTIVITY 

MONITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS 

Michael R. Backhouse 1, 2 , Derrick White 2 , Elizabeth Hensor 1, 2 , 

Anne-Maree Keenan 2 , Philip Helliwell 1, 2 , Anthony Redmond 1, 2 

1. 


Leeds, United Kingdom. 2. NIHR Leeds Biomedical Research 

Unit, University of Leeds, Leeds, United Kingdom. 

12 FACTORS ASSOCIATED WITH ADHERENCE IN RHEUMATOID 

ARTHRITIS 

Anna M. Ferguson 1 , Abdel Douiri 2 , David L. Scott 1 , 

Heidi Lempp 1 

1. 

Academic Rheumatology, King’s College London University, 

London, United Kingdom. 2. Department of Primary Care And 

Public Health Sciences, King’s College London, London, 


13 HEALTH PROFESSIONALS’ PERCEPTIONS OF THE EFFECTS 

OF EXERCISE ON JOINT HEALTH IN RHEUMATOID ARTHRITIS 

(RA) PATIENTS I; A QUESTIONNAIRE STUDY 

Serena Halls 1 , Rebecca-Jane Law 1 , Jeremy Jones 1,2 , 

David Markland 1 , Peter Maddison 1 , Jeanette Thom 1 

1. 


University, Bangor, United Kingdom. 2. Rheumatology, Betsi 

Cadwaladr University Health Board, Bangor, United Kingdom. 

14 CARTILAGE TURNOVER, SYSTEMIC AND SYNOVIAL 

INFLAMMATION; THE ACUTE RESPONSE TO HIGH-INTENSITY 

AEROBIC AND RESISTANCE EXERCISE 

Rebecca-Jane Law 1 , Jeanette M. Thom 1 , Peter Maddison 1 , 

Anne Breslin 2 , Alexandra Kraus 3 

1. 


University, Bangor, United Kingdom. 2. Rheumatology, Betsi 

Cadwaladr University Health Board, Bangor, United Kingdom. 

3. 

Radiology, Betsi Cadwaladr University Health Board, Bangor, 


15 THE CONTINUING NEED OF BME COMMUNITIES FOR 

ARTHRITIS EDUCATION 

Chandrika Gordhan 1,2 , Sean Dennis 1 , John Connor 1 , Bhavani 

Chowdhary 1 , Neena Lottay 1 , Parmjit Juneja 1 , Paul A. Bacon 2, 1 

1. 

Birmingham Arthritis resource Centre, Birmingham Central 

Library, Birmingham, United Kingdom. 2. Rheumatology, 

University of Birmingham, Birmingham, United Kingdom. 

16 MEASURING THE RESPONSE OF EXTRA HEPATIC 

SYMPTOMS AND QUALITY OF LIFE TO ANTIVIRAL 

TREATMENT IN PATIENTS WITH HEPATITIS C 

David Isaacs 1 , James Jack 2 , Majella Keller 2 , Jeremy Tibble 2 , 

Inam Haq 1 

1. 

Brighton & Sussex Medical School, Brighton, United 

Kingdom. 2. Medicine, Royal Sussex County Hospital, 

Brighton, United Kingdom.


17 DEVELOPMENT OF THE EVALUATION OF DAILY ACTIVITY 

QUESTIONNAIRE (EDAQ) IN MUSCULOSKELETAL 

CONDITIONS: PHASE ONE 

Alison Hammond 1 , Rachel Gill 1 , Sarah Tyson 1 , Alan Tennant 2 , 

Ulla Nordenskiold 3 

1. 

Centre for Health Sciences Research, University of Salford, 

Salford, United Kingdom. 2. Academic Rehabilitation, 

University of Leeds, Leeds, United Kingdom. 3. Rehabilitation 

Medicine, Sahlgrenska Academy, Goteborg, Sweden. 

BHPR – Clinical evaluation and audit delivery 

18 AUDIT: ARE POTENTIAL REACTIVE ARTHRITIS PATIENTS 

SCREENED FOR A SEXUAL AETIOLOGY? 

Emily E. Pease 1 , Colin T. Pease 1 

1. 

Rheumatology, Chapel Allerton Hospital, Leeds, 


19 CONNECTIVE TISSUE DISEASE SERVICE IN A DISTRICT 

HOSPITAL - ARE WE ACHIEVING QUALITY OF CARE? 

Anne Trehane 1 , Fouz Rahmeh 1 , Patricia Cornell 1 , 

Sarah L. Westlake 1 

1. 

Rheumatology, Poole Hospital NHS Trust, Poole, 


20 MONITORING IGG FOLLOWING RITUXIMAB THERAPY FOR 

RHEUMATOID ARTHRITIS 

Katy Rose 1 , Catherine Fouad Alber 1 , Liam Watson 1 , 

Richard Stratton 2,1 , Mark Lazarus 2 

1. 

Medical School, UCL , London, London, United Kingdom. 

2. 

Rheumatology, Royal Free Hospital, London, United 

Kingdom. 

21 A SERVICE EVALUATION OF A PHYSIOTHERAPY 

EXTENDED SCOPE PRACTITIONER COMMUNITY-LED 

INJECTION SERVICE 

Natasha E. McNeilly 1, 2 , Jackie Waterfield 2 

1. 

Musculoskeletal Service, Solihull Community Services 

(HEFT), Solihull, United Kingdom. 2. Physiotherapy, 

Keele University, Staffordshire, United Kingdom. 

22 POST-OPERATIVE REHABILITATION PROVIDES UNMET NEED 

FOR BETTER PATIENT SUPPORT AND ADVICE FOLLOWING 

LUMBAR SPINAL FUSION 

Mike Hurley 1 , James Greenwood 2 

1. 

School of Rehabilitation Sciences, St George’s University 

of London, London, United Kingdom. 2. Physiotherapy 

Department, University College Hospital, London, 


23 SELF REFERRAL TO RHEUMATOLOGY PHYSIOTHERAPY: 

A VITAL COMPONENT OF SELF MANAGEMENT 

Ann M. Clayton 1,2 , Michael Lynch 1 , Adrian Clewes 1 , 

Julie Dawson 1 , Veronica Abernethy 1 , Ann E. Griffiths 1,2 

1. 

Rheumatology, St Helens & Knowsley Teaching Hospitals, 

St. Helens, United Kingdom. 2. Secondary Care Therapy 

Service, KIPS at 5 Boroughs Partnership, St. Helens, 


24 DOES OUR TELEPHONE ADVICE LINE SERVICE MEET 

CURRENT NATIONAL GUIDANCE? 

Victoria A. Chamberlain 1 , YokeMei McLoughlin 1 , 

Sophie Campbell 1 , Janita Hayes 1 , Claire Moffat 1 , 

Frank McKenna 1 , Preeti Shah 1 

1. 

Rheumatology, Trafford Healthcare NHS Trust, Manchester, 


25 EVALUATION OF PREEXISTING PULMONARY DISEASE IN RA 

PATIENTS INITIATING ANTITNF 

Rizwan Rajak 1 , Ann Williams 1 , Ceril Rhys-Dillon 1 , 

Rhian Goodfellow 1 , James C. Martin 1 

1 

Rheumatology, Cwm Taf Health Board, Llantrisant, 


26 ALL WALES RE-AUDIT OF THE INITIAL MANAGEMENT OF 

GIANT CELL ARTERITIS (GCA) 

Rizwan Rajak 1 , Farhan Bari 1 , Gwenan Hughes 1 , Eleri Thomas 1 

1. 

Rheumatology Dept, Princess of Wales Hospital, ABM Health 

Board, Bridgend, United Kingdom. 

27 CHRONIC KIDNEY DISEASE MAY BE UNDERRECOGNISED IN 

RHEUMATOLOGY PATIENTS ON DMARDS 

Sarah Baker 1 , David Collins 1 , Elizabeth Price 1 , Lyn Williamson 1 

1. 

Rheumatology, Great Western Hospital, Swindon, Swindon, 

United Kingdom.


28 AUDIT: IN A ROUTINE RHEUMATOLOGY OPD WHAT IS THE 

UTILITY OF WHOLE SPINE MRI IN PATIENTS WITH 

SUSPECTED INFLAMMATORY BACK PAIN (IBP)? 

Lisa Dunkley 1 , Matthew J. Youll 1 

1. 

Rheumatology, Sheffield Teaching Hospitals NHS Trust, 

Sheffield, South Yorkshire, United Kingdom. 

29 A RE-AUDIT OF SERUM 25-HYDROXY VITAMIN D IN A 

RHEUMATOLOGY OUTPATIENT CLINIC 

Mia Rodziewicz 1,2 , John A. Reynolds 2 , Jacqueline Berry 3,2 , 

Chee Pavey 2 , Kimme Hyrich 2 , Rachel Gorodkin 2 , 

Kate Wilkinson 2 , Ian Bruce 2 , Anne Barton 2 , Alan Silman 2 , 

Pauline Ho 2 

1. 

Medical School, The University of Manchester, Manchester, 

United Kingdom. 2. The Kellgren Centre for Rheumatology, 

Manchester Royal Infirmary, Manchester, United Kingdom. 

3. 

Vitamin D Research Group, Manchester Royal Infirmary, 

Manchester, United Kingdom. 

Award winner 

30 DOES INFORMING PATIENTS ABOUT THE LINK BETWEEN 

GUM DISEASE AND RHEUMATOID ARTHRITIS (RA) 

ENCOURAGE BETTER DENTAL CARE? 

Tricia Cornell 1 , Sarah L. Westlake 1 , Selwyn Richards 1 

1. 

Poole Hospital NHS Foundation Trust, Poole, 


31 IMPACT OF ANTI-TNF THERAPY ON BASDAI AND 

EMPLOYMENT IN ANKYLOSING SPONDYLITIS 

A. Holmes 1 , S. Parker 1 , H. Smith 1 , N. Briggs 1 , S. Arthanari 1 , 

M. Nisar 1 

1. 

Department of Rheumatology, Burton Hospitals NHS 

Foundation Trust, Burton on Trent, United Kingdom. 

32 A REVIEW OF THE IMPLEMENTATION OF CURRENT 

GUIDELINES REGARDING TRIPLE DMARD THERAPY FOR 

EARLY RA: IS IT HAPPENING IN PRACTICE? 

Catharine Thwaites 1,2 , Sarah Ryan 2,1 , Sanjeet Kamath 2 , 

Shyra Price 2 

33 NEGOTIATING TARGETS FOR THERAPY ACROSS THE RANGE 

OF FOLLOW-UP RHEUMATOLOGICAL CONDITIONS 

Sandra M. Robinson 1 , David Walker 1 

1. 

Musculoskeletal Directorate, Newcastle Upon Tyne Hospitals 

NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom. 

34 AN AUDIT ON VACCINATIONS IN PATIENTS WITH 

AUTOIMMUNE RHEUMATIC DISEASES 

Hazel Coop 1 , Wahab Al-Allaf 1 

1. 

Rheumatology, Royal Wolverhampton NHS trust, 

Wolverhampton, United Kingdom. 

35 PERSISTENCE WITH HYDROXYCHLOROQUINE IN A 

RHEUMATOLOGY COHORT 

Sarah Baker 1 , Lyn Williamson 1 , Elizabeth Price 1 , David Collins 1 

1. 

Rheumatology, Great Western Hospital, Swindon, United 

Kingdom. 

36 AN AUDIT OF THE EFFECTIVENESS OF SILDENAFIL IN 

THE MANAGEMENT OF PATIENTS WITH MULTI-TREATMENT 

RESISTANT RAYNAUD’S PHENOMENON 

Rebecca C. Charleton 1 , Bridget Griffiths 1 

1 

Rheumatology Department, Newcastle Hospitals Foundation 

Trust, Newcastle upon Tyne, United Kingdom. 

37 THE APPROPRIATENESS OF ANA REQUESTING BY GENERAL 

PRACTITIONERS AND THE RELEVANCE OF A POSITIVE TEST 

Elizabeth A. Edwards 1 , Rosamund Partlett 1 , Keith Martin 2 , 

Mike Tarzi 2 , Sathianathan Panthakalam 1 

1. 

Rheumatology, East Sussex Healthcare NHS, Eastbourne, 

United Kingdom. 2. Immunology, East Sussex Healthcare NHS, 

Eastbourne, United Kingdom. 

38 AN AUDIT TO ASSESS THE EFFICACY OF THE OXFORD 

MUSCULOSKELETAL REFERRAL HUB SERVICE 

Tanya Freeman 1 , Louise Ainley 1 , Michael Turner 1 

1. 

Oxford university, Oxford, United Kingdom. 

1. 

School of Nursing and Midwifery, Keele University, 

Newcastle-under-Lyme, Staffordshire, United Kingdom. 

2. 

Rheumatology Department, Haywood Hospital, 

Stoke-on Trent, Staffordhsire, United Kingdom.


39 DO PATIENTS WITH RHEUMATOID ARTHRITIS (RA) WANT 

SMS TEXT MESSAGES TO REMIND THEM ABOUT HOSPITAL 

APPOINTMENTS AND DRUG ADHERENCE? 

Lyndsay Hughes 1 , Bridget Russell 1 , Suzanne Jenkins 2 , 

John Done 1 , Adam Young 2 

1. 

Centre for Lifespan and Chronic Illness Research, University 

of Hertfordshire, Hatfield, United Kingdom. 2. Rheumatology, 

West Herts Hospital NHS Trust, St.Albans, United Kingdom. 

40 THE FEASIBILITY, ACCEPTABILITY AND USEFULNESS OF 

EXTENDED DATA COLLECTION IN RHEUMATOID ARTHRITIS 

Tadeusz Jones 1 , Ian C. Gaywood 1 , Ira Pande 1 , 

Marie-Josèphe Pradère 1 

1. 

Rheumatology, Nottingham University Hospitals NHS Trust, 

Nottingham, United Kingdom. 

41 AN AUDIT OF ASSESSING RISK AND TREATING 

MYCOBACTERIAL INFECTION IN PATIENTS WITH 

INFLAMMATORY ARTHRITIS PRIOR TO STARTING AN 

ANTI-TNF AGENT 

Mahua Bhaduri 1 , Angela Smith 1 , Haley Cook 1 , 

Sonya Abraham 1 

1. 

Imperial College London, London, United Kingdom. 

42 IMPACT OF SEXUAL DYSFUNCTION AND PSYCHOLOGICAL 

EFFECTS IN WOMEN WITH SYSTEMIC SCLEROSIS 

Tanaka Ngcozana 1 , Christopher P. Denton 1 , Louise Parker 1 , 

Carol M. Black 1 , Voon Ong 1 

1. 

Centre of Rheumatology and Connective Tissue Diseases, 

Royal Free Hampstead NHS Trust, London, United Kingdom. 

Imaging 

43 AN OBSERVATIONAL STUDY OF THE UTILITY OF CRANIAL 

ULTRASOUND IN SUSPECTED GIANT CELL ARTERITIS 

Nicola Thompson 1 , Catherine White 1 , Martin Duddy 2 , 

Paresh Jobanputra 1 

1. 

Department of Rheumatology, Queen Elizabeth Hospital, 

Birmingham, United Kingdom. 2. Department of Radiology, 

Queen Elizabeth Hospital, Birmingham, United Kingdom. 

44 DEVELOPMENT OF AN ACCREDITED INNOVATIVE FOCUSSED 

ULTRASOUND TRAINING COURSE FOR REGISTERED HEALTH 

PROFESSIONALS 

Pauline Bacon 1 , Jacqueline Smith 2 , Ann Richardson 3 , 

Giorgio Giancola 3 , Vicky Soh 3 , Simon Spencer 3 , 

Ann Greenhalgh 3 , Mark Hanson 1 , Denise De Lord 2 

1. 

Medical Physics, EKHUFT, Canterbury, United Kingdom. 

2. 

Rheumatology, EKHUFT, Canterbury, United Kingdom. 

3. 

Radiology, EKHUFT, Canterbury, United Kingdom. 

45 THE POWER OF PET/CT 

Mark Lloyd 1 , Henna Wong 4 , Damian Wren 2 , Bob Grover 6 , 

John Hall 7 , Cai Neville 5 , Peter Alton 3 

1. 

Rheumatology, Frimley Park Hospital, Frimley, United 

Kingdom. 2. Neurology, Frimley Park Hospital, Frimley, 

United Kingdom. 3. Haematology, Frimley Park Hospital, 

Frimley, United Kingdom. 4. Immunology, John Radcliffe 

Infirmary, Oxford, United Kingdom. 5. Rheumatology, Royal 

Surrey County Hospital, Guildford, United Kingdom. 

6. 

Gastroenterology, Hillingdon Hospital, Hillingdon, 

United Kingdom. 7. Radiology, Frimley Park Hospital, 

Frimley, United Kingdom. 

46 ULTRASOUND GUIDED SYNOVIAL BIOPSIES: SAFETY, 

TOLERABILITY, AND TISSUE QUALITY 

Stephen Kelly 1 , Michele Bombardieri 1 , Fran Humby 1 , 

Nora Ng 1 , Maria Di Cicco 1 , Rebecca Hands 1 , Oscar Epis 5 , 

Andrew Filer 2 , Christopher Buckley 2 , Iain McInnes 4 , 

Peter Taylor 3 , Costantino Pitzalis 1 

1. 

Experimental Medicine and Rheumatology, Queen Marys 

University of London, London, United Kingdom. 

2. 


Birmingham, United Kingdom. 3. Nuffield Department of 

Orthopaedics, Rheumatology and Musculoskeletal Sciences, 

University of Oxford, Oxford, United Kingdom. 4. Glasgow 

Biomedical Research Centre, University of Glasgow, Glasgow, 

United Kingdom. 5. Rheumatology, A.O. Ospedale Niguarda 

Ca’ Granda, Milan, Italy.


47 USEFULNESS OF NOVEL WHOLE BODY MULTIPLE JOINT 

MRI IMAGING IN ESTABLISHING ACCURATE AND TIMELY 

DIAGNOSES IN PATIENTS PRESENTING WITH 

INFLAMMATORY ARTHRITIS 

Jane Freeston 1,2 , Philip Conaghan 1,2 , Andrew Grainger 3 , 

Philip J. O’Connor 3 , Rob Evans 2 , Paul Emery 1,2 , 

Richard Hodgson 2 

1. 


Leeds, United Kingdom. 2. Leeds Musculoskeletal Biomedical 

Research Unit, Chapel Allerton Hospital, Leeds, United 

Kingdom. 3. Leeds Teaching Hospitals NHS Trust, Chapel 

Allerton Hospital, Leeds, United Kingdom. 

48 PREDICTORS OF RADIOGRAPHIC PROGRESSION IN 

METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID 

ARTHRITIS BASED ON ONE-YEAR RADIOGRAPHIC DATA 

FROM THE GO-BEFORE GOLIMUMAB CLINICAL TRIAL 

Paul Emery 1 , Roy Fleischmann 2 , Chenglong Han 3 , Desiree Van 

de Heide 4 , Philip Conaghan 1 , Weichun Xu 5 , Elizabeth Hsia 5,6 

1. 

NIHR Leeds Musculoskeletal Biomedical Research Unit, 

University of Leeds, Leeds, United Kingdom. 2. Metroplex 

Clinical Research Center, University of Texas Southwest 

Medical Center, Dallas, TX, United States. 3. Worldwide Market 

Access, Janssen Global Services, LLC, Malvern, PA, United 

States. 4. Rheumatology, Leiden University Medical Center, 

Leiden, Netherlands. 5. Immunology, Janssen Research & 

Development, Inc, Malvern, PA, United States. 

6. 

Rheumatology, University of Pennsylvania School of 

Medicine, Philadelphia, PA, United States. 

49 GOLIMUMAB TREATMENT INHIBITS PROGRESSION IN JOINT 

DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS 

REGARDLESS OF BASELINE DISEASE SEVERITY 

Arthur Kavanaugh 1 , Dafna Gladman 2 , 

Chandrabhusan Chattopadhyay 3 , Anna Beutler 4 , 

Chenglong Han 5 

1. 

Rheumatology, Allergy and Immunology, University of 

California San Diego, San Diego, CA, United States. 

2. 

Rheumatology, University of Toronto, Toronto, ON, Canada. 

3. 

Rheumatology, Wrightington Hospital, Toronto, United 

Kingdom. 4. Immunology, Janssen Research & Development, 

Inc, Malvern, PA, United States. 5. Worldwide Market Access, 

Janssen Global Services, L.L.C, Malvern, PA, United States. 

50 ULTRASOUND DETECTED BONE EROSIONS: ARE THEY 

SPECIFIC FOR RHEUMATOID ARTHRITIS? 

Ahmed S. Zayat 1 , Philip Conaghan 1 , Jane Freeston 1 , 

Elizabeth Hensor 1 , Karen Ellegard 2 , Lene Terslev 2 , Paul Emery 1 , 

Richard J. Wakefield 1 

1. 

Academic Unit of Musculoskeletal Disease, University of 

Leeds, Leeds, United Kingdom. 2. Copenhagen University 

Hospital, Parker Institute, Copenhagen, Denmark. 

51 THE USEFULNESS OF A MUSCULOSKELETAL ULTRASOUND 

(MUS) SCORING SYSTEM FOR 22 HAND JOINTS 

EXAMINATION FOR THE DETECTION OF EARLY 

UNDIFFERENTIATED INFLAMMATORY ARTHRITIS AND 

TREATMENT DECISIONS MAKING IN ESTABLISHED 


Coziana Ciurtin 1 , Maria Leandro 1 , Dzifa Dey 1 , 

Anupama Nandagudi 1 , Ian Giles 1 , Mike Shipley 1 , 

Vanessa Morris 1 , John Ioannou 1 , Michael Ehrenstein 1 , Debajit 

Sen 1 

1. 

Department of Rheumatology, University College London 

Hospitals, London, United Kingdom. 

Metabolic and crystal arthropathies 

52 AUDIT OF THE ADHERENCE TO BSR GUIDELINES ON THE 

MANAGEMENT OF GOUT (2007), IN TWO PRIMARY CARE 

CENTRES WITHIN THE MERSEYSIDE REGION 

Marian Chan 1 , Tim M. Quinlan 2 , Richard Brophy 2 , Devesh 

Mewar 1 

1. 

Rheumatology, Royal Liverpool University and Broadgreen 

Hospital, Liverpool, United Kingdom. 2. General Practice, 

Mersey Deanery, Mersey, United Kingdom. 

53 A CASE OF SPINAL GOUT 

Dipti Patel 1 , M. J. Wilby 3 , Vincent Pellegrini 2 , Brian Eyes 2 , 

Daniel Crooks 4 , Marina Anderson 1 

1. 

Rheumatology, Aintree University Hospital NHS Foundation 

Trust, Liverpool, United Kingdom. 2. Radiology, Aintree 

University Hospital NHS Foundation Trust, Liverpool, United 

Kingdom. 3. Neurosurgery, The Walton Centre NHS Foundation 

Trust, Liverpool, United Kingdom. 4. Histopathology, The Walton 

Centre NHS Foundation Trust, Liverpool, United Kingdom.


Miscellaneous rheumatic diseases 

54 STEROID INJECTION IN PLANTAR FASCIITIS - A PLACEBO 

CONTROLLED TRIAL 

Elisabeth Ball 1 , Helen McKeeman 1 , James Burns 1 , 

Wing Hoi Yau 1 , Owen Moore 1 , Joanne Foo 1 , Claire Benson 1 , 

Chris Patterson 2 , Gary Wright 1 , Allister Taggart 1 

1. 

Rheumatology, Musgrave Park Hospital, Belfast, United 

Kingdom. 2. Medical Statistics, Queens’ University, Belfast, 


55 HELPLINE AUDIT: DOES THE NRAS TELEPHONE HELPLINE 

SERVICE BENEFIT USERS WHO HAVE BEEN DIAGNOSED 

WITH RHEUMATOID ARTHRITIS? 

Sarah Drew 1 , Lorraine Tanner 2 

1. 

Fundraising Team, National Rheumatoid Arthritis Society, 

Maidenhead, United Kingdom. 2. Helpline Team, National 

Rheumatoid Arthritis Society, Maidenhead, United Kingdom. 

56 PRESENTATION AND CLINICAL OUTCOME OF SARCOIDOSIS 

PATIENTS PRESENTING TO RHEUMATOLOGY: A REGIONAL 

AUDIT 

Kaushik Sanyal 1 , Brian E. Bourke 1 , Mark Lloyd 3 , Claire Alston 2 , 

Charlotte Baqai 3 , Michael Chard 6 , Virinderjit Sandhu 1 , 

Cai Neville 4 , Kelsey Jordan 6 , Catherine Munns 3 , Louisa Zouita 3 , 

Warren Shattles 2 , Ursula Davies 2 , Raad Makadsi 2 , 

Sian Griffith 2 , Patrick D. Kiely 1 

1. 

Rheumatology, St. George’s Hospital NHS Trust, London , 

United Kingdom. 2. Rheumatology, East Surrey Hospital NHS 

Trust, Redhill, United Kingdom. 3. Rheumatology, Frimley Park 

Hospital NHS Trust, Frimley, United Kingdom. 4. Rheumatology, 

Royal Surrey County Hospital NHS Trust, Guildford, United 

Kingdom. 5. Rheumatology, Brighton and Sussex University 

Hospital NHS Trust, Brighton, United Kingdom. 

6. 

Rheumatology, Worthing Hospital NHS Trust, Worthing, 


57 SERUM LEPTIN LEVELS IN PATIENTS WITH 

HYPOTHYROIDISM AND SYMPTOMS OF INFLAMMATORY 

ARTHRITIS IS SIGNIFICANTLY INCREASED COMPARED 

WITH A MATCHED GROUP WITHOUT PERIPHERAL JOINTS 

ASSOCIATED SYMPTOMS 

Coziana Ciurtin 1,2 , Ionela Dimofte 2 , Mihaela Dabu 2 , 

Bogdan Dabu 2 

1. 

Department of Rheumatology, UCLH, London, London, 

United Kingdom. 2. Department of Molecular Biology, 

Carol Davila University of Medicine and Pharmacy, 

Bucharest, Romania. 

58 CLINICAL EFFECTIVENESS OF PAH SPECIFIC THERAPIES IN 

SARCOIDOSIS-RELATED PULMONARY HYPERTENSION 

David Dobarro 1 , Benjamin E. Schreiber 1 , Clare Warrell 1 , 

Clive Handler 1 , Gerry Coghlan 1 , Chris Denton 1 

1. 

Pulmonary Hypertension, Royal Free Hampstead Hospital 

NHS Trusts, London, United Kingdom. 

59 CLINICAL AND LABORATORY FEATURES OF PATIENTS 

PRESENTING TO A RHEUMATOLOGY CLINIC WITH POSITIVE 

ANTI-C1Q ANTIBODY SEROLOGY 

Jasmine Ishorari 1 , Chris Bunn 1 , Huw Beynon 1 , 

Christopher P. Denton 1 , Richard Stratton 1 

1. 

Rheumatology Department, Royal Free hospital, London, 


Rheumatoid arthritis: clinical features 

60 COMPARISON OF MOBILE AND FIXED BEARING TOTAL KNEE 

REPLACEMENTS IN RHEUMATOID ARTHRITIS 

Joby J. George Malal 1 , Ben Boton-Maggs 1 

1. 

Orthopaedics, St Helens & Knowsley Teaching Hospitals, 

Widnes, United Kingdom. 

61 DEFINING CRITERIA FOR RHEUMATOID ARTHRITIS 

PATIENT-DERIVED DISEASE ACTIVITY SCORE (PDAS) THAT 

CORRESPOND TO DISEASE ACTIVITY SCORE 28 (DAS28) 

AND CLINICAL DISEASE ACTIVITY INDEX (CDAI) BASED 

DISEASE STATUSES AND RESPONSE CRITERIA 

Alexander Leung 1 , Daniel Farewell 2 , Ernest Choy 1 

1. 

Rheumatology, Cardiff University School of Medicine, Cardiff, 

United Kingdom. 2. Institute of Primary Care & Public Health, 

Cardiff University School of Medicine, Cardiff, United Kingdom.


62 PREDICTING ONGOING ACTIVE DISEASE IN EARLY RA USING 

CLINICAL MEASURES 

Nicola J. Gullick 1 , Adam Young 2 , Ernest H. Choy 3 , 

David L. Scott1 

1. 

Academic Department of Rheumatology, King’s College 

London, London, United Kingdom. 2. Rheumatology, St Albans 

City Hospital, Cardiff, United Kingdom. 3. Section of 

Rheumatology, Cardiff University School of Medicine, Cardiff, 


63 THE ROLE OF AMINO-PROPEPTIDE OF TYPE III COLLAGEN 

AND HYALURONIC ACID AS BIOMARKERS FOR SYNOVIAL 

VOLUME IN PATIENTS WITH RHEUMATOID ARTHRITIS 

Chris Wincup 1 , Ben Fisher 1 , Peter Charles 1 , Peter Taylor 2 

1. 

Kennedy Institute of Rheumatology, Imperial College, 

London, United Kingdom. 2. Kennedy Institute of 

Rheumatology, University of Oxford, Oxford, United Kingdom. 

64 TEMPORAL IMPROVEMENTS IN DISEASE ACTIVITY IN 

OUTPATIENTS WITH RHEUMATOID ARTHRITIS 

Nicola J. Gullick 1,2 , Louise C. Pollard 1 , Bruce W. Kirkham 2 , 

David L. Scott 1 

1. 

Academic Department of Rheumatology, King’s College, 

London, London, United Kingdom. 2. Rheumatology, Guy’s & 

St Thomas’ NHS Foundation Trust, London, United Kingdom. 

65 BIOMAKER SIGNATURE IN RHEUMATOID ARTHRITIS 

PATIENTS WITH LOW DISEASE ACTIVITY: THE 

REMIRA STUDY 

Margaret H. Ma 1 , Saroja Ramanujan 2 , Guy Cavet 2 , 

Doug Haney 2 , Gabrielle H. Kingsley 1 , David Scott 1 , 

Andrew Cope 1 

1. 

Rheumatology, King’s College London, London, United 

Kingdom. 2. Informatics, Crescendo Bioscience, South 

San Francisco, CA, United States. 

67 LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID 

ARTHRITIS CLINICAL TRIALS 

Mark C. Genovese 1 , Anthony Sebba 2 , Andrea Rubbert-Roth 3 , 

Juan Scali 4 , Moshe Zilberstein 5 , Liz Thompson 6 , Ronald Van 

Vollenhoven 7 

1. 

Rheumatology , Stanford University Medical Center, Palo 

Alto, CA, United States. 2. Rheumatology, University of South 

Florida, Palm Harbor, FL, United States. 3. Rheumatology, 

University of Cologne, Cologne, Germany. 4. Rheumatology, 

Durand University Hospital, Buenos Aires, Argentina. 5. Roche, 

Roche Nutley, Nutley, NJ, United States. 6. Roche, Roche UK, 

Welwyn, United Kingdom. 7. Rheumatology, Karolinska 

University Hospital, Stockholm, Sweden. 

68 THE EFFICACY OF TOCILIZUMAB IN PATIENTS WITH 

SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 52-WK DATA 

FROM A PHASE 3 CLINICAL TRIAL 

Fabrizio De Benedetti 1 , Hermine Brunner 2 , Roger Allen 3 , 

Diane Brown 2 , Jeffrey Chaitow 3 , Manuela Pardeo 3 , 

Graciela Espada 3 , Berit Flato 3 , Gerd Horneff 3 , Clare Devlin 4 , 

Andrew Kenwright 4 , Rayfel Schneider 5 , Patricia Woo 6 , 

Alberto Martini 3 , Daniel Lovell 2 , Nicola Ruperto 3 

1. 

Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, 

Rome, Italy. 2. Pediatric Rheumatology Collaborative Study 

Group [PRCSG], Pediatric Rheumatology Collaborative Study 

Group [PRCSG], Cincinnati, OH, United States. 3. Paediatric 

Rheumatology International Trials Organisation – IRCCS 

[PRINTO], Paediatric Rheumatology International Trials 

Organisation – IRCCS [PRINTO] , Genova, Italy. 4. Roche, 

Roche, Welwyn, United Kingdom. 5. Hospital for Sick Children, 

University of Toronto, Toronto, ON, Canada. 6. University 

College London Medical School, University College London 

Medical School, London, United Kingdom. 

66 SENSITIVITY AND SPECIFICITY OF ANTIBODIES TO 

CITRULLINATED VIMENTIN IN RHEUMATOID ARTHRITIS: 

EXPERIENCE FROM A LARGE SECONDARY CARE CENTRE 

Animesh Singh 1 , Jo Wilson 2 , Anthony Isaacs 1 , Charlotte Wing 1 , 

Maeve McLaughlin 1 , Henry Penn 1 

1. 

Department of Rheumatology, Northwick Park Hospital, 

London, United Kingdom. 2. Department of Immunology, 

Northwick Park Hospital, London, United Kingdom.


Rheumatoid arthritis: comorbidities 

69 A RANDOMISED CONTROLLED TRIAL OF A COGNITIVE BE- 

HAVIOURAL PATIENT EDUCATION INTERVENTION VERSUS A 

TRADITIONAL INFORMATION LEAFLET TO ADDRESS THE 

CARDIOVASCULAR ASPECTS OF RHEUMATOID DISEASE 

Holly John 1,2 , Elizabeth D. Hale 1,2 , Gareth J. Treharne 3 , 

George D. Kitas 1,4 , Douglas Carroll 2 

1. 

Department of Rheumatology, Dudley Group of Hospitals 

NHS Trust, Dudley, United Kingdom. 2. Department of Sport 

and Exercise Sciences, University of Birmingham, Birmingham, 

United Kingdom. 3. Department of Psychology, University of 

Otago, Dunedin, New Zealand. 4. AR-UK Epidemiology Unit, 

University of Manchester, Manchester, United Kingdom. 

70 OUTCOME OF WOMEN WITH PREVIOUS CARCINOMA IN 

SITU OF THE CERVIX WITH RESPECT TO FEMALE GENITAL 

CANCER, FOLLOWING TREATMENT WITH NON-BIOLOGIC 

DMARD OR ANTI-TNF FOR RHEUMATOID ARTHRITIS: 

RESULTS FROM THE BSRBR 

Louise Mercer 1 , Audrey Low 1 , James Galloway 1 , Kath Watson 1 , 

Mark Lunt 1 , BSRBR Control Centre Consortium 1 , 

Deborah Symmons 1 , Kimme Hyrich 1 , On Behalf of the BSRBR 2 

1. 


Manchester, Manchester, United Kingdom. 2. British Society 

for Rheumatology, London, United Kingdom. 

71 CARDIOVASCULAR MORTALITY RATES (SMR) ARE ELEVATED 

IN A NATIONAL COHORT OF SUBJECTS WITH RHEUMATOID 

ARTHRITIS COMPARED TO THE UK GENERAL POPULATION 

WHETHER OR NOT THEY WERE TREATED WITH BIOLOGIC 

DRUGS: RESULTS FROM THE BSRBR 

Audrey Low 1 , Louise Mercer 1 , James Galloway 1 , 

Rebecca Davies 1 , Kath Watson 1 , Mark Lunt 1 , BSRBR Control 

Centre Consortium 2 , William Dixon 1 , Kimme Hyrich 1 , 

Deborah Symmons 1,2 

1. 



for Rheumatology, Bride House, London, United Kingdom. 

72 AN AUDIT OF INVESTIGATION OF ANAEMIA IN RHEUMATOID 

ARTHRITIS 

Sharmili Balarajah 1 , Amrita Sandhu 1 , Mercy Ariyo 1 , 

Elizabeth Rankin 1 

1. 

University Hospitals Birmingham NHS Foundation Trust, 

Birmingham, United Kingdom. 

73 ANTI-TNFα THERAPY TRANSIENTLY IMPROVES HIGH 

DENSITY LIPOPROTEIN LEVELS AND MICROVASCULAR 

ENDOTHELIAL FUNCTION IN PATIENTS WITH RHEUMATOID 

ARTHRITIS: A LONGITUDINAL STUDY 

Aamer Sandoo 1,2 , Jet J. Veldhuijzen van Zanten 2,1 , 

Tracey E. Toms 1,3 , Douglas Carroll 2 , George D. Kitas 1,3 

1. 

Rheumatology, Dudley Group of Hospitals, Dudley, United 

Kingdom. 2. School of Sport and Exercise Sciences, University 

of Birmingham, Birmingham, United Kingdom. 3. Arthritis 

Research UK Epidemiology Unit, University of Manchester, 


74 PREDICTORS OF SUBENDOCARDIAL VIABILITY RATIO IN 

PATIENTS WITH RA: THE ROLE OF INFLAMMATION AND 

CLASSICAL CARDIOVASCULAR DISEASE RISK FACTORS 

Aamer Sandoo 1,2 , Jacqueline P. Smith 1 , George D. Kitas 1,3 

1. 

Rheumatology, Dudley Group of Hospitals, Dudley, United 

Kingdom. 2. School of Sport and Exercise Sciences, University 

of Birmingham, Birmingham, United Kingdom. 3. Arthritis 

Research UK Epidemiology Unit, University of Manchester, 


75 IS THE NATURAL HISTORY OF INTERSTITIAL LUNG DISEASE 

IN RHEUMATOID ARTHRITIS CHANGING? 

Saadia Malik 1,2 , Elizabeth Toberty 1 , Nishanthi Thalayasingam 1 , 

Jennifer Hamilton 1 , Clive Kelly 1,2 

1. 

QEH Rheumatology, Gateshead, United Kingdom. 

2. 

Medicine, University of Newcastle upon Tyne, Newcastle, 


76 SEVERE URINARY TRACT INFECTIONS IN PATIENTS WITH 


Daniel Puntis 1 , Saadia Malik 1 , Jennifer Hamilton 1 , 

Vadivelu Saravanan 1 , Martin Rynne 1 , Carol Heycock 1 , 

Clive Kelly 1 

1. 

QEH Rheumatology, Gateshead, United Kingdom.


77 THORACIC HRCT STUDY TO ASSESS FOR PREEXISTING 

LUNG DISEASE IN RA PATIENTS DUE TO START ANTI-TNF 

THERAPY 

Rizwan Rajak 1 , Rhian Goodfellow 1 , Ceril Rhys-Dillon 1 , 

Richard Winter 1 , Phil Wardle 1 , James C. Martin 1 

1. 

Rheumatology, Cwm Taf Health Board, Llantrisant, 


78 THE EFFECT OF ANTI-INFLAMMATORY THERAPY ON LIPID 

SUB-FRACTIONS AND VASCULAR FUNCTION IN 

RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY 

Tracey Toms 1 , Aamer Sandoo 1 , Jacqueline Smith 1 , 

Susan Cadman 1 , Peter Nightingale 3 , George Kitas 1,2 

1. 

Rheumatology, Dudley group of hospitals NHS trust, Dudley, 

United Kingdom. 2. Arthritis Research UK epidemiology unit, 

Manchester University, Manchester, United Kingdom. 

3. 

Wolfson computer laboratory, Birmingham University, 


79 HIGH CRP IS THE BEST MARKER OF DYSLIPIDEMIA IN 

PATIENTS WITH EARLY INFLAMMATORY POLYARTHRITIS (IP): 

RESULTS FROM THE NORFOLK ARTHRITIS REGISTRY (NOAR) 

Awal Z. Alhusain 1 , Suzanne M. Verstappen 1 , Hoda Mirjafari 1 , 

Mark Lunt 1 , Valentine Charlton-Menys 2 , Diane Bunn 3 , 

Deborah Symmons 1 , Paul Durrington 2 , Ian Bruce 1 

1. 


Manchester, Manchester, United Kingdom. 2. Cardiovascular 

Research Group, University of Manchester, Manchester, United 

Kingdom. 3. Norfolk Arthritis Register, University of East Anglia, 

Norwich, United Kingdom. 

80 RHEUMATOID ARTHRITIS PATIENTS ARE TOO FAT AND UNFIT 

Jennifer K. Cooney 1 , Jeanette M. Thom 1 , Jonathan P. Moore 1 , 

Andrew Lemmey 1 , Jeremy G. Jones 2 , Peter J. Maddison 1 , 

Yasmeen A. Ahmad 2 

1. 

School of Sport Health and Exercise Science, Bangor 

University, Bangor, United Kingdom. 2. The Department of 

Rheumatology, Betsi Cadwaladr University Health Board 

(West), Llandudno, United Kingdom. 

81 DEPRESSION AND RHEUMATOID ARTHRITIS: THE 

PREVALENCE AND PREDICTORS OF DEPRESSION IN A 

RHEUMATOID ARTHRITIS POPULATION 

Tazeen J. Ahmed 1 , Francesca Leone 1 , Patrick D. Kiely 1 

1. 

St Georges Healthcare NHS Trust, London, United Kingdom. 

Scleroderma and related disorders 

82 AN AUDIT OF THE TREATMENT OF RAYNAUD’S 

PHENOMENON SECONDARY TO CONNECTIVE TISSUE 

DISEASE AND A COST-EFFECTIVENESS STUDY OF THESE 

TREATMENTS 

Hannah K. Browne 1 , Ceril Rhys-Dillon 1 

1. 

Rheumatology Dept, Royal Glamorgan Hospital, Llantrisant, 


83 ANTI-CENTROMERE ANTIBODY PREDICTS FALL IN ANKLE 

BRACHIAL PRESSURE INDEX (ABPI)IN PATIENTS WITH 

SYSTEMIC SCLEROSIS 

Surabhi Wig 1 , Aurelie Chevance 2 , Tonia Moore 1 , 

Joanne Manning 1 , Andy Vail 2 , Ariane L. Herrick 1 

1. 

Musculoskeletal Research Group, School of Translational 

Medicine, Manchester Academic Health Science Centre, 

Salford Royal NHS Foundation Trust, Salford, Salford, United 

Kingdom. 2. School of Community Based Medicine, University 

of Manchester, Manchester Academic Health Science Centre, 

Salford Royal NHS Foundation Trust, Salford, Salford, United 

Kingdom. 

84 EXPRESSION PROFILING OF SKIN AND LUNG TISSUE AND 

EXPLANTED FIBROBLASTS IN THE TβRIIΔK-FIB TRANSGENIC 

MOUSE MODEL OF SCLERODERMA 

Emma Derrett-Smith 1 , Rachel Hoyles 1 , Pia Moinzadeh 1 , 

Cecilia Chighizola 1 , Korsa Khan 1 , Voon Ong 1 , David Abraham 1 , 

Christopher P. Denton 1 

1. 


UCL Medical School, London, United Kingdom. 

85 BIG IS BEAUTIFUL: BODY SIZE AND SURVIVAL IN 

CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY 

ARTERIAL HYPERTENSION 

Benjamin E. Schreiber 1 , David Dobarro 1 , Clare E. Warrell 1 , 

Clive Handler 1 , Christopher P. Denton 1 , Gerry Coghlan 1 

1. 

Royal Free Hampstead NHS Trust, London, United Kingdom.


86 SURGICAL PROCEDURES ON THE FINGERS IN PATIENTS 

WITH SYSTEMIC SCLEROSIS 

Rebecca Sykes 1 , Lindsay Muir 2 , Holly Ennis 1 , Ariane L. Herrick 1 

1. 

Musculoskeletal Research Group, School of Translational 

Medicine, Manchester Academic Health Science Centre, 

University of Manchester, Manchester, United Kingdom. 

2. 

Department of Hand Surgery, Salford Royal NHS Foundation 

Trust, Salford, United Kingdom. 

87 FAK/SRC INHIBITION ALLEVIATES THE PERSISTENT FIBROTIC 

PHENOTYPE OF LESIONAL SCLERODERMA FIBROBLASTS 

Xu Shiwen 1 , Katherine Thompson 2 , Korsa Khan 1 , 

Shangxi Liu 2 , Christopher P. Denton 1 , Andrew Leask 2 , 

David J. Abraham 1 

1. 

Rheumatology, Royal Free Hospital, London, United Kingdom. 

2. 

Dentistry and Physiology and Pharmacology, University of 

Western Ontario, London ON, ON, Canada. 

88 AUTOANTIBODY PROFILE AND CLINICAL ASSOCIATIONS IN A 

BRITISH COHORT WITH SCLERODERMA 

Gemma Strickland 1 , John Pauling 1 , Zoe Betteridge 2 , 

Juliet Dunphy 2 , Pat Owen 2 , Neil McHugh 2,3 

1. 

Rheumatology, RNHRD, Bath, United Kingdom. 2. Research, 

Bath Institute for Rheumatic Diseases, Bath, United Kingdom. 

3. 

Pharmacy and Pharmacology, University of Bath, Bath, 


89 ELF SCORE: A VALIDATED SERUM TEST STRONGLY 

PREDICTIVE OF FIBROSIS IN SYSTEMIC SCLEROSIS 

Giuseppina Abignano 1,2 , Giovanna Cuomo 2 , Maya H. Buch 1 , 

William M. Rosenberg 3 , Gabriele Valentini 2 , Paul Emery 1 , 

Francesco Del Galdo 1 

1. 

Section of Musculoskeletal Diseases, Leeds Institute of 

Molecular Medicine, Leeds, United Kingdom. 2. Rheumatology 

Unit, Second University of Naples, Naples, Italy. 3. Centre for 

Hepatology, University College of London, London, United 

Kingdom. 

90 PULMONARY FUNCTION TEST ABNORMALITIES IN PATIENTS 

WITH SYSTEMIC SCLEROSIS AND ANTICENTROMERE 

AUTOANTIBODIES WITHOUT ESTABLISHED 

CARDIOPULMONARY DISEASE 

Jessica Jenkins 1 , John D. Pauling 1 , Neil McHugh 1,2 

1. 

Department of Rheumatology, Royal National Hospital for 

Rheumatic Diseases, Bath, United Kingdom. 2. Department of 

Pharmacy and Pharmacology, University of Bath, Bath, United 

Kingdom. 

91 IMPACT OF IL-6 TRANS-SIGNALLING IN DRIVING FIBROSIS 

VIA JAK2/STAT3 SIGNALLING PATHWAYS IN EARLY DCSSC 

Korsa Khan 1 , Xu Shiwen 1 , David Abraham 1 , 

Christopher P. Denton 1 , Voon Ong 1 

1. 


UCL Medical School, London, United Kingdom. 

92 IMPACT OF ANA SUBTYPE ON PROGRESSION FROM 

ISOLATED RP TO SSC: IMPLICATIONS FOR CLASSIFICATION 

AND EARLY DIAGNOSIS 

Pia Moinzadeh 1,2 , Kevin Howell 1 , Voon Ong 1 , 

Svetlana Nihtyanova 1 , Christopher P. Denton 1 

1. 


UCL Medical School, Royal Free Hospital, London, United 

Kingdom. 2. Dermatology, University of Cologne, Cologne, 

Germany. 

93 IL7 AXIS IN SSC: ANALYSIS OF LIGAND AND RECEPTOR SNP 

POLYMORPHISMS AND SERUM IL7 LEVELS 

Pia Moinzadeh 1,2 , Carmen Fonseca 1 , Korsa Khan 1 , 

David Abraham 1 , Voon Ong 1 , Christopher P. Denton 1 

1. 


UCL Medical School, Royal Free Hospital, London, 

United Kingdom. 2. Dermatology, University of Cologne, 

Cologne, Germany.


94 THE HAND ISCHAEMIA SCORE: A NOVEL HAND ISCHAEMIA 

OUTCOME MEASURE IN SYSTEMIC SCLEROSIS 

Anshuman P. Malaviya 1 , Andreas V. Hadjinicolaou 2 , 

Muhammad K. Nisar 1 , Michael Ruddlesden 3 , Anita Furlong 1 , 

Sharon Baker 4 , France C. Hall 2,1 

1. 

Rheumatology, Cambridge Uviversiy Hospitals NHS 

Foundation Trust, Cambridge, United Kingdom. 

2. 

Rheumatology, University of Cambridge School of Clinical 

Medicine, Cambridge, United Kingdom. 3. None, Abbey 

College, Ramsey, Cambridgeshire, United Kingdom. 

4. 

Cambridge Research Facility, Addenbrooke’s Hospital, 

Cambridge, United Kingdom. 

95 REGIONAL OXYGEN SATURATION AS A NOVEL OUTCOME 

MEASURE IN SYSTEMIC SCLEROSIS-ASSOCIATED HAND 

ISCHAEMIA 

Andreas V. Hadjinicolaou 1 , Anshuman P. Malaviya 2 , 

Muhammad K. Nisar 2 , Michael Ruddlesden 3 , 

Dominique Raut-Roy 2 , Anita Furlong 2 , Sharon Baker 4 , 

Frances C. Hall 1,2 

1. 

None, University of Cambridge School of Clinical Medicine, 

Cambridge, United Kingdom. 2. Rheumatology, Cambridge 

University Hospitals NHS Foundation Trust, Cambridge, United 

Kingdom. 3. None, Abbey College, Ramsey, United Kingdom. 

4. 

ACCI, Cambridge Research Facility, Cambridge, United 

Kingdom. 

Spondylarthropathies (including psoriatic arthritis) 

96 DISCOVERTEBRAL EROSION IN PATIENTS WITH 

ENTEROPATHIC ARTHRITIS DETECTED BY MRI 

Rosario Peluso 1 , Di Minno M. N Dario 1 , Iervolino Salvatore 1 , 

Luisa Costa 1 , Atteno Mariangela 1 , Lofrano Mariana 1 , 

Soscia Ernesto 2 , Castiglione Fabiana 1 , Foglia Francesca 1 , 

Scarpa Raffaele 1 

1. 

Clinical and Experimental Medicine, University Federico II, 

Naples, Italy. 2. Biostructures and Bioimaging Institute, 

National Council of Research, Naples, Italy. 

97 USE OF THE WORLD HEALTH ORGANISATION FRACTURE 

RISK ASSESSMENT TOOL (FRAX) IN ANKYLOSING 

SPONDYLITIS 

Dinny Wallis 1 , Amanda Thomas 1 , Ingrid Hill 1 , Brisa France 1 , 

Raj Sengupta 1 

1. 


Diseases, Bath, Bath, United Kingdom. 

98 PREDICTING JOINT AND SKIN REMISSION AT 24 WEEKS IN 

PATIENTS WITH PSORIATIC ARTHRITIS 

Maxime Dougados 1 , Edward Keystone 3 , Michele Heckaman 4 , 

Philip Mease 2 

1. 

Department of Rheumatology, University of Paris V, Cochin 

Hospital, Paris, France. 2. Department of Rheumatology, 

Swedish Medical Center and University of Washington, Seattle, 

WA, United States. 3. Mount Sinai Hospital, University of 

Toronto, Toronto, ON, Canada. 4. GPRD, Abbott, Abbott Park, 

IL, United States. 

99 SEVERITY OF BASELINE SKIN DISEASE DOES NOT 

CORRELATE WITH CLINICAL, PATIENT-REPORTED, OR 

RADIOGRAPHIC RESPONSES IN PATIENTS WITH PSORIATIC 

ARTHRITIS TREATED WITH ADALIMUMAB 

Robert Landewé 1 , Dianne Nguyen 2 , Michele Heckaman 3 , 

Philip Mease 4 

1. 

Department of Rheumatology, Maastricht University Medical 

Center, Maastricht, Netherlands. 2. GPRD, Abbott, Singapore, 

Singapore, Singapore. 3. GPRD, Abbott, Abbott Park, IL, United 

States. 4. Department of Rheumatology, Swedish Medical 

Center and University of Washington, Seattle, WA, United 

States. 

100 BASDAI: IT IS EASIER AND QUICKER TO USE NUMERIC 

RATING SCALES (NRS) RATHER THAN VISUAL ANALOGUE 

SCALES 

Rachel A. Winfield 1 , Claire Dyke 1 , Mark Clemence 1 , 

Kirsten Mackay 1 

1. 

Rheumatology, South Devon Healthcare NHS Foundation 

Trust, Torbay, United Kingdom. 

101 ASSESSING FATIGUE IN ANKYLOSING SPONDYLITIS: 

THE IMPORTANCE OF FREQUENCY AND SEVERITY 

Kirstie L. Haywood 1 , Jon Packham 2,3 , Kelvin P. Jordan 2 

1. 

Royal College of Nursing Research Institute, School of Health 

and Social Studies, University of Warwick, Coventry, United 

Kingdom. 2. Arthritis Research UK Primary Care Centre, 

Primary Care Sciences, Keele University, Stoke-on-Trent, 

United Kingdom. 3. Staffordshire Rheumatology Centre, 

Haywood Hospital, Stoke-on-Trent, United Kingdom.


102 SELF-MANAGING FATIGUE IN ANKYLOSING SPONDYLITIS 

AND POTENTIAL INTERVENTIONS: A QUALITATIVE STUDY OF 

PATIENT’S PERSPECTIVES 

Helen Davies 1 , Sinead Brophy 1 , Elizabeth Irvine 1 , Roxanne 

Cooksey 1 , Michael S. Dennis 1 , Stefan Siebert 1 

1. 

College of Medicine, Swansea University, Swansea, 


103 QUALITY OF LIFE IN PSORIATIC ARTHRITIS: COMPARATIVE 

RESULTS TO RHEUMATOID ARTHRITIS USING SF36 IN 

TRIALS USING METHOTREXATE 

Gabrielle H. Kingsley 1 , Fowzia Ibrahim 1 , David L. Scott 1 

1 


Kingdom. 

104 EARLY AND SUSTAINED REMISSION ASSOCIATED WITH 

NORMALIZED PHYSICAL FUNCTION, HEALTH-RELATED 

QUALITY OF LIFE & SIGNIFICANTLY IMPROVED 

PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC 

ARTHRITIS TREATED WITH GOLIMUMAB: 2-YEAR DATA 

FROM PHASE III GO-REVEAL TRIAL 

Arthur Kavanaugh 1 , Iain McInnes 2 , Chandrabhusan 

Chattopadhyay 3 , Gerald Krueger 4 , Dafna Gladman 5 , Anna 

Beutler 6 , Tim Gathany 7 , Surekha Mudivarthy 6 , Michael Mack 6 , 

Neeta Tandon 8 , Chenglong Han 7 , Philip Mease 9 

1. 

Division of Rheumatology, Allergy and Immunology, UCSD, 

San Diego, CA, United States. 2. Division Immunology, 

Infection and Inflammation, University of Glasgow, Glasgow, 

United Kingdom. 3. Rheumatology, Wrightington Hospital, 

Wigan, United Kingdom. 4. Division of Dermatology, U of Utah 

Health Sciences Center, Salt Lake City, UT, United States. 

5. 

Rheumatology, The Toronto Western Hospital, Toronto, ON, 

Canada. 6. Immunology, Janssen Research and Development, 

Inc, Malvern, PA, United States. 7. Worldwide Market Access, 

Janssen Global Services LLC, Malvern, PA, United States. 

8. 

Health Economics & Outcomes Research, Janssen Scientific 

Affairs, LLC, Horsham, PA, United States. 9. Rheumatology, 

Swedish Med Ctr/U of Washington, Seattle, WA, United States. 

105 EFFECT OF SECUKINUMAB ON SIGNS AND SYMPTOMS OF 

PSORIATIC ARTHRITIS (PsA): RESULTS OF A 24-WEEK 

MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 

PLACEBO-CONTROLLED TRIAL 

Iain McInnes 1 , Joachim Sieper 2 , Jürgen Braun 3 , Paul Emery 4 , 

Désirée van der Heijde 5 , John Isaacs 6 , Georg Dahmen 7 , 

Jürgen Wollenhaupt 8 , Hendrik Schulze-Koops 9 , 

Sandro Gsteiger 10 , Arthur Bertolino 11 , Wolfgang Hueber 12 , 

Paul P. Tak 13 

1. 


Glasgow, United Kingdom. 2. Department of Gastroenterology, 

Charitè Campus Benjamin Franklin, Berlin, Germany. 

3. 

Department of Medicine, Rheumazentrum Ruhrgebiet, 

Herne, Germany. 4. Leeds Institute of Molecular Medicine, 

University of Leeds, Leeds, United Kingdom. 5. Department of 

Rheumatology, Leiden University Medical Center, Leiden, 

Netherlands. 6. Newcastle University, and the Freeman 

Hospital, Newcastle-upon-Tyne, United Kingdom. 

7. 

Department of Medicine, Praxis fuer klinische Studien, 

Hamburg, Germany. 8. Klinik für Rheumatologie, Eilbeck 

Hospital, Hamburg, Germany. 9. Klinikum Innenstadt der 

Ludwig-Maximilians-Universität, Rheumatologie, Munich, 

Germany. 10. Modelling & Simulation Statistics, Novartis 

Pharma AG, Basel, Switzerland. 11. Translational Medicine 

Dermatology, Novartis Institutes for BioMedical Research, 

Basel, Switzerland. 12. Translational Medicine Autoimmunity, 

Novartis Institutes for BioMedical Research, Basel, 

Switzerland. 13. Division of Clinical Immunology and 

Rheumatology, University of Amsterdam, Amsterdam, 

Netherlands. 

106 A CCR6 VARIANT STRONGLY ASSOCIATED WITH 

RHEUMATOID ARTHRITIS IN TWO POPULATIONS IS NOT 

ASSOCIATED WITH ANKYLOSING SPONDYLITIS 

Carla J. Cohen 2 , Tugce Karaderi 2 , Jennifer J. Pointon 1,2 , 

Bryan P. Wordsworth 1,2 

1. 

NIHR Oxford Comprehensive Biomedical Research Centre, 

Botnar Research Centre, Oxford, United Kingdom. 2. NIHR 

Oxford Musculoskeletal Biomedical Research Unit, Botnar 

Research Centre, Oxford, United Kingdom.


107 THE EFFECT OF PHYSICAL ACTIVITY AND MOTIVATION ON 

FUNCTION IN ANKYLOSING SPONDYLITIS 

Roxanne Cooksey 1 , Helen Davies 1 , Michael S. Dennis 1 , 

Stefan Siebert 1 , Sinead Brophy 1 

1. 

College of Medicine, Swansea University, Swansea, United 

Kingdom. 

108 A RAPID SINGLE TUBE METHOD FOR TYPING rs4349859, 

THE SNP THAT TAGS HLA-B27 

Sarah Keidel 1,2 , Jennifer J. Pointon 1,2 , Claire Farrar 3 , 

Tugce Karaderi 2 , Louise H. Appleton 1,2 , Bryan P. Wordsworth 1,2 

1. 

NIHR Oxford Comprehensive Biomedical Research Centre, 

Botnar Research Centre, Oxford, United Kingdom. 2. NIHR 

Oxford Musculoskeletal Biomedical Research Unit, Botnar 

Research Centre, Oxford, United Kingdom. 3. NIHR Thames 

Valley CLRN, Botnar Research Centre, Oxford, United Kingdom. 

109 REFERRAL RECOMMENDATIONS FOR AN EARLY 

INFLAMMATORY BACK PAIN SERVICE 

Rebecca Adshead 1 , Hasan Tahir 1 , Mandy Greenwood 1 , 

Simon P. Donnelly 1 

1. 

Rheumatology, Whipps Cross University Hospital Trust, 

London, United Kingdom. 

110 ASSESSING PSORIATIC ARTHRITIS: A MODULAR APPROACH 

Julekha Wajed 1 , Bruce Kirkham 1 

1. 

Rheumatology, Guy’s & St.Thomas’ Hospital, London, 

United Kingdom




Wed 2 May 2012

Poster viewing: Wednesday 2 May 2012 

Wednesday 2 May 2012 | Poster viewing 93 

Muscle Disorders 

111 THE IMPACT OF FATIGUE IN PATIENTS WITH IDIOPATHIC 

INFLAMMATORY MYOPATHY: A MIXED METHOD STUDY 

Richard Campbell 2,1 , Darija Hofmann 1 , Stephani Hatch 3 , 

Patrick Gordon 2,1 , Heidi Lempp 1 

1. 

Academic Rheumatology, Kings College , London, United 

Kingdom. 2. Rheumatology, King’s College Hospital NHS 

Foundation Trust, London, United Kingdom. 3. Psychological 

Medicine, Institute of Psychiatry, King’s College, London, 


112 IMMUNOHISTOCHEMICAL MAJOR HISTOCOMPATIBILITY 

COMPLEX CLASS I AND II EXPRESSION IN IDIOPATHIC 

INFLAMMATORY MYOPATHIES 

Leena Das 1 , Peter Blumbergs 2 , Vidya Limaye 1 

1. 

Rheumatology, Royal Adelaide Hospital, Adelaide, SA, 

Australia. 2. Hanson Institute, Centre for Neurological 

Diseases,University of Adelaide, Adelaide, SA, Australia. 

113 EVIDENCE FOR IMMUNOTHERAPY IN DERMATOMYOSITIS 

AND POLYMYOSITIS: A SYSTEMATIC REVIEW 

Erin Vermaak 1 , Neil McHugh 1 

1. 

Department of Rheumatology, Royal National Hospital for 

Rheumatic Diseases, Bath, United Kingdom. 

114 MUSCLE SIZE AND STRENGTH AS PREDICTORS OF BONE 

STRUCTURE, FALLS AND FRACTURES IN THE 

HERTFORDSHIRE COHORT STUDY 

Mark H. Edwards 1 , Karen Jameson 1 , Avan Aihie Sayer 1 , 

Elaine Dennison 1 , Cyrus Cooper 1 

1. 

MRC Lifecourse Epidemiology Unit, University of 

Southampton, Southampton, Hampshire, United Kingdom. 

115 MUSCLE OUTCOME IN PATIENTS WITH IDIOPATHIC 

INFLAMMATORY MYOPATHIES 

Fernando B. Salvador 1,3 , Carolina Huertas 2,3 , David Isenberg 3 

1. 

Internal Medicine, Centro Hospitalar de Trás-os-Montes e 

Alto Douro, Vila Real, Portugal. 2. Rheumatology, Hospital 

General Universitario Gregorio Marañón, Madrid, Spain. 

3. 

Rheumatology, University College London Hospital, 


Orthopaedics and rehabilitation 

Medical student bursary winner 

116 A CASE CONTROL STUDY OF RISK FACTORS FOR ELECTIVE 

HIP REPLACEMENT OR RESURFACING SURGERY IN 

HIV-INFECTED ADULTS 

Elizabeth J. Jackson 1 , Annie Middleton 1 , Duncan Churchill 2 , 

Karen Walker-Bone 1,2 

1. 

Rheumatology, Brighton & Sussex Medical School, Brighton, 

United Kingdom. 2. HIV and GU Medicine, Brighton & Sussex 

University Hospitals NHS Trust, Brighton, United Kingdom. 

117 CLINICAL OUTCOMES FOLLOWING MOTOR CONTROL 

REHABILITATION FOR SHOULDER IMPINGEMENT 

Peter R. Worsley 1 , Sarah Mottram 1 , Martin Warner 1 , 

Dylan Morrissey 2 , Stephan Gadola 3 , Andrew Carr 4 , 

Cyrus Cooper 5 , Maria Stokes 1 

1. 


Southampton, Hampshire, United Kingdom. 2. Centre for 

Sports and Exercise Medicine, Queen Mary University of 

London, London, United Kingdom. 3. Faculty of Medicine, 

University of Southampton, Southampton, Hampshire, United 

Kingdom. 4. Oxford NIHR Musculoskeletal Biomedical 

Research Unit, University of Oxford, Oxford, United Kingdom. 

5. 

MRC Lifecourse Epidemiology Unit, Southampton University 

Health Trust, Southampton, United Kingdom. 


118 WHICH RADIOLOGICAL FEATURE IS A TRUE PREDICTOR OF 

CLINICAL SEVERITY IN KNEE OSTEOARTHRITIS? 

Rajeshwar N. Srivastava 1 , Divya Sanghi 1 

1. 

Orthopaedic Surgery, KG Medical College, CSM Medical 

University, Lucknow, UP, India. 



poster tours!

94 Poster viewing | Wednesday 2 May 2012 

119 INFLUENCE OF DIETARY NUTRIENTS IN PREVALENCE OF 

OSTEOARTHRITIS (OA) KNEE 

Rajeshwar N. Srivastava 1 , Divya Sanghi 1 

1. 

Orthopaedic Surgery, KG Medical College, CSM Medical 

University, Lucknow, UP, India. 

120 A NEW NON-INVASIVE BIOMECHANICAL THERAPY FOR 

KNEE OSTEOARTHRITIS IMPROVES CLINICAL SYMPTOMS 

AND GAIT PATTERNS 

Avi Elbaz 1 , Amit Mor 1 , Ganit Segal 1 , Michael Drexler 2 , 

Doron Norman 3 , Eli Peled 3 , Nimrod Rozen 4 

1. 

AposTherapy research group, Apos Medical and Sports 

Technologies, Herzliya, Israel. 2. Department of Orthopedic 

Surgery, Sourasky Medical Center, Tel Aviv, Israel. 

3. 

Department of Orthopedic Surgery, Rambam Medical Center, 

Haifa, Israel. 4. Department of Orthopedic Surgery, HaEmek 

Medical Center, Afula, Israel. 

121 FOOT CENTER OF PRESSURE MANIPULATION AND GAIT 

THERAPY INFLUENCE LOWER LIMB MUSCLE ACTIVATION IN 

PATIENTS WITH OSTEOARTHRITIS OF THE KNEE 

Yulia Goryachev 1 , Eytan M. Debbi 1 , Amir Haim 1,2 , 

Nimrod Rozen 3 , Alon Wolf 1 

1. 

Biorobotics and Biomechanics Lab, Faculty of Mechanical 

Engineering, Technion-Israel Institute of Technology, Haifa, 

Israel. 2. Department of Orthopedic Surgery, Sourasky Medical 

Center, Tel Aviv, Israel. 3. Department of Orthopedic Surgery, 

Ha’Emek Medical Center, Afula, Israel. 

122 DIFFERENCES IN GAIT BETWEEN MADIAL AND FRONTAL 

KNEE PAIN IN PATIENTS WITH OSTEOARTHRITIS OF THE 

KNEE 

Ronen Debi 1 , Amit Mor 2 , Ganit Segal 2 , Eytan M. Debbi 2 , 

Marc S. Cohen 2 , Ilya Igolnikov 2 , Yaron Bar Ziv 3 , Vadim 

Benkovich 4 , Benjamin Bernfeld 5 , Nimrod Rozen 6 , Avi Elbaz 2 

1. 

Department of orthopedic surgery, Barzilay Medical Center, 

Ashkelon, Israel. 2. AposTherapy research group, Apos, 

Herzliya, Israel. 3. Department of orthopedic surgery, Assaf 

Harofeh Medical Center, Zerifin, Israel. 4. Department of 

orthopedic surgery, Soroka University Medical Center, Beer 

Sheva, Israel. 5. Department of orthopedic surgery, Carmel 

Medical Center, Haifa, Israel. 6. Department of orthopedic 

surgery, HaEmek Medical Center, Afula, Israel. 

123 EFFECT OF OXYGEN TENSION AND PH ON MITOCHONDRIAL 

FUNCTION IN HUMAN OSTEOARTHRITIC ARTICULAR 

CHONDROCYTES (HOAC) 

John Collins 1 , Robert Moots 2 , Peter D. Clegg 1 , Peter I. Milner 1 

1. 

Institute of aging and chronic disease, University of Liverpool, 

Leahurst campus, Neston, United Kingdom. 2. Institute of 

aging and chronic disease, University of Liverpool, University 

Hospital Aintree, Aintree, United Kingdom. 

124 STUDY SHOWS THAT ENDOGENOUS RETROVIRUS ERV-3 IS 

NOT IMPLICATED IN RHEUMATOID ARTHRITIS BUT MAY 

PROVIDE A BIOMARKER OF OSTEOARTHRITIS 

Hora D. Ejtehadi 1 , Paul N. Nelson 2 

1. 

Health Sciences, Birmingham City University, Birmingham, 

West Midland, United Kingdom. 2. Research Institute in 

Healthcare Sciences, University of Wolverhampton, 

Wolverhampton, United Kingdom. 

125 DYNAMIC, CONTRAST-ENHANCED MAGNETIC RESONANCE 

IMAGING OF THE OSTEOARTHRITIC KNEE IN ASSESSMENT 

OF RESPONSE TO INTRA-ARTICULAR (IA) CORTICOSTEROID 

Claire Wenham 1,2 , Sharon Balamoody 1,3 , Richard Hodgson 1,3 , 

Philip Conaghan 1,2 

1. 

NIHR Leeds Musculoskeletal Biomedical Research Unit, 

University of Leeds, Leeds, United Kingdom. 2. Section of 

Musculoskeletal Disease, Chapel Allerton Hospital, Leeds, 

United Kingdom. 3. Department of Musculoskeletal Radiology, 

Leeds Teaching Hospitals Trust, Leeds, United Kingdom. 

126 IDENTIFYING THE KEY TARGETS TO IMPROVE PARTICIPATION 

IN OLDER ADULTS WITH LOWER LIMB OSTEOARTHRITIS: 

PROSPECTIVE COHORT STUDY 

Ross Wilkie 1 , Milisa Blagojevic 1 , Kelvin P. Jordan 1 , 

John Mcbeth 1 

1. 

Keele University, Keele, United Kingdom. 

127 ABSOLUTE QUANTIFICATION OF CARTILAGE MATRIX 

PROTEINS 

Mandy J. Peffers 1 , Robert J. Beynon 2 , David J. Thornton 3 , 

Peter D. Clegg 1 

1. 

Institute of Ageing and Chronic Disease, University of 

Liverpool, Neston, United Kingdom. 2. Proteomics and 

Functional Genomics Group, University of Liverpool, Liverpool, 

United Kingdom. 3. Wellcome Trust Centre for Cell-Matrix 

Research, University of Manchester, Manchester, United 

Kingdom.


128 ACTIVATION OF PERIPHERAL TRPV1 RECEPTORS INDUCES 

SENSITIZATION OF KNEE JOINT NOCICEPTORS 

Rebecca Chapman 1,2 , Victoria Chapman 1 , David Walsh 1 , 

Sara Kelly 1,2 

1. 

Arthritis Research UK Pain Centre, University of Nottingham, 

Nottingham, United Kingdom. 2. Biosciences, University of 

Nottingham, Sutton Bonington, United Kingdom. 

129 PATTERNS OF HIP MIGRATION IN OSTEOARTHRITIS OF 

THE HIP 

Michelle Hui 1 , Weiya Zhang 1 , Sally Doherty 1 , Frances Rees 1 , 

Kenneth Muir 1 , Rose Maciewicz 2 , Michael Doherty 1 

1. 

Academic Rheumatology, University of Nottingham, 

Nottingham, United Kingdom. 2. AstraZeneca, AstraZeneca, 

Macclesfield, United Kingdom. 

130 DKK3 CAN PREVENT CARTILAGE DEGRADATION AND 

REGULATE CHONDROCYTE CELL SIGNALLING 

Sarah Snelling 1,2 , Rose K. Davidson 1 , Tracey Swingler 1 , 

Andrew Price 2 , Ian Clark 1 

1. 

BMRC, The University of East Anglia, Norwich, United 

Kingdom. 2. NDORMS, University of Oxford, Oxford, United 

Kingdom. 

131 SUPRASPINAL CHANGES IN NEURONAL AND GLIAL CELLS 

IN ANIMAL MODELS OF OSTEOARTHRITIC PAIN 

Elizabeth Stockley 1 , Gareth Hathway 1 , Henryk Faas 2 , 

Dorothee Auer 2 , Victoria Chapman 1 

1. 

School of Biomedical Science, University of Nottingham, 

Nottingham , United Kingdom. 2. Academic Radiology, 

University of Nottingham, Nottingham, United Kingdom. 

132 PSYCHOLOGICAL FACTORS INCLUDING ILLNESS 

PERCEPTIONS MAY PREDICT RESPONSE TO 

CORTICOSTEROID INJECTION IN OSTEOARTHRITIS 

George Hirsch 1,2 , Elizabeth Hale 1 , George Kitas 1,2 , 

Rainer Klocke 1,2 

1. 

Clinical Research Unit, Dudley Group NHS FT, Dudley, West 

midlands, United Kingdom. 2. Arthritis Research UK Clinical 

Epidemiology Unit, University of Manchester, Manchester, 


133 LIFECOURSE PREDICTORS OF ULTRASOUND FEATURES 

OF HIP OSTEOARTHRITIS: THE NEWCASTLE THOUSAND 

FAMILIES STUDY 

Ajay Abraham 1 , Mark S. Pearce 1 , Kay D. Mann 1 , Roger M. 

Francis 2 , Fraser Birrell 3 

1. 


Newcastle upon Tyne, United Kingdom. 2. Institute for Ageing 

and Health, Newcastle University, Newcastle upon Tyne, 

United Kingdom. 3. Musculoskeletal Research Group, Institute 

of Cellular Medicine, Newcastle University, Newcastle upon 

Tyne, United Kingdom. 

134 PILOT STUDY TO ASSESS THE VALIDITY OF A SIMPLE 

ACCELEROMETRIC METHOD TO ASSESS HEEL STRIKE 

TRANSIENTS IN PATIENTS WITH MEDIAL KNEE JOINT 

OSTEOARTHRITIS 

Marian Tucker 1 , Stephen J. Mellon 1 , Luke Jones 1 , 

Andrew J. Price 1 , Paul A. Dieppe 2 , Harinderjit S. Gill 1 

1. 

NDORMS, University of Oxford, Oxford, United Kingdom. 

2. 

Peninsula College of Medicine & Dentistry, Universities of 

Exeter & Plymouth, Exeter, United Kingdom. 

135 INCREASED SENSITIVITY TO NERVE GROWTH FACTOR 

IN THE MONOSODIUM-IODOACETATE MODEL OF 


Sadaf Ashraf 1 , Victoria Chapman 1 , David A. Walsh 1 

1. 


Nottingham, United Kingdom. 

Osteoporosis and metabolic bone disease 

136 THE IMPACT OF COMPLEX REGIONAL PAIN SYNDROME TYPE 

1 ON BONE MINERAL DENSITY 

David McCollum 1 , Candy McCabe 2,3 , Sharon Grieve 3 , 

Jacqueline Shipley 4 , Rachel Gorodkin 5 

1. 

Undergraduate Medicine, University of Manchester, 

Manchester, United Kingdom. 2. Faculty of Health and Life 

Sciences, University of the West of England, Bristol, United 

Kingdom. 3. Bath Centre for Pain Services, Royal National 

Hospital for Rheumatic Diseases, Bath, United Kingdom. 

4. 

Clinical Measurement, Royal National Hospital for Rheumatic 

Diseases, Bath, United Kingdom. 5. Kellgren Centre for 

Rheumatology, Manchester Royal Infirmary, Manchester, 

United Kingdom.


137 INCREASING AGE IS ASSOCIATED WITH DECREASED 

FEMORAL NECK CROSS-SECTIONAL MOMENT OF INERTIA 

IN FEMALES ONLY: A POSSIBLE FACTOR IN AGE AND 

SEX-RELATED FRACTURE RISK 

Alexander G. Oldroyd 1,2 , Bronwen Evans 2 , Cathi Greenbank 2 , 

Marwan Bukhari 2,3 

1. 

School of Health and Medicine, Lancaster University, 

Lancaster, United Kingdom. 2. Rheumatology, Royal Lancaster 

Infirmary, Lancaster, United Kingdom. 3. School of Clinical 

Sciences, University of Liverpool, Liverpool, United Kingdom. 

138 OSTEOPOROSIS SCREENING & MANAGEMENT IN PATIENTS 

COMMENCING AROMATASE INHIBITORS FOR BREAST 

CANCER 

Rizwan Rajak 1 , Cheryl Bennett 1 , Ann Williams 1 , 

James C. Martin 1 

1. 

Rheumatology, Royal Glamorgan Hospital, Llantrisant, 


139 IMPROVING REFERRAL RATE OF VERTEBRAL FRACTURES TO 

FRACTURE LIAISON SERVICE: A SERVICE EVALUATION 

Rita Abdulkader 1 , Carolyn MacNicol 1 , Karen Brixey 1 , 

Sonya Stephenson 1 , Gavin Clunie 1 

1. 

Rheumatology, The Ipswich Hospital NHS Trust, Ipswich, 


140 THE ASSOCIATION BETWEEN BREAST CANCER, AROMATASE 

INHIBITION THERAPY AND OSTEOPOROSIS 

Rebecca N. Andrews 1,2 , Alexander G. Oldroyd 1,2 , 

Bronwen Evans 2 , Cathi Greenbank 2 , Marwan Bukhari 2,3 

1. 

School of Health and Medicine, Lancaster University, 

Lancaster, United Kingdom. 2. Rheumatology, Royal Lancaster 

Infirmary, Lancaster, United Kingdom. 3. School of Clinical 

Sciences, University of Liverpool, Liverpool, United Kingdom. 

141 LATERAL DXA SCANNING FOR VERTEBRAL FRACTURE 

ASSESSMENT IS MORE USEFUL IN POPULATION-BASED 

SETTINGS THAN AS PART OF FRACTURE LIAISON 

SERVICES (FLS) 

Emma M. Clark 1 , Virginia C. Gould 1 , Louise Carter 2 , 

Leigh Morrison 1 , Jon H. Tobias 1 

1. 

Academic Rheumatology, University of Bristol, Bristol, United 

Kingdom. 2. Rheumatology, North Bristol NHS Trust, Bristol, 


142 ACTIVE VITAMIN D (1,25-DIHYDROXYVITAMIN D) AND BONE 

HEALTH IN MIDDLE AGED AND ELDERLY MEN: RESULTS 

FROM THE EUROPEAN MALE AGEING STUDY 

Stephen R. Pye 1 , Dirk Vanderschueren 2,3 Terence W. O’Neill1, 

David M. Lee1, Ivo Jans 3 , Jaak Billen 3 , Evelien Gielen 4 , 

Michael Laurent 4,5 , Frank Claessens 5 , Judith E. Adams 6 , 

Kate A. Ward 7 , Gyorgy Bartfai 8 , Felipe Casanueva 9 , 

Joseph D. Finn 10 , Gianni Forti 11 , Aleksander Giwercman 12 , 

Thang S. Han 13 , Ilpo Huhtaniemi 14 , Krzysztof Kula 15 , 

Michael E. Lean 16 , Neil Pendleton 17 , Margus Punab 18 , 

Frederick C. Wu 10 , Steven Boonen 4 

1. 


Manchester, Manchester, United Kingdom. 2. Department of 

Andrology and Endocrinology, Katholieke Universiteit Leuven, 

Leuven, Belgium. 3. Department of Laboratory Medicine, 

Katholieke Universiteit Leuven, Leuven, Belgium. 4. Leuven 

University Division of Geriatric Medicine and Centre for 

Metabolic Bone Diseases, Katholieke Universiteit Leuven, 

Leuven, Belgium. 5. Department of Molecular Cell Biology, 

Katholieke Universiteit Leuven, Leuven, Belgium. 6. Clinical 

Radiology, Imaging Science and Biomedical Engineering, 

The University of Manchester, Manchester, United Kingdom. 

7. 

MRC Human Nutrition Research, Elsie Widdowson 

Laboratory, Cambridge, United Kingdom. 8. Department of 

Obstetrics, Gynaecology and Andrology, Albert Szent-Gyorgy 

Medical University, Szeged, Hungary. 9. Department of 

Medicine, Santiago de Compostela University, Santiago de 

Compostela, Spain. 10. Andrology Research Unit, The University 

of Manchester, Manchester, United Kingdom. 11. Department 

of Clinical Physiopathology, University of Florence, Florence, 

Italy. 12. Department of Urology, University of Lund, Malmo, 

Sweden. 13. Department of Endocrinology, Royal Free and 

University College Hospital Medical School, London, United 

Kingdom. 14. Department of Surgery and Cancer, Imperial 

College London, London, United Kingdom. 15. Department of 

Andrology and Reproductive Endocrinology, Medical University 

of Lodz, Lodz, Poland. 16. Department of Human Nutrition, 

University of Glasgow, Glasgow, United Kingdom. 17. School of 

Community Based Medicine, The University of Manchester, 

Manchester, United Kingdom. 18. Andrology Unit, United 

Laboratories of Tartu University Clinics, Tartu, Estonia.


143 MANAGEMENT OF GLUCOCORTICOID INDUCED 

OSTEOPOROSIS 

Cecilia Mercieca 1 , Jackie Webb 2 , Jacqueline Shipley 2 , 

Ashok Bhalla 2 

1. 

Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, 

United Kingdom. 2. Rheumatology, Royal National Hospital for 

Rheumatic Diseases, Bath, United Kingdom. 

144 IS THERE AN ASSOCIATION BETWEEN ADOLESCENT 

FEMALES’ SKIN TONE AND BEHAVIOUR WITH RESPECT 

TO SUN EXPOSURE? 

Sue Fairbanks 1 , Katie E. Moss 2 , Catherine Collins 3 , 

Philip Sedgwick 4 

1. 

Undergraduate, St George’s Hospital, University of London, 

London, United Kingdom. 2. Rheumatology, St George’s 

Hospital, University of London, London, United Kingdom. 

3. 

Dietetics, St George’s Hospital, University of London, 

London, United Kingdom. 4. Education, St George’s Hospital, 

University of London, London, United Kingdom. 

145 NHS RADIOGRAPH REPORTS OF VERTEBRAL FRACTURE 

COMPARE FAVOURABLY WITH FORMAL STANDARDISED 

REPORTING METHODS, BUT SOME NHS REPORTS ARE 

UNCLEAR 

Emma M. Clark 1 , Virginia C. Gould 1 , Leigh Morrison 1 , 

Jon H. Tobias 1 

1. 

University of Bristol, Bristol, United Kingdom. 

146 INFLUENCE OF ANTI-EPILEPTIC DRUGS ON BONE MIENRAL 

DENSITY 

Joshua Parker 1 , Cathy Greenbank 1 , Bronwen Evans 1 , 

Alexander G. Oldroyd 1 , Marwan Bukhari 1 

1. 

Rheumatology, Royal Lancaster Infirmary, Lancaster, United 

Kingdom. 

147 FETAL AND INFANT GROWTH PREDICT HIP GEOMETRY AT 

SIX YEARS OLD: FINDINGS FROM THE SOUTHAMPTON 

WOMEN’S SURVEY 

Nicholas C. Harvey 1 , Zoe A. Cole 1 , Sarah R. Crozier 1 , Georgia 

Ntani 1 , Pam A. Mahon 1 , Sian M. Robinson 1 , Hazel M. Inskip 1 , 

Keith M. Godfrey 1,2 , Elaine M. Dennison 1 , Cyrus Cooper 1 

1. 


Southampton, Southampton, United Kingdom. 

2. 

Southampton NIHR Nutrition, Diet and Lifestyle Biomedical 

Research Unit, University of Southampton, Southampton, 


148 FRAX/NOGG HAS LOW SENSITIVITY IN PREDICTING WRIST 

FRACTURES IN POST-MENOPAUSAL WOMEN 

Matthew Bridges 1 , Sheila Ruddick 1 

1. 

Rheumatology, Darlington Memorial Hospital, Darlington, 


149 PLACENTAL SIZE PREDICTS OFFSPRING BONE MASS: 

FINDINGS FROM THE SOUTHAMPTON WOMEN’S SURVEY 

Christopher R. Holroyd 1 , Pam Mahon 1 , Sarah R. Crozier 1 , 

Keith Godfrey 1 , Hazel M. Inskip 1 , Cyrus Cooper 1,2 , 

Nicholas C. Harvey 1 

1. 


Southampton, Southampton, Hampshire, United Kingdom. 

2. 

NIHR Musculoskeletal Biomedical Research unit, Institute of 

Musculoskeletal Sciences, University of Oxford, Oxford, 

Oxfordshire, United Kingdom. 

150 MODIFYING FRAX / NOGG GUIDELINES IN RHEUMATOLOGY 

PATIENTS RECIEVING CORTICOSTEROIDS: DOES IT MAKE 

ANY DIFFERENCE? 

Matthew Bridges 1 , Sheila Ruddick 1 

1. 

Rheumatology, Darlington Memorial Hospital, Darlington, 


151 TERIPARATIDE IN DAILY PRACTICE: THE BELFAST 

EXPERIENCE 

Thomas McNeilly 1 , Collette McNally 1 , Tim Beringer 2 , 

Michael Finch 1 

1. 

Musgrave Park Hospital, Belfast HSCT, Belfast, Northern 

Ireland, United Kingdom. 2. Royal Victoria Hospital, Belfast 

HSCT, Belfast, Northern Ireland, United Kingdom. 

Paediatric and adolescent rheumatology 

152 PRE-FORMED ORTHOSES IN JUVENILE IDIOPATHIC 

ARTHRITIS: RESULTS FROM AN RCT 

Andrea Coda 1 , Joyce Davidson 2 , Jo Walsh 2 , Peter Fowlie 3 , 

Tom Carline 1 , Derek Santos 1 

1. 

Podiatry, Queen Margaret University, Edinburgh, United 

Kingdom. 2. Paediatric Rheumatology, Royal Hospital for Sick 

Children, Edinburgh, United Kingdom. 3. Paediatric 

Rheumatology, Ninewells Hospital, Edinburgh, United Kingdom.


153 COMPARISON OF METHOTREXATE INDUCED NAUSEA AND 

VOMITING BETWEEN ADOLESCENT AND ADULT PATIENTS 

WITH INFLAMMATORY ARTHRITIS 

Pravin Patil 1 , Christine Rawcliffe 2 , Abigail Olaleye 2 , 

Samantha Moore 2 , Amy Fox 2 , Debajit Sen 2 , Yiannis Ioannou 2 

1. 

Rheumatology, Southend University Hospital, Southend, 

United Kingdom. 2. Rheumatology, University College London 

Hospital, London, United Kingdom. 

154 OSTEOSARCOMA CELL CULTURE ON COLLAGEN SURFACES 

AND IN HYPOXIA ALTERS MMP EXPRESSION 

Sohail Nisar 1 , Kenneth Rankin 1 , Mark Birch 1 

1. 

University of Newcastle upon Tyne, Musculoskeletal Research 

Group, Institute of Cellular Medicine, Newcastle upon Tyne, 


155 PROTEOMIC PROFILING OF THE SYNOVIAL MEMBRANE IN 

JUVENILE IDIOPATHIC ARTHRITIS 

Sorcha Finnegan 1 , Madeleine Rooney 1 , David S. Gibson 1 

1. 

Centre for Infection and Immunity, Queen’s University, 

Belfast, Belfast, United Kingdom. 

156 EXPLORING THE RELATIONSHIPS BETWEEN ADULT JUVENILE 

IDIOPATHIC ARTHRITIS AND EMPLOYMENT 

Ajay Malviya 1 , Calum M. Ferris 2 , Stephen P. Rushton 3 , 

Helen E. Foster 4 , Helen Hanson 4 , Karthik Muthumayandi 4 , 

David J. Deehan 4 

1. 

Wansbeck General Hospital, Northumbria Healthcare NHS 

Foundation Trust, Ashington, United Kingdom. 2. Medical 

School, Newcastle University, Newcastle upon Tyne, United 

Kingdom. 3. School of Biology, Newcastle University, Newcastle 

upon Tyne, United Kingdom. 4. Freeman Hospital, The 

Newcastle upon Tyne Hospitals NHS Foundation Trust, 

Newcastle upon Tyne, United Kingdom. 

157 UNDERSTANDING THE CHILD AND PARENT’S PERSPECTIVES 

ON MULTIDISCIPLINARY INTERVENTIONS FOR BENIGN JOINT 

HYPERMOBILITY SYNDROME 

Linda Birt 1 , Fiona Poland 1 , Alexander MacGregor 3 , 

Kate Armon 3 , Michael Pfeil 2 

1. 

School of Allied Health Professions, University of East Anglia, 

Norwich, United Kingdom. 2. School of Nursing Sciences, 

University of East Anglia, Norwich, United Kingdom. 

3. 

Department of Rheumatology , Norfolk and Norwich 

University Hospitals NHS Foundation Trust, Norwich, United 

Kingdom. 

158 DOES EXCLUSION OF THE ESR FROM JADAS AFFECT 

VALIDITY IN THE ROUTINE CLINICAL SETTING? 

Flora McErlane 1,2 , Michael W. Beresford 2,3 , 

Eileen M. Baildam 3 , Wendy Thomson 1 , Kimme Hyrich 1 , 

Alice Chieng 7 , Joyce Davidson 6 , Helen E. Foster 5 , 

Janet Gardner-Medwin 6 , Mark Lunt 1 , Lucy Wedderburn 4 

1. 

School of Translational Medicine, University of Manchester, 

Manchester, United Kingdom. 2. Institute of Child Health, 

University of Liverpool, Liverpool, United Kingdom. 3. Paediatric 

Rheumatology, Alder Hey Children’s Hospital, Liverpool, United 

Kingdom. 4. Rheumatology Unit, Institute of Child Health, 

London, United Kingdom. 5. Rheumatology, Newcastle Medical 

School, Newcastle, United Kingdom. 6. Rheumatology, Royal 

Hospital for Sick Children, Glasgow, United Kingdom. 

7. 

Rheumatology, Royal Manchester Children’s Hospital, 


159 GLYCOSYLATION OF VITAMIN D BINDING PROTEIN REDUCED 

IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AT RISK OF 

DISEASE EXTENSION 

David S. Gibson 1,2 , Sorcha Finnegan 1 , Keri Newell 2 , 

Alexandra Evans 2 , Gwen Manning 3 , Caitriona Scaife 3 , 

Catherine McAllister 1 , Stephen R. Pennington3, 

Mark Duncan 2,4 , Terry Moore 5 , Madeleine Rooney 1 

1. 

Arthritis Research Group, Queen’s University Belfast, Belfast, 

County Anrtim, United Kingdom. 2. Division of Endocrinology, 

Metabolism and Diabetes, University of Colorado, Denver, CO, 

United States. 3. Proteome Research Centre, University 

College Dublin, Dublin, Ireland. 4. Obesity Research Center, 

King Saud University, Riyadh, Saudi Arabia. 5. Division of Adult 

and Pediatric Rheumatology, Saint Louis University, St. Louis, 

MO, United States. 

160 A NOVEL ASSAY FOR DETECTING NITRATED NUCLEOSOMES: 

A POTENTIAL SURROGATE BIOMARKER FOR JUVENILE 

ONSET SYSTEMIC LUPUS ERYTHEMATOSUS 

Charis Pericleous 1,3 , Sara C. Croca 1 , Ian Giles 1 , Karim Alber 1 , 

Harry Yong 1 , David Isenberg 1 , Angela Midgely 2 , 

Michael W. Beresford 2 , Anisur Rahman 1 , Yiannis Ioannou 1,3 

1. 

Adolescent Rheumatology, UCL, London, United Kingdom. 

2. 

Paediatric Rheumatology, Alder Hey Children’s NHS 

Foundation Trust Hospital, Liverpool, United Kingdom. 

3. 

Paediatric Rheumatology, Institute of Child Health, London, 

United Kingdom.


Primary Care 

161 THE COURSE OF COMORBID ANXIETY SYMPTOMS IN 

PATIENTS PRESENTING TO GENERAL PRACTICE WITH 

SYMPTOMATIC OSTEOARTHRITIS (OA): LATENT CLASS 

GROWTH ANALYSIS 

Magdalena Rzewuska 1 , Christian Mallen 1 , Vicky Y. Strauss 1 , 

John Belcher 1 , George Peat 1 

1. 

Arthritis Research UK Primary Care Centre, Primary Care 

Sciences, Keele University, Keele, United Kingdom. 

162 PRIMARY CARE ATTITUDES TO METHOTREXATE MONITORING 

Rachel Byng-Maddick 1 , Madhavi Wijendra 1 , Henry Penn 1 

1. 

Rheumatology, Northwick Park Hospital, London, 


163 THE ASSOCIATION OF GOUT WITH SLEEP DISORDERS AND 

SLEEP APNOEA: A CROSS-SECTIONAL EPIDEMIOLOGICAL 

STUDY IN PRIMARY CARE 

Edward Roddy 1 , Sara Muller 1 , Richard Hayward 1 , 

Christian Mallen 1 

1. 


Stoke-on-Trent, United Kingdom. 

164 ABSTRACT WITHDRAWN 

165 MANAGEMENT OF GOUT IN A PRIMARY CARE PRACTICE 

Fawzi Kamlow 1 , Angela Pakozdi 2 , Ali Jawad 2 

1. 

General Practice, The Burnham Surgery, 

Burnham-on-Crouch, United Kingdom. 2. Rheumatology, 

Barts and the London NHS Trust, London, United Kingdom. 

166 FATIGUE AS A PRECURSOR TO POLYMYALGIA RHEUMATICA 

(PMR): A RETROSPECTIVE COHORT STUDY 

Daniel J. Green 1 , Sara Muller 1 , Christian Mallen 1 , 

Sam L. Hider 1 

1. 

Primary Care Sciences, Arthritis Research UK Primary Care 

Centre, Keele University, Staffordshire, United Kingdom. 

Psychology, measurement and management of pain 

168 DEVELOPMENT AND EVALUATION OF A COMPUTER 

GRAPHICS APPLICATION FOR COMMUNICATING BODY 

PERCEPTION IN PATIENTS WITH COMPLEX REGIONAL 

PAIN SYNDROME 

Ailie Turton 1 , Mark Palmer 2 , Sharon Grieve 3 , Jenny Lewis 3 , 

Tim Moss 1 , Candy McCabe 1,3 

1. 

Faculty of Health and Life Sciences, University of the West 

of England, Bristol, Bristol, United Kingdom. 2. Faculty of 

Environment and Technology, University of the West of 

England, Bristol, United Kingdom. 3. Bath Centre for Pain 

Services, Royal National Hospital for Rheumatic Diseases, 

Bath, United Kingdom. 

169 AN INVESTIGATION OF PSYCHOLOGICAL CHARACTERISTICS 

LINKED TO PHYSICAL ACTIVITY AND SLEEP IN RHEUMATOID 

ARTHRITIS 

Claire E. Goodchild 1 , Nicole Tang 2,1 , David Scott 3 , 

Paul Salkovskis 4,1 

1. 

Psychology, Institute of Psychiatry, King’s College London, 

London, United Kingdom. 2. Arthritis Research UK Primary 

Care Centre, Keele University, Keele , United Kingdom. 

3. 

Academic Department of Rheumatology, The medical School, 

King’s College London, London, United Kingdom. 

4. 

Psychology, University of Bath, Bath, United Kingdom. 

170 GOOD SLEEP HYGIENE MAY IMPROVE PAIN IN 


Shilpa Selvan 1 , Lyn Williamson 1 

1. 

Rheumatology, Great Western Hospital, Swindon, 


171 A MIND MAP FOR SLEEP FOR ARTHRITIS PATIENTS 

Shilpa Selvan 1 , Lyn Williamson 1 

1. 

Rheumatology, Great Western Hospital, Swindon, 


167 COMMUNITY-BASED JOINT INJECTION CLINIC 

Sarabjit Singh Bawa 2 , Sandeep Bawa 1 

1. 

Dept of Rheumatology, Gartnavel General Hospital, Glasgow, 

United Kingdom. 2. Surgery, Glenboig, Lanarkshire, Scotland, 

United Kingdom.


172 THE EFFECT OF VITAMIN D LEVELS ON THE ASSESSMENT 

OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS AND THE 

COMPONENTS OF THE DISEASE ACTIVITY SCORE 

Nishanthi Thalayasingam 1,2 , Matthew Higgins 3,2 , 

Vadivelu Saravanan 2 , Martin Rynne 2 , Jennifer D. Hamilton 2 , 

Carol Heycock 2 , Clive Kelly 2 

1. 

Northern Deanery, Newcastle, United Kingdom. 

2. 

Rheumatology, Queen Elizabeth Hospital, Gateshead, United 

Kingdom. 3. Medical School, Newcastle University, Newcastle 

upon Tyne, United Kingdom. 

173 THE SYNCHRONOUS RELATIONSHIP BETWEEN SOMATIC 

SYMPTOMS AND PSYCHOLOGICAL DISTRESS IN EARLY 

RHEUMATOID ARTHRITIS: FINDINGS FROM A PROSPECTIVE 

OBSERVATIONAL STUDY 

Sam Norton 1 , Amanda Sacker 4 , John Done 2 , Adam Young 3 

1. 

Institute of Public Health, University of Cambridge, 

Cambridge, United Kingdom. 2. School of Psychology, 

University of Hertfordshire, Hatfield, United Kingdom. 

3. 

Rheumatology Department, City Hospital, St Albans, United 

Kingdom. 4. Institute for Social & Economic Research, 

University of Essex, Colchester, United Kingdom. 


174 TREATING RHEUMATOID ARTHRITIS TO TARGET: OUTCOMES 

AND PREDICTORS IN EARLY RHEUMATOID ARTHRITIS 

PATIENTS TREATED WITH ADALIMUMAB PLUS 

METHOTREXATE, METHOTREXATE ALONE, OR 

METHOTREXATE PLUS SUBSEQUENT ADALIMUMAB 

Josef S. Smolen 1 , Roy M. Fleischmann 2 , Paul Emery 3 , 

Ronald F. van Vollenhoven 4 , Benoît Guérette 5 , 

Sourav Santra 6 , Hartmut Kupper 7 , Laura Redden 6 , 

Arthur Kavanaugh 8 

1. 

Department of Rheumatology, Medical University of Vienna 

and Hietzing Hospital, Vienna, Austria. 2. Department of 

Medicine, University of Texas-Southwestern, Dallas, TX, United 

States. 3. Department of Rheumatology, Leeds Teaching 

Hospital, Leeds, United Kingdom. 4. Department of 

Rheumatology, The Karolinska Institute, Stockholm, Sweden. 

5. 

GPRD, Abbott, Rungis, France. 6. GPRD, Abbott, Abbott Park, 

IL, United States. 7. GPRD, Abbott GmbH & Co, Ludwigshafen, 

Germany. 8. Department of Rheumatology, University of 

California at San Diego, La Jolla, CA, United States. 

175 INITIAL COMBINATION THERAPY WITH ADALIMUMAB PLUS 

METHOTREXATE LEADS TO BETTER LONG-TERM OUTCOMES 

IN PATIENTS WITH ADVANCED RHEUMATOID ARTHRITIS: 

ANALYSIS OF THE FINAL 10-YEAR RESULTS OF AN 

OPEN-LABEL EXTENSION OF A PHASE 3 TRAIL 

Edward C. Keystone 1 , Desiree Van de Heide 2 , 

Michael E. Weinblatt 3 , Neelufar Mozaffarian 4 , 

Benoît Guérette 5 , Hartmut Kupper 6 , Shufang Liu 4 , 

Arthur Kavanaugh 7 

1. 

Department of Medicine, University of Toronto, Toronto, ON, 

Canada. 2. Department of Rheumatology, Leiden University 

Medical Center, Leiden, Netherlands. 3. Division of 

Rheumatology, Immunology and Allergy , Brigham and 

Women’s Hospital, Boston, MA, United States. 4. GPRD, 

Abbott, Abbott Park, IL, United States. 5. GPRD, Abbott, 

Rungis, France. 6. GPRD, Abbott GmbH & Co KG, 

Ludwigshafen, Germany. 7. Department of Rheumatology, 

University of California at San Diego, La Jolla, CA, United 

States. 

176 DOES METHOTREXATE INCREASE THE RISK OF VARICELLA 

OR HERPES ZOSTER INFECTION IN PATIENTS WITH 

RHEUMATOID ARTHRITIS? A SYSTEMATIC LITERATURE 

REVIEW 

Natalie Zhang 2 , Sarah Wilkinson 2 , Mehmmod Riaz 2 , 

Andrew J. Ostor 1 , Muhammad K. Nisar 1 

1. 

Rheumatology, Addenbrookes Hospital, Cambridge, 

United Kingdom. 2. School of Clinical Medicine, University 

of Cambridge, Cambridge, United Kingdom. 

177 SAFETY AND EFFECTIVENESS OF ADALIMUMAB IN PATIENTS 

WITH RHEUMATOID ARTHRITIS DURING MORE THAN 5 

YEARS OF THERAPY OBSERVED IN A PHASE 3B AND 

POST-MARKETING OBSERVATIONAL STUDY 

G. Burmester 1 , X. Mariette 2 , F. Navarro-Blasco 3 , U. Oezer 4 , 

S. Kary 4 , K. Unnebrink 4 , H. Kupper 4 

1. 

Rheumatology and Clinical Immunology, Charité - University 

Medicine, Berlin, Germany. 2. Department of Rheumatology, 

Université Paris-Sud Hôpital Bicêtre, Le Kremlin Bicêtre, 

France. 3. Department of Rheumatology, Hospital General, 

Universitario de Elche, Alicante, Spain. 4. GPRD, Abbott GmbH 

& Co KG, Ludwigshafen, Germany.


178 RANDOMISED EFFICACY AND DISCONTINUATION STUDY OF 

ETANERCEPT VS ADALIMUMAB (RED SEA): A PRAGMATIC, 

OPEN-LABEL, NON-INFERIORITY STUDY OF FIRST TNF 

INHIBITOR USE IN RHEUMATOID ARTHRITIS: 1-YEAR DATA 

Paresh Jobanputra 1,2 , Fiona Maggs 1 , Alison Deeming 3 , 

David Carruthers 3 , Elizabeth Rankin 1,2 , Alison Jordan 1,2 , 

Abdul Faizal 4 , Carolyn Goddard 5 , Mark Pugh 5 , 

Simon Bowman 1,2 , Sue Brailsford 1 , Peter Nightingale 6 

1. 

Department of Rheumatology, Queen Elizabeth Hospital 

Birmingham, Birmingham, West Midlands, United Kingdom. 

2. 

Infection & Immunity, University of Birmingham, Birmingham, 

West Midlands, United Kingdom. 3. Department of 

Rheumatology, City Hospital, Sandwell and West Birmingham 

Hospitals NHS Trust, Birmingham, West Midlands, United 

Kingdom. 4. Department of Rheumatology, Solihull Hospital, 

Heart of England NHS Foundation Trust, Solihull, West 

Midlands, United Kingdom. 5. Department of Rheumatology, 

St Mary’s Hospital, Newport, Isle of Wight, United Kingdom. 

6. 

Wellcome Trust Clinical Research Facility, Queen Elizabeth 

Hospital Birmingham, Birmingham, West Midlands, United 

Kingdom. 

179 METHOTREXATE THERAPY, RHEUMATOID ARTHRITIS AND 

LIFE-THREATENING LIVER COMPLICATIONS: SHOULD WE BE 

MONITORING MORE CLOSELY? 

Nicola Tugnet 1 , Sheldon C. Cooper 2 , Karen M. Douglas 3 

1. 

Rheumatology, The Royal Wolverhampton Hospitals NHS 

Trust, Wolverhampton, United Kingdom. 2. Gastroenterology, 

Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom. 

3. 

Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, 


180 LEFLUNOMIDE-ASSOCIATED SEVERE DYSLIPIDAEMIA IN A 

RHEUMATOID ARTHRITIS PATIENT 

Chong Seng Edwin Lim 1 , Samantha Bee Lian Low 2 , 

Clayton Joy 1 , Lynne Hill 1 , Paul Davies 1 

1. 

Rheumatology, Broomfield Hospital, MEHT, Chelmsford, 

Essex , United Kingdom. 2. General Medicine, Queens 

Hospital, BHRUT, Romford, Essex, United Kingdom. 

181 TIGHT CONTROL OF RHEUMATOID ARTHRITIS (RA) IN 

PRACTICE AT A DISTRICT GENERAL HOSPITAL (DGH) 

THROUGH MONTHLY REVIEW AT NO ADDITIONAL COST 

Sandeep Mukherjee 1 , Patricia Cornell 1 , Sarah L. Westlake 1 , 

Selwyn Richards 1 , Fouz Rahmeh 1 , Paul W. Thompson 1 

1. 

Rheumatology, Poole Hospital NHS Foundation Trust, 

Poole, Dorset, United Kingdom. 

182 INITIAL COMBINATION THERAPY WITH ADALIMUMAB PLUS 

METHOTREXATE LEADS TO BETTER LONG-TERM OUTCOMES 

THAN WITH EITHER MONOTHERAPY IN PATIENTS WITH 

EARLY RHEUMATOID ARTHRITIS: 8-YEAR RESULTS OF AN 

OPEN-LABEL EXTENSION OF A PHASE 3 TRIAL 

Ferdinand Breedveld 1 , Edward Keystone 2 , 

Desiree Van de Heide 1 , Robert Landewé 3 , Josef S. Smolen 4 , 

Benoît Guérette 5 , Melissa McIlraith 5 , Hartmut Kupper 6 , 

Shufang Liu 7 , Arthur Kavanaugh 8 

1. 

Department of Rheumatology, Leiden University Medical 

Center, Leiden, Netherlands. 2. Department of Rheumatology, 

University of Toronto, Toronto, ON, Canada. 3. Department of 

Rheumatology, Academic Medical Center, Amsterdam, 

Netherlands. 4. Department of Rheumatology, Medical 

University of Vienna, Vienna, Austria. 5. GPRD, Abbott, Rungis, 

France. 6. GPRD, Abbott GmbH & Co KG, Ludwigshafen, 

Germany. 7. Abbott, Abbott Park, IL, United States. 

8. 

Department of Rheumatology, University of California at 

San Diego, La Jolla, CA, United States. 

183 CASE SERIES OF TUBERCULOSIS IN ANTI-TNF THERAPY 

Rachel Byng-Maddick 1 , Henry Penn 1 

1. 

Rheumatology, Northwick Park Hospital, Harrow, United 

Kingdom. 

184 LATE ONSET NEUTROPAENIA IN RHEUMATOID ARTHRITIS 

TREATED WITH B-CELL DEPLETION 

Rita Abdulkader 1 , Chethana Dharmapalaiah 1 , L. Shand 1 , 

Ginny Rose 1 , Gavin Clunie 1 , Richard Watts 1 

1. 

Rheumatology Department, The Ipswich hospital NHS Trust, 

Ipswich, United Kingdom. 

185 ARE PATIENTS WITH LONG-STANDING RHEUMATOID 

ARTHRITIS TREATED-TO-TARGET? AN AUDIT OF FOLLOW-UP 

PATIENTS IN RHEUMATOLOGY CLINIC 

Amr Eldashan 1 , Bhaskar Dasgupta 1 , Frances A. Borg 1 

1. 

Rheumatology, Southend Hospital, Westcliff-on-Sea, Essex, 

United Kingdom.


186 AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS IN 


Gillian M. Bell 1,2 , Amy E. Anderson 1 , Rachel A. Harry 1 , 

Jeroen N. Stoop 1 , Catharien M. Hilkens 1 , John Isaacs 1,2 , 

Anne Dickinson 3 , Elaine McColl 4 

1. 

Musculoskeletal Research Group, Newcastle University, 

Newcastle upon Tyne, Tyne and Wear, United Kingdom. 

2. 

Musculoskeletal Unit, Freeman Hospital, Newcastle upon 

Tyne, Tyne and Wear, United Kingdom. 3. Haematological 

Sciences, Newcastle University, Newcastle upon Tyne, Tyne 

and Wear, United Kingdom. 4. Clinical Trials Unit, Newcastle 

University, Newcastle upon Tyne, Tyne and Wear, United 

Kingdom. 

187 TUBERCULOSIS PROPHYLAXIS BEFORE ANTI-TNF-α: 

BTS V T SPOT 

Snehashish Banik 1 , Lorna Smith 2 , Janice France 1 , 

Sandeep Bawa 1 

1. 

Rheumatology, Gartnavel General Hospital, Glasgow, United 

Kingdom. 2. School of Medicine, Glasgow University, Glasgow, 


188 THE EVALUATION OF MUSCULOSKELETAL ULTRASOUND IN 

THE MANAGEMENT OF INFLAMMATORY ARTHRITIS 

Andrew Rutherford 1 , Ann Scott Russell 3 , Jacqueline Smith 4 , 

Imad Jassim 1 , Robin Withrington 4 , Pauline Bacon 2 , 

Denise De Lord 1 

1. 

Rheumatology, QEQM Hospital, EKHUFT, Margate, United 

Kingdom. 2. Medical Physics, EKHUFT, Canterbury, United 

Kingdom. 3. Rheumatology, William Harvey Hospital, EKHUFT, 

Ashford, United Kingdom. 4. Rheumatology, Kent & Canterbury 

hospital, EKHUFT, Canterbury, United Kingdom. 

189 TRIPLE THERAPY IN EARLY ACTIVE RHEUMATOID ARTHRITIS: 

5 YEAR FOLLOW UP 

Laura McGregor 1 , Islay Morrison 1 , Anne Stirling 2 , 

Duncan R. Porter 2 , Sarah A. Saunders 1 

1. 

Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 

Glasgow, United Kingdom. 2. Rheumatology Department, 

Gartnavel General Hospital, Glasgow, United Kingdom. 

190 AUDIT OF SAFETY AND EFFICACY OF COMBINATION 

METHOTREXATE AND LEFLUNOMIDE IN EARLY ARTHRITIS 

USING AN ESCALATION STRATEGY 

Sara Else 1 , Olga Semenova 1 , Helen Thompson 1 , 

Olabambo Ogunbambi 1 , Sathish Kallankara 1 , Elaine Baguley 1 , 

Yusuf Patel 1,2 

1. 

Rheumatology, Hull Royal Infirmary, Hull, United Kingdom. 

2. 

Senior Lecturer, Hull York Medical School, Hull, United 

Kingdom. 

191 INCOMPLETE RESPONSE OF INFLAMMATORY ARTHRITIS TO 

TNFα BLOCKADE IS ASSOCIATED WITH THE TH17 PATHWAY 

Saba Alzabin 1 , Sonya Abraham 2 , Taher E. Taher 3 , 

Andrew Palfeeman 1 , Dobrina Hull 1 , Kay McNamee 1 , 

Ali Jawad 3 , Ejaz Pathan 1 , Anne Kinderlerer 4 , Peter Taylor 1 , 

Richard O. Williams 1 , Rizgar A. Mageed 3 

1. 

Kennedy Institute of Rheumatology, University of Oxford, 

London, United Kingdom. 2. Division of Immunology and 

Inflammation, Imperial College London, London, United 

Kingdom. 3. William Harvey Research Institute, Queen Mary 

University of London, London, United Kingdom. 4. St Mary’s 

Hospital, Imperial College NHS trust, London, United Kingdom. 

192 EFFECTS OF DIFFERENT NONBIOLOGICAL 

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) 

ON RADIOGRAPHIC PROGRESSION OF RHEUMATOID 

ARTHRITIS (RA) DEPENDING ON DISEASE DURATION 

(RESULTS OF 2 YEARS OF MONITORING) 

Oleg Iaremenko 1 , Ganna Mikitenko 1 

1. 

Department of Internal Medicine, National Medical University 

named O.O.Bogomolets, Kyiv, Ukraine. 

193 DEVELOPMENT OF A NOVEL RECOMBINANT 

BIOTHERAPEUTIC WITH APPLICATIONS IN TARGETED 

THERAPY OF HUMAN ARTHRITIS 

Mathieu Ferrari 1 , Tahereh Kamalati 1 , Costantino Pitzalis 1 

1. 

Experimental Medicine and Rheumatology, Queen Mary 

University of London, London, United Kingdom.


194 TO WHAT EXTENT IS THE NICE GUIDANCE ON THE 

MANAGEMENT OF RHEUMATOID ARTHRITIS IN ADULTS 

BEING IMPLEMENTED? - REGIONAL AUDIT OF THE 

MIDLANDS 

Nicola Tugnet 1 , Fiona Pearce 2 , Sofia Tosounidou 3 , 

Karen Obrenovic 4 , Nicola Erb 4 , Jonathan Packham 5 , 

Ravinder Sandhu 4 

1. 


Trust, Wolverhampton, United Kingdom. 2. Rheumatology, 

Nottingham University Hospitals NHS Trust, Nottingham, 

United Kingdom. 3. Rheumatology, Sandwell and West 

Birmingham Hospitals NHS Trust, Birmingham, United 

Kingdom. 4. Rheumatology, Dudley Group NHS Foundation 

Trust, Dudley, United Kingdom. 5. Rheumatology, University 

Hospital of North Staffordshire NHS Trust, Stoke, United 

Kingdom. 

195 IMMUNOGLOBULIN MONITORING IN PATIENTS WITH 

RHEUMATOID ARTHRITIS TREATED WITH RITUXIMAB 

Catherine White 1 , Caroline M. Cardy 1 , Elizabeth Justice 1 , 

Madeline Frank 1 , Lisa Li 1 

1. 

Department of Rheumatology, Queen Elizabeth Hospital 

Birmingham, Birmingham, United Kingdom. 

196 METHOTREXATE MONITORING - INITIAL EXPERIENCE WITH 

TRANSIENT ELASTOGRAPHY (FIBROSCAN) 

Mark Lloyd 1 , Ayesha Ahmed 2 , Samantha Readhead 2 , 

Aftab Ala 2 

1. 

Rheumatology, Frimley Park Hospital, Frimley, United 

Kingdom. 2. Hepatology, Frimley Park Hospital, Frimley, 


197 AN AUDIT OF HEPATITIS B SEROLOGY IN PATIENTS 

RECEIVING TNF-α BLOCKADE AND THE UNCERTAIN ROLE OF 

PROPHYLACTIC THERAPY IN THOSE WITH EVIDENCE OF 

PAST INFECTION 

Matthew Fittall 1 , Jessica Manson 1 , Yiannis Ioannou 1 

1. 

Rheumatology, UCLH, London, none, United Kingdom. 

198 ABATACEPT CONFERS CLINICAL EFFICACY REGARDLESS OF 

BASELINE CRP STATUS IN PATIENTS WITH RHEUMATOID 

ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE 

IN THE AIM TRIAL 

Jean Sibilia 1 , René Marc Flipo 2 , Bernard Combe 3 , 

Corine Gaillez 4 , Manuela Le Bars 4 , Coralie Poncet 5 , 

Ayanbola Elegbe 6 , Rene Westhovens 7 

1. 

Department of Rheumatology, Louis Pasteur University, 

Strasbourg, France. 2. Department of Rheumatology, Centre 

Hospitalier Universitaire de France, Lille, France. 

3. 

Immuno-Rheumatology, Hôpital Lapeyronie, Montpellier, 

France. 4. Medical Affairs, Bristol-Myers Squibb, 

Rueil-Malmaison, France. 5. Department of Biostatistics, Docs 

International, Sèvres, France. 6. Global Biometric Sciences, 

Bristol-Myers Squibb, Princeton, NJ, United States. 

7. 

Department of Rheumatology, UZ Gasthuisberg, Leuven, 

Belgium. 

199 WHAT IS THE ROLE OF SUBCUTANEOUS METHOTREXATE IN 

THE TREATMENT OF RHEUMATOID ARTHRITIS? 

Roya Hassanzadeh 2 , Clodagh Mangan 2 , Janice France 1 , 

Sandeep Bawa 1 

1. 

Dept of Rheumatology, Gartnavel General Hospital, Glasgow, 

United Kingdom. 2. School of Medicine, Glasgow University, 

Glasgow, United Kingdom. 

200 CERTOLIZUMAB PEGOL IN PATIENTS WITH ACTIVE 

RHEUMATOID ARTHRITIS ALIGNED WITH NICE GUIDANCE 

FOR ANTI-TNF THERAPY: POST-HOC ANALYSES OF THE 

REALISTIC PHASE IIIB RANDOMISED CONTROLLED STUDY 

M. E. Weinblatt 1 , R. Fleischmann 2 , R. van Vollenhoven 3 , 

P. Emery 4 , T. W. J.Huizinga 5 , R. Goldermann 6 , B. Duncan 7 , 

J. Timoshanko 8 , K. Luijtens 9 , O. Davies 9 , M. Dougados 10 

1. 

Brigham and Women’s Hospital, Boston, MA, United States. 

2. 

MCRC, University of Texas, Dallas, TX, United States. 

3. 

Karolinska Institute, Stockholm, Sweden. 4. University of 

Leeds, Leeds, United Kingdom. 5. Leiden University Medical 

Centre, Leiden, Netherlands. 6. UCB Pharma, Monheim, 

Germany. 7. UCB Pharma, Raleigh, NC, United States. 8. UCB 

Pharma, Slough, United Kingdom. 9. UCB Pharma, Brussels, 

Belgium. 10. René Descartes University, Paris, France.


201 RHEUMATOID ARTHRITIS AND PHYSIOTHERAPY: A NATIONAL 

SURVEY CONDUCTED BY THE NATIONAL RHEUMATOID 

ARTHRITIS SOCIETY AND THE CHARTERED SOCIETY OF 

PHYSIOTHERAPY 

Jamie Hewitt 1 

1. 

National Rheumatoid Arthritis Society, Maidenhead, 

Berkshire, United Kingdom. 

202 BED-TIME SINGLE DOSE PREDNISOLONE IN CLINICALLY 

STABLE RHEUMATOID ARTHRITIS PATIENTS 

Mohammadbagher Owlia 1 

1. 

Medicine, Shahid Sadoughi University of Medical Sciences, 

Yazd, Iran, Islamic Republic of. 

203 CLINICAL EFFICACY OF ABATACEPT AND INFLIXIMAB IN 

COMBINATION WITH METHOTREXATE ACCORDING TO 

BASELINE RHEUMATOID FACTOR STATUS IN THE 

ATTEST TRIAL 

Maxime Dougados 1 , Corine Gaillez 2 , Manuela Le Bars 2 , 

Coralie Poncet 3 , Ayanbola Elegbe 4 , Michael Schiff 5 

1. 

Department of Rheumatology, Hôpital Cochin, Descartes 

University, Paris, France. 2. Medical Affairs, Bristol-Myers 

Squibb, Rueil-Malmaison, France. 3. Department of 

Biostatistics, Docs International, Sèvres, France. 4. Global 

Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, 

United States. 5. Department of Rheumatology, University of 

Colorado, Denver, CO, United States. 

204 SAFETY PROFILE OF SUBCUTANEOUS ABATACEPT 

FOCUSING ON CLINICALLY RELEVANT EVENTS IN PATIENTS 

WITH RHEUMATOID ARTHRITIS AND UP TO 4.5 YEARS OF 

EXPOSURE 

Rieke Alten 1 , Jeffrey L. Kaine 2 , Edward Keystone 3 , 

Peter T. Nash 4 , Ingrid Delaet 5 , Keqin Qi 6 , Mark C. Genovese 7 

1. 

Rheumatology Department, Schlossparkklinik, Berlin, Germany. 

2. Rheumatology, Sarasota Arthritis Center, Sarasota, 

FL, United States. 3. Rebecca MacDonald Centre for Arthritis 

and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, 

Canada. 4. Rheumatology Research Unit, University of 

Queensland, Brisbane, QLD, Australia. 5. Global Clinical 

Research Immunology, Bristol-Myers Squibb, Princeton, NJ, 

United States. 6. Global Biometric Sciences, Bristol-Myers 

Squibb, Princeton, NJ, United States. 7. Division of 

Immunology and Rheumatology, Stanford University Medical 

Center, Palo Alto, CA, United States. 

205 DISEASE ACTIVITY SCORE (DAS) RESPONSE TO ANTI-TNF IN 

RA PATIENTS 

Judith Clark 1 , Sally Kardash 1 , Ernest Wong 1 , Richard Hull 1 , 

Fiona McCrae 1 , Ragai Shaban 1 , Lynn Thomas 1 , 

Steven Young-Min 1 , Joanna Ledingham 1 

1. 

Rheumatology Department, Queen Alexandra Hospital, 

Portsmouth, United Kingdom. 

206 SUBCUTANEOUS ABATACEPT (ABA) VERSUS INTRAVENOUS 

ABA IN PATIENTS (PTS) WITH RA: LONG-TERM DATA FROM 

THE ACQUIRE TRIAL 

Mark C. Genovese 1 , Arturo Covarrubias Cobos 2 , 

Gustavo Leon 3 , Eduardo F. Mysler 4 , Mauro W. Keiserman 5 , 

Robert M. Valente 6 , Peter T. Nash 7 , 

J. Abraham Simon Campos 8 , Wieslawa Porawska 9 , 

Jane H. Box 10 , Clarence W. Legerton III 11 , 

Evgeny L. Nasonov 12 , Patrick Durez 13 , Ramesh Pappu 14 , 

Ingrid Delaet 14 , Julie Teng 14 , Rieke Alten 15 

1. 

Division of Immunology and Rheumatology, Stanford 

University Medical Center, Palo Alto, CA, United States. 

2. 

Rheumatology, Medical Center of the Americas, Mérida, 

Mexico. 3. Rheumatology, Instituto De Ginecologia Y Reproduccion, 

Lima, Peru. 4. Department of Rheumatology, 

Organizacion Medica de Investigación, Buenos Aires, 

Argentina. 5. Internal Medicine Department - Rheumatology 

Section, Pontiphycial Catholic University, Porto Alegre, Brazil. 

6. 

Rheumatology, Arthritis Center of Nebraska, Lincoln, NE, 

United States. 7. Rheumatology Research Unit, University of 

Queensland, Brisbane, QLD, Australia. 8. Rheumatology, 

Centro De Especialidades Médicas, Mérida, Mexico. 

9. 

Novamed, Poznañski Ooerodek Medyczny, Poznan, Poland. 

10. 

Box Arthritis & Rheumatology of the Carolinas, Dark Road, 

Charlotte, NC, United States. 11. Low Country Rheumatology, 

2860 Tricom St, Charleston, SC, United States. 12. Institute of 

Rheumatology, Russian Academy of Medical Sciences, 

Moscow, Russian Federation. 13. Department of Rheumatology 

Saint-Luc, Université Catholique de Louvain, Brussels, 

Belgium. 14. Global Clinical Research Immunology, 

Bristol-Myers Squibb, Princeton, NJ, United States. 

15. 

Rheumatology Department, Schlossparkklinik, Berlin, 

Germany.


207 REGIONAL DIFFERENCES IN THE TREATMENT OF 

RHEUMATOID ARTHRITIS IN THE UK 

Christopher J. Edwards 1 , Nigel Arden 2,3 , Jennifer Campbell 4 , 

Tjeerd van Staa 4 , Claire Housden 5 , Ify Sargeant 6 

1. 

Department of Rheumatology, University Hospital 

Southampton NHS Foundation Trust, Southampton, United 

Kingdom. 2. Nuffield Department of Orthopaedics, 

Rheumatology and Musculoskeletal Sciences, University of 

Oxford , Oxford, United Kingdom. 3. University of Southampton, 

University Hospital Southampton NHS Foundation Trust, 

Southampton, United Kingdom. 4. The General Practice 

Research Database, Medicines and Healthcare Products 

Regulatory Agency, London, United Kingdom. 5. NHS Life 

Sciences Innovation Delivery Unit and NHS National 

Programmes, Roche Products Ltd, Welwyn Garden City, 

United Kingdom. 6. Communications, ismedica Ltd, Wrinehill, 


208 TEMPORAL TRENDS IN THE TREATMENT OF RHEUMATOID 

ARTHRITIS IN THE UK WITH REFERENCE TO BEST PRACTICE 

Christopher J. Edwards 1 , Nigel Arden 2,3 , Jennifer Campbell 4 , 

Tjeerd van Staa 4 , Claire Housden 5 , Ify Sargeant 6 

1. 

Department of Rheumatology, University Hospital 

Southampton NHS Foundation Trust, Southampton, United 

Kingdom. 2. Nuffield Department of Orthopaedics, 

Rheumatology and Musculoskeletal Sciences, University of 

Oxford, Oxford, United Kingdom. 3. University of Southampton, 

University Hospital Southampton NHS Foundation Trust, 

Southampton, United Kingdom. 4. The General Practice 

Research Database, Medicines and Healthcare Products 

Regulatory Agency, London, United Kingdom. 5. NHS Life 

Sciences Innovation Delivery Unit and NHS National 

Programmes, Roche Products Ltd, Welwyn Garden City, 

United Kingdom. 6. Communications, ismedica Ltd, Wrinehill, 


209 VARIATION IN THE USE OF BIOLOGICS IN THE MANAGEMENT 

OF RHEUMATOID ARTHRITIS (RA) ACROSS THE UNITED 

KINGDOM 

Ernest Choy 1 , Sandra McAuliffe 2 , Kirsty Roberts 3 , Ify Sargeant 4 

1. 

Section of Rheumatology, Department of Medicine, Cardiff 

University School of Medicine , Cardiff, United Kingdom. 

2. 

Consultancy, McAuliffe Interim Options Ltd, Oxfordshire, 

United Kingdom. 3. Market Insight and Analysis Group, Roche 

Products Ltd, Welwyn Garden City, United Kingdom. 

4. 

Communications, ismedica Ltd, Wrinehill, United Kingdom. 

210 RELATIVE EFFICACY OF RITUXIMAB VERSUS AN 

ALTERNATIVE TNF INHIBITOR IN PATIENTS WITH 

RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE 

TO A SINGLE PREVIOUS TNF INHIBITOR: INTERIM RESULTS 

FROM SWITCH-RA, A GLOBAL, COMPARATIVE- 

EFFECTIVENESS, OBSERVATIONAL STUDY 

Paul Emery 1,2 , Piercarlo Sarzi-Puttini 3 , Robert J. Moots 4 , 

Alexandros Andrianakos 5 , Thomas P. Sheeran 6 , 

Denis Choquette 7 , Axel Finckh 8 , Marie-Laetitia Desjuzeur 9 , 

Eric K. Gemmen 10 , Chiedzo Mpofu 9 , Jacques-Eric Gottenberg 11 

1. 

Division of Musculoskeletal Disease, Leeds Institute of 

Molecular Medicine, University of Leeds, Leeds, United 

Kingdom. 2. NIHR Leeds Musculoskeletal Biomedical 

Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, 

United Kingdom. 3. Rheumatology Unit, L Sacco University 

Hospital, Milano, Italy. 4. Clinical Sciences Centre, University of 

Liverpool, Liverpool, United Kingdom. 5. Hellenic Foundation 

for Rheumatological Research, Athens, Greece. 

6. 

Rheumatology Department, Cannock Chase Hospital, 

Cannock, United Kingdom. 7. Rheumatology Department, 

University of Montreal, Notre-dame Hospital, Montreal, QC, 

Canada. 8. Department of Medical Specialties (DSM), Division 

of Rheumatology, University Hospital of Geneva, Geneva, 

Switzerland. 9. F Hoffmann-La Roche Ltd, Basel, Switzerland. 

10. 

Quintiles Inc, Rockville, MD, United States. 11. Department 

of Rheumatology, CHU Strasbourg, Strasbourg, France. 

211 COMMISSIONER QUALITY METRICS IN RHEUMATOID 

ARTHRITIS: IMPACT ON CLINICAL PRACTICE AND QUALITY 

OF CARE 

Marwan Bukhari 1,2 , Preeti Shah 5 , George Kitas 4 , Maureen 

Cox 7 , Alan Nye 6 , Anne O’Brien 8 , Peter Jones 3 , Ify Sargeant 9 

1. 

Rheumatology Department, University Hospitals of 

Morecambe Bay NHS Foundation Trust, Royal Lancaster 

Infirmary, Lancaster, United Kingdom. 2. Clinical Sciences, 

University of Liverpool, Liverpool, United Kingdom. 3. Statistics, 

Keele University, Keele, United Kingdom. 4. Rheumatology, 

Dudley group of hospitals NHS trust, Dudley, United Kingdom. 

5. 

Rheumatology, Trafford General Hospital, Trafford, United 

Kingdom. 6. Rheumatology, Pennine MSK partnership, 

Oldham, United Kingdom. 7. Rheumatology, Nuffield 

Orthopaedic centre, Oxford, United Kingdom. 8. School of 

Health and Rehabilitation, Keele University, Keele, United 

Kingdom. 9. Communications, ismedica Ltd, Wrinehill, 

United Kingdom.


212 THE EFFECTIVENESS OF PRACTITIONER-BASED 

COMPLEMENTARY AND ALTERNATIVE THERAPIES IN THE 

MANAGEMENT OF RHEUMATOID ARTHRITIS 

Gareth T. Jones 1 , Priya Paudyal 1,2 , Hugh MacPherson 3 , 

Julius Sim 4 , Mike Doherty 5 , Edzard Ernst 2 , Margaret Fisken 1 , 

George Lewith 6 , Jane Tadman 7 , Gary J. Macfarlane 1 

1. 

Aberdeen Musculoskeletal Research Group (Epidemiology), 

University of Aberdeen, Aberdeen, United Kingdom. 

2. 

Peninsula College of Medicine & Dentistry, Universities of 

Exeter and Plymouth, Plymouth, United Kingdom. 

3. 

Department of Health Sciences, University of York, York, 

United Kingdom. 4. School of Health and Rehabilitation, Keele 

University, Keele, United Kingdom. 5. Arthritis Research UK 

Pain Centre, University of Nottingham, Nottingham, United 

Kingdom. 6. Community Clinical Sciences, University of 

Southampton, Southampton, United Kingdom. 7. Press Office, 

Arthritis Research UK, Chesterfield, United Kingdom. 

213 POOLED ANALYSIS OF THE RISK OF SERIOUS INFECTIONS 

AND OPPORTUNISTIC INFECTIONS IN CLINICAL TRIALS OF 

CERTOLIZUMAB PEGOL FOR RHEUMATOID ARTHRITIS 

X. Mariette 1 , P. Bertin 2 , C. Arendt 3 , I. Terpstra 4 , B. VanLunen 5 , 

M. de Longueville 6 

1. 

Service de Rhumatologie, Université Paris-Sud, Hôpital 

Bicêtre, Le Kremlin-Bicêtre Paris, France. 2. Service de 

Rhumatologie, C.H.U. Dupuytren, Limoges, France. 3. Clinical 

Development, UCB Pharma, Brussels, Belgium. 4. GCSP Drug 

Safety, UCB Pharma, Brussels, Belgium. 5. Global Biostatistics, 

UCB BioSciences Inc, Research Triangle Par, NC, United 

States. 6. Global Medical Affairs, UCB Pharma, Brussels, 

Belgium. 

214 KEY PHARMACOLOGICAL PARAMETERS SUPPORT MONTHLY 

DOSING FOR GOLIMUMAB 

Honghui Zhou 1 , Ann Cai 1 , Eilyn Lacy 1 , Jonathan Kay 2 , 

Ed Keystone 3 , Eric Matteson 4 , Chuanpu Hu 1 , Elizabeth Hsia 1,5 , 

Mittie Doyle 1,5 , Mahboob Rahman 1 , David Shealy 1 

1. 

Immunology, Janssen Research & Development, Inc, 

Malvern, PA, United States. 2. Rheumatology Center, UMass 

Memorial Medical Center, Worcester, MA, United States. 

3. 

Rheumatology, University of Toronto, Toronto, ON, Canada. 

4. 

Rheumatology, Mayo Clinic, Rochester, ON, Canada. 

5. 

Rheumatology, University of Pennsylvania School of 

Medicine, Philadelphia, PA, United States. 

215 COMBINATION ANTI-RHEUMATIC DRUGS IN EARLY 

RHEUMATOID ARTHRITIS: COMPARISON OF FINDINGS IN 

TWO RANDOMISED CONTROLLED TRIALS 

David L. Scott 1 , Fowzia Ibrahim 1 , Hanan Abozaid 1 , 

Ernest Choy 1 , Andrew Hassell 2 , Michael Plant 3 , 

Selwyn Richards 4 , David Walker 5 , Gemma Simpson 1 , 

Anna Kowalczyk 1 

1. 


Kingdom. 2. Rheumatology, Haywood Hospital, Stoke On Trent, 

United Kingdom. 3. Rheumatology, James Cook University 

Hospital, Middlesbrough, United Kingdom. 4. Rheumatology, 

Poole Hospital, Poole, United Kingdom. 5. Rheumatology, 

Freeman Hospital, Newcastle Upon Tyne, United Kingdom. 

216 COMPLIANCE WITH NICE CLINICAL GUIDELINE 79 IN THE 

MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS 

IN 5 NHS TRUSTS IN ENGLAND 

Peter Prouse 1 , Andrew Brown 2 , Mano George 3 , 

Namita Kumar 4 , Kirsten Mackay 5 , Samantha Marshall 6 

1. 

Department of Rheumatology, Basingstoke and North 

Hampshire NHS Foundation Trust, Basingstoke, United 

Kingdom. 2. Department of Rheumatology, York Teaching 

Hospital NHS Foundation Trust, York, United Kingdom. 

3. 

Department of Rheumatology, Wirral University Teaching 

Hospital NHS Foundation Trust, Wirral, United Kingdom. 

4. 

Department of Rheumatology, County Durham and 

Darlington NHS Foundation Trust , Durham, United Kingdom. 

5. 

Department of Rheumatology, South Devon Healthcare NHS 

Foundation Trust, Torbay, United Kingdom. 6. pH Associates, 

Marlow, United Kingdom. 

217 EFFICACY, SAFETY AND PHARMACOKINETICS OF 

SUBCUTANEOUS ABATACEPT IN PATIENTS WITH 

RHEUMATOID ARTHRITIS, WITH OR WITHOUT AN 

INTRAVENOUS (IV) LOADING DOSE 

Peter T. Nash 1 , Charles L. Ludivico 2 , Ingrid Delaet 3 , Keqin Qi 4 , 

Bindu Murthy 3 , Michael Corbo 5 , Jeffrey L. Kaine 6 

1. 

Rheumatology Research Unit, University of Queensland, 

Brisbane, QLD, Australia. 2. Rheumatology, East Penn 

Rheumatology Associates, Bethlehem, PA, United States. 

3. 

Global Clinical Research Immunology, Bristol-Myers Squibb, 

Princeton, NJ, United States. 4. Global Biometric Sciences, 

Bristol-Myers Squibb, Princeton, NJ, United States. 5. Global 

Clinical Research, Bristol-Myers Squibb (at time of study), 

Princeton, NJ, United States. 6. Rheumatology, Sarasota 

Arthritis Center, Sarasota, FL, United States.


218 EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL AFTER 

INCOMPLETE RESPONSE TO DMARDS IN RHEUMATOID 

ARTHRITIS PATIENTS WITH LOW MODERATE DISEASE 

ACTIVITY: RESULTS FROM CERTAIN, A PHASE IIIB STUDY 

Paul Emery 1 , Josef S. Smolen 2 , W. Samborski 3 , 

F. Berenbaum 4 , Owen Davies 5 , J. Ambrugeat 5 , B. Bennett 6 , 

H. Burkhardt 7 

1. 

Academic Unit of Musculoskeletal Disease, University of 

Leeds, Leeds, United Kingdom. 2. Divisions of Rheumatology 

and Medicine , Medical University of Vienna and Hietzing 

Hospital, Vienna, Austria. 3. Department of Rheumatology, K. 

Marcinkowski University of Medical Sciences, Poznan, Poland. 

4. 

Department of Rheumatology, AP-HP St -Antoine Hospital, 

Paris, France. 5. UCB, UCB Pharma, Brussels, Belgium. 

6. 

UCB, UCB Pharma, Smyrna, GA, United States. 7. Division of 

Rheumatology, Johan Wolfgang Goethe University, Frankfurt 

am Main, Germany. 

219 COMPLIANCE WITH NICE TECHNOLOGY APPRAISALS TA130 

AND TA186 IN THE USE OF TNF-α INHIBITOR THERAPY IN 

PATIENTS WITH RHEUMATOID ARTHRITIS IN 5 NHS TRUSTS 

IN ENGLAND 

Peter Prouse 1 , Andrew Brown 2 , Mano George 3 , 

Namita Kumar 4 , Kirsten Mackay 5 , Samantha Marshall 6 

1. 

Department of Rheumatology, Basingstoke and North 

Hampshire NHS Foundation Trust, Basingstoke, United 

Kingdom. 2. Department of Rheumatology, York Teaching 

Hospital NHS Foundation Trust , York, United Kingdom. 

3. 

Department of Rheumatology, Wirral University Teaching 

Hospital NHS Foundation Trust, Wirral, United Kingdom. 

4. 

Department of Rheumatology, County Durham and 

Darlington NHS Foundation Trust , Durham, United Kingdom. 

5. 

Department of Rheumatology, South Devon Healthcare NHS 

Foundation Trust, Torbay, United Kingdom. 6. pH Associates, 

Marlow, United Kingdom. 

220 TOCILIZUMAB AS MONOTHERAPY OR WITH ADD-ON 

DISEASE-MODIFYING DRUGS IN RHEUMATOID ARTHRITIS 

PATIENTS WITH INADEQUATE RESPONSE TO PREVIOUS 

TREATMENTS 

Vivian Bykerk 1 , Andrew J. Ostor 2 , José Román Ivorra 3 , 

Jurgen Wollenhaupt 4 , Andrea Stancati 5 , Corrado Bernasconi 5 , 

Jean Sibilia 6 

1. 

Rheumatology, Brigham & Women’s Hospital, Boston, MA, 

United States. 2. Rheumatology, University of Cambridge, 

Cambridge, United Kingdom. 3. Rheumatology, Hospital 

Universitario La Fe, Valencia, Spain. 4. Rheumatology, Schön 

Klinik, Hamburg, Germany. 5. Roche, Roche, Basel, 

Switzerland. 6. Rheumatology, CHU Hautepierre, Strasbourg, 

France. 

221 A RETROSPECTIVE STUDY OF THE EFFECTS OF SWITCHING 

FROM ORAL TO SUBCUTANEOUS (SC) METHOTREXATE 

(MTX): THE METHOTREXATE EVALUATION OF NORWICH 

TREATMENT OUTCOMES IN RA (MENTOR) STUDY 

David G I. Scott 1 , Pearl Claydon 1 , Corrinne Ellis 1 , Scot Buchan 2 

1. 

Rheumatology, Norfolk and Norwich University Hospital, 

Norwich, Norfolk, United Kingdom. 2. Strategen Ltd, 

Basingstoke, Hampshire, United Kingdom. 

222 RAPID REDUCTIONS IN FATIGUE AND SLEEP PROBLEMS 

AND CORRELATION WITH IMPROVEMENTS IN PATIENT- 

REPORTED OUTCOMES IN PATIENTS WITH ACTIVE RA 

TREATED WITH CERTOLIZUMAB PEGOL IN THE REALISTIC 

12-WEEK PHASE IIIB RANDOMISED CONTROLLED STUDY 

Janet Pope 1 , Roy Fleischmann 2 , Maxime Dougados 3 , 

Clifton O. Bingham 4 , Elena M. Massarotti 5 , J. Wollenhaupt 6 , 

B. Duncan 7 , Geoffroy Coteur 8 , Michael Weinblatt 5 

1. 

Division of Rheumatology, University of Western Ontario, 

London, ON, Canada. 2. MCRC, University of Texas, Dallas, TX, 

United States. 3. Department of Rheumatology, René 

Descartes University, Paris, France. 4. Divisions of 

Rheumatology and Allergy, Johns Hopkins University, 

Baltimore, MD, United States. 5. Division of Rheumatology, 

Brigham and Women’s Hospital, Boston, MA, United States. 

6. 

Department of Rheumatology, Klinikum Eilbek, Hamburg, 

Germany. 7. UCB, UCB Pharma, Raleigh, NC, United States. 

8. UCB, UCB Pharma, Brussels, Belgium. 

223 ANTI-TNF THERAPY IMPROVES HAND FUNCTION IN 

RHEUMATOID ARTHRITIS WITHIN 3 MONTHS 

Dobrina Hull 1 , Catherine Ball 1 , Sonya Abraham 2 

1. 

Kennedy Institute of Rheumatology, University of Oxford, 

London, United Kingdom. 2. Department of Medicine, Imperial 

College, London, United Kingdom.


224 A NEW APPROACH WITHIN PERSUASIVE DESIGN THEORY 

TO IMPROVE PATIENT ENGAGEMENT WITH EXERCISE 

THERAPIES 

Tom Ainsworth 1 , Jyri Kermik 1 , Jonathan Woodham 1 , Inam Haq 2 

1. 

Faculty of Arts and Architecture, University of Brighton, 

Brighton, Sussex, United Kingdom. 2. Brighton and Sussex 

Medical School, Falmer, Sussex, United Kingdom. 

225 EFFICACY AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH 

RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE: TWO 

YEARS’ EXPERIENCE 

Estefania Quesada-Masachs 1 , Ana Carolina Diaz 1 , 

Gabriela Avila 1 , Isabel Acosta 1 , Xavier Sans 1 , Cayetano Alegre 1 , 

Sara Marsal 1 

1. 

Rheumatology, Hospital Universitari Vall d’Hebron, 

Barcelona, Spain. 

226 PREDICTING WHICH PATIENTS WITH EARLY RA WILL CHANGE 

DMARD DURING THE FIRST 2 YEARS: THE ERAN COHORT 

Dan McWilliams 1 , Patrick D. Kiely 3 , Adam Young 2 , 

David A. Walsh 1,4 

1. 

Arthritis UK Pain Centre, University of Nottingham, 

Nottingham, United Kingdom. 2. Rheumatology, West 

Hertfordshire Hospitals NHS Trust, St Albans, United Kingdom. 

3. 

Rheumatology, St Georges Healthcare NHS Trust, London, 

United Kingdom. 4. Rheumatology, Sherwood Forest Hospitals 

NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom. 

227 IMPROVED QUALITY OF LIFE AND PRODUCTIVITY IN 

PATIENTS WITH MODERATE OR SEVERE RHEUMATOID 

ARTHRITIS ACTIVELY SWITCHED TO TREATMENT WITH 

INFLIXIMAB FROM ADALIMUMAB OR ETANERCEPT THERAPY 

Roy Fleischmann 1 , Rebecca Bolce 2 , Jianping Wang 3 , 

Mike Ingham 2 , Ralph Dehoratius 2 , Dennis Decktor 2 

1. 

Metroplex Clinical Research Center, University of 

Texas/Southwestern Medical Center, Dallas, TX, United States. 

2. 

Medical Affairs, Janssen Services, LLC, Dallas, TX, United 

States. 3. Bio Programming , Johnson & Johnson 

Pharmaceutical Research and Development, LLC, Belle Mead, 

NJ, United States. 

228 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR 

(CV) EVENTS (MACE) IN RHEUMATOID ARTHRITIS (RA) 

PATIENTS (PTS) TREATED WITH TOCILIZUMAB (TCZ) 

Vijay Rao 1,2 , Andrey Pavlov 3 , Micki Klearman 1 , 

Dave Musselman 4 , Jon Giles 5 , Joan Bathon 5 , Naveed Sattar 6 , 

Janet Lee 4 

1. 

Genentech, Genentech, South San Francisco, CA, United 

States. 2. Division of Cardiology, UCSF, San Francisco, CA, 

United States. 3. Everest, Everest, Toronto, ON, Canada. 

4. 

Roche, Roche, Nutley, NJ, United States. 5. Division of 

Rheumatology, Columbia University, New York, NY, United 

States. 6. Rheumatology, University of Glasgow, Glasgow, 


229 A PROSPECTIVE SURVEY OF TOCILIZUMAB USE IN 

SCOTLAND; IMPLICATIONS FOR DAILY PRACTICE 

Derek Baxter 1 , John S. McLaren 2 , Margaret-Mary Gordon 3 , 

Kyaw Z. Thant 4 

1. 

Department of Rheumatology, Southern General Hospital , 

Glasgow, United Kingdom. 2. Fife Rheumatic Diseases Unit, 

Whyteman’s Brae Hospital , Kirkcaldy, United Kingdom. 

3. 

Department of Rheumatology, Gartnavel General Hospital , 

United Kingdom. 4. Department of Medicine, Wishaw General 

Hospital, 5. Netherton Street, Glasgow, United Kingdom. 

230 USE OF INTRAMUSCULAR DEPOMEDRONE IN 

INFLAMMATORY ARTHRITIS-DOES OBESITY INFLUENCE 

RESPONSE TO INJECTION? 

Emma L. Williams 1 , Susannah Earl 3 , Paula White 2 , 

Julie Williams 2 , Sarah L. Westlake 4 , Joanna Ledingham 2 

1. 

Bone & Joint Research Group, University of Southampton 

Medical School, Southampton, Hampshire, United Kingdom. 

2. 


Portsmouth, Hampshire, United Kingdom. 3. Rheumatology 

Department, Royal Devon & Exeter NHS Foundation Trust, 

Wonford, Devon, United Kingdom. 4. Rheumatology Department, 

Poole Hospital NHS Foundation Trust, Poole, Dorset, 


Soft tissue and regional musculoskeletal disease, 

fibromyalgia 

231 SERUM 25-HYDROXY VITAMIN D LEVELS IN PATIENTS WITH 

FIBROMYALGIA 

Adnan K. Jan 1 , Azher I. Bhatti 1 , Catriona Stafford 1 , 

Martina Carolan 1 , Sekharipuram A. Ramakrishnan 1 

1. 

Department of Rheumatology, Our Lady’s Hospital, Navan, 

Co. Meath, Ireland.




Thu 3 May 2012

Poster viewing: Thursday 3 May 2012 

Thursday 3 May 2012 | Poster viewing 109 

Basic Science 

232 CERTOLIZUMAB PEGOL PREVENTS PRO-INFLAMMATORY 

ALTERATIONS IN ENDOTHELIAL CELL FUNCTION 

Sarah Heathfield 1,2 , Ben Parker 1,2 , Leo Zeef 3 , Ian Bruce 2 , 

Yvonne Alexander 1 

1. 

Cardiovascular Research Group, University of Manchester, 

Manchester, United Kingdom. 2. Arthritis Research UK 


United Kingdom. 3. Wellcome Trust Centre for Cell-Matrix 

Research, University of Manchester, Manchester, United 

Kingdom. 

233 DEATH RECEPTOR 3 AND TL1A: A DRIVING FORCE IN 

OSTEOCLAST DIFFERENTIATION AND POTENTIAL TARGET 

FOR RHEUMATOID ARTHRITIS THERAPY 

Fraser Collins 1 , Michael Stone 2 , Edward Wang 1 , 

Anwen S. Williams 1 

1. 

Institute of Infection and Immunity, School of Medicine, 

Cardiff University, Cardiff, United Kingdom. 2. Geriatric 

Medicine Department, Llandough Hospital, Cardiff, United 

Kingdom. 

234 DISCOVERING CYTOKINE-SPECIFIC GENE EXPRESSION 

PROFILES IN INFLAMMATORY NEUTROPHILS USING 

WHOLE TRANSCRIPTOME SEQUENCING 

Helen L. Wright 1 , Huw B. Thomas 1 , Robert J. Moots 2 , 

Steven W. Edwards 1 

1. 

Institute of Integrative Biology, University of Liverpool, 

Liverpool, United Kingdom. 2. Institute of Ageing and Chronic 

Disease, University of Liverpool, Liverpool, United Kingdom. 



poster tours! 

235 BLOCKADE OF CALCITONIN GENE-RELATED PEPTIDE 

RECEPTORS BY CGRP27-37 INHIBITS RESPONSES OF 

KNEE JOINT PRIMARY AFFERENTS IN THE MIA MODEL OF 


Craig Bullock 1,2 , Victoria Chapman 1,3 , David A. Walsh 1,4 , 

Ali Mobasheri 5 , David Kendall 3 , Sara Kelly 1,2 

1. 


Nottingham, United Kingdom. 2. School of Biosciences, 


3. 

School of Biomedical Sciences, University of Nottingham, 

Nottingham, United Kingdom. 4. School of Clinical Sciences, 


5. 

School of Veterinary Medicine and Science, University of 

Nottingham, Nottingham, United Kingdom. 

236 THE EFFECTS OF ACUTE EXPOSURE TO CIGARETTE SMOKE 

EXTRACT ON T CELL RECEPTOR SIGNALLING 

Rachel Bayley 1 , Chris D. Buckley 1 , Stephen P. Young 1 

1. 

School of Immunity and Infection, University Of Birmingham, 


237 AN ASSESSMENT OF CC CHEMOKINES PRESENT ON THE 

MICROVASCULATURE OF SYNOVIAL TISSUE IN PATIENTS 

WITH RHEUMATOID ARTHRITIS 

Lisa Rump-Goodrich 1 , Jim Middleton 2 

1. 

ARC, Keele University, Oswestry, Shropshire, United 

Kingdom. 2. Faculty of Medicine and Dentistry, Bristol 

University, Bristol, United Kingdom. 

238 INVESTIGATING THE ROLE OF ENDOPLASMIC RETICULUM 

AMINOPEPTIDASE-1 IN ANKYLSOING SPONDYLITIS 

Liye Chen 1 , Roman Fisher 2 , Simon Kollnberger 1 , 

Nilabh Shastri 3 , Benedikt M. Kessler 2 , Paul Bowness 1 

1. 

MRC Human Immunology Unit, Weatherall Institute of 

Molecular Medicine, University of Oxford, Oxford, United 

Kingdom. 2. Centre for Clinical and Molecular Medicine, 

University of Oxford, Oxford, United Kingdom. 3. Division of 

Immunology and Pathogenesis, Department of Molecular and 

Cell Biology, University of California, Berkeley, CA, United 

States.

110 Poster viewing | Thursday 3 May 2012 

239 NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+) 

BIOSYNTHESIS ENZYMES IN RHEUMATOID ARTHRITIS 

Abdul Nazeer Moideen 1,2 , Laura Evans 2 , Louise Osgood 2 , 

Anwen S. Williams 2 , Simon A. Jones 2 , Mari A. Nowell 2 

1. 

Trauma & Orthopaedics, University Hospital of Wales, Cardiff, 

United Kingdom. 2. Institute of Infection & Immunity, Cardiff 

University, Cardiff, United Kingdom. 

240 CHARACTERISATION OF A PATIENT’S ANTIBODIES TO THE 

ANTI-CD20 THERAPEUTIC RITUXIMAB 

Younis Mahadik 1 , Stephen Young 1 , Matthew Morgan 2 , 

Caroline Gordon 1 , Lorraine Harper 2 

1. 

Rheumatology Research Group, School of Immunity & 

Infection, College of Medical and Dental Sciences, 

Birmingham, United Kingdom. 2. Renal Immunobiology Group, 

School of Immunity & Infection, College of Medical and Dental 

Sciences, Birmingham, United Kingdom. 

241 FUNCTIONAL AND EXPRESSION ANALYSIS OF COMPLEMENT 

C5 POLYMORPHISMS ASSOCIATED WITH RHEUMATOID 

ARTHRITIS 

Joanna L. Giles 1 , B.Paul Morgan 1 , Claire L. Harris 1 

1. 

Institute of Infection and Immunity, Cardiff University, 

Cardiff, United Kingdom. 

242 HLA-B27 HEAVY CHAIN DIMER EXPRESSION IN 

SPONDYLOARTHRITIS 

Oliwia J. Rysnik 1 , Kirsty McHugh 1 , Simon Kollnberger 1 , 

Sravan Payeli 3 , Osiris Marroquin 3 , Jacqueline Shaw 1 , 

Christoph Renner 3,4 , Paul Bowness 1,2 

1. 

MRC Human Immunology Unit, Weatherall Institute of 

Molecular Medicine, Nuffield Department of Clinical Medicine, 

University of Oxford, Oxford, United Kingdom. 2. NDORMS, 

University of Oxford, Oxford, United Kingdom. 3. Department 

of Oncology, University of Zurich, Zurich, Switzerland. 

4. 

Department of Oncology, University Hospital Zurich, 

Zurich, Switzerland. 

243 ECTOPIC LYMPHONEOGENESIS IN A NOVEL MURINE MODEL 

OF SALIVARY GLANDS SIALOADENITIS IS CHARACTERIZED 

BY ASYNCHRONY IN THE LYMPHANGIOGENETIC AND 

ANGIOGENETIC PROGRAM 

Saba Nayar 1 , Tom Cloake 1 , Michele Bombardieri 2 , 

Costantino Pitzalis 2 , Chris Buckley 1 , Francesca Barone 1 

1. 


Edgbaston, United Kingdom. 2. Experiemental Rheumatology, 

Queen Mary University, London, United Kingdom. 

244 COOPERATION OF INNATE AND ACQUIRED IMMUNE SYSTEM 

DERIVED SIGNALS INDUCES STROMAL CELL ACTIVATION 

DURING CHRONIC INFLAMMATION AND ECTOPIC 

LYMPHONEOGENESIS 

Francesca Barone 1 , Saba Nayar 1 , Tom Cloake 1 , Peter Lane 2 , 

Mark Coles 3 , Chris Buckley 1 

1. 


Edgbaston , United Kingdom. 2. Infection and Immunity, 

Birmingham University , Edgbaston , United Kingdom. 

3. 

Centre for Immunology and Infection, University of York, 

York, United Kingdom. 

245 INFLAMMATORY CYTOKINES AND BIOENGINEERING 

STRATEGIES FOR ARTHRITIS: FRIEND OR FOE? 

Emma L. Williams 1,2 , Christopher J. Edwards 2,1 , 

Cyrus Cooper 3,2 , Richard O. Oreffo 1 

1. 

Bone & Joint Research Group, University of Southampton 

Medical School, Southampton, Hampshire, United Kingdom. 

2. 

Rheumatology Department, University Hospital Southampton 

NHS Foundation Trust, Southampton, Hampshire, United 

Kingdom. 3. MRC Lifecourse Epidemiology Unit, University 

Hospital Southampton NHS Foundation Trust, Southampton, 

Hampshire, United Kingdom. 

Biology of bone, cartilage and connective tissue disease 

246 THE EFFECTS OF CANNABINOIDS ON IL-1 INDUCED MATRIX 

METALLOPROTEINASE EXPRESSION 

Sara Dunn 1 , Aileen Crawford 2 , Mark Wilkinson 3 , 

Christine Le Maitre 1 , Rowena Bunning 1 

1. 

Biomedical Research Centre, Sheffield Hallam University, 

Sheffield, United Kingdom. 2. Restorative Dentistry, University 

of Sheffield, Sheffield, United Kingdom. 3. Bone Biomedical 

Research Unit, Centre for Biomedical Research Northern 

General Hospital, Sheffield, United Kingdom.


Cell receptor-ligand interaction, signalling, activation 

and apoptosis 

247 INTRACELLULAR SIGNALLING MECHANISMS INDUCED BY 

IL-1 IN HUMAN NUCLEUS PULPOSUS CELLS 

Jodie Daniels 1 , Kate L E. Phillips 1 , Neil Chiverton 2 , 

Christine L. Le Maitre 1 

1. 


Sheffield, United Kingdom. 2. Spinal Surgery, Sheffield 

Teachning Hospitals, Sheffield, South Yorkshire, 


248 THE ROLE OF HLA-B27 KIR3DL2 INTERACTIONS IN THE 

PATHOGENESIS OF SPONDYLOARTHRITIS 

Simon Kollnberger 1 , Jackie Shaw 1 , Anna Ridley 1 , 

Isabel Wong-Baeza 1 , Kirsty McHugh 1 , Sarah Keidel 1 , 

Antoni Chan 2 , Paul Bowness 1 

1. 

NDORMS, Botnar Research Centre, Oxford, United Kingdom. 

2. 

Dept of Rheumatology, Royal Berkshire Hospital, Reading, 

Berkshire, United Kingdom. 

Cytokines and inflammatory mediators 

249 CONVENTIONAL THERAPY FOR EARLY INFLAMMATORY 

ARTHRITIS DOES NOT MODIFY PERIPHERAL BLOOD 

CYTOKINE PROFILES 

Nicola J. Gullick 1,3 , Hanan S. Abozaid 1,4 , David M. Jayaraj 2, 3 , 

Hayley G. Evans 2,3 , David L. Scott 1,3 , Ernest H. Choy 3,5 , 

Leonie S. Taams 2,3 

1. 

Academic Department of Rheumatology, King’s College, 

London, London, United Kingdom. 2. Centre for Molecular and 

Cellular Biology of Inflammation, King’s College London, 

London, United Kingdom. 3. NIHR comprehensive Biomedical 

Research Centre, Guy’s and St. Thomas’ Hospital and King’s 

College London, London, United Kingdom. 4. Rheumatology 

Department, Sohag Faculty of Medicine, Sohag, Egypt. 

5. 

Section of Rheumatology, Cardiff University School of 

Medicine, Cardiff, United Kingdom. 

250 SAFETY AND PHARMACOKINETICS OF CDP6038, AN 

ANTI-IL-6 MONOCLONAL ANTIBODY, ADMINISTERED BY 

SUBCUTANEOUS INJECTION AND INTRAVENOUS INFUSION 

TO HEALTHY MALE VOLUNTEERS: A PHASE 1 STUDY 

M. Hickling 1 , G. Golor 2 , A. Jullion 3 , S. Shaw 1 , K. Kretsos 1 

1. 

UCB, Celltech, Slough, United Kingdom. 2. PAREXEL, 

International GmBH, Berlin, Germany. 3. Arlenda, Liege, 

Belgium. 

251 DEVELOPMENT OF A HIGH FIDELITY SIMULATION FOR THE 

TRAINING & TEACHING OF THE IDENTIFICATION AND 

MANAGEMENT OF INFUSION REACTIONS TO BIOLOGIC 

AGENTS 

Syed F. Bari 1 , Brian Rhys-Dillon 1 , Nicholson Amos 2 , 

Stefan Siebert 3 

1. 

Rheumatology, Princess of Wales Hospital , Bridgend, United 

Kingdom. 2. MPEC, Princess of Wales Hospital, Bridgend, 

United Kingdom. 3. Rheumatology, Swansea University, 

Swansea, United Kingdom. 

252 CYTOKINE AND CHEMOKINE EXPRESSION PROFILE IN 

HUMAN INTERVERTEBRAL DISC DEGENERATION 

Kate L E. Phillips 1 , Neil Chiverton 2 , Rowena D. Bunning 1 , 

Gail Haddock 1 , Alison K. Cross 1 , Christine L. Le Maitre 1 

1. 



Teaching Hospitals, Sheffield, United Kingdom. 

253 THE ROLE OF CYTOKINES AND CHEMOKINES IN HUMAN 

INTERVERTEBRAL DISC DEGENERATION 

Kate L E. Phillips 1 , Alison Cross 1 , Neil Chiverton 2 , 

Gail Haddock 1 , Rowena A D. Bunning 1 , Christine L. Le Maitre 1 

1. 

Biomedical Reserach Centre, Sheffield Hallam University, 


Teachning Hospitals, Sheffield, United Kingdom.


Rheumatoid arthritis: aetiopathogenesis and 

animal models 

254 DEFECTIVE CD8+CD28- REGULATORY T CELL SUPPRESSOR 

FUNCTION IN RHEUMATOID ARTHRITIS IS DUE TO SOLUBLE 

MEDIATORS AND REDUCED SENSITIVITY OF RESPONDER 

CELLS. 

Sabrina Ceeraz 1 , Jo Spencer 2 , Ernest Choy 3 , Valerie Corrigall 1 

1. 

Academic Department of Rheumatology, Centre for 

Molecular and Cellular Biology of Inflammation , Kings College 

London, London, United Kingdom. 2. Peter Gorer Department 

of Immunobiology, Division of Immunology, Infection and 

Inflammatory Disease, Kings College London, London, 

United Kingdom. 3. Section of Rheumatology, Cardiff University 

School of Medicine, Cardiff University School of Medicine, 

Cardiff, United Kingdom. 

255 PROTEINASE-ACTIVATED RECEPTOR-2 MODULATES IL-17 

GENERATION IN COLLAGEN INDUCED ARTHRITIS 

Anne Crilly 1 , Helen Palmer 1 , John Lockhart 1 , Robin Plevin 2 , 

William R. Ferrell 3 , Iain McInnes 3 

1. 

School of Science, University of the West of Scotland, 

Paisley, Scotland, United Kingdom. 2. Strathclyde Institute of 

Pharmacy and Biomedical Sciences, University of Strathclyde, 

Glasgow, Scotland, United Kingdom. 3. Institute of Infection, 

Immunity & Inflammation, University of Glasgow, Glasgow, 

Scotland, United Kingdom. 

256 CIGARETTE SMOKING HISTORY IS MORE STRONGLY 

ASSOCIATED WITH VERY STRONGLY POSITIVE RHEUMATOID 

FACTOR RATHER THAN VERY STRONGLY POSITIVE 

ANTI-CITRULLINATED PROTEIN ANTIBODY POSITIVITY 

WITHOUT VERY STRONGLY POSITIVE RHEUMATOID FACTOR 

IN RHEUMATOID ARTHRITIS. 

David Hutchinson 1 , Liz Perry 1 

1. 

Rheumatology Department, Royal Cornwall Hospital, 

Cornwall, United Kingdom. 

257 THE PATHOBIOLOGY OF EARLY ARTHRITIS COHORT (PEAC): 

A PRELIMINARY ANALYSIS CORRELATING 

HISTOMORPHOLOGY AND DISEASE ACTIVITY 

Maria DiCicco 1 , Frances Humby 2,1 , Stephen Kelly 1 , 

Rebecca Hands 2 , Chris Buckley 5 , Ian McInnes 3 , Peter Taylor 4 , 

Michele Bombardieri 2,1 , Costantino Pitzalis 2,1 

1. 

Rheumatology, Barts and the London NHST Trust, London, 

United Kingdom. 2. William Harvery research Institute, Barts 

and the London School of Medicine, London, United Kingdom. 

3. 


Glasgow, United Kingdom. 4. Kennedy Institute of 

Rheumatology, University of Oxford, Oxford, United Kingdom. 

5. 

School of Immunity and Infection, University of Birmingham, 


Case reports 

258 HYPOPHOSPHATAEMIC RICKETS AND ANKYLOSING 

SPONDYLITIS-LIKE FEATURES ASSOCIATED WITH AN 

INACTIVATING ENPP1 MUTATION, A NOVEL 

PATHOGENETIC LINK 

Puja Mehta 1 , Adam Mitchell 2 , Carolyn Tysoe 3 , 

Richard Caswell 4 , Martina Owens 3 , Tonia Vincent 1 

1. 

Rheumatology, Charing Cross Hospital, London, United 

Kingdom. 2. Radiology, Chelsea and Westminster Hospital, 

London, United Kingdom. 3. Molecular Genetics, Royal Devon 

& Exeter NHS Foundation Trust, Exeter, United Kingdom. 

4. 

Institute of Biomedical and Clinical Science, Peninsula 

Medical School, Exeter, United Kingdom. 

259 REACTIVE ARTHRITS(ReA) AND TRISMUS POST 

INTRAVESICAL BCG IMMUNOTHERAPY FOR BLADDER 

CARCINOMA 

Tahir M. HASHMI 1 , Alec Price-Forbes 1 

1. 

Rheumatology, University Hospitals of Coventry & 

Warwickshire, Coventry, England, United Kingdom. 

260 IT REALLY CAN’T BE GOUT-WHAT IS IT? CRYOPYRIN- 

ASSOCIATED PERIODIC FEVERS: A DELAYED DIAGNOSIS 

Charlotte A. Sharp 1 , Helen Murphy 2 , Elizabeth F. Wood 1 

1. 

Rheumatology, Furness General Hospital, Barrow in Furness, 

United Kingdom. 2. Clinical Genetics, St Mary’s Hospital, 

Manchester, United Kingdom.


261 SYSTEMATIC LUPUS ERYTHEMATOSUS, MOLLUSCUM 

CONTAGIOSUM (MC) AND HUMAN IMMUNODEFICIENCY 

VIRUS (HIV) 

Teresa Doherty 1 , Jo Sheldon 2 , Nidhi Sofat 1 

1. 

St Georges Hospital, London, United Kingdom. 

2. 

Immunology, St Georges, London, United Kingdom. 

262 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME 

(PRES) ASSOCIATED WITH TOCILIZUMAB 

Iain Goff 1,2 , Philip N. Platt 1 

1. 

Department of Rheumatology, Newcastle Upon Tyne 

Hospitals NHS Foundation Trust, Newcastle, United Kingdom. 

2. 

School of Medical Sciences, Newcastle University, Newcastle 

upon Tyne, United Kingdom. 

263 DIFFUSE OSTEONECROSIS IN ANTI-PHOSPHOLIPID 

SYNDROME (APLS) MANIFESTING WITH HIGH BONE 

MINERAL DENSITY 

Rita Abdulkader 1 , Gavin Clunie 1 

1. 

Rheumatology, The Ipswich hospital NHS trust, Ipswich, 


264 AN UNUSUAL CASE OF CHILDHOOD DERMATOMYOSITIS 

RECURRING HALF A CENTURY LATER 

Mediola Ismajli 1 , Elena Nikiphorou 1 , Adam Young 1 

1. 

Rheumatology, St Albans City Hospital, St Albans, 

Hertfordshire, United Kingdom. 

265 INEXPLICABLE IMMUNOLOGY?: NEW-ONSET RHEUMATOID 

ARTHRITIS IN A RENAL TRANSPLANT PATIENT ON TRIPLE 

IMMUNOSUPPRESSIVE THERAPY 

Nicola Tugnet 1 , Josh Dixey 1 

1. 


Trust, Wolverhampton, United Kingdom. 

266 DOES RHEUMATOLOGY HAVE A ROLE IN IDIOPATHIC 

RETROPERITONEAL FIBROSIS (RPF)? 

Snehashish Banik 1 , Desmond Alcorn 2 , John Hunter 1 

1. 


Kingdom. 2. Radiology, Gartnavel General Hospital, Glasgow, 


267 TADALAFIL: A NOVEL TREATMENT FOR VASCULAR 

MANIFESTATIONS OF SYSTEMIC SCLEROSIS AND OTHER 

CONNECTIVE TISSUE DISEASES 

Win Win Maw 1 , Pravin Patil 1 , Fiona Hayes 1 , Way Main Wong 1 , 

Frances A. Borg 1 , Bhaskar Dasgupta 1 

1. 

Rheumatolgy Department, Southend University Hospital, 

Southend-On-sea, United Kingdom. 

268 HARLEQUIN SYNDROME: A CASE REPORT AND REVIEW OF 

LITERATURE 

Anshuman P. Malaviya 1 , Andrew J. Ostor 1 

1. 

Rheumatology, Cambridge University Hospitals NHS 

Foundation Trust, Cambridge, United Kingdom. 

269 SUCCESSFUL USE OF TOCILIZUMAB IN A CAUCASIAN 

PATIENT WITH RELAPSING POLYCHONDRITIS COMPLICATED 

BY SWEETS SYNDROME 

Jasroop K. Chana 1 , Azeem A. Ahmed 1 , Sally Edmonds 1 

1. 

Rheumatology, Stoke Mandeville Hospital, Aylesbury, 


270 A PRECIOUS METAL: COPPER DEFICIENCY PRESENTING 

AS MYELONEUROPATHY 

Fiona Hayes 1 , Lucy Coward 2 , Frances Borg 1 

1. 

Rheumatology, Southend General Hospital, Southend, 

United Kingdom. 2. Neurology, Southend General Hospital, 

Southend, United Kingdom. 

271 REMISSION OF RESISTANT LIFE-THREATENING NON-RENAL 

WEGENER’S GRANULOMATOSIS WITH RITUXIMAB AND 

MYCOPHENOLATE MOFITIL 

Jonathan Heaney 1 , Nicole Amft 1 , John Simpson 2 , 

Veena Dhillon 1 

1. 

Rheumatology, Western General Hospital, Edinburgh, United 

Kingdom. 2. Respiratory medicine, Freeman Hospital, 

Newcastle-Upon-Tyne, United Kingdom. 

272 ANTIPHOSPHOLIPID ANTIBODY SYNDROME PRESENTING AS 

HEMI-CHOREA IN SECOND TRIMESTER PREGNANCY 

Yezenash Ayalew 1 , Fazlihakim Khattak 1 , Mary Gayed 1 

1. 

Rheumatology, Sandwell General Hospital, West Bromwich, 

United Kingdom.


273 CASE PRESENTATION OF INFLAMMATORY MONO-ARTHRITIS 

TREATED WITH INTRA-ARTICULAR INFLIXIMAB 

Roshan I. Amarasena 1 , Frank McKenna 1 

1. 

Rheumatology, Trafford NHS Trust, Trafford, United Kingdom. 

274 A CASE OF ANTI-SYNTHETASE SYNDROME THAT 

RESPONDED TO RITUXIMAB TREATMENT 

Roshan I. Amarasena 1 , Frank McKenna 1 

1. 

Rheumatology, Trafford NHS Trust, Trafford, United Kingdom. 

275 HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT 

WITH WEGENER’S GRANULOMATOSIS 

Maeve Mc Laughlin 1 , Krishnan Baburaj 1 

1. 

Rheumatology, Watford General Hospital, Watford, United 

Kingdom. 

276 ANTI TA/MA2 ANTIBODIES IN BRAINSTEM VASCULITIS 

WITHOUT MALIGNANCY 

Zozik Fattah 1 , Nora Ng 1 , Wilson Jo 1 , Bernard Colaco 1 

1. 

Central Middlesex Hospital, London, United Kingdom. 

277 USE OF RITUXIMAB TO TREAT RHEUMATOID ARTHRITIS 

AND FOCAL SEGMENTAL GLOMERULAR SCLEROSIS 

Mark R. Williams 1 , Tochukwu Adizie 1 , Bhaskar Dasgupta 1 

1. 

Southend Hospital, Westcliff-on-sea, United Kingdom. 

Education research 

Medical student bursary winner 

278 CAN PEER ASSISTED LEARNING DELIVERED BY MEDICAL 

STUDENTS BE USEFUL IN TRAINING SENIOR COLLEAGUES 

IN USE OF REMS TECHNIQUE FOR MSS EXAMINATION? 

A PILOT STUDY 

Matthew Casey 1 , Stefanie Lip 1 , Shaun Tan 1 , David Anderson 1 , 

Calum Robertson 1 , Ian Devanny 1 , Max Field 1 

1. 

Wolfson Medical School Building, University of Glasgow, 

Glasgow, United Kingdom. 

279 DRUG KNOWLEDGE IN PATIENTS ESTABLISHED ON 

LONG-TERM TREATMENT WITH METHOTREXATE 

David Walker 1 , Sandra Robinson 1 , Sarah Ryan 2 , 

Andrew Hassell 2 

1. 

Rheumatology, Freeman Hospital, Newcastle on Tyne, 

United Kingdom. 2. Rheumatology , Stoke PCT, Stoke on Trent, 


280 OPEN ACCESS MUSCULOSKELETAL ONLINE 

EDUCATION- VIRTUAL PATIENTS LEADING THE WAY 

James Bateman 1,2 , Maggie Allen 2 , David Davies 1 

1. 

Institute of Clinical Education, University of Warwick, 

Coventry, United Kingdom. 2. Department of Rheumatology, 

University Hospitals Coventry and Warwickshire NHS Trust, 

Coventry, United Kingdom. 

281 CHOOSING A CAREER IN A MUSCULOSKELETAL SPECIALTY: 

HOW POPULAR ARE RHEUMATOLOGY AND ORTHOPAEDICS 

AMONG MEDICAL STUDENTS AND WHAT FACTORS ARE 

RELEVANT IN THE CHOICE? 

Carina Crouch 1 , Karen Walker-Bone 1 , Nicola Gainsborough 2 

1. 

Rheumatology, Brighton & Sussex Medical School, Brighton, 

United Kingdom. 2. Stroke Medicine, Brighton and Sussex 

University Hospitals NHS Trust, Brighton, United Kingdom. 

282 DELIVERING THE RHEUMATOLOGY CURRICULUM: A REVIEW 

FROM THE TRAINEE AND TRAINER PERSPECTIVE 

Nicola J. Gullick 1 , Pamela M. Lutalo 2 , Ursula M. Davies 2,3 , 

Karen Walker-Bone 3,4 

1. 

Rheumatology, Brighton & Sussex University Hospitals, 

Brighton, United Kingdom. 2. Rheumatology, East Surrey 

Hospital, Redhill, United Kingdom. 3. Rheumatology, Kent, 

Surrey & Sussex Deanery, Brighton, United Kingdom. 

4. 

Rheumatology, Brighton & Sussex Medical School, 

Brighton, United Kingdom. 

283 BENEFICIAL EFFECTS OF OMEGA-3-POLYUNSATURATED 

FATTY ACIDS ON SF-36 SCORES IN SYSTEMIC LUPUS 

ERYTHEMATOSUS 

Jennifer R. Mckew 1 , Auleen M. Millar 1 , Stephen A. Wright 1 , 

Aubrey L. Bell 1 

1. 

Department of Rheumatology, Musgrave Park Hospital, 

Belfast, United Kingdom. 

284 MEDICAL STUDENTS PERCEPTION OF RHEUMATOLOGY AS 

AN OPTION DURING FOUNDATION TRAINING: RESULTS 

FROM OPEN RESPONSES OF A NATIONAL SURVEY 

Muryum Thapper 1 , Thalia Roussou 2,1 

1. 

Queen Mary’s, Barts and The London School of Medicine 

and Dentistry, London, E1 2AD, United Kingdom. 2. Rheumatology 

& Rehabilitation, King George Hospital Barking Havering 

and Redbridge University NHS TRUST, London, IG3 8YB, United 

Kingdom.


285 THE INFORMATION AND SUPPORT NEEDS OF PEOPLE 

LIVING WITH RHEUMATOID ARTHRITIS 

Jo Cumming 1 , Richard G. Hull 2 

1. 

Helplines, Arthritis Care, London, United Kingdom. 

2. 

Trustee, Arthritis Care, London, United Kingdom. 

286 ARE MEDICAL STUDENTS INTERESTED IN SELECTING 

MUSCULOSKLEETAL MEDICINE (RHEUMATOLOGY & 

ORTHOPAEDICS COMBINED} AS A FOUNDATION YEAR 

TRAINING ROTATION? 

Muryum Thapper 1 , Thalia Roussou 2,1 

1. 

Queen Marys University, Barts and the London, School of 

Medicine and Denitstry, London, United Kingdom. 

2. 

Rheumatology & Rehabilitation, King George Hospital 

Barking Havering and Redbridge University NHS TRUST, 


287 SUN EXPOSURE AND THE USE OF SUNSCREEN AMONG 

INFLAMMATORY ARTHROPATHY PATIENTS RECEIVING 

ANTI-TNF THERAPY 

John McKeogh 1 , Mortimer B. O’Connor 2 , Ahmed I. Hassan 2 , 

Ursula Bond 2 , Joan Swan 2 , Mark J. Phelan 2 

1. 

Medicine, South Infirmary Victoria University Hospital, Cork, 

Ireland. 2. Rheumatology, South Infirmary Victoria University 

Hospital, Cork, Ireland. 

288 EVALUATION OF THE FIRST BSR TEACHING THE TEACHERS 

COURSE 

David Coady 1 , Namita Kumar 2 

1. 

City Hospitals Sunderland, Sunderland, United Kingdom. 

2. 

Rheumatology, University Hospital of North Durham, Durham, 


Epidemiology 

289 PREDICTORS OF LOW BONE MINERAL DENSITY IN MEN & 

WOMEN UNDER 50 YEARS OF AGE 

Luke Farrow 2 , Marwan Bukhari 1 , Alexander G. Oldroyd 2 , 

Cathi Greenbank 1 

1. 

Rheumatology, Royal Lancaster Infirmary, Lancaster, 

United Kingdom. 2. Centre for Medical Education, Lancaster 

University, Lancaster, United Kingdom. 

290 CHRONIC WIDESPREAD PAIN, CO-MORBID DEPRESSION 

AND FATIGUE IN OLDER PEOPLE 

John McBeth 1 , Rosie Duncan 1 , Deborah Brown 1 , 

Michael Horan 2 , Neil Pendleton 2 , Alison Littlewood 1 , 

Lis Cordingley 2 , Matthew Mulvey 1 

1. 


Manchester, Manchester, United Kingdom. 2. School of 

Medicine, University of Manchester, Manchester, United 

Kingdom. 

291 LEAN MASS IS POSITIVELY ASSOCIATED WITH HIP 

STRENGTH AND GEOMETRY IN CHILDHOOD: FINDINGS 

FROM THE SOUTHAMPTON WOMEN’S SURVEY 

Elizabeth M. Curtis 1 , Zoe A. Cole 1 , Sarah R. Crozier 1 , 

Ntani Georgia 1 , Siân M. Robinson 1 , Keith M. Godfrey 1,2 , 

Avan A. Sayer 1 , Hazel M. Inskip 1 , Cyrus Cooper 1 

1. 


Southampton, Southampton, United Kingdom. 2. NIHR 

Nutrition, Diet and Lifestyle Biomedical Research Unit, 

University of Southampton, Southampton, United Kingdom. 

292 DOES DEPRESSION AFFECT RESPONSE TO ANTI-TUMOUR 

NECROSIS FACTOR THERAPY IN PATIENTS WITH 

RHEUMATOID ARTHRITIS? RESULTS FROM THE BRITISH 

SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER 

Rebecca Davies 1 , Louise Mercer 1 , James Galloway 1 , 

Audrey Low 1 , Kath Watson 1 , Mark Lunt 1 , BSRBR Control 

Centre Consortium 2 , Deborah Symmons 1 , Kimme Hyrich 1 , 

1. 



for Rheumatology, London, United Kingdom 

293 INITIAL TRIPLE DMARD THERAPY PREDICTS ACR EULAR 

REMISSION IN AN EARLY RHEUMATOID ARTHRITIS 

INCEPTION COHORT. 

Sarang Chitale 1 , Cristina Estrach 1 , Robert J. Moots 1 , 

Nicola J. Goodson 1 

1. 

Department of rheumatology, Aintree University Hospital, 

University of Liverpool, Liverpool, United Kingdom.


294 ASSOCIATION BETWEEN PERIODONTAL DISEASE AND 

RHEUMATOID ARTHRITIS IN A LARGE CHINESE COHORT: 

FINDINGS FROM THE GUANGZHOU BIOBANK 

COHORT STUDY 

Elizabeth Rankin 1 , C. Q. Jiang 3 , K. K. Cheng 2 , T. H. Lam 4 , 

Peymané Adab 2 

1. 

Rheumatology, University Hospitals Birmingham, 

Birmingham, United Kingdom. 2. Department of Public Health 

and Epidemiology, University of Birmingham, Birmingham, 

United Kingdom. 3. Guangzhou Occupational Health, 

Guangzhou no 12 Hospital, Ghangzhou, China. 

4. 

Department of Community Medicine, University of Hong 

Kong, Hong Kong, China. 

295 OBESE EARLY RHEUMATOID ARTHRITIS PATIENTS HAVE A 

REDUCED RESPONSE TO DMARD THERAPY DURING THEIR 

FIRST YEAR OF TREATMENT 

Stephanie Ling 1,2 , Sarang Chitale 1,2 , Robert J. Moots 1,2 , 

Cristina Estrach 2 , Nicola J. Goodson 1,2 

1. 

Institute of Ageing and Chronic Disease, University of 

Liverpool, Liverpool, United Kingdom. 2. Rheumatology, 

University Hospital Aintree, Liverpool, United Kingdom. 

296 OBESITY IS ASSOCIATED WITH HIGHER HAQ SCORES IN 

PATIENTS WITH EARLY INFLAMMATORY POLYARTHRITIS: 

RESULTS FROM THE NORFOLK ARTHRITIS REGISTER 

Jennifer Humphreys 1 , Corrinne Ellis 2 , Diane Bunn 2 , 

Suzanne M. Verstappen 1 , Deborah Symmons 1 

1. 


Translational Medicine, University of Manchester, Manchester, 

United Kingdom. 2. Department of Rheumatology, Norfolk and 

Norwich University Hospital, Norwich, United Kingdom. 

297 DO ELECTRONIC AND PAPER QUESTIONNAIRES PRODUCE 

EQUIVALENT RESULTS? A SYSTEMATIC REVIEW 

Elisa Fluess 1 , Gary J. Macfarlane 1 , Christine Bond 2 , 

Gareth T. Jones 1 

1. 

Aberdeen Pain Research Collaboration (Epidemiology Group), 


2. 

Aberdeen Pain Research Collaboration (Primary Care), 


298 A SYSTEMATIC REVIEW AND META-ANALYSIS OF 

ALCOHOL AS A PROTECTIVE FACTOR AGAINST RHEUMATOID 

ARTHRITIS 

Ian C. Scott 1,2 , Sophia Steer 3 , Cathryn M. Lewis 1 , 

Andrew Cope 2 

1. 

Department of Medical and Molecular Genetics, King’s 

College London, London, United Kingdom. 2. Department of 

Academic Rheumatology, King’s College London, London, 

United Kingdom. 3. Department of Rheumatology, King’s 

College Hospital, London, United Kingdom. 

299 JOINT HYPERMOBILITY PREDICTS DISABLING AND LIMITING 

MUSCULOSKELETAL PAIN: RESULTS FROM THE MUSICIAN 

SURVEY 

Matthew R. Mulvey 1 , Gary J. Macfarlane 2 , 

Deborah Symmons 1 , Karina Lovell 3 , Philip Keeley 3 , 

Steve Woby 4 , Marcus Beasley 2 , John McBeth 1 

1. 

Arthritis Research UK, Epidemiology Unit, The University of 

Manchester, Manchester, United Kingdom. 2. Aberdeen Pain 

Research Collaboration, University of Aberdeen, Aberdeen, 

United Kingdom. 3. School of Nursing, Midwifery & Social 

Work, The University of Manchester, Manchester, United 

Kingdom. 4. The Pennine Acute Hosiptals NHS Trust, North 

Manchester NSH Trust, Manchester, United Kingdom. 

Genetics 

300 FURTHER REPLICATION OF THE TRAF1/C5 GENETIC 

ASSOCIATION WITH RADIOLOGICAL DAMAGE IN PATIENTS 

WITH RHEUMATOID ARTHRITIS 

Sebastien Viatte 1,4 , Darren Plant 1,4 , Mark Lunt 1 , Bo Fu 1 , 

Ben Parker 1 , James Galloway 1 , Csilla Solymossy 2 , 

Jane Worthington 1 , Deborah Symmons 1 , Josh Dixey 

1. 

Arthritis Research UK Epidemiology Unit, Manchester 

Academic Health Science Center, The University of 

Manchester, Manchester, United Kingdom. 2. Rheumatology 

Department, St Albans City Hospital, St Albans, United 

Kingdom. 3. Department of Rheumatology, New Cross 

Hospital, Wolverhampton, United Kingdom. 

4. 

Equal, contribution, Manchester, United Kingdom.


301 SPINE CURVATURE IS HERITABLE AND ASSOCIATED WITH 

DISC DEGENERATION 

Frances M. Williams 1 , Daniel-Clement Osei-Bordom 1 , 

Maria Popham 1 , Alex MacGregor 1,2 , Tim Spector 1 

1. 

Dept of Twin Research and Genetic Epidemiology, King’s 

College London, London, United Kingdom. 2. Dept of Medicine, 


302 A SYNONYMOUS VARIANT IN TREX1 IS ASSOCIATED WITH 

AN INCREASED RISK OF SYSTEMIC SCLEROSIS 

Jayne Little 1 , Ariane Herrick 3 , S. Pushpakom 2 , H. Ennis 3 , 

H. McBurney 2 , J. Worthington 3 , W. Newman 2 

1. 

School of Translational Medicine, Manchester University, 

Manchester, Greater Manchester, United Kingdom. 2. NIHR 

Biomedical Research Centre, Royal Liverpool Hospital, 

Liverpool, Mersyside, United Kingdom. 3. Department of 

Rheumatology, Salford Royal Hospital, Salford, Greater 


303 CORRELATION OF CRP HAPLOTYPES WITH RESPONSE TO 

ANTI-TNF THERAPY IN UK PATIENTS: RESULTS FROM THE 

BRAGGSS COHORT 

Ibrahim Ibrahim 1 , Darren Plant 1 , Kimme Hyrich 1 , 

Anne Morgan 3 , Anthony Wilson 4 , John Isaacs 2 , Anne Barton 1 

1. 

ARC-EU, University of Manchester, Manchester, United 

Kingdom. 2. Musculoskeletal Research Group, Newcastle 

University, Newcastle, United Kingdom. 3. NIHR-Leeds 

Musculoskeletal Biomedical Research Unit, University of 

Leeds, Leeds, United Kingdom. 4. Section of Musculoskeletal 

Sciences, University of Sheffield, Sheffield, United Kingdom. 

Health services research, economics and outcomes 

research 

304 DO PATIENTS’ TREATMENT PRIORITIES VARY ACCORDING 

TO ETHNICITY AND CULTURE? A UK COMPARISON OF 

WHITE BRITISH AND PUNJABI RHEUMATOID ARTHRITIS 

PATIENTS 

Tessa Sanderson 1 , Sarah Hewlett 1,2 , Michael Calnan 3 , 

Marianne Morris 1 , Karim Raza 4,5 , Kanta Kumar 4,5 

1. 

School of Health and Social Care, University of West of 

England, Bristol, United Kingdom. 2. Department of 

Rheumatology, University Hospitals Bristol NHS Foundation 

Trust, Bristol, United Kingdom. 3. School of Social Policy, 

Sociology and Social Research, University of Kent, Canterbury, 

United Kingdom. 4. College of Medical and Dental Sciences, 

University of Birmingham, Birmingham, United Kingdom. 

5. 

Department of Rheumatology, Sandwell and West Birmingham 

Hospitals NHS Trust, Birmingham, United Kingdom. 

305 LITIGATION RELATED TO RHEUMATOLOGY: AN ANALYSIS OF 

CLAIMS AGAINST THE NHS 2000 TO 2010 

Caroline M. Cardy 1 

1. 

Rheumatology, University Hospitals Birmingham, 


306 IMPACT OF A RHEUMATOLOGY BASED ECHOCARDIOGRAPHY 

AND DEDICATED OUTPATIENT CLINIC SERVICE ON 

CARDIOPULMONARY SCREENING IN SYSTEMIC SCLEROSIS 

John D. Pauling 1 , Jessica Jenkins 1 , Sue J. Brown 1 , 

Neil McHugh 1,2 

1. 


Diseases, Bath, United Kingdom. 2. Department of Pharmacy 

and Pharmacology, University of Bath, Bath, United Kingdom. 

307 BIOLOGIC DRUGS ACCOUNT FOR A MAJOR PART OF THE 

COST BURDEN UP TO 15 YEARS AFTER DISEASE ONSET IN 

INFLAMMATORY POLYARTHRITIS 

Elena Nikiphorou 1,2 , Miranda Mugford 3 , Charlotte Davies 3 , 

Nicola Cooper 4 , Alan Brooksby 5 , Diane Bunn 6 , 

Deborah Symmons 6 , Alex MacGregor 3 

1. 

Research Department of Epidemiology & Public Health, 

University College London, London, United Kingdom. 

2. 

Department of Rheumatology, St Albans City Hospital, 

St Albans, United Kingdom. 3. Norwich Medical School, 


4. 

Department of Epidemiology & Public Health, University of 

Leicester, Leicester, United Kingdom. 5. Clinical Effectiveness 

& Audit Department, Norfolk & Norwich University Hospital, 

Norwich, United Kingdom. 6. Arthritis Research UK 


United Kingdom.


308 WHY DO WE NEED TO PILOT INTERVENTIONS? ESSENTIAL 

REFINEMENTS IDENTIFIED DURING PILOTS OF A FATIGUE 

INTERVENTION 

Emma Dures 1 , Nick Ambler 2 , Debbie Fletcher 3 , Denise Pope 3 , 

Frances Robinson 4 , Royston Rooke 4 , Sarah Hewlett 1 

1. 

Faculty of Health and Life Sciences, University of the West 

of England, Bristol, United Kingdom. 2. Pain Management, 

Frenchay Hospital, Bristol, United Kingdom. 3. Rheumatology 

Department, University Hospitals Bristol, Bristol, United 

Kingdom. 4. Academic Rheumatology, University of Bristol, 

Bristol, United Kingdom. 

309 RHEUMATOLOGY EMAIL ADVICE AND LIAISON: A NEW 

SERVICE 

Claire L. Gorman 1 , Piero Reynolds 1 

1. 

Rheumatology, Homerton University Hospital NHS Trust, 


310 PAN-LONDON STANDARDS OF CARE FOR INFLAMMATORY 

ARTHRITIS & INFLAMMATORY BACK PAIN 

Alan J. Hakim 1 , Ailsa Bosworth 2 , Dan Weaver 3 , 

Patrick D. Kiely 4 

1. 

Trust HQ, Whipps Cross University Hospital NHS Trust, 

London, United Kingdom. 2. Head Office, NRAS, Maidenhead, 

United Kingdom. 3. General Practice, NHS Havering, 

Hornchurch, United Kingdom. 4. Dept of Rheumatology, 

St Georges Hospital, London, United Kingdom. 

311 NORTH WEST REGIONAL AUDIT OF THE DIAGNOSIS AND 

MANAGEMENT OF RHEUMATOID ARTHRITIS 

Sarah Skeoch 1 , Meghna Jani 5 , Roshan Amarasena 6 , 

Chandini Rao 4 , Elizabeth Macphie 3 , Yokemei McLoughlin 2 , 

Preeti Shah 2 

1. 

Rheumatology, Pennine Acute NHS Trust, Manchester, United 

Kingdom. 2. Rheumatology, Trafford Healthcare NHS Trust, 

Manchester, United Kingdom. 3. Rheumatology, Lancashire 

Care NHS Foundation Trust, Preston, United Kingdom. 

4. 

Rheumatology, Blackpool Hospitals NHS Foundation Trust, 

Blackpool, United Kingdom. 5. Rheumatology, University 

Hospitals of Morcambe Bay NHS Foundation Trust, Lancaster, 

United Kingdom. 6. Rheumatology, Stockport NHS Foundation 

Trust, Stockport, United Kingdom. 

312 HOW MANY EXTRA PATIENTS COULD BE ELIGIBLE FOR 

BIOLOGICS IF WE ADOPTED BSR GUIDELINES IN AN EARLY 

ARTHRITIS POPULATION? 

Sara Else 1 , Olga Semenova 1 , Helen Thompson 1 , 

Olabambo Ogunbambi 1 , Sathish Kallankara 1 , Yusuf Patel 1,2 , 

Elaine Baguley 1 

1. 

Rheumatology, Hull Royal Infirmary, Hull, United Kingdom. 

2. 

Senior Lecturer, Hull York Medical School, Hull, United 

Kingdom. 

313 STRATEGY TO REDUCE RHEUMATOLOGY AND PAIN CLINIC 

REFERRALS VIA MONTHLY MULTIDISCIPLINARY TEAM 

MEETINGS 

Meghna Jani 1 , John Halsey 2 , Andrew Severn 3 , 

Marwan Bukhari 2 

1. 

Department of rheumatology, Salford Royal NHS foundation 

trust, Salford, United Kingdom. 2. Department of 

Rheumatology, Royal Lancaster Infirmary, Lancaster, United 

Kingdom. 3. Department of Anaesthesia and Chronic Pain, 

Royal Lancaster Infirmary, Lancaster, United Kingdom. 

314 REQUESTING IMMUNOLOGICAL TESTS; THE IMPORTANCE 

OF RATIONALIZING REQUESTS 

Shilpa Selvan 1 , Elizabeth Price 1 

1. 

Rheumatology, Great Western Hospital, Swindon, United 

Kingdom. 

315 IMPACT OF ANKYLOSING SPONDYLITIS ON WORK AND 

PRODUCTIVITY 

Muhammad J. Husain 1 , Sinead Brophy 2 , Ceri J. Phillips 3 , 

Roxanne Cooksey 2 , Elizabeth Irvine 2 , Stefan Siebert 2 

1. 

Keele Managment School (Economics), Keele University, 

Newcastle-under-Lyme, Staffordshire, United Kingdom. 

2. 

College of Medicine, Swansea University, Swansea, 

Swansea, United Kingdom. 3. College of Human and Health 

Sciences, Swansea University, Swansea, United Kingdom.


316 EVALUATING HEALTH STATUS OF 620 PATIENTS WITH 

PRIMARY SJÖGREN’S SYNDROME USING EQ-5D 

Dennis Lendrem 1 , Sheryl Mitchell 1 , Simon Bowman 2 , 


Jacqueline Andrews 4 , Michele Bombardieri 5 , Nurhan Sutcliffe 5 

1. 

Rheumatology, Newcastle Hospitals NHS Foundation Trust, 

Newcastle upon Tyne, United Kingdom. 2. Rheumatology, 

University Hospital Birmingham, Birmingham, United Kingdom. 

3. 

Rheumatology, Great Western Hospitals NHS Foundation 

Trust, Swindon, United Kingdom. 4. NIHR Leeds 

Musculoskeletal Biomedical Research Unit, Leeds Teaching 

Hospitals Trust, Leeds, United Kingdom. 5. Rheumatology, 

Barts and the London School of Medicine and Dentistry, 

London, United Kingdom. 6. Rheumatology, Nottingham 

University Hospital, Nottingham, United Kingdom. 

7. 


Kingdom. 8. Rheumatology, NHS Fife, Whyteman’s Brae 

Hospital, Kirkcaldy, United Kingdom. 9. Rheumatology, Royal 

Derby Hospital, Derby, United Kingdom. 10. Rheumatology, 

Royal Hampshire County Hospital, Winchester, United Kingdom. 

11. Rheumatology, University College London Hospitals 

NHS Foundation Trust, London, United Kingdom. 12. Newcastle 

University, Newcastle upon Tyne, United Kingdom. 

13. 

Rheumatology, Queen Elizabeth Hospital, Gateshead, 

United Kingdom. 14. Rheumatology, Sunderland Royal Hospital, 

Sunderland, United Kingdom. 15. Rheumatology, Royal 

National Hospital for Rheumatic Diseases, Bath, United 

Kingdom. 

317 ELICITATION OF HEALTH STATE UTILITIES ASSOCIATED WITH 

DIFFERENT DURATIONS OF MORNING STIFFNESS IN 


Bhaskar Dasgupta 1 , Peter Taylor 2 , Itrat Iqbal 3 , Louise Heron 4 , 

Claire Pilling 4 

1. 

Department of Rheumatology, Southend Hospital NHS Trust, 

Westcliff-on-Sea, Essex, United Kingdom. 2. Kennedy Institute 

of Rheumatology, Nuffield Department of Orthopaedics, 

Rheumatology and Musculoskeletal Sciences, Oxford University 

(Botnar Research Centre), Headington, Oxford, United 

Kingdom. 3. Health Economics, Mundipharma International 

Limited, Cambridge Science Park, Milton Road, Cambridge, 

United Kingdom. 4. Value Insight and Communication, Mapi 

Values UK, Bollington, Cheshire, United Kingdom. 

318 HAS NICE GUIDANCE AFFECTED NON-STEROIDAL 

ANTI-INFLAMMATORY DRUG (NSAID) USE FOR 

OSTEOARTHRITIS? 10 YEARS OF CROSS-SECTIONAL 

DATA FROM A LARGE DISTRICT GENERAL HOSPITAL 

Jonathan Marks 1 , Richard Hull 1 , Jo Ledingham 1 

1. 


Portsmouth, United Kingdom. 

319 EMPLOYABILITY-ADJUSTED-LIFE-YEARS IN PATIENTS WITH 

RHEUMATOID ARTHRITIS TREATED WITH GOLIMUMAB PLUS 

METHOTREXATE OR METHOTREXATE ALONE 

Chenglong Han 1 , Tim Gathany 1 , Neeta Tandon 2 , Elizabeth Hsia 3 

1. 

Worldwide Market Access, Janssen Global Services, LLC, 

Malvern, PA, United States. 2. Health Economics & Outcomes 

Research, Janssen Scientific Affairs, LLC, Horsham, PA, United 

States. 3. Immunology, Janssen Research & Development, Inc, 

Malvern, PA, United States. 

320 PATIENT EXPECTATIONS OF TREATMENT GOALS AND 

GOAL-SETTING PRACTICES IN RHEUMATOID ARTHRITIS IN 

THE UNITED KINGDOM 

P. Taylor 1 , V. Strand 2 , T. Sensky 3 , N. Harta 4 , S. Fleming 5 

1. 

NDORMS, Oxford University, Oxford, United Kingdom. 

2. 

Stanford University, Palo Alto, CA, United States. 3. Imperial 

College, London, United Kingdom. 4. Opinion Matters, London, 

United Kingdom. 5. UCB Pharma, Slough, United Kingdom. 

321 PREVIOUS EXPOSURE TO VARICELLA ZOSTER INFECTION IS 

THE NORM IN ADULT PATIENTS STARTING BIOLOGIC DRUG 

THERAPY FOR INFLAMMATORY ARTHRITIS 

Lesley Kay 1 , Michelle Rutherford 1 , Karl Nicholl 1 

1. 


Newcastle upon Tyne, United Kingdom. 

322 AN ELECTRONIC ALERT SYSTEM TO NOTIFY THE 

RHEUMATOLOGY TEAM OF HOSPITAL ADMISSION, 

TRANSFER OR DISCHARGE OF RHEUMATOLOGY PATIENTS 

TAKING BIOLOGIC DRUGS 

Lesley Kay 1 , Michelle Rutherford 1 , Karl Nicholl 1 , Tracey Eyre 1 , 

Gillian Wilson 1 , Phil Johnson 1 

1. 


Newcastle upon Tyne, United Kingdom.


323 OBSERVATION OF PERSISTENCE RATES AND COSTS 

SAVINGS ASSOCIATED WITH CERTOLIZUMAB PEGOL 

TREATMENT FOR RA IN ENGLAND, WALES AND NORTHERN 

IRELAND CLINICAL PRACTICE 

M. Russell 1 , J. Timoshanko 1 , G. Duncan 2 , A. Spandley 1 , 

S. Roskell 3 

1. 

UCB Pharma, Slough, United Kingdom. 2. Healthcare at 

Home Ltd, Burton on Trent, United Kingdom. 3. Rheumatology, 

Cannock Chase Hospital , Cannock, United Kingdom. 

324 DEVELOPING A PATIENT VISION: GIVING PATIENTS A VOICE 

David Coady 1 , Louise West 1 

1. 

City Hospitals Sunderland, Sunderland, United Kingdom. 

325 EARLY INFLAMMATORY BACK PAIN SERVICE (EIBPS) TO 

PROVIDE ASSESSMENT, DIAGNOSIS AND PROMPT 

TREATMENT FOR PATIENTS WITH AXIAL 

SPONDYLOARTHROPATHIES 

Rebecca Adshead 1 , Simon P. Donnelly 1 , Simon Ashton 1 , 

Hasan Tahir 1 

1. 

Rheumatology, Whipps Cross University Hospital Trust, 


326 SCREENING FOR LATENT TUBERCUIOSIS IN PATIENTS 

STARTING ANTI TNF THERAPY 

Dipti Patel 1 , James Darroch 2 , Nicola J. Goodson 1 

1. 

Rheumatology, Aintree University Hospital NHS Foundation 

Trust, Liverpool, United Kingdom. 2. Immunology, Royal 

Liverpool University Hospital, Liverpool, United Kingdom. 

327 CAPACITY AND DEMAND IN RHEUMATOLOGY: A SYSTEM 

DYNAMICS APPROACH 

John Boulton 1 

1. 

Department of Rheumatology, Sheffield Teaching Hospitals 

NHS Foundation Trust, Sheffield, United Kingdom. 

328 ATTITUDES TOWARDS PERSONAL HEALTH BUDGETS OF 

PEOPLE WITH MUSCULOSKELETAL AND 

RHEUMATOLOGICAL CONDITIONS 

Benjamin Ellis 1,2 , Ron Finlay 2 

1. 

Kings Collge Hospital, London, United Kingdom. 2. Policy 

and Public Affairs Unit, Arthritis Research UK, London, 


Sjögren’s syndrome and other connective tissue 

disorders 

329 HOW GOOD ARE THE EULAR SJÖGREN’S SYNDROME 

DISEASE ACTIVITY INDEX (ESSDAI), AND EULAR SJÖGREN’S 

SYNDROME PATIENTS REPORTED INDEX (ESSPRI) IN 

PREDICTING HEALTH STATUS IN PRIMARY SJÖGREN’S 

SYNDROME? 

Dennis Lendrem 1 , Sheryl Mitchell 1 , Simon Bowman 3 , 


Jacqueline Andrews 5 , Michele Bombardieri 7 , Nurhan Sutcliffe 7 

1. 

Rheumatology, Newcastle Hospitals NHS Foundation Trust, 

Newcastle upon Tyne, United Kingdom. 2. Newcastle 

University, Newcastle upon Tyne, United Kingdom. 

3. 

Rheumatology, University Hospital Birmingham, Birmingham, 

United Kingdom. 4. Rheumatology, Great Western Hospitals 

NHS Foundation Trust, Swindon, United Kingdom. 5. NIHR 

Leeds Musculoskeletal Biomedical Research Unit, Leeds 

Teaching Hospitals Trust, Leeds, United Kingdom. 

6. 

Rheumatology, Nottingham University Hospital, Nottingham, 

United Kingdom. 7. Rheumatology, Barts and the London 

School of Medicine and Dentistry, London, United Kingdom. 

8. 


Kingdom. 9. Rheumatology, NHS Fife, Whyteman’s Brae 

Hospital, Kirkcaldy, United Kingdom. 10. Rheumatology, 

Royal Derby Hospital, Derby, United Kingdom. 

11. 

Rheumatology, Royal Hampshire County Hospital, 

Winchester, United Kingdom. 12. Rheumatology, University 

College London Hospitals NHS Foundation Trust, London, 

United Kingdom. 13. Rheumatology, Queen Elizabeth Hospital, 

Gateshead, United Kingdom. 14. Rheumatology, Sunderland 

Royal Hospital, Sunderland, United Kingdom. 

15. 


Diseases, Bath, United Kingdom. 

330 MONOCYTE-DERIVED IL-32 EXPRESSION CORRELATES WITH 

THE LEVEL OF INFLAMMATION IN SALIVARY GLANDS OF 

SJÖGREN’S SYNDROME 

William Murray-Brown 1 , R. Priori 2 , T. Tappuni 3 , S. Vartoukian 3 , 

N. Seoudi 3 , G. Picarelli 2 , F. Fortune 3 , G. Valesini 2 , C. Pitzalis 1 , 

M. Bombardieri 1 

1. 

Centre for Experimental Medicine & Rheumatology, Queen 

Mary University of London, London, United Kingdom. 

2. 

Rheumatology, University of Rome, La Sapienza, Italy. 

3. 

Oral Medicine, Queen Mary University of London, London, 

United Kingdom.


SLE and antiphospholipid syndrome 

331 ULTRASOUND ASSESSMENT OF EROSIVE HAND DISEASE IN 

SYSTEMIC LUPUS ERYTHEMATOSUS 

Elisabeth Ball 1 , Madeleine Rooney 1 , Aubrey Bell 1 

1. 

Rheumatology, Musgrave Park Hospital/Queens’ University, 

Belfast, Belfast, United Kingdom. 

332 ANTINUCLEAR AUTOANTIBODIES SEROCONVERSION IN 100 

PATIENTS WITH LUPUS 

Angeles Acosta Mérida 1 , David Isenberg 2 

1. 

Hospital Universitario de Gran Canaria Dr. Negrín, Servicio 

Reumatología, Las Palmas de Gran Canaria, Canary Islands, 

Spain. 2. University College London, Centre for Rheumatology 

Research, London, United Kingdom. 

333 PATTERNS OF IMMUNOGLOBULIN-G GLYCOSYLATION 

DISTINGUISH DIFFERENT CLINICAL PHENOTYPES OF 

ANTIPHOSPHOLIPID ANTIBODY POSITIVITY 

Edward Tarelli 1 , John Axford 1 , Ian Giles 2 , Charis Pericleous 2 , 

Silvia S. Pierangeli 3 , John Ioannou 2 , Anisur Rahman 2 , 

Azita Alavi 1 

1. 

Division of Clinical Sciences, St. George’s University of 

London, London, United Kingdom. 2. Division of Medicine/ 

Centre for Rheumatology Research, University College London, 

London, United Kingdom. 3. Rheumatology/Internal Medicine, 

University of Texas Medical Branch, Galveston, TX, United 

States. 

334 A CASE CONTROL STUDY OF OSTEOPOROSIS IN SYSTEMIC 

LUPUS ERYTHEMATOSUS 

Michael Hughes 1 , Bronwen Evans 1 , Marwan Bukhari 1,2 

1. 

Rheumatology, Royal Lancaster Infirmary, Lancaster, 

United Kingdom. 2. Rheumatology, University of Liverpool, 

Liverpool, United Kingdom. 

335 A COMPARISON OF PULSE AMPLITUDE TONOMETRY (PAT) 

AND FLOW-MEDIATED DILATATION (FMD) OF THE BRACHIAL 

ARTERY AS MEASURES OF ENDOTHELIAL FUNCTION IN 

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 

Ben Parker 1,2 , Awal Zaki 1 , Yvonne Alexander 2 , Ian Bruce 1,3 

1. 


Manchester, Manchester, United Kingdom. 2. Cardiovascular 

Research Group, University of Manchester, Manchester, United 

Kingdom. 3. Kellgren Centre for Rheumatology, Manchester 

Royal Infirmary, Manchester, United Kingdom. 

336 LONG-TERM OUTCOMES IN LUPUS NEPHRITIS: A 

THREE-CENTRE AUDIT 

Michelle Hui 1,2 , Rozeena Garner 1 , Frances Rees 2 , 

Riaz Bavakunji 4 , Priya Daniel 3 , Sneha Varughese 3 , 

Asha Srikanth 1 , Mariano Andres 1 , Fiona Pearce 1 , Jansen L 

1. 

Rheumatology, Nottingham University Hospitals, Nottingham, 

United Kingdom. 2. Rheumatology , Royal Derby Hospital, 

Derby, United Kingdom. 3. Rheumatology, Kings Mill Hospital, 

Sutton-in-Ashfield, United Kingdom. 4. Nephrology, Nottingham 

University Hospitals, Nottingham, United Kingdom. 

5. 

Nephrology, Royal Derby Hospital, Derby, United Kingdom. 

Medical Student bursary winner 

337 PERIPHERAL NEUROPATHY IN SYSTEMIC LUPUS 

ERYTHEMATOSUS 

Amin Oomatia 1 , Michelle Petri 2 , Hong Fang 2 , Julius Birnbaum 2 

1. 

University of Cambridge School of Clinical Medicine, 

University of Cambridge, Cambridge, United Kingdom. 

2. 

Department of Rheumatology, Johns Hopkins Medical 

Institute, Baltimore, MD, United States. 

338 MEASUREMENT OF ARTERIAL STIFFNESS IN A 

CROSS-SECTION OF SLE PATIENTS AND RELATIONSHIP TO 

TREATMENT WITH INTRAVENOUS METHLYPREDNISOLONE: 

A PILOT STUDY 

Maame Amissah-Arthur 1 , Mary Gayed 2 , Kirsty Stewart 2 , 

Hannah Jennens 2 , Simon Braude 2 , Caroline Gordon 1,2 

1. 

Rheumatology, University Hospital Birmingham, Birmingham, 

United Kingdom. 2. Rheumatology, Sandwell & West 

Birmingham Hospitals, Birmingham, United Kingdom.


339 BILAG BIOLOGICS PROSPECTIVE COHORT: THE USE OF 

NOVEL BIOLOGICAL THERAPIES IN THE TREATMENT OF 

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE UK 

Emily J. Sutton 1 , Kath D. Watson 1 , Caroline Gordon 2 , 

Chee-Seng Yee 2 , Peter Lanyon 3 , David Jayne 4 , 

David Isenberg 5 , Anisur Rahman 5 , Mohammed Akil 6 , McHugh 7 , 

Yasmeen Ahmad 8 , Nicole Amft 9 , David D’Cruz 10 , 

Christopher J. Edwards 11 , Bridget Griffiths 12 , Munther 

Khamashta 10 , Lee-Suan Teh 13 , Asad Zoma 14 , Ian Bruce 1 

1. 


Manchester, Manchester, United Kingdom. 2. Rheumatology 

Research Group, University of Birmingham, Birmingham, 

United Kingdom. 3. Rheumatology, Nottingham University 

Hospital, Nottingham, United Kingdom. 4. Department of 

Nephrology, Addenbrooke’s Hospital, Cambridge, United 

Kingdom. 5. Centre for Rheumatology, University College 

London, London, United Kingdom. 6. Department of 

Rheumatology, Sheffield Teaching Hospitals NHS Trust, 

Sheffield, United Kingdom. 7. Department of Rheumatology, 

Royal National Hospital for Rheumatic Diseases NHS Trust, 

Bath, United Kingdom. 8. Department of Rheumatology, North 

West Wales NHS Trust, Bangor, United Kingdom. 9. Rheumatic 

Diseases Unit, Western General Hospital, Edinburgh, United 

Kingdom. 10. Lupus Research Unit, St Thomas’ Hospital, 

London, United Kingdom. 11. Department of Rheumatology, 

University of Southampton, Southampton, United Kingdom. 

12. 

Department of Rheumatology, Freeman Hospital, 

Newcastle-upon-Tyne, United Kingdom. 13. Department of 

Rheumatology, Royal Blackburn Hospital, Blackburn, United 

Kingdom. 14. Department of Rheumatology, Hairmyres 

Hospital, Lanarkshire, United Kingdom 

340 A NESTED CASE CONTROL STUDY OF THE ASSOCIATION 

BETWEEN SYSTEMIC LUPUS ERYTHEMATOSUS AND 

CANCER 

Ida D. Dey 1,2 , Ernest Kenu 2 , David Isenberg 1 

1. 

Department of rheumatology, University College London 

Hospitals, London, United Kingdom. 2. Department of 

Medicine and Therapeutics, Korlebu Teaching Hospital, 

Accra, Ghana. 

341 PROFILING SUB-TYPES OF ANTI-Β2 GLYCOPROTEIN I AND 

ANTI-DOMAIN I ANTIBODIES MAY DISTINGUISH BETWEEN 

DIFFERENT CLINICAL PHENOTYPES OF THE 

ANTIPHOSPHOLIPID SYNDROME 

Charis Pericleous 1 , Acely Garza-Garcia 2 , Lucy Murfitt 2 , 

Paul C. Driscoll 2 , David Isenberg 1 , Silvia Pierangeli 3 , Ian Giles 1 , 

Yiannis Ioannou 1 , Anisur Rahman 1 

1. 

Centre for Rheumatology, Division of Medicine, University 

College London, London, United Kingdom. 2. Structural 

Biology, MRC National Institute of Medical Research, London, 

United Kingdom. 3. Division of Rheumatology, Department 

of Internal Medicine , University of Texas Medical Branch, 

Galveston, TX, United States. 

342 INTERFERON-MEDIATED VASCULAR DAMAGE IN SLE: 

FAILURE OF ENDOTHELIAL REPAIR RATHER THAN DIRECT 

ENDOTHELIAL TOXICITY? 

John A. Reynolds 1 , David W. Ray 2 , Terence O’Neill 1 , 

Yvonne Alexander 3 , Ian Bruce 1 

1. 


Translational Medicine, The University of Manchester, 

Manchester, United Kingdom. 2. Endocrine Sciences Research 

Group, The University of Manchester, Manchester, United 

Kingdom. 3. Cardiovascular Research Group, The University of 

Manchester, Manchester, United Kingdom. 

343 SOLUBLE VASCULAR CELL ADHESION MOLECULE-1 

(SVCAM-1) LEVEL IN PATIENTS WITH ANTHIPHOSPOLIPID 

SYNDROME (APS), ITS ASSOCIATION WITH DISEASE 

ACTIVITY AND ENDOTHELIUM DYSFUNCTION 

Iuliia Segeda 1 , Sergii Shevchuk 1 , Inna Kuvikova 1 

1. 

Institute of Invalid Reabilitation, Vinnitsa, Ukraine. 

Vasculitis 

344 PREVENTION OF TREATMENT RELATED MORBIDITY IN 

ANCA- ASSOCIATED VASCULITIS: THE PATIENT’S 

PERSPECTIVE 

Nina Brown 1 , Ian Bruce 3,2 , Michael Venning 1 

1. 

Renal, Central Manchester Foundation Trust, Manchester, 

United Kingdom. 2. Rheumatology, Central Manchester 

Foundation Trust, Manchester, United Kingdom. 3. Arthritis 

Research Council Epidemiology Unit, University of Manchester, 

Manchester, United Kingdom.


345 TAKAYASU’S ARTERITIS IN PREGNANCY: A BRITISH CASE 

SERIES 

Puja Mehta 1 , Mandish Dhanjal 2 , Justin Mason 1 , 

Catherine Nelson-Piercy 2 

1. 

Department of Rheumatology, Imperial College Healthcare 

NHS Trust, London, United Kingdom. 2. Department of 

Obstetric Medicine, Queen Charlotte’s and Chelsea Hospital, 

Imperial College Healthcare NHS Trust, London, United 

Kingdom. 

346 MULTI-DISCIPLINARY MANAGEMENT OF FATIGUE IN ANCA 

ASSOCIATED VASCULITIS: A PILOT STUDY 

Neil Basu 1 , Priya Paudyal 1 , Marie Stockton 3 , Sally Lawton 3 , 

Caroline Dent 3 , Kathy Kindness 3 , Gillian Meldrum 3 , 

Elizabeth John 3 , Catherine Arthur 3 , Lucy West 

1. 

Institute of Applied Health Sciences (Epidemiology Group), 

University of Aberdeen, Aberdeen, United Kingdom. 2. Division 

of Applied Medicine, University of Aberdeen, Aberdeen, United 

Kingdom. 3. Roxburghe House, NHS Grampian, Aberdeen, 


349 DEVELOPMENT OF AN INDEX TO ASSESS DISEASE-RELATED 

DAMAGE IN TAKAYASU ARTERITIS AND USE IN OUTCOME OF 

VASCULAR INTERVENTIONS 

Rajappa Sivakumar 1 , Ramnath Misra 2 , Debashish Danda 3 , 

Km Mahendranath 4 , Paul A. Bacon 5 

1. 

Cerebrovascular Centre, Cerebrovascular and Vasculitis 

Research Foundation, Chennai, United Kingdom. 2. Clinical 

Immunology, Sanjay Gandhi Post Graduate Institute of Medical 

Sciences, Lucknow, India. 3. Rheumatology, Christian Medical 

College, Vellore, India. 4. Rheumatology, Samarpan Medical 

Centre, Bangalore, India. 5. Rheumatology, University of 

Birmingham, Birmingham, United Kingdom. 

350 ARE THERE SUFFICIENT DATA TO JUSTIFY CHANGING THE 

BSR GUIDELINES FOR ANEURYSM SCREENING IN GIANT 

CELL ARTERITIS? A SYSTEMATIC LITERATURE REVIEW 

Sarah L. Mackie 1,2 , Colin T. Pease 2 

1. 

NIHR-Leeds Musculoskeletal Biomedical Research Unit, 

University of Leeds, Leeds, United Kingdom. 2. Rheumatology, 

Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. 

347 SYSTEMATIC REVIEW OF STEROID TRIALS IN GIANT CELL 

ARTERITIS 

Max Yates 1 , Yoon Loke 2 , Richard Watts 2,3 , Alex MacGregor 1,2 

1. 

Department of Rheumatology, NNUH, Norwich, United 

Kingdom. 2. Norwich Medical School, UEA, Norwich, United 

Kingdom. 3. Department of Rheumatology, Ipswich Hospital, 

Ipswich, United Kingdom. 

348 SUCCESFUL USE OF LEFLUNOMIDE IN TREATMENT OF 

REFRACTORY POLYMYALGIA RHEUMATICA AND GIANT 

CELL ARTERITIS 

Tochukwu Adizie 1 , Dimitrios Christidis 1 , Bhaskar Dasgupta 1 , 

Mark Williams 1 

1. 

Southend Hospital , Westcliff-on-sea, United Kingdom.

124 Poster viewing | Thursday 3 May 2012

Exhibition 

Exhibition

A STRONG ANALGESIC WITH TWO 

MECHANISMS OF ACTION IN ONE MOLECULE 1 

Start to unlock severe chronic back pain 

with Palexia SR 

Palexia SR (tapentadol prolonged release tablets) is indicated for the treatment of severe 

chronic pain in adults, which can be adequately managed only with opioid analgesics 2 

Tapentadol is a Controlled Drug, Schedule 2 

visit www.palexia.co.uk for more information 

PALEXIA ® SR and PALEXIA ® Prescribing Information. 

Refer to the Summary of Product Characteristics (SmPCs) before prescribing. 

Presentation: Palexia SR: 50 mg (white), 100 mg (pale yellow), 150 mg (pale pink), 

200 mg (pale orange) and 250 mg (brownish red) prolonged-release tablets contain 

50 mg, 100 mg, 150 mg, 200 mg and 250 mg of tapentadol (as hydrochloride) 

respectively. Palexia: 50 mg (white) and 75 mg (pale yellow) fi lm-coated tablets contain 

50 mg and 75 mg of tapentadol (as hydrochloride) respectively. Indication: Palexia 

SR is indicated for the management of severe chronic pain in adults, which can be 

adequately managed only with opioid analgesics. Palexia is indicated for the relief of 

moderate to severe acute pain in adults, which can be adequately managed only with 

opioid analgesics. Dosage and method of administration: Individualise according 

to severity of pain, the previous treatment experience and the ability to monitor the 

patient. Swallowed whole with suffi cient liquid, with or without food. Palexia SR should 

not be divided or chewed. Palexia SR dosage: Initial dose 50 mg twice a day. Switching 

from other opioids may require higher initial doses. Titrate in increments of 50 mg 

twice a day every 3 days for adequate pain control. Total daily doses greater than 500 

mg not recommended. Palexia dosage: Initial dose 50 mg every 4 to 6 hours. On the 

fi rst day of dosing, an additional dose may be taken 1 hour after the initial dose, if no 

pain control. The fi rst day’s dose should not exceed 700 mg. Maximum maintenance 

daily dose of up to 600 mg. Discontinuation of treatment: Taper dose gradually to 

prevent withdrawal symptoms. Renal/hepatic impairment: Not recommended in 

severe patients. Caution and dose adjustments with moderate hepatic impairment. 

Elderly: May need dose adjustments. Children below 18 years: Not recommended. 

Contraindications: Hypersensitivity to ingredients, suspected or having paralytic 

ileus, acute alcohol intoxication, hypnotics, centrally acting analgesics or psychotropics. 

Not for use when mu-opioid receptor agonists are contraindicated (e.g. signifi cant 

respiratory depression, acute or severe bronchial asthma or hypercapnia). Special 

warnings and precautions: At risk patients may require monitoring due to misuse, 

abuse, addiction or diversion. At high doses or in mu-opioid receptor agonist sensitive 

patients, dose-related respiratory depression may occur. Caution and monitoring 

required with impaired respiratory function. Should not use in patients susceptible to 

intracranial effects of carbon dioxide retention (e.g. increased intracranial pressure, 

impaired consciousness or coma). Use with caution with head injury, brain tumors, 

history or at risk of seizures, moderate hepatic impairment, biliary tract disease or acute 

pancreatitis. Not recommended with severe renal or hepatic impairment. Avoid use in 

patients who have taken monoamine oxidase inhibitors (MAOIs) within the last 14 days, 

due to cardiovascular events. Should not use with hereditary problems of galactose 

intolerance, Lapp lactase defi ciency or glucose-galactose malabsorption. Interactions: 

Use with benzodiazepines, barbiturates and opioid analgesics, antitussive drugs 

and substitutive treatments may enhance the risk of respiratory depression. 

Central nervous system (CNS) depressants (e.g. benzodiazepines, antipsychotics, 

H1-antihistamines, opioids, alcohol) can enhance the sedative effect and 

impair vigilance. Consider dose reduction with respiratory or CNS depressant 

agents. In isolated cases, serotonin syndrome has been reported with Palexia 

SR/Palexia in combination with serotoninergic medicinal products (e.g. serotonin 

re-uptake inhibitors). Care should be taken with mixed mu-opioid agonist/antagonists 

or partial mu-opioid agonists due to risk of reducing the analgesic effect. Use 

with strong inhibitors of uridine diphosphate transferase isoenzymes (involved in 

glucuronidation) may increase systemic exposure of Palexia SR/Palexia. Risk of 

decreased effi cacy or adverse events if used with strong enzyme inducing drugs 

(e.g. rifampicin, phenobarbital, St John’s Wort). Pregnancy and lactation: Do not 

use. Driving and using machines: May have major effect on ability to drive and 

use machines, especially at the beginning or change in treatment, in connection 

with alcohol or tranquilisers. Undesirable effects: Very common (1/10): dizziness, 

somnolence, headache, nausea. Palexia SR only: constipation. Palexia only: vomiting. 

Common (1/100,

126 Exhibition | 1-3 May 2012 

Exhibitor List 

4S Dawn Clinical Software stand 88 

A. Algeo Ltd stand 44 

Abbott stand 38 

ARMA stand 8 

Arthritis Care stand 18 

Arthritis Research UK stand 56 

BARC/BSSA stand 22 

BioMarin Europe Ltd stand 70 

British Health Professionals in Rheumatology stand 32 

British Society for Rheumatology stand 32 

BSR Biologics Register stand 32 

Britsol-Myers Squibb Pharmaceuticals stand 114 

Cellestis GmbH stand 64 

Central Homecare stand 40 

Eli Lilly stand 42 

Esaote stand 68 

Excellence in Rheumatology stand 94 

Fibromyalgia Association UK stand 13 

Genus stand 106 

Genzyme stand 110 

GlaxoSmithKline/Human genome Sciences stand 60 

Grünenthal Ltd stand 74 

Healthcare at Home Ltd stand 6 

Internis Pharmaceuticals Ltd stand 61 

Lupus UK stand 12 

Medac stand 52 

Miltenyi Biotec Ltd stand 90 

Mivenion GmbH stand 48 

MSD stand 78 

Myositis stand 14 

NASS stand 15 

NRAS stand 17 

Oxford Diagnostic Laboratories stand 46 

Pfizer Ltd stand 34 

Philips Healthcare stand 50 

PMR & GCA stand 11 

PSALV stand 20 

Pulmonary Hypertension Association UK stand 92 

RCN stand 16 

Roche Products Ltd stand 98 

Rapport stand 104 

Rheumatology and Oxford University Press stand 62 

RAF stand 72 

Royal Society of Medicine stand 4 

Sanofi Aventis stand 63 

Savient Pharma Ireland Limited stand 66 

Scleroderma Society stand 10 

Servier Lab Ltd stand 76 

SOBI stand 65 

TRB Chemedica (UK) Ltd stand 49 

UCB stand 26 

Vertec Scientific stand 51 

Wisepress stand 2

Exhibition floor plan 

HALL 5 

1-3 May 2012 | Exhibition 127 

Poster Viewing 

Poster Viewing 

Disabled 

Toilets 

Press area 

Catering Point 

Poster 

registration 

110 100 

114 108 

102 

98 

107 

106 

104 

94 

92 

90 

88 


65 

63 

61 

68 

60 

66 

64 

62 

70 

71 

76 

74 

56 52 

Cyber 

Café 

48 49 

50 

51 

78 

46 42 

44 40 


22 

20 

26 

32 

34 38 

18 

17 

16 

15 

14 

Exit 

8 

Registration 6 4 2 

10 

11 

12 

13 

Entrance 

DOOR 5A 

DOOR 5B


Rheumatology 2012 exhibitors 

4S Dawn Clinical Software stand 88 

4S DAWN Clinical Software heralds the new era of Rheumatology 

software. DAWN removes the frustration of searching for results and 

information! The frustration of filling out forms! The fear that some 

patients are not being monitored or followed up! 

Fall in love with DAWN Rheumatology Clinic Software and Embrace 

improved safety, quality and productivity. Make your patients feel 

cared for with printed hand-held records, text-messaging, dictated 

letters and so much more... 

A. Algeo Ltd stand 44 

A.Algeo Ltd (Algeos) are proud suppliers to the podiatry and foot 

health sectors. We specialise in foot orthotics, instruments, 

diagnostics and podiatry equipment. We also stock a large range of 

gel items, comfort materials, pharmaceuticals and clinic furniture. 

Abbott stand 38 

Abbott is a global, broad-based health care company devoted 

to discovering new medicines, new technologies and new ways 

to manage health. Abbott scientists are applying innovative 

monoclonal antibody technology to discover and develop novel 

therapies to treat diseases of the immune system including 

rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, 

Crohn’s disease and psoriasis. Tel: 01628 77 33 55 

Fax: 01628 64 43 05 Website: www.abbottuk.com 

ARMA stand 8 

ARMA is the umbrella body for the musculoskeletal community 

consisting of 37 members including user groups, professional bodies 

and research groups. Together with its members, ARMA provides a 

forum for organisations active in the musculoskeletal field to 

communicate with each other, co-ordinate their activities and speak 

with a collective voice in order to improve the quality of life of people 

with musculoskeletal disorders. www.arma.uk.net 

Arthritis Care stand 18 

Come and visit us at Stand 18 and see how Arthritis Care can 

enhance the value of your service. Influencing health policy and 

services through campaigning, and providing self management 

training courses, to help patients manage their condition. Offering 

a free confidential helpline to support your patients throughout their 

experience of their condition and providing award winning information 

enabling patients to make better use of appointments. 

Arthritis Research UK stand 56 

Arthritis Research UK is the charity leading the fight against arthritis. 

Arthritis affects more than 10 million people in the UK. We’re working 

to take the pain away for sufferers of all forms of the condition and 

to help people to remain active. We fund high class research and 

provide a comprehensive range of information for patients, the 

public and health professionals. www.arthritisresearchuk.org 

BARC stand 22 

Birmingham Arthritis Resource Centre (BARC) 

Our fundamental aim is to promote ‘self care’ and 

‘self-management’, supporting people with chronic and painful 

conditions to cope with their problems. We encourage clients to take 

an active role in managing their care. The Centre is run by a team of 

volunteers who are trained as (Patient Educators) and do have a 

relevant personal disease experience. 

BSSA stand 22 

The British Sjögren's Syndrome Association (BSSA) is a registered 

charity which aims to raise awareness of the disease and support 

research into its cause and treatment. The BSSA supports patients 

and carers, educates the public and professionals and raises funds 

for research into Sjögren’s by providing research grants on an annual 

basis. No cure currently exists for the condition and the cause 

remains unknown. Sjögren’s Syndrome is the second most common 

auto immune rheunmatic disease affecting 3-4% of adults in the UK, 

but it is under diagnosed and may go untreated. It is characterised 

by the degeneration of mucus-secreting glands, particularly the tear 

ducts and the saliva glands of the mouth. Other symptoms can 

include arthritis and extreme fatigue, disabling joint pain and muscle 

aches. http://www.bssa.uk.net/


BioMarin Europe Ltd stand 70 

BioMarin Pharmaceutical Inc. develops and commercialises 

promising new therapeutics for patients with severe and 

life-threatening diseases. Headquartered in Novato, California, the 

company operates subsidiary offices in Europe, Latin America and 

the Middle East and since it was founded in 1997, the company has 

successfully advanced three breakthrough products from bench, to 

market, to patients which is a testament to the company's passion 

and dedication to patients with serious unmet medical needs. 

BioMarin Europe Limited 3rd Floor 164 Shaftesbury Avenue London 

WC2H 8HL Tel (Direct): +44 (0)207 420 0800 

Fax: +44 (0)207 420 0829 Email: biomarin-europe@bmrn.com 

British Health Professionals in Rheumatology stand 32 

British Health Professionals in Rheumatology (BHPR) unites and 

supports members of the multi-disciplinary team in delivering best 

quality care which meets the needs of individuals with 

musculoskeletal conditions. We have a growing membership, 

fast approaching the 500 mark, from many professions: nursing, 

physiotherapy, occupational therapy, podiatry, psychology, medicine, 

pharmacy and others. Come and visit our stand and learn more 

about the work we are doing and how to get involved. 

www.rheumatology.org.uk 

British Society for Rheumatology stand 32 

The British Society for Rheumatology (BSR) promotes excellence in 

the treatment of people with arthritis and musculoskeletal conditions, 

and supports those delivering it. Come and visit our stand to find out 

more about our work and for more information about becoming a 

member. www.rheumatology.org.uk 

Bristol-Myers Squibb Pharmaceuticals stand 114 

Bristol-Myers Squibb is working to fight serious diseases in 

several areas of unmet medical need. Our medications are 

helping millions of patients worldwide battle illnesses including 

schizophrenia, HIV/AIDS, cancer, chronic hepatitis B, 

cardiovascular disease and rheumatoid arthritis. Our mission is 

to extend and enhance human life, the opportunities ahead to 

combat disease and positively impact people’s lives around the 

world have never been more promising. 

Cellestis GmbH stand 64 

Cellestis is a listed Australian biotechnology company that is a 

leader in the detection and control of tuberculosis, with the 

development of its breakthrough blood test QuantiFERON®-TB 

Gold In-Tube (QFT). Cellestis is focused on developing 

diagnostics tests that measure immune function for diseases 

with an unmet medical need. 

Central Homecare stand 40 

Central Homecare, a member of Alliance Boots, is a national 

provider of clinical homecare services, supporting patients across 

a wide range of therapeutic areas Patients are managed by 

experienced Patient Co-ordinators who provide a full range of support 

services, including arranging patient training by our own therapy 

trained nurses. For further information, please visit the Central 

Homecare stand 40 or visit our web site www.centralhomecare.co.uk 

Tel: 01420 453400. 

BSR Biologics Registers stand 32 

The BSR Biologics Registers (BSRBR) track the progress of patients 

who are receiving biologic agents, monitoring the safety and 

effectiveness of these treatments over the long term. The BSRBR 

currently manage the Rheumatoid Arthritis (RA) register, which has 

been running for 10 years and has successful registered over 20,000 

patients and continues to grow. This register is based at the Arthritis 

Research UK Epidemiology Unit at the University of Manchester and 

monitors the safety of seven biologic therapies. The Ankylosing 

Spondylitis (AS) register launched in April 2012 and is run by the 

University of Aberdeen and will monitor the safety of two biologic 

therapies. www.rheumatology.org.uk/bsr_biologics_register


Eli Lilly stand 42 

Eli Lilly and Company Limited is one of the world's largest 

research-based bio-pharmaceutical companies, dedicated to creating 

and delivering innovative pharmaceutical healthcare solutions that 

enable people to live longer, healthier and more active lives. Our 

research and development efforts constantly strive to address the 

world’s growing unmet medical needs in several different clinical 

areas. Eli Lilly has a significant presence in the UK at several 

locations: 

Erl Wood, Surrey: Home to our European HQ and largest R&D 

facility outside the US. 

Speke, Merseyside: A bulk biotech manufacturing plant which 

makes both human and animal health products. 

Basingstoke, Hampshire: The Headquarters for the UK 

pharmaceutical business. 

For information about our products or services, please come and talk 

to us at the Lilly stand, or log on to the Eli Lilly website at 

www.lilly.com. We look forward to meeting you. 

Esaote stand 68 

Esaote is one of the world’s leading producers of medical diagnostic 

systems and is committed to providing high quality ultrasound & 

extremity MRI system solutions. Our systems offer the latest 

technologies, unmatched performance and ease of use. 

With systems designed for Rheumatology, from Point of Care to 

High End cart ultrasound and extremity MRI, Esaote offer stunning 

image quality allowing you to focus on your patient. 

Excellence in Rheumatology stand 94 

Excellence in Rheumatology (EiR) is the annual international 

conference of the Excellence in Rheumatology Institute. The 2013 

edition will take place in Lisbon, Portugal, 24-27 January 2013 and 

will present cutting edge scientific findings as they relate to clinical 

practice. 

Fibromyalgia Association UK stand 13 

FMA UK provides information to the general public and medical 

professionals on fibromyalgia. Our volunteer led charity lobbies for 

quicker diagnosis and more effective treatment for the estimated 

1.2m people with fibromyalgia in the UK. There are no approved 

guidelines for treatment with many people suffering in constant 

pain without a diagnosis for many years. FMA UK is determined 

to improve this unacceptable situation. 

Genus Pharmaceuticals Limited stand 106 

Genus Pharmaceuticals is a medium sized pharmaceutical company 

specialising in supply of Rheumatology, Dermatology and Parkinson’s 

Disease Medicines. Genus focuses on a number of different therapy 

areas to improve the quality of life of patients and works with health 

care professionals to enhance patient outcomes and efficiency. 

Genzyme stand 110 

Genzyme has pioneered the development and delivery of 

transformative therapies for patients affected by rare and debilitating 

diseases for over 30 years. With a focus on rare diseases and 

multiple sclerosis, we are dedicated to making a positive impact 

on the lives of the patients and families we serve. 

GlaxoSmithKline/Human genome Sciences stand 60 

Website: www.gsk.com, www.hgsi.com 

At GSK we have a challenging and inspiring mission: to improve the 

quality of human life by enabling people to do more, feel better and 

live longer. 

At Human Genome Sciences, we believe that solving critical 

medical challenges takes careful planning, relentless resilience, 

the best scientific minds, and rigorous clinical trials. 

Grünenthal Ltd stand 74 

Grünenthal is an independent, family-owned international research 

based pharmaceutical company with a focus on the treatment of 

pain. Grünenthal has affiliates in 35 countries worldwide, and its 

products treat patients in more than 100 countries. 

Healthcare at Home Ltd stand 6 

The UK leader in high-tech clinical homecare and speciality 

pharmacy. We also deliver services on-site throughout the NHS and 

independent sector. Our 1,000 staff includes over 400 highly skilled 

and experienced nurses. With operations throughout the UK, we 

provide a vast range of services to over 150,000 patients each year. 

Tel: 0870 600 1540 Email: info@hah.co.uk Website: www.hah.co.uk 

Internis Pharmaceuticals Ltd stand 61 

Founded in 2010, Internis is a pharmaceutical company engaged 

in the development and commercialisation of highly effective and 

innovative new medicines aimed at the treatment and prevention 

of a range of common bone disorders, such as osteoporosis and 

vitamin D3 deficiency.



Lupus UK stand 12 

LUPUS UK is the only national charity for people with lupus offering 

support through our voluntary network of over 20 Regional Groups. 

Our priorities are to increase lupus awareness amongst the public 

and the medical profession, provide support to our members, and 

raise funds towards research and Lupus Nurses. Tel: 01708 

731251 (24 hour answer phone) website www.lupusuk.org.uk 

Medac stand 52 

Medac is a German based pharmaceutical manufacturer with a 

growing number of branches around the world. Metoject was 

launched by Medac in the UK in 2006 as the first range of prefilled 

syringes of methotrexate licensed for use in rheumatoid arthritis. 

Miltenyi Biotec Ltd stand 90 

Miltenyi Biotec’s products support basic biomedical research 

through to clinical cell isolation and culture, cryopreservation, and 

Ig and LDL immunoadsorption therapy. 

TheraSorb Therapeutic Apheresis: the treatment option for 

pathogenic immunoglobulin-associated disease (e.g. SLE, Vasculitis, 

Scleroderma, Pemphigus, etc.) 

CliniMACS® Cell Separation System: clinical grade isolation of 

therapeutic cell populations (e.g. TRegs, TolDC’s, MSC’s, etc.) 

MACS® GMP Products: culture, differentiation and expansion of 

cell therapy products. 

Mivenion GmbH stand 48 

Mivenion offers Xiralite, a fluorescence-optical system for imaging 

of rheumatic disorder in the hands. The altered microcirculation in 

active inflammation is visualized, providing information on disease 

activity, differential diagnosis, and quantification of treatment 

response. It is tailored to the diagnostic needs of rheumatologists, 

is easy to use, and allows full integration into the patient workflow, 

thus providing fast and reliable information for treatment decisions. 

MSD stand 78 

Today's MSD is a global healthcare leader who is working to help 

the world be well. 

Myositis Support Group stand 14 

The Myositis Support Group is a UK charity providing advice and 

support to individuals and their families affected by Dermatomyositis, 

Polymyositis, Inclusion Body Myositis and Juvenile Dermatomyositis. 

We also raise funds and promote medical research to improve the 

diagnosis, treatment, management and understanding of these 

rare illnesses. 

NASS stand 15 

The National Ankylosing Spondylitis Society (NASS) was founded 

over 30 years ago to provide support and advice for patients and 

their families. NASS works to raise awareness of AS and provides a 

website, publications and information as well as running a branch 

network of around 95 branches throughout the UK offering regular 

supervised exercise sessions. NASS members also participate in 

ongoing genetic research into the disease. 

NRAS stand 17 

The National Rheumatoid Arthritis Society (NRAS) was launched in 

October 2001 and in a relatively short time has become established 

as the voice in the UK for people with Rheumatoid Arthritis (RA). 

NRAS provides assistance to all people in the UK with RA, their 

carers and families. We offer a range of services, including support, 

information, dedicated education programmes and peer to peer 

support. We also campaign to raise awareness of the disease and 

ensure fair treatment for all. 

Oxford Diagnostic Laboratories stand 46 

TB Screening Just Got Easier: Visit Oxford Diagnostic Laboratories 

on stand no. 46 to learn about the most Simple, Reliable and Cost 

Effective TB Testing Service available in the UK. 

Oxford Diagnostic Laboratories is the only national service laboratory 

dedicated to running the T-SPOT®.TB IGRA for accurate detection 

of tuberculosis. 

Contact us for more information: 

E-mail: odl@oxfordimmunotec.com Tel: 01235 433164 

www.tbtestingservices.com 

Through our medicines, vaccines, biologic therapies, and consumer 

and animal products, we collaborate with human and animal health 

professionals across the UK and in more than 140 countries to 

deliver innovative health solutions. 

Beyond this, we have a commitment to increasing access to 

healthcare through far-reaching programmes that donate and 

deliver our products to people who need them. 

For more information, please go to www.msd-uk.co.uk.


Pfizer Ltd stand 34 

WORKING TOGETHER FOR A HEALTHIER WORLD 

At Pfizer, we strive to set the standard for quality, safety and 

value in the discovery, development and manufacturing of 

medicines for people. For more than 150 years, Pfizer has 

worked to make a difference for all who rely on us. In the UK, 

Pfizer has its business headquarters in Surrey and is the major 

supplier of medicines to the NHS. To learn more about our 

commitments, please visit us at www.pfizer.co.uk 

RCN stand 16 

The Royal College of Nurses represents the interests of nurses and 

nursing. It aims to educate nurses both academically and 

professionally, promoting the art and science of nursing and its 

professional practice. The rheumatology forum aims to promote this 

role within the field of rheumatology, providing support and 

continuing professional development for nurses to ensure they 

influence and deliver the best possible care for patients with 

rheumatological conditions. 

Philips Healthcare stand 50 

Philips will exhibit its latest platform of their Vision 2012, iU22 

Premium Performance ultrasound system featuring the very latest 

advanced technology on the linear transducer range. The transducers 

have been expertly optimized to enhance image quality for all 

musculo-skeletal examinations. Come and visit our stand to discuss 

how Philips leading edge Elastography can increase diagnostic 

confidence in inflammatory joint conditions. 

www.philips.com/healthcare 

PMR & GCA stand 11 

Polymyalgia Rheumatica and Giant Cell Arteritis Scotland was the 

first charity in the UK specifically for people with these neglected 

conditions. We provide information and support through monthly 

meetings, our website www.pmrandgca.org.uk, by email 

info.scotland@pmrandgca.org.uk, telephone 01382 562 974 and 

mail. Through various organisations we raise the profile of these 

conditions and try to improve the extremely variable and sometimes 

unacceptable standards of care. 

PSALV stand 20 

PSALV, Psoriasis Scotland, Scotland's only patient-led registered 

charity for those with psoriasis and psoriatic arthritis, supports 

people with these conditions, their families & carers, raises 

awareness & provides information to all, campaigning, lobbying & 

liaising with the Scottish NHS, Scottish Government & clinicians for 

better & more equitable services throughout Scotland. PSALV holds 

information days, has a website, a newsletter and publishes 

literature on psoriasis & PsA. 

Pulmonary Hypertension Association UK stand 92 

The Pulmonary Hypertension Association (PHA UK) is the only charity 

in the UK especially for people with pulmonary hypertension (PH). 

We are committed to helping improve the lives of people with PH, 

and supporting the PH community in the UK. We do this by funding 

research into PH, raising awareness of the condition, and helping 

people in their day-to-day lives. 

Roche Products Ltd stand 98 

Roche is one of the world’s leading research-focused healthcare 

groups in the fields of pharmaceuticals and diagnostics. As a 

supplier of innovative products and services for the early 

detection, prevention, diagnosis and treatment of diseases, 

the Group contributes on a broad range of fronts to improving 

people’s health and quality of life. 

RApport stand 104 

RApport: education for nurses by nurses 

Developed and implemented by a specialist Steering Committee of 

healthcare professionals in partnership with Roche Products Limited 

and Chugai Pharma UK Limited, RApport is an educational platform 

designed to help the NHS enhance patient care in the field of 

rheumatoid arthritis (RA). 

Please visit the RApport stand to hear more about the National 

Meeting, meet with members of the Steering Committee and gather 

information to support you in your ongoing clinical audits. 

Rheumatology and OUP stand 62 

Rheumatology is the international scientific journal published by 

Oxford University Press on behalf of the BSR. This year come and 

meet at the Editor at the Stand or find out about the developments 

taking place the in the Journal. 

Royal Air Force Medical Service stand 72 

To succeed in our missions takes more than planes and pilots, 

there’s a team of highly skilled people behind every aircraft that takes 

to the skies, and that’s where you come in. Come and meet the 

team today to find out about the career that could await you as a 

RAF Medical Officer.



Royal Society of Medicine stand 4 

The Royal Society of Medicine is one of the largest providers of 

continuing medical education in the UK. Each year the RSM 

organises over 400 CPD accredited conferences, courses and 

meetings allowing doctors, dentists, veterinary surgeons, including 

students of these disciplines, and other healthcare professionals 

their continuing freedom to practise. 

For more information: Email: membership@rsm.ac.uk 

Tel: 020 7290 2991 www.rsm.ac.uk 

Sanofi stand 63 

Sanofi, a global and diversified healthcare leader, discovers, develops 

and distributes therapeutic solutions focused on patients’ needs. 

Sanofi has core strengths in the field of healthcare with seven growth 

platforms: diabetes solutions, human vaccines, innovative drugs, rare 

diseases, consumer healthcare, emerging markets and animal 

health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York 

(NYSE: SNY). 

Savient Pharma Ireland Limited stand 66 

Savient Pharma Ireland Limited, a wholly-owned subsidiary of Savient 

Pharmaceuticals, is a specialty biopharmaceutical company seeking 

regulatory approval for KRYSTEXXA® in the European Union for the 

treatment of refractory chronic gout. KRYSTEXXA is available in the 

European Union through a Named Patient Programme and is 

currently the only FDA approved product for this indication in the 

United States. 

Scleroderma Society stand 10 

Come and visit our Stand, we have updated leaflets, Understanding 

and Managing Scleroderma booklet used by patients, GP’s and 

health professionals. Our latest leaflet “Hospital Checklist” provides 

a guide to nursing patients with SSc. Other services we provide 

include a free confidential helpline to support your patients 

throughout their experience of their condition, new website and 

quarterly newsletter. www.sclerodermasociety.co.uk 

Servier Lab Ltd stand 76 

Servier Laboratories is the UK subsidiary of The Servier Research 

Group, a French research based pharmaceutical company 

established in 1954 by Dr Jacques Servier. Created in 1963 with only 

two people, the UK subsidiary was the first subsidiary outside France. 

In just over fifty years, The Servier Research Group has developed in 

stature from a small family-owned, provincial pharmacy employing 

nine people to a multi-national operation, established in 140 

countries and with over 20,000 employees worldwide. 

SOBI stand 65 

Swedish Orphan Biovitrum is a Swedish based niche specialty 

pharmaceutical company with an international market presence. 

The company is focused on providing and developing specialist 

pharmaceuticals for rare disease patients with high medical needs. 

The portfolio consists of about 60 marketed products and an 

emerging late stage clinical development pipe-line. Our current 

marketed products in the UK are in the fields of: haematology, 

rheumatology, inherited metabolic disorders and emergency 

medicine. 

TRB Chemedica (UK) Ltd stand 49 

We are specialists in bio-synthetic Sodium Hyaluronate. OSTENIL® 

is an intra-articular injectable preparation of Sodium Hyaluronate for 

the treatment of degenerative joint disease. OSTENIL® PLUS offers 

clinicians and patients the convenience of an effective single 

injection option viscosupplement. VISCOSEAL® - a post arthroscopic 

synovial fluid replacement - promotes restoration of homeostasis 

inside the joint. To find out more please visit our stand at 

Rheumatology 2012. 

UCB stand 26 

UCB, Brussels, Belgium (www.ucb.com) is a global 

biopharmaceutical company focused on the discovery and 

development of innovative medicines and solutions to transform 

the lives of people living with severe diseases of the immune 

system or of the central nervous system. With more than 8,500 

people in about 40 countries, the company generated revenue 

of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels 

(symbol: UCB). 

Vertec Scientific stand 51 

Established in 1985, Vertec Scientific is a leading distributor of 

world class systems for diagnostic imaging and radiotherapy in the 

UK. It’s portfolio features DXA and intraoperative x-ray c-arms from 

Hologic, radiotherapy patient immobilisation systems from Klarity 

Medical, ultrasound from Zonare, portable CT from Neurologica, 

virtual colonoscopy from Viatronix, radiation protection from 

Scanflex, ISP Gafchromic dosimetry film and Picsara, a highly 

innovative multi-image management system. 

Wisepress stand 2 

Wisepress.com, Europe's leading conference bookseller, has a 

complete range of relevant books and journals which can be 

purchased at the stand or posted to you. We also have a 

comprehensive medical bookshop online with great offers. 

bookshop@wisepress.com www.wisepress.com


Abstract reviewers 

The BSR Heberden Committee was expanded substantially for the purposes of abstract 

assessment to ensure that every abstract was peer reviewed, blind, by at least three 

reviewers. The Heberden Committee is extremely grateful for the assistance of everyone 

who gave up their time to review abstracts and acknowledges them accordingly: 

Heberden Committee 

Dr Richard Watts (Chair) 

Prof Chris Denton 

Dr Andrew Keat 

Prof Michael Ehrenstein 

Prof Costantino Pitzalis 

Dr Hoda Mirjafari 

Prof Robert Moots 

Dr Jacqui Clinch 

Dr Michael Backhouse 

Dr Lindsay Bearne 

Dr Emmanuel George 

Dr Jon Packham 

Dr Ben Parker 

Prof Ian Clark 

Prof Elaine Hay 

Dr Ed Roddy 

Prof Gary Macfarlane 

Dr Hector Chinoy 

Dr Nicholas Shenker 

Dr Karen Walker Bone 

Dr Yasmeen Ahmad 

Dr Nicole Amft 

Dr Marina Anderson 

Dr Jacqueline Andrews 

Prof Nigel Arden 

Dr Eileen Baildem 


Prof Michael Beresford 

Dr Rupa Bessant 

Dr Fraser Birrell 

Dr Cathy Bowen 

Dr Simon Bowman 

Dr Paul Bowness 

Prof Matt Brown 

Prof Ian Bruce 

Prof Chris Buckley 

Dr David Carruthers 

Prof Tim Cawston 

Prof Kuntal Chakravarty 

Prof Ernest Choy 

Dr Gavin Clunie 

Dr David Collins 

Prof Philip Conaghan 

Prof Andy Cope 

Mrs Trish Cornell 

Prof Jane Dacre 

Dr Julie Dawson 

Prof Chris Deighton 

Dr Cristina Estrach 

Dr Karl Gaffney 

Dr Lyn Goodacre 

Dr Caroline Gordon 

Dr Celia Gregson 

Dr Bridget Griffiths 

Ms Elizabeth Hale 

Dr Frances Hall 

Dr Alison Hammond 

Prof Elaine Hay 

Dr Philip Helliwell 

Prof Sarah Hewlett 

Dr Clare Higgins 

Dr Neil Hopkinson 

Dr Philippa Hulley 

Dr Charles Hutton 

Dr Kimmie Hyrich 

Dr John Ioannou 

Prof John Isaacs 

Dr Paresh Jobanputra 

Dr Jeremy Jones 

Prof David Kane 

Dr Lesley Kay 

Dr Clive Kelly 

Dr George Kitas 

Dr Ellie Korendowych 

Dr Peter Lanyon 

Dr Thomas Lawson 

Dr Jo Ledingham 

Dr Jenny Lewis 

Prof Ian McInnes 

Dr Chetan Mukhtyar 

Dr Fai Ng 

Dr Andrew Ostor 

Dr John Pauling 

Prof George Peat 

Dr Ken Poole 

Dr Duncan Porter 

Dr Elizabeth Price 

Dr Elizabeth Rankin 

Dr Karim Raza 

Dr Ruth Richmond 

Prof David L. Scott 

Dr Deborah Symmons 

Prof Patrick Venables 

Ms Karen Vinall 

Dr Nikki Walsh 

Dr Louise Warburton 

Dr Andrew Whallet 

Dr Anita Williams 

Dr Lyn Williamson 

Dr Gerry Wilson 

Dr Elspeth Wise 

Prof Jane Worthington 

Dr Adam Young 

If you would be interested in reviewing abstracts for next year’s conference, 

please email events@rheumatology.org.uk letting us know your area of expertise.


Prize and bursary assessors 

The BSR and BHPR would like to thank all of the judges who have 

given up their time to assess the prizes at Rheumatology 2012 

BSR awards and bursaries 

Prof David L Scott, BSR President 

Dr Chris Deighton 

Prof Kuntal Chakravarty 

Dr Simon Bowman 

Prof David Isenberg 

BSR Heberden Committee 

BHPR prizes and bursaries 

Mrs Lindsey Hawley, BHPR President 

Mr Robert Field 

Mrs Patricia Cornell 

Dr Michael Backhouse 

Dr Jill Firth 

Dr Jo Adams 

Prof Krysia Dziedzic 

Dr Maggie McArthur 


Dr Kristie Haywood 

Dr George Peat


Notes 

Rheumatology 2013 abstract deadline 

Wednesday 21 November 2012 

















Rheumatology 2013 abstract deadline 

Wednesday 21 November 2012 


BSR 

The British Society for Rheumatology 

Education 

Courses 

Musculoskeletal Medicine and Pregnancy Course 

Oxford | 06 July 2012 

Can Biologics Cure Rheumatoid Arthritis? 

London | 07 September 2012 

Foot and Ankle Course 

Leeds | 27 – 28 September 2012 

Basic Ultrasound Course 

Southend-on-Sea | 19 – 21 October 2012 

Core Skills in Rheumatology Course 

Newcastle | 15 – 16 November 2012 

Allied Health Professionals Course in RA 

Keele | 21 – 22 November 2012 

Advanced Course 

Oxford | 03 – 04 December 2012 

Advanced Ultrasound Course 

Liverpool | 06 – 07 December 2012 

of delegates would recommend 

91% BSR courses to a colleague 

www.rheumatology.org.uk/education

Let’s talk about membership... 

Join us at Stand 32 for a free coffee and take the 

opportunity to discuss your membership, update 

your details, and talk about membership issues 

with the BSR/BHPR Membership Team! 

Interested in 

becoming a member? 

Please join us at the stand to hear about the 

exciting benefits the BSR can offer such as 

subscription to our journal Rheumatology, 

discounted rates for the BSR/BHPR annual 

conference and many more! 

Please join us at the stand to hear about the 

great benefits BHPR can offer such as high-quality 

CPD accredited training, subscription to the 

Musculoskeletal Care Journal, discounted rates for the 

BSR/BHPR annual conference and many more! 

Contact Details: 

Subscriptions Department 

18-20 Bride House 

Bride Lane 

London EC4Y 8EE 

T: +44(0)20 7356 0949 

E: subscriptions@rheumatology.org.uk

View conference programme - The British Society for Rheumatology

Create successful ePaper yourself

Delete template?

Save as template?